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ABSTRACT	  	  Obesity	   is	   widely	   considered	   a	   primary	   risk	   factor	   for	   type	   2	   diabetes	   (T2D).	  However,	  less	  is	  known	  about	  the	  early	  adaptive	  responses	  to	  short-­‐term	  periods	  of	  high-­‐fat	  energy	  excess	   (HFEE).	  Previous	  reports	  detailing	  whole-­‐body	  adaptation	   to	  fat	  and	  energy	  oversupply	  are	  equivocal,	  perhaps,	   in	  part,	  owing	   to	  use	  of	  different	  experimental	   protocols,	   varying	   durations	   of	   dietary	   manipulation	   and	   participant	  cohorts	  with	  individuals	  of	  varying	  characteristics.	  	  	  In	   addition	   to	   use	   of	   different	   dietary	   protocols	   between	   studies,	   alterations	   in	  functional	   end-­‐point	   measures	   due	   to	   the	   type	   of	   dietary	   fat	   consumed	   warrants	  consideration.	  Daily	  n-­‐3	  PUFA	   intake,	   commonly	  obtained	   from	  pelagic	   fish	  oil	   (FO)	  consumption,	   has	   been	   shown	   to	   positively	   associate	   with	   insulin	   sensitivity	   in	  epidemiological	  studies	  and	  thus	  may	  be	  a	  useful	  dietary	  strategy	  for	  slowing	  insulin	  resistance	  development.	  	  
Chapter	  2	  of	  this	  thesis	  extends	  previous	  literature	  by	  demonstrating	  that	  6	  d	  HFEE	  (150	  %	  habitual	  energy	  intake;	  60	  %	  of	  energy	  from	  fat)	  does	  not	  clearly	  alter	  whole-­‐body	   insulin	   sensitivity,	   irrespective	   of	   FO	   consumption.	   However,	   investigation	   of	  metabolism	  at	  the	  tissue	  level,	  as	  presented	  in	  Chapter	  3	  of	  this	  thesis,	  offers	  insight	  into	   a	   potential	   tissue-­‐specific	   level	   of	   regulation	   that	   precedes	   whole-­‐body	  regulation.	   Skeletal	   muscle	   insulin	   signalling	   protein	   (e.g.	   protein	   kinase	   B	   (PKB))	  activity,	   levels	   of	   certain	   ceramide	   species,	   and	   AMPK	   α2	   activity	   were	   altered	  following	   HFEE	   and	   may	   explain	   the	   early	   maladaptive	   responses	   to	   short-­‐term	  HFEE.	  Moreover,	   FO	   intake	  as	  10	  %	  of	   total	   fats	  mediated	   some	  of	   these	  molecular	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responses,	  including	  PKB	  and	  AMPK	  α2	  activity,	  reflecting	  possible	  functional	  effects	  of	  FO	  at	  the	  subcellular	  level.	  	  	  Regulation	   of	   these	  metabolic	   /	  molecular	   responses	   at	   both	   the	   tissue	   and	  whole-­‐body	   level	   can	   be	   explained,	   in	   part,	   by	   genetic	   predisposition,	   environmental	  influence	  and	  more	  recently	  epigenetics,	  including	  microRNAs	  (miRNAs).	  In	  Chapter	  
4,	  we	   characterised	   the	  plasma	  and	   skeletal	  muscle	  miRNA	   responses	   to	  HFEE	  and	  oral	  glucose	  ingestion.	  We	  demonstrate	  transient	  changes	  in	  levels	  of	  certain	  miRNAs	  following	   oral	   glucose	   ingestion	   in	   both	   tissue	   types	   and	   in	   response	   to	   HFEE	   in	  skeletal	   muscle.	   However,	   no	   significant	   correlations	   between	   basal	   plasma	   and	  skeletal	  muscle	  miRNA	   levels	  were	  observed,	   suggesting	   that	  our	   candidate	  plasma	  miRNAs	  may	  be	  co-­‐ordinating	  functional	  changes	  in	  other	  tissue	  types.	  Plasma	  miR-­‐145-­‐5p	   and	   skeletal	   muscle	   miR-­‐204-­‐5p	   predicted	   a	   significant	   proportion	   of	   the	  variance	   in	  mean	  whole-­‐body	   insulin	  sensitivity	  change	   in	  response	  to	  HFEE.	  These	  data	   indicate	   that	   these	   miRNAs	   may	   be	   useful	   biomarkers	   of	   insulin	   resistance	  development	  following	  HFEE.	  	  	  A	   constraint	   of	   this	   thesis	   is	   that	   all	   conclusions	   are	   made	   within	   the	   context	   of	  statistically	   unaltered	   insulin	   sensitivity.	   Therefore,	   future	   investigations	   of	   diet-­‐induced	   maladaptation	   should	   consider	   establishing	   a	   time	   course	   of	   insulin	  resistance	   development	   in	   response	   to	   HFEE,	   or	   use	   different	   study	   populations.	  Populations	   that	   are	   more	   susceptible	   to	   T2D	   development,	   e.g.,	   overweight,	  sedentary	   individuals	   would	   be	   of	   particular	   interest.	   These	   data	   would	   aid	  development	   of	   a	   working	   model	   of	   diet-­‐induced	   insulin	   resistance	   that	   has	   more	  direct	   application	   to	   T2D	   progression	   and	   extends	   the	   data	   presented	   herein.
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CHAPTER	  1	  General	  introduction.	  
	  
	  
1.0.	  Introduction	  Macronutrient	  and	  energy	  excess	  positively	  associate	  with	  obesity,	  insulin	  resistance	  and	   type	   2	   diabetes	   (T2D;	   (1,2)).	   The	   proportion	   of	   16-­‐64	   year	   olds	   classified	   as	  overweight	  or	  obese	   in	  Scotland	   increased	   from	  52.4	   to	  61.9	  %	   from	  1995	   to	  2012	  (3).	  Moreover,	   of	   all	   T2D	   individuals	  with	   their	  BMI	  on	   record,	   87.1	  %	  were	   either	  overweight	   or	   obese	   (4).	   In	   a	   recent	  meta-­‐analysis,	   being	  overweight	   or	   obese	  was	  associated	   with	   a	   3	   or	   7	   times	   greater	   risk	   of	   developing	   T2D,	   respectively,	   than	  normal	  body	  weight	  (5).	  These	  data	  highlight	  the	  significant	  implications	  of	  positive	  energy	  balance	  for	  T2D	  risk.	  	  	  Current	   estimated	   worldwide	   prevalence	   rates	   of	   diabetes	   stand	   at	   347	   million	  people	  (6),	  with	  T2D	  accounting	  for	  90	  %	  of	  this	  figure	  (7).	  T2D	  is	  characterised	  by	  insulin	   resistance,	   i.e.,	   the	   failure	   of	   key	   organs	   to	   respond	   effectively	   to	   insulin	  secretion	   from	   the	   pancreas	   (8,9).	   T2D-­‐associated	   complications	   include	  cardiovascular	  disease,	  renal	  failure,	  retinopathy	  (possibly	  leading	  to	  blindness),	  and	  neuropathy	  (possibly	  leading	  to	  limb	  amputation)	  (2,10).	  The	  annual	  cost	  to	  the	  NHS	  from	  T2D-­‐related	  illness	  is	  around	  £9	  billion	  (11),	  with	  10	  %	  of	  the	  healthcare	  budget	  in	   Scotland	   given	   to	   diabetes	   care	   (12).	   With	   increasing	   T2D	   prevalence	   rates,	   a	  substantial	  burden	  is	  being	  placed	  on	  the	  national	  healthcare	  budget	  and	  thus	  health	  and	  economic	  policy.	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The	  sharp	  rise	  in	  T2D	  prevalence	  rates	  over	  the	  preceding	  decades	  raises	  a	  ‘gluttony	  
vs.	   sloth’	   debate	   regarding	   the	   primary	   cause	   of	   energy	   imbalance	   (13).	   Both	  increased	  energy	  intake	  and	  decreased	  physical	  activity	  undoubtedly	  contribute	  to	  a	  more	  positive	  energy	  balance.	  However,	  over	  the	  past	  40	  years	  and	  for	  the	  first	  time	  in	   history,	   food	   availability	   has	   exceeded	   human	   requirements,	   particularly	   in	   the	  Western	   world	   (14,15).	   Increased	   food	   availability	   has	   contributed	   to	   energy	  overconsumption,	   particularly	   in	   Western,	   well-­‐developed	   countries	   (16),	   and	   has	  coincided	  with	  increasing	  T2D	  prevalence	  rates.	  Investigation	  of	  energy	  excess	  and	  its	  role	   in	  T2D	  development	   is	   central	   to	  understanding	  T2D	  pathology	  and	  associated	  metabolic	  perturbations.	  	  	  The	   study	   of	   insulin	   resistance	   and	   T2D	   spans	   several	   experimental	   models	   that	  include	   human,	   rodent	   and	   cell-­‐based	   systems.	   In	   addition	   to	   chronic	   models	   of	  insulin	   resistance	   (e.g.	  overweight	   /	   obese	   /	  T2D	   individuals),	   acute	  models	   can	  be	  used	  to	  investigate	  early	  responses	  leading	  to	  T2D	  onset.	  Lipid	  and	  heparin	  infusions	  (e.g.	  (17)),	   feeding	   of	   a	   high-­‐fat	  meal	   or	   diet	   (e.g.	   (18,19)),	   and	   exercise	   restriction	  (e.g.	   (20))	   all	   are	   commonly	   used	   models	   of	   acute	   insulin	   resistance.	   However,	  arguably	  the	  most	  valid	  model	  to	  study	  energy	  excess	  is	  feeding	  of	  a	  hyperenergetic	  meal	  or	  diet.	  Investigations	  of	  this	  nature	  have	  been	  less	  frequent	  than	  investigations	  using	  other	  models,	  and	  with	  largely	  varied	  findings.	  Establishing	  a	  working	  model	  of	  short-­‐term	   energy	   excess	   leading	   to	   insulin	   resistance	   would	   benefit	   future	  investigations	   into	   the	   early	   adaptive	   responses	   to	   overfeeding	   and	   T2D	  development.	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Pharmacological	   (ant)agonists	   /	   agents,	   exercise	   prescription	   and	   dietary	  manipulation	  all	  have	  been	   investigated	  as	   strategies	   to	  prevent	  or	   slow	  T2D	  onset	  (2).	  Increased	  dietary	  or	  supplemental	  intake	  of	  n-­‐3	  polyunsaturated	  fatty	  acids	  (n-­‐3	  PUFA(s)),	   commonly	   obtained	   from	   pelagic	   fish	   oil	   (FO),	   is	   one	   candidate	   dietary	  strategy.	   Epidemiological	   studies	   demonstrate	   a	   positive	   relationship	   between	  habitual	  dietary	  intake	  of	  n-­‐3	  PUFAs	  and	  metabolic	  health	  (21,22).	  The	  mechanisms	  governing	  this	  association	  may	  relate	  to	  a	  more	  permeable	  cell	  membrane	  resulting	  from	  n-­‐3	   PUFA	   incorporation	   that	   alters	   signalling	   and	   nutrient	   transport	   between	  cells	   (23–25).	   Enhancing	   the	   delivery	   of	   nutrients,	   particularly	   glucose,	   into	   tissue	  will	  increase	  insulin	  sensitivity,	  perhaps	  slowing	  T2D	  onset.	  Therefore,	  consumption	  of	  n-­‐3	  PUFAs	  during	  a	  period	  of	  energy	  excess	  may	  be	  a	  viable	  strategy	  for	  reducing	  insulin	  resistance	  development.	  	  	  	  Environmental	   influences	   including	   dietary	   manipulation,	   combined	   with	   genetic	  predisposition	  underpin	  the	  development	  of	  T2D.	  However,	  environmental	  exposure	  also	   is	   likely	   coded	   into	   the	   biological	   system	   by	   epigenetic	   mechanisms	   (26,27).	  Epigenetic	  mechanisms	  are	   involved	   in	   gene	   regulation	  and	   include	   the	  non-­‐coding	  RNA	  molecules,	  microRNAs	  (miRNAs)	  (28).	  Heritable	  changes	   in	  phenotype	  or	  gene	  expression	  that	  occur	  in	  the	  absence	  of	  changes	  in	  the	  DNA	  sequence	  are	  considered	  epigenetic	   in	  nature	  (29).	  The	  main	  modes	  of	  miRNA	  action	  on	  gene	  expression	  are	  twofold;	   i)	   to	   inhibit	   translation	   initiation	  of	  nascent	  mRNA	   transcripts	   and	  /	  or	   ii)	  degradation	   of	   mRNA	   transcripts	   (30,31).	   These	   processes	   result	   in	   a	   reduced	  expression	  of	  genes	  encoded	  by	  the	  targeted	  mRNA	  transcripts.	  The	  role	  of	  the	  mRNA	  target	  as	  a	  stimulator	  or	  inhibitor	  of	  a	  given	  pathway	  will	  determine	  the	  direction	  of	  change	   in	   flux	   through	   the	   pathway	   as	   a	   result	   of	   this	   reduced	  mRNA	   expression.	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MiRNAs	   are	   tightly	   regulated	   and	   integral	   for	   ‘normal’	   whole-­‐body	   metabolic	  regulation	   (32).	   However,	   altered	   miRNA	   levels	   have	   been	   shown	   in	   a	   variety	   of	  disease	  states	  including	  T2D	  and	  atherosclerosis	  (33,34),	  suggesting	  miRNAs	  may	  be	  useful	   biomarkers	   of	   disease	   and	   are	   likely	   important	   in	   health	   maintenance	   and	  adaptations	  to	  diet.	  	  A	   significant	   body	   of	   research	   exists	   characterising	   the	   influence	   of	   nutritional	  interventions	   on	   insulin	   sensitivity,	   yet	   the	   precise	   molecular	   mechanisms	  underpinning	  these	  adaptive	  responses	  are	  incompletely	  understood.	  What	  is	  known,	  is	   that	   a	   series	   of	   phosphorylation	   cascades	   involving	   insulin	   signalling	   through	  protein	   kinase	   B	   (PKB)	   play	   a	   crucial,	   defining	   role	   in	   glucose	   uptake	   in	   insulin	  sensitive	   tissues	   (e.g.	   (8,35–37)).	   Therefore,	   in	   this	   chapter,	   an	   overview	   of	   insulin	  signalling	  first	  will	  be	  presented,	  followed	  by	  a	  critical	  review	  of	  existing	  studies	  that	  characterise	  adaptive	  responses	  to	  short-­‐term	  lipid	  and	  energy	  oversupply.	  The	  focus	  for	  discussion	  of	   these	  studies	  will	  be	  on	  glucose	  metabolism,	   lipid	  metabolism	  and	  epigenetic	  regulation.	  Cumulatively,	   the	  aim	  of	   this	  chapter	   is	   to	  provide	   the	  reader	  with	  an	  appreciation	  for	  the	  philosophy	  of	  this	  thesis,	  including	  the	  existing	  evidence	  base	  and	  principal	  rationale	  for	  the	  experimental	  data	  presented	  herein.	  	  	  	  
1.1.	  Insulin	  signalling	  Carbohydrate	   feeding	   is	   the	  primary	  stimulus	   for	   insulin	  secretion	  (38,39).	  Glucose,	  from	  carbohydrate	  digestion,	  is	  sensed	  by	  the	  pancreatic	  β-­‐cells	  which	  are	  clustered	  in	  islets	   with	   a	   high	   degree	   of	   vascularisation	   (38).	   This	   highly	   vascularised	   network	  augments	   the	   transport	   of	   blood	   to,	   and	   from,	   the	   pancreas	   and	   enables	   greater	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nutrient	   exchange	   across	   the	   tissue	   bed	   (38).	   The	   glucose	   transporter	   (GLUT)	  isoform,	  GLUT2,	  expressed	  in	  pancreatic	  β-­‐cells,	  is	  deployed	  to	  the	  plasma	  membrane	  in	  an	  insulin-­‐independent	  manner	  and	  is	  the	  first	  β-­‐cell	  micro-­‐domain	  to	  be	  exposed	  to,	  and	  thus	  sense,	  circulating	  blood	  glucose	  (38).	  Following	  entry	  of	  glucose	  into	  the	  cell	   via	   GLUT2	   transporters,	   glucose	   is	   phosphorylated	   by	   glucokinase	   to	   form	  glucose-­‐6-­‐phosphate	   (38).	   Glucose	   influx	   enhances	   glucose	   metabolism	   and	   flux	  through	  the	  tricarboxylic	  acid	  (TCA)	  cycle;	  leading	  to	  a	  raised	  adenosine	  triphosphate	  (ATP):	   adenosine	   diphosphate	   (ADP)	   ratio	   from	   both	   glycolytic	   and	   oxidative	  metabolism	  (38,39).	  As	  a	  result,	  plasma	  membrane	  depolarisation	  (via	  closure	  of	  the	  ATP-­‐sensitive	   potassium	   channels)	   mediates	   subsequent	   calcium	   influx	   by	  stimulating	   the	   opening	   of	   voltage-­‐dependent	   calcium	   channels	   (39,40).	   The	   fusion	  and	  exocytosis	  of	  insulin-­‐containing	  granules	  is	  stimulated	  from	  this	  sudden	  calcium	  influx	  -­‐	  leading	  to	  insulin	  secretion	  into	  the	  circulation	  for	  action	  on	  tissue	  (38,39).	  	  	  Insulin	  stimulates	  a	  series	  of	  post-­‐translational	  modifications	  during	  the	  period	  from	  insulin	  binding	  to	  its	  receptor,	  to	  insulin-­‐mediated	  glucose	  uptake.	  This	  series	  of	  post-­‐translational	   modifications	   forms	   a	   signalling	   cascade	   and	   is	   considered	   an	  amplification	  process	   (41).	  Amplification	   through	   the	   signalling	  cascade	  means	   that	  even	   a	   small	   activation	   of	   proximal	   genes	   can	   cause	   significant	   activation	   of	  downstream	   targets	   and	   thus	  glucose	  uptake	   (41).	  The	   insulin	   signalling	   cascade	   is	  best	   characterised	   in	   skeletal	  muscle,	   but	   liver	   and	  adipose	   tissue	   also	   are	  primary	  insulin-­‐responsive	   tissues	   with	   important	   integrated	   functions	   in	   glucose	  homeostasis	  (Figure	  1.1;	  (42,43)).	  	  




1.1.1.	  Skeletal	  muscle	  Skeletal	   muscle	   is	   an	   important	   site	   of	   blood	   glucose	   regulation,	   accounting	   for	  approximately	  75	  %	  of	  whole-­‐body	  non-­‐oxidative	  glucose	  disposal	  (9,44,45).	  Several	  reports	   have	   reviewed	   the	   skeletal	   muscle	   insulin	   signalling	   process	   in	   detail	  (9,35,37,46,47),	  and	  a	  schematic	  is	  depicted	  in	  Figure	  1.2A.	  	  	  Binding	  of	  insulin	  leads	  to	  autophosphorylation	  of	  the	  insulin	  receptors	  on	  the	  muscle	  membrane	   via	   activation	   of	   the	   tyrosine	   residues	  within	   the	   receptors	   (46).	   These	  autophosphorylated,	   active	   receptors	   promote	   recruitment	   of	   a	   variety	   of	   docking	  proteins	  with	  key	  substrates	  being	  the	  family	  of	  insulin	  receptor	  substrates	  (IRS)	  and	  
	  
Figure	  1.1	  Integrated	  tissue	  cross-­‐talk	  for	  insulin-­‐stimulated	  glucose	  and	  lipid	  homeostasis.	  Insulin	  has	   inhibitory	  actions	  on	  glucose	  production	  and	  FA	  mobilisation,	  promoting	  glucose	  uptake	   into	  skeletal	   muscle	   and	   adipose	   tissue.	   Green	   arrows	   denote	   stimulation	   /	   increase,	   flat	   red	   lines	  denote	  inhibition.	  Adapted	  from	  (287).	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in	   particular,	   IRS-­‐1	   (46).	   Human	   IRS-­‐1	   contains	   several	   tyrosine	   and	   serine	   /	  threonine	   phosphorylation	   sites	   that	   can	   interact	   with	   downstream	   signalling	  proteins.	   In	   an	   insulin	   sensitive	   state,	   IRS	   proteins	   are	   phosphorylated	   on	   their	  tyrosine	   residue	   by	   the	   lipid	   kinase,	   phosphoinositide	   3-­‐kinase	   (PI3K)	   (47).	   PI3K	  consists	  of	  both	  a	  regulatory	  and	  catalytic	  subunit,	  with	  different,	  but	  complementary,	  features.	   It	   is	   the	   regulatory	   subunit	   that	   interacts	   with	   IRS	   proteins,	   whereas	   the	  catalytic	   subunit	   promotes	   the	   phosphorylation	   of	   phosphoinositols	   located	  within	  the	  plasma	  membrane	  (9,47).	  One	  particular	  catalytic	  action	  of	  PI3K	  is	  the	  conversion	  of	   phosphatidylinositol	   4,5-­‐biphosphate	   (PIP2)	   to	   phosphatidylinositol	   (3,4,5)-­‐triphosphate	   (PIP3)	   at	   the	   plasma	   membrane	   (9).	   It	   is	   the	   generation	   of	   PIP3	   in	  particular	  that	  drives	  subsequent	  downstream	  actions	  (35).	  	  	  One	   of	   the	   key	   downstream	   effectors	   of	   glucose	   uptake	   is	   PKB.	   Three	   ubiquitously	  expressed	  isoforms	  of	  PKB	  exist	  in	  skeletal	  muscle,	  with	  PKB1	  and	  PKB2,	  rather	  than	  PKB3,	   involved	   in	   insulin	  signal	   transduction	  (9,35).	  Phosphorylation	  of	  PKB	  at	   two	  key	   sites,	   Thr308	   and	   Ser473,	   is	   necessary	   for	   full	   protein	   activation	   (9,48)	   and	   the	  phosphoinositide-­‐dependent	  kinase	  (PDK)	  proteins	  are	  important	  in	  this	  process	  (9).	  Specifically,	  PDK1	  and	  PDK2	  are	  thought	  to	  act	  on	  PKB1	  and	  PKB2,	  respectively	  (9).	  The	  PDK	  proteins	  also	  stimulate	  phosphorylation	  of	  atypical	  protein	  kinase	  C	  (aPKC),	  which	   amplifies	   the	   signal	   for	   glucose	   uptake.	   PKB	   acts	   as	   a	   branching	   point	   for	  glucose	   uptake,	   glycogen	   synthesis	   and	   anabolic	   signalling	   (49).	   Glycogen	   synthase	  kinase	   (GSK)-­‐3	   is	   inhibited	   by	   the	   phosphorylation	   of	   PKB,	   which	   results	   in	   the	  removal	   of	   glycogen	   synthesis	   suppression.	   The	   subsequent	   increase	   in	   glycogen	  synthesis	   further	   augments	   the	   signal	   for	   glucose	   uptake	   by	   reducing	   intracellular	  glucose	   concentrations	   (46).	  The	  other	  mechanism	  of	  PKB	   is	  phosphorylation	  of	   its	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substrate,	   TBC	   domain	   family	   member	   4	   (TBC1D4)	   (35).	   When	   TBC1D4	   is	  phosphorylated,	   the	  Rab-­‐GTPase	  proteins	  are	  activated.	  Upon	  activation	  of	   the	  Rab-­‐GTPase	   proteins,	   suppression	   of	   the	   facilitated	   glucose	   transporter,	   GLUT4,	   is	  released,	  enabling	  GLUT4	  translocation	  to	  the	  plasma	  membrane	  (9,35).	  GLUT4	  is	  the	  predominant	   skeletal	   muscle	   isoform	   of	   the	   glucose	   transporter	   family	   members.	  Once	   at	   the	   plasma	  membrane,	   GLUT4	   facilitates	   the	   transport	   of	   glucose	   from	   the	  bloodstream	   into	   tissue	   (9,35).	  The	  net	   effect	  of	   insulin-­‐mediated	  glucose	  uptake	   is	  decreased	   blood	   glucose	   concentrations	   and	   increased	   skeletal	   muscle	   glycogen	  synthesis	  and	  /	  or	  glucose	  oxidation.	  	  	  	  	  
1.1.2.	  Liver	  Glucose	  homeostasis	   is	   regulated	  by	   insulin	  action	  on	   liver	   tissue.	   Insulin	  promotes	  glucose	  uptake	  into	  liver	  via	  many	  of	  the	  same	  mechanisms	  as	  skeletal	  muscle,	  albeit	  culminating	   with	   GLUT2,	   rather	   than	   GLUT4,	   translocation	   (50,51).	   However,	  arguably	  the	  most	  significant	  role	  of	  insulin	  within	  the	  liver	  is	  suppression	  of	  hepatic	  glucose	   output	   (50,52).	   Suppression	   of	   glucose	   output	   from	   liver	   will	   reduce	   the	  contribution	  of	  endogenous	  glucose	  to	  the	  plasma	  glucose	  pool	  in	  order	  to	  offset	  the	  increased	   glucose	   availability	   from	   exogenous	   sources.	   Another	   insulin-­‐mediated	  mechanism	  within	  the	  liver	  is	  the	  stimulation	  of	  glycogen	  synthesis	  which	  occurs	  via	  two	   primary	   mechanisms.	   First,	   glycogen	   synthase	   is	   activated	   following	   PKB-­‐mediated	   phosphorylation	   and	   thus	   inactivation	   of	   GSK-­‐3β	   (50).	   Second,	  gluconeogenic	   enzymes	   are	   suppressed	   by	   forkhead	   box	   protein	   O1	   (FOXO1)	   (50).	  The	   combination	   of	   reduced	   glucose	   output	   from	   the	   liver	   and	   increased	   glucose	  
Chapter	  1:	  General	  Introduction	   11	  
	  	  
uptake	  into	  both	  skeletal	  muscle	  and	  liver	  facilitates	  the	  restoration	  of	  blood	  glucose	  concentrations	  to	  their	  normal	  level.	  	  	  	  
1.1.3.	  Adipose	  tissue	  Adipose	   tissue	   is	   a	   storage	   depot	   for	   triglyceride	   (TG)	   but	   also	   has	   functional	  relevance	  within	  the	  context	  of	  energy,	  and	  glucose,	  homeostasis	  (53).	  Adipose	  tissue	  is	  regarded	  as	  an	  efficient	  buffer	  for	  substrate	  (and	  in	  particular	  fatty	  acid	  (FA))	  flux	  during	   postprandial	   periods	   (53).	   Insulin	   contributes	   to	   this	   buffering	   action	   via	  suppression	  of	  lipolysis	  and	  reduced	  mobilisation	  of	  FAs	  from	  adipose	  tissue	  (53).	  A	  reduction	   in	   circulating	   FA	   levels	   will	   cause	   a	   switch	   towards	   carbohydrate	  metabolism	   based	   on	   fuel	   availability.	   This	   switch	   in	   fuel	   utilisation	   creates	   a	  concentration	   gradient	   for	   glucose	   uptake	   into	   skeletal	   muscle	   and	   liver	   as	   more	  glucose	   is	  being	  oxidised	  within	   the	   cell.	  Thus,	   insulin	  action	  on	  adipose	   tissue	  will	  promote	  glucose	  uptake	  into	  tissue.	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B.	  Insulin	  resistant	  state	  
	  
	  
Figure	   1.2	   Insulin	   signalling	   pathway	   in	   an	   insulin-­‐sensitive	   state	   (A)	   and	   insulin-­‐resistant	   state	  (B).	  Broken	  lines	  indicate	  membrane	  translocation,	  arrows	  denote	  phosphorylation	  and	  flat-­‐ended	  lines	   denote	   inhibition	   of	   phosphorylation.	   With	   an	   increase	   in	   cellular	   DAGs	   and	   ceramides,	  functional	   phosphorylation	   of	   key	   signalling	   intermediates	   including	   IRS-­‐1	   and	   PKB	   is	   reduced.	  Reduced	  phosphorylation	  of	  these	  signalling	  proteins	  results	  in	  impaired	  glucose	  uptake.	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1.2.	  Insulin	  resistance	  Defects	   in	   insulin	  action	  are	  different	  between	   type	  1	  diabetes	   (T1D)	  and	  T2D.	  The	  inability	   to	   produce	   enough	   insulin	   is	   a	   key	   feature	   of	   T1D	   (54),	   whereas	   T2D	  sufferers	  are	  able	  to	  produce	  sufficient	  insulin	  but	  are	  unable	  to	  effectively	  respond	  to	  this	  insulin	  stimulus	  (35).	  The	  failure	  of	  key	  organs	  to	  respond	  effectively	  to	  normal	  circulating	   levels	   of	   insulin	   is	   termed	   insulin	   resistance	   (8,9).	  An	   effort	   to	  maintain	  euglycaemia	   in	   the	   early	   stages	   of	   insulin	   resistance	   development	   is	   made	   by	  increasing	  insulin	  secretion	  from	  the	  pancreas	  (8).	  However,	  following	  this	  period	  of	  compensated	   insulin	  resistance,	  glucose	  uptake	   is	   impaired	  despite	  elevated	   insulin	  secretions	  (8).	  For	   these	  reasons,	  hyperinsulinemia	  and	  /	  or	  hyperglycaemia	  reflect	  an	  insulin-­‐resistant	  state.	  	  	  The	  mechanism	  by	  which	  glucose	  uptake	   is	   impaired	   in	   insulin-­‐resistant	  states	  was	  widely	   investigated	   in	   the	   1990s.	   Glycogen	   synthesis	   plays	   a	  major	   role	   in	   glucose	  metabolism	   in	   the	   postprandial	   state,	   and	   is	   the	   primary	   driver	   of	   glucose	   uptake	  (55–57).	   However,	   glycogen	   synthesis	   is	   impaired	   in	   T2D	   (58,59)	   and	   is	   largely	  responsible	  for	  the	  associated	  insulin	  resistance-­‐mediated	  hyperglycaemia	  (55).	  The	  rate	  of	  muscle	  glycogen	  synthesis	  is	  regulated	  by	  glycogen	  synthase	  activity	  (60,61),	  hexokinase	   II	   activity	   (62–64)	   and	   glucose	   transport	   (65).	   Glucose	   transport	   is	  considered	  the	  primary	  rate	  limiting	  step	  for	  glycogen	  synthesis	  (55,66–68).	  Glucose	  transport	   is	   limited	   by	   insulin	   signal	   transduction	   and	   thus	   the	   responsiveness	   of	  peripheral	  tissue	  to	  elevated	  insulin	  levels	  (9,35,44,65,69).	  	  	  Impaired	   insulin	   signal	   transduction	   in	   insulin-­‐resistant	   states	   is	   largely	  characterised	  by	  a	  blunted	  phosphorylation	  of	  key	  kinases	  within	  the	  pathway	  (see,	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Figure	   1.2B).	   Reduced	   tyrosine	   phosphorylation	   of	   IRS-­‐1	   (and	   increased	  dysfunctional	  serine	  /	  threonine	  phosphorylation)	  (70),	  reduced	  PI3K	  activation	  (71)	  and	   reduced	   PKB	   phosphorylation	   (72,73)	   are	   all	   consistent	   features	   of	   insulin	  resistance	   /	   T2D.	   Reductions	   in	   phosphorylation	   of	   these	   kinases,	   indicative	   of	  protein	   activation	   in	   this	   instance,	   result	   in	   impaired	   insulin	   signal	   transduction,	  reduced	  GLUT4	  translocation	   to	   the	  plasma	  membrane	  and	  reduced	  glucose	  uptake	  into	  the	  cell.	  	  	  The	  mechanisms	   regulating	  defective	  phosphorylation	  of	   kinases	  within	   the	   insulin	  signalling	   cascade	   are	   multifactorial.	   However,	   lipid	   metabolism	   is	   considered	   a	  major	   player	   in	   the	   (dys)regulation	   of	   these	   proteins	   (37,50,74–76).	   Excess	   energy	  and	  lipid	  intake	  is	  associated	  with	  an	  accumulation	  of	   lipid	  derivative	  intermediates	  that	  downregulate	   insulin	   signalling	  protein	   activation	   (77).	  These	   lipid	  derivatives	  include	   diacylglycerol	   (DAG),	   long-­‐chain	   fatty	   acyl-­‐CoA	   (LCFA-­‐CoA)	   and	   the	  sphingolipid,	   ceramide	   (78).	   DAGs	   and	   ceramides	   are	   probably	   the	   most	   widely	  investigated	  lipid	  derivatives	  within	  the	  context	  of	  insulin	  resistance,	  and	  herein,	  will	  form	  the	  basis	  for	  discussion	  of	  lipid-­‐mediated	  insulin	  resistance.	  	  Insulin	   resistance	   is	   associated	   with	   elevated	   skeletal	   muscle	   TG	   levels	   (79,80).	  However,	  high	  TG	   levels	  also	  are	  regularly	  observed	   in	  highly	   trained	  athletes	   (79),	  creating	   what	   is	   termed	   the	   athlete’s	   paradox.	   This	   paradoxical	   finding	   was	   a	   key	  factor	   leading	  to	  early	   investigations	   into	  the	  role	  of	  DAGs	   in	   insulin	  resistance	  as	  a	  way	  to	  explain	  (dysfunctional)	  high	  TG	  levels	  in	  the	  insulin-­‐resistant	  state	  (81).	  DAG	  synthesis	  occurs	  synonymously	  with	  TG	  synthesis,	   thus	   increases	   in	  both	  DAGs	  and	  TGs	  are	   common	   traits	  of	   insulin	   resistance	   (80,81).	  Moreover,	  DAGs	  are	  known	   to	  
Chapter	  1:	  General	  Introduction	   15	  
	  	  
allosterically	   activate	   protein	   kinase	   C	   (PKC)	   isoforms	   involved	   in	   serine	  phosphorylation	   of	   IRS-­‐1	   and	   thus	   impaired	   insulin	   signal	   transduction	   (81).	  Using	  lipid	   /	   heparin	   infusion	  methodology	   in	   healthy	   humans,	   Itani	   and	   colleagues	   (81)	  demonstrated	   an	   increase	   in	   skeletal	   muscle	   DAG	   content	   and	   PKC	   activity,	  concomitant	   with	   reduced	   insulin	   sensitivity	   (81).	   Moreover,	   in	   vitro	   data	  demonstrated	   a	   SFA-­‐mediated	   increase	   in	   DAG	   content	   in	   human	   (82)	   and	  mouse	  myotubes	   (83).	   These	   increases	   in	   DAG	   content	   occurred	   in	   combination	   with	  impaired	  insulin-­‐stimulated	  glucose	  uptake	  (82)	  and	  inhibition	  of	  insulin-­‐stimulated	  GSK-­‐3β	  and	  PKB	  phosphorylation	  (83).	  Taken	  together,	  skeletal	  muscle	  DAG	  content	  inversely	   associates	  with	   insulin	   sensitivity,	   perhaps	   at	   the	   level	   of	   IRS-­‐1	   and	   /	   or	  PKB.	  	  	  Ceramides	  are	  another	  lipid	  derivative	  involved	  in	  insulin	  resistance.	  Ceramides	  are	  synthesised	   via	   two	   primary	   pathways	   including	   de	   novo	   synthesis	   from	   palmitate	  and	  recycling	  of	  sphingosine	  via	  the	  salvage	  pathway,	  catalysed	  by	  ceramide	  synthase	  (84).	  Ceramide	   synthesis	   is	   regulated	  by	  adipokine	   concentrations,	   SFA	  availability,	  inflammation	  and	  endoplasmic	  reticulum	  stress	  (84,85).	  Ceramide	  action	  is	  primarily	  through	  the	  secondary	  intermediates	  PKCζ	  and	  protein	  phosphatase	  2A	  (PP2A)	  which	  dephosphorylate	   PKB	   (84–87),	   resulting	   in	   decreased	   distal	   insulin	   action	   and	  reduced	   glucose	   uptake	   into	   the	   cell	   (84,85).	   Considering	   impaired	   glucose	   uptake	  into	  tissue	  is	  a	  hallmark	  of	  T2D,	  recent	  attention	  has	  been	  afforded	  to	  ceramides	  in	  an	  endeavour	  to	  better	  understand	  the	  development	  of	  insulin	  resistance.	  	  	  
Intramuscular	  ceramide	  levels	  have	  been	  implicated	  in	  T2D	  pathology	  with	  increased	  skeletal	   muscle	   ceramide	   levels	   observed	   in	   obese,	   insulin-­‐resistant	   individuals	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compared	   to	   controls	   (72,88).	  Moreover,	   data	   from	   in	  vitro	  work	  highlight	   a	   causal	  relationship	   between	   increased	   ceramide	   levels	   and	   insulin	   resistance.	   Palmitate-­‐induced	  ceramide	  production	  causes	  inhibition	  of	  insulin	  signalling	  at	  the	  level	  of	  PKB	  (reduced	   phosphorylation)	   (89)	   in	   a	   dose-­‐dependent	  manner	   (87).	   Ceramides	   now	  are	   commonly	   associated	   with	   human	   insulin	   resistance	   (77,90,91).	   Whereas	   the	  action	   of	   ceramides	   is	   on	   proteins	   more	   distal	   to	   those	   inhibited	   by	   DAGs,	   the	  resultant	  outcome	  of	  decreased	  glucose	  uptake	   is	   the	  same	  with	   increases	   in	  either	  lipid	   derivative.	   Thus,	   lipid	   metabolism	   is	   a	   key	   area	   of	   investigation	   for	   studies	  designed	  to	  unravel	  mechanisms	  of	  insulin	  resistance	  development.	  	  	  
1.3.	  High	  fat	  feeding	  -­‐	  Impact	  of	  energy	  excess	  on	  insulin	  signalling	  Given	  that	  chronic	  overfeeding	  is	  a	  key	  stimulus	  for	  the	  development	  of	  obesity	  and	  insulin	  resistance,	   investigation	  of	   the	  early	  adaptive	  responses	  to	  short-­‐term,	  high-­‐fat	   energy	   excess	   (HFEE)	  may	   help	   inform	   the	   basis	   for	   T2D	   progression.	   Chronic	  overfeeding	   is	   associated	   with	   elevated	   circulating	   FFA	   and	   TG	   levels	   (92,93).	  Historically,	   elevated	   lipid	   levels	   were	   thought	   to	   impair	   glycolytic	   carbohydrate	  metabolism	   via	   inhibition	   of	   phosphofructokinase	   (94,95).	   Reduced	   glycolytic	   flux	  inhibits	   glucose	   metabolism	   and	   results	   in	   a	   concentration	   gradient	   that	   is	   not	   in	  favour	  of	  glucose	  uptake.	  This	  concept	  was	  coined	  the	  Randle	  Cycle	  after	  work	  by	  Sir	  Phillip	   Randle	   and	   colleagues	   in	   the	   1960s	   (94,95).	   Specifically,	   their	   research,	  conducted	  in	  heart	  and	  skeletal	  muscle	  preparations,	  demonstrated	  that	  an	  increase	  in	   circulating	   FAs	   (e.g.	   from	   fat	   consumption	   or	   increased	   adipose	   tissue	   lipolysis)	  leads	   to	   an	   accumulation	   of	   acetyl-­‐CoA	   and	   citrate	   (from	   elevated	   rates	   of	   fat	  oxidation	  via	  Krebs	  Cycle	  metabolism).	  Raised	  levels	  of	  acetyl-­‐CoA	  and	  citrate	  cause	  a	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concentration	  gradient	   to	  develop	  whereby	  an	  excess	  of	   these	  products	   inhibits	   the	  catalysing	   activities	   of	   pyruvate	   dehydrogenase	   and	   phosphofructokinase,	  respectively.	  Inhibition	  of	  these	  enzymes	  reduces	  glycolytic	  flux	  resulting	  in	  a	  build-­‐up	   of	   glucose-­‐6-­‐phosphate	   inside	   the	   cell.	   Another	   high	   product	   concentration	  gradient	   is	   created	   from	   increased	  glucose-­‐6-­‐phosphate	   levels,	   resulting	   in	   reduced	  activity	   of	   hexokinase	   and	   limiting	   glucose	   uptake	   into	   the	   cell.	   Limited	   glucose	  uptake	   into	   the	   cell	   results	   in	   a	   state	   of	   hyperglycaemia;	   one	   of	   the	   defining	  characteristics	   of	   insulin	   resistance	   and	   T2D	   (8).	   Thus,	   based	   on	   this	   mechanism,	  carbohydrate	  metabolism	  can	  be	  regulated	  by	  fat	  metabolism.	  	  These	   studies	  performed	  by	  Randle	  et	  al.	   (94,95)	  were	  devised	  on	   the	   concept	   that	  metabolically	  active	  tissues,	  such	  as	  cardiac	  and	  skeletal	  muscle,	  have	  the	  capacity	  to	  readily	   switch	   between	   carbohydrate	   and	   fat	  metabolism	  depending	   on	   the	   energy	  status	  of	  the	  cell	  (96).	  Whereas	  Randle	  and	  colleagues	  focussed	  much	  of	  their	  work	  on	  the	  metabolic	  switch	  to	  fat	  oxidation,	  the	  opposite	  switch	  (i.e.	  from	  fat	  metabolism	  to	  carbohydrate	   metabolism)	   also	   occurs.	   Mechanisms	   associated	   with	   increased	  carbohydrate	  metabolism	   can	   lead	   to	   an	   inhibition	   of	   fat	  metabolism.	   For	   example,	  increased	   glucose	   metabolism	   has	   been	   linked	   to	   elevated	   levels	   of	   malonyl-­‐CoA	  within	   the	   cell	   (96).	   Malonyl-­‐CoA	   is	   carboxylated	   from	   acetyl-­‐CoA	   by	   acetyl-­‐CoA	  carboxylase	   (ACC)	   (96).	   Malonyl-­‐CoA	   is	   a	   potent	   inhibitor	   of	   carnitine	  palmitoyltransferase	   (CPT)-­‐1	   activity;	   a	  major	   control	   point	   in	   the	   transport	   of	   fats	  into	  the	  mitochondria	  for	  oxidation	  (96).	  LCFA-­‐CoAs	  will	  accumulate	  intramuscularly	  in	  the	  absence	  of	  β-­‐oxidation	  (medium	  chain	  lengths	  can	  enter	  the	  mitochondria	  for	  oxidation	  without	   the	  need	   for	   transporter	  proteins	   (97))	   and	  FAs	  will	   be	  diverted	  towards	   esterification	   (96).	   This	   increased	   FA	   environment	   and	   drive	   towards	   FA	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1.4.	  Impact	  of	  n-­‐3	  PUFAs	  on	  insulin	  sensitivity	  	  Given	   the	   current	   global	   T2D	   prevalence	   rates,	   strategies	   that	   prevent	   or	   slow	  associated	   declines	   in	   insulin	   sensitivity	   are	   clearly	   attractive	   for	   the	   mass	  population.	  One	  such	  dietary	  strategy	  is	  consumption	  of	  n-­‐3	  PUFAs.	  Data	  are	  starting	  to	   accumulate	   regarding	   the	   efficacy	   of	   n-­‐3	   PUFA	   intake	   for	   reducing	   metabolic	  disease	  risk.	  	  	  n-­‐3	  PUFAs	  are	  a	  class	  of	  polyunsaturated	  fatty	  acids	  that	  have	  a	  double	  bond	  located	  on	  the	  third	  carbon	  from	  the	  methyl	  end	  of	  the	  fatty	  acyl	  chain	  (23).	  The	  n-­‐3	  PUFA,	  α-­‐linolenic	  acid	  (ALA;	  C18:3n-­‐3)	  is	  an	  essential	  FA	  (23)	  and	  is	  used	  as	  substrate	  for	  the	  synthesis	   of	   other	   n-­‐3	   PUFAs,	   including	   the	   highly	   metabolically	   active	  eicosapentaenoic	   acid	   (EPA;	   C20:5n-­‐3)	   and	   docosahexaenoic	   acid	   (DHA;	   C22:6n-­‐3)	  (23).	  Despite	  these	  synthetic	  pathways,	  dietary	  ingestion	  remains	  the	  primary	  source	  of	   EPA	   and	   DHA.	   Oily,	   pelagic	   fish,	   including	   salmon,	   mackerel	   and	   trout	   are	   key	  dietary	   sources	  of	  EPA	  and	  DHA	   (117).	  Thus,	   fish	  oil	   (FO)	   is	  often	  used	   to	   increase	  consumption	  of	  n-­‐3	  PUFAs.	  	  	  EPA	  and	  DHA	  synthesis	  from	  ALA	  occurs	  primarily	  in	  the	  liver	  and	  involves	  a	  series	  of	  desaturation	  and	  elongation	  reactions	  (23).	  The	  rate	  of	  EPA	  and	  DHA	  synthesis	  from	  ALA	   is	   limited	  by	   the	  availability	  of	  Δ6-­‐desaturase;	  an	  enzyme	   that	   is	   competitively	  used	  in	  the	  synthesis	  of	  longer	  chain	  n-­‐6	  PUFAs	  (e.g.	  arachidonic	  acid	  (AA;	  C20:4n-­‐6))	  from	   linoleic	   acid	   (23).	  Due	   to	   this	   enzyme	  competition,	   the	  n-­‐3	   class	  of	  PUFAs	  are	  often	  considered	  in	  combination	  with	  n-­‐6	  PUFAs.	  A	  high	  ratio	  of	  consumed	  n-­‐6	  PUFAs	  to	  n-­‐3	  PUFAs	  (n-­‐6/n-­‐3)	  is	  commonly	  observed	  in	  Western	  societies	  and	  is	  associated	  with	  disease	  risk	  (118).	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  Epidemiological	  data	  provide	  rationale	  for	  the	  potential	  protective	  effects	  of	  high	  n-­‐3	  PUFA	  consumption	  on	  CV	  disease.	  Historically,	  high	  intake	  of	  n-­‐3	  PUFAs,	  for	  example,	  from	   whale	   and	   seal	   blubber	   routinely	   consumed	   by	   Inuit	   populations,	   was	  associated	   with	   lower	   CV	   disease	   prevalence	   within	   this	   population	   (24,119–121).	  However,	  it	  must	  be	  acknowledged	  that	  traditional	  Inuit	  populations	  also	  had	  highly	  physically	   active	   lifestyles	   (122);	   the	   benefits	   of	   which	   cannot	   easily	   be	   discerned	  from	  their	  dietary	  habits.	  Nonetheless,	  data	  are	  beginning	  to	  accumulate	  from	  other	  populations	   in	  support	  of	   the	   inverse	  relationship	  between	  n-­‐3	  PUFA	  intake	  and	  CV	  mortality	  (24,123–125).	  Moreover,	  pathologies	  including	  cancer,	  neurodegeneration,	  and	   autoimmune	   diseases	   have	   been	   associated	   with	   a	   high	   n-­‐6/n-­‐3	   ratio	  (23,118,126),	   suggesting	   increased	   n-­‐3	   PUFA	   intake	  may	   be	   protective	   against	   the	  development	  of	  these	  disorders.	  Whereas	  associative	  epidemiological	  data	  are	  largely	  in	   support	   of	   the	   benefits	   of	   n-­‐3	   PUFA	   for	   a	   host	   of	   pathologies	   (23),	   randomised	  controlled	  trials	  are	  less	  clear	  (reviewed	  in	  (127))	  and	  the	  mechanisms	  behind	  any	  n-­‐3	  PUFA-­‐mediated	  effects	  still	  require	  a	  degree	  of	  clarity.	  	  Dietary	   or	   supplemental	   n-­‐3	   PUFA	   intake	   is	   reflected	   by	   increased	   n-­‐3	   PUFA	  composition	  of	   the	  erythrocyte	   (128,129),	  adipocyte	   (130),	  and	  myocyte	   (128,131);	  although	  the	  temporal	  incorporation	  of	  n-­‐3	  PUFA	  differs	  between	  tissues	  (130).	  The	  intracellular	   lipid	   environment,	  which	   is	   largely	   reflective	   of	   dietary	   lipid	   intake,	   is	  closely	  matched	   to	   the	   composition	   of	   cell	   membranes	   (132).	   Thus,	   increasing	   the	  amount	  of	  n-­‐3	  PUFAs	  in	  the	  diet	  increases	  their	  proportion	  within	  the	  cell	  membrane	  (130).	  This	  alteration	  is	  often	  at	  the	  expense	  of	  n-­‐6	  PUFAs,	  particularly	  the	  n-­‐6	  PUFA,	  AA.	  The	   incorporation	  of	  n-­‐3	  PUFAs	   into	  cell	  membrane	  phospholipids	   is	  purported	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to	   alter	  membrane	   function	   and	   signalling	   (133–135).	   The	   kinked	  nature	   of	   the	   FA	  side-­‐chain	   due	   to	  multiple	   unsaturated	   bonds	   renders	   the	   phospholipid	  membrane	  more	   permeable	   due	   to	   gaps	   between	   adjoining	   lipids	   (136).	   In	   contrast,	   a	   highly	  saturated	   cell	  membrane	   is	   tightly	   packed	  with	   limited	   space	   in	   between	   lipids	   for	  cell	  endocytosis	  and	  exocytosis	  (136).	  Thus,	  n-­‐3	  PUFA	  intake	  may	  result	  in	  preferable	  membrane	  composition	  for	  cell	  signalling.	  	  
	  Increased	  consumption	  of	  n-­‐3	  PUFAs	  results	  in	  several	  other	  pleiotropic	  adaptations,	  additional	   to	   increased	   membrane	   permeability.	   These	   adaptations	   include	   a	  decreased	  production	  of	  prostaglandins,	  reduced	  inflammation,	  and	  reduced	  platelet	  formation	  (25).	  	  Obesity	  and	  T2D	  are	  characterised	  by	  low-­‐grade	  inflammation	  (137),	  which	   is	   associated	   with	   accumulation	   of	   intramyocellular	   lipids	   (138).	   Acute	  inflammation	   is	   a	   well-­‐adapted,	   protective	   response.	   However,	   the	   chronic	  inflammation	   that	   is	   characteristic	   of	   many	   pathologies	   including	   T2D	   is	  dysfunctional	   (139,140).	   Several	   studies,	   therefore,	   have	   investigated	   the	   anti-­‐inflammatory	   effects	   of	   n-­‐3	   PUFAs	   for	   effectively	   counteracting	   the	   inflammation-­‐associated	  pathology	  of	  insulin	  resistance.	  	  	  The	  anti-­‐inflammatory	  effects	  of	  n-­‐3	  PUFAs	  are	  manifested	  in	  eicosanoid	  metabolism.	  Eicosanoids	   are	   generated	   from	   both	   n-­‐3	   and	   n-­‐6	   PUFAs	   and	   their	   metabolism	  impacts	   inflammatory	   /	   immune	   responses	   (137).	   Substrate	   competition	   exists	  between	   the	   n-­‐3	   PUFAs,	   EPA	   and	   DHA,	   and	   the	   n-­‐6	   PUFA,	   AA	   (137).	   Generally,	  eicosanoids	  produced	  from	  EPA	  and	  DHA	  have	  anti-­‐inflammatory	  actions,	  compared	  to	   the	   pro-­‐inflammatory	   tendencies	   of	   eicosanoids	   generated	   from	  AA	   (137).	   Since	  dietary	  intake	  of	  n-­‐3	  PUFAs	  results	  largely	  in	  a	  displacement	  of	  AA	  within	  the	  plasma	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membrane,	  n-­‐3	  PUFA	  intake	  may	  be	  a	  viable	  strategy	  for	  increasing	  the	  production	  of	  anti-­‐inflammatory	   lipid	   mediators	   (137).	   With	   an	   increased	   production	   of	   anti-­‐inflammatory	   lipid	   mediators	   including	   resolvins	   and	   protectins,	   the	   low-­‐grade	  inflammation	  associated	  with	  the	  insulin-­‐resistant	  state	  may	  be	  effectively	  overcome	  and	  insulin	  sensitivity	  improved.	  	  	  N-­‐3	  PUFA	  consumption	  has	  been	  associated	  with	   reductions	   in	   circulating	  TGs.	   For	  many	   years,	   obesity	   and	   insulin	   resistance	   have	   been	   positively	   associated	   with	  circulating	  TG	  and	  FA	   levels	   (74,92,93,100),	  although	   this	   finding	   is	  now	  somewhat	  contentious	   (141).	  Moreover,	   following	   acute	   lipid	   emulsion	   and	   heparin	   infusions,	  circulating	   FA	   concentrations	   are	   increased	   with	   concomitant	   declines	   in	   insulin	  sensitivity	   (101).	   Thus,	   strategies	   to	   reduce	   circulating	   fat	   levels	   may	   be	   effective	  targets	   for	   reducing	   T2D	   risk	   /	   prevalence.	   Concentrations	   of	   circulating	   TGs	   are	  reduced	   with	   consumption	   of	   ‘practical’	   n-­‐3	   FA	   doses	   in	   patients	   with	  hypertriglyceridemia	   (142,143)	   and	   healthy	   controls	   (143).	   Moreover,	   associative	  epidemiological	  (21)	  and	  experimental	  (reviewed	  in	  (144))	  data	  lend	  support	  to	  the	  insulin-­‐sensitising	  effects	  of	  n-­‐3	  PUFA	   intake.	  Although	   in	  T2D,	   supplementing	  with	  varying	  FO	  doses	  does	  not	  improve	  glycaemic	  control	  (145).	  The	  mechanistic	  action	  of	   n-­‐3	   PUFA-­‐mediated	   TG	   lowering	   effects	   is	   likely	   related	   to	   increased	   basal	   fat	  oxidation	  (146)	  and	  altered	  lipoprotein	  metabolism	  (144);	  perhaps	  regulated	  by	  the	  PPAR	  family	  of	  transcription	  factors	  (23).	  Thus,	  several	  mechanisms	  may	  contribute	  to	  reductions	  in	  TGs	  with	  FO	  intake.	  	  Studies	  investigating	  the	  influence	  of	  n-­‐3	  PUFA	  intake	  on	  insulin	  sensitivity	  markers	  within	   the	  context	  of	  short-­‐term	   lipid	  and	  /	  or	  energy	  supply	  are	   limited.	  However,	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some	   preliminary	   indications	   exist	   regarding	   the	   potential	   benefits	   of	   n-­‐3	   PUFA	  intake	  during	  energy	  surplus.	   In	  a	   crossover	   study	  by	  Turvey	  et	  al.	  (147),	  oxidative	  CHO	  enzyme	  activities	  were	  increased	  with	  HF	  overfeeding,	  but	  attenuated	  with	  n-­‐3	  PUFA	   supplementation	   in	   the	   absence	   of	   changes	   in	   glucose	   /	   insulin	   profiles.	   In	  another	   study	   of	   crossover	   design,	   Faeh	   and	   colleagues	   (148)	   demonstrated	   no	  insulin-­‐sensitising	  effect	  of	  FO	  when	  combined	  with	  fructose	  and	  energy	  oversupply.	  However,	   fractional	   hepatic	   de	   novo	   lipogenesis	   was	   reduced	   by	   ~20	   %	   with	   FO	  (although	  not	  significant).	  Taken	  together,	  some	  FO-­‐mediated	  protective	  mechanisms	  may	  exist,	  that	  although	  not	  translated	  into	  preservation	  of	  insulin	  sensitivity,	  may	  be	  beneficial	   for	   long-­‐term	  metabolic	  disease	  risk.	  Although	  by	  no	  means	  conclusive	  at	  this	   stage,	   such	   dietary	   manipulation	   warrants	   consideration	   when	   we	   consider	  typical	  Western	  lipid-­‐rich	  dietary	  habits.	  	  	  
1.5.	  Epigenetics	  -­‐	  Impact	  of	  epigenetics	  on	  insulin	  signalling	  Development	   of	   T2D	   is	   underpinned	   by	   both	   genetic	   predisposition	   and	  environmental	  influence.	  The	  influence	  of	  our	  environment,	  including	  global	  changes	  in	   food	   availability	   and	   consequent	   energy	   overconsumption	   and	   increasing	  sedentary	  behaviours,	  has	  been	  discussed	  in	  detail	  throughout	  this	  chapter.	  However,	  the	  role	  of	  genetics,	  and	  in	  particular	  epigenetics,	  requires	  further	  attention.	  	  	  	  Genetic	   familial	   studies	  conducted	   in	   the	  1980s	  by	  Claude	  Bouchard	  and	  colleagues	  revealed	   that	   genetic	   heritability	   accounted	   for	   ~25	  %	   of	   the	   variance	   in	   body	   fat	  percentage	   and	   absolute	   fat	   mass	   between	   individuals	   (149,150).	   Moreover,	   the	  correlation	   coefficients	   following	   appropriate	   corrections	   between	   monozygotic	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twins	  for	  fat	  mass	  gains	  following	  	  22	  d	  energy	  excess,	  and	  body	  mass	  gains	  following	  	  84	  d	  energy	  excess,	  indicated	  a	  moderate	  contribution	  of	  genetics	  to	  this	  response	  (r	  =	  0.65	  and	  0.51,	  respectively)	  (151,152).	  Whereas	  these	  values	  undoubtedly	  highlight	  the	   significant	   contribution	   of	   genetic	   predisposition	   to	   metabolic-­‐stress	   mediated	  body	   and	   fat	   mass	   gains,	   a	   significant	   proportion	   of	   unaccounted	   variance	   exists.	  Environmental	   influences	   such	   as	   long-­‐term	   dietary	   patterns	   and	   habitual	   physical	  activity	   levels	  are	  obvious	  confounding	  factors.	  However,	  more	  recently,	  epigenetics	  also	   has	   been	   touted	   as	   a	   possible	   explanation	   for	   the	   variation	   in	   individual	  responses	  to	  various	  stimuli.	  	  The	   term	   epigenetics	   was	   coined	   in	   the	   late	   1930s	   when	   Professor	   Conrad	  Waddington	  proposed	  the	  term	  based	  on	  developmental	  theory	  and	  the	  Greek	  word,	  
epigenesis	  in	   relation	   to	  embryonic	  differentiation	   (153,154).	  For	   the	  next	  50	  years,	  biologists	   with	   interests	   in	   genetics	   and	   development	   arguably	   studied	   epigenetic	  mechanisms	   by	   means	   of	   investigating	   various	   processes	   that	   were	   difficult	   to	  interpret	  with	  regard	  to	  genetics	  alone	  but	  had	  clear	  heritable	  traits	  (154).	  However,	  the	   lack	  of	   clarity	   regarding	   the	   essence	  of	   epigenetics,	   and	   the	   associated	  possible	  interpretations,	   meant	   that	   for	   many	   years	   several	   potential	   mechanisms	   went	  undocumented	   or	   were	   not	   considered	   within	   the	   study	   of	   epigenetics	   (154).	  Arguably,	  it	  was	  not	  until	  publication	  of	  a	  paper	  in	  1987	  by	  Professor	  Robin	  Holliday	  (155)	  that	  the	  study	  of	  epigenetics	  emerged	  as	  we	  understand	  it	  today	  (156).	  	  	  Many	   definitions	   of	   epigenetics	   exist	   that	   are	   largely	   indicative	   of	   the	   study	   of	  epigenetics	   spanning	   several	   scientific	   disciplines.	   However,	   probably	   the	   most	  widely	  accepted	  definition	  refers	   to	   the	  study	  of	  epigenetics	  as	  heritable	  changes	   in	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phenotype	   or	   gene	   expression	   that	   occur	   in	   the	   absence	   of	   changes	   in	   the	   DNA	  sequence	   (e.g.	   (29)).	   Epigenetic	   regulatory	   mechanisms	   include	   DNA	   methylation,	  histone	  modification	  and	  miRNA	  regulation	  (157).	  However,	  for	  the	  purposes	  of	  this	  thesis,	  the	  focus	  will	  be	  on	  miRNA	  regulation.	  
	  
	  
1.5.1.	  miRNAs	  Completion	  of	  the	  human	  genome	  project	  lead	  to	  the	  realisation	  that	  the	  vast	  majority	  of	   our	   genome	   sequence	   contains	   non-­‐coding	   material	   (158).	   Evolutionary	  conservation	   of	   these	   non-­‐coding	   sections	   suggests	   a	   level	   of	   functional	   relevance.	  MiRNAs	   are	   short-­‐stranded,	   non-­‐coding	   RNA	   that	   have	   received	   a	   large	   amount	   of	  research	  attention	  in	  recent	  years	  following	  their	  discovery	  in	  1993	  (159)	  and	  in	  light	  of	   the	   outcomes	   from	   the	   human	   genome	   project.	   Although	   the	   exact	   cellular	  functions	  of	  the	  majority	  of	  miRNAs	  are	  largely	  unknown,	  it	  is	  estimated	  that	  miRNAs	  may	   target	   up	   to	   a	   third	   of	   all	   genes,	   and	   that	   each	  miRNA	  may	   act	   on	   up	   to	   200	  messenger	   RNA	   (mRNA)	   (160).	   Thus,	   it	   seems	   clear	   that	   non-­‐coding	   material	   has	  functional	   relevance	   and	   may	   be	   involved	   in	   the	   adaptive	   regulation	   of	   gene	  expression.	  	  	  MiRNA	  biogenesis	  and	  processing	  has	  been	  described	  in	  detail	  elsewhere	  (28,30,31)	  and	   is	   depicted	   in	  Figure	   1.3.	   The	   process	   of	  miRNA	   biogenesis	   begins	  within	   the	  nucleus	   of	   the	   cell	   as	   long	  nucleotide	   sequence	  primary-­‐miRNAs	   (pri-­‐miRNAs)	   that	  have	  been	  transcribed	  from	  miRNA	  genes	  by	  RNA	  polymerase	  II	  or	  III	  (30).	  These	  pri-­‐miRNA	  transcripts	  are	  cleaved	  by	  the	  Microprocessor	  complex,	  involving	  Drosha	  and	  its	  binding	  partner	  DGCR8,	  into	  ~70	  nucleotide	  hairpin-­‐structure	  miRNA	  precursors	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(pre-­‐miRNA)	   (28).	  Exportin	  5	   transports	   the	  pre-­‐miRNAs	   from	  the	  nucleus	   into	   the	  cytoplasm	   where	   Dicer	   and	   its	   binding	   partner,	   transactivation-­‐responsive	   RNA-­‐binding	   protein	   (TRBP),	   cleaves	   the	   pre-­‐miRNAs	   into	   short	   (~22	   nucleotide)	  imperfect	  double-­‐stranded	  RNA	  duplexes	  (161).	  Each	  duplex	  consists	  of	   the	  mature	  miRNA	  and	  a	  complementary	  strand.	  The	  mature	  miRNA	  strand	  (and	  in	  rare	  cases	  the	  complementary	   strand)	   is	   incorporated	   into	   the	   RNA-­‐induced	   silencing	   complex	  (RISC)	  for	  action	  on	  target	  mRNAs	  (161).	  	  MiRNAs	   incorporated	  within	   the	  RISC	  alter	  gene	  expression	  via	   two	  mechanisms;	   i)	  inhibition	   of	   translation	   initiation	   of	   nascent	   mRNA	   transcripts	   and	   /	   or	   ii)	  degradation	  of	  mRNA	  (31).	  The	  resultant	  effect	  of	  one	  or	  both	  of	   these	  processes	   is	  reduced	  expression	  of	  genes	  encoded	  by	  the	  targeted	  mRNA	  transcripts.	  However,	  in	  a	  handful	  of	   cases	  miRNAs	  activate	  mRNAs	   rather	   than	   repressing	   their	   translation	  (162,163).	   Thus,	   depending	   on	   the	   gene	   target,	   an	   increase	   in	   miRNA	   levels	   can	  increase	   or	   decrease	   the	   relative	   protein	   expression	   and	   thus	   increase	   or	   decrease	  flux	   through	   the	   pathway.	   These	   regulatory	   functions	   by	   miRNAs	   are	   integral	   for	  ‘normal’	  whole-­‐body	  metabolic	  regulation	  (32).	  Altered	   levels	  of	  miRNAs	  have	  been	  shown	  in	  a	  variety	  of	  disease	  states	  (33,164,165),	  lending	  support	  to	  the	  notion	  that	  miRNAs	   may	   be	   useful	   biomarkers	   of	   disease	   and	   are	   likely	   important	   in	   health	  maintenance	  and	  adaptations	  to	  diet	  /	  nutrition.	  	  	  
Chapter	  1:	  General	  Introduction	   31	  
	  	  
	  	  MiRNAs	   exert	   their	   function	   on	  mRNA	   transcripts	  within	   tissue.	  However,	   in	   2008,	  miRNAs	   were	   discovered	   at	   stable	   levels	   within	   the	   circulation	   (166,167).	   Their	  presence	   within	   plasma	   is	   considered	   possible	   due	   to	   incorporation	   into	   secreted	  exosomes,	   co-­‐localisation	   with	   RISC	   or	   via	   binding	   to	   lipoproteins;	   preventing	  degradation	   by	  RNases	   (32,168–170).	   Rather	   than	  non-­‐specific	   release	   from	   tissue,	  miRNAs	   are	   actively	   secreted	   into	   the	   circulation	   (171,172).	   Not	   all	   tissue	  miRNAs	  exist	   in	   plasma	   and	   miRNAs	   present	   within	   secreted	   exosomes	   exist	   in	   different	  proportions	  to	  those	  in	  their	  cell	  type	  of	  origin	  (171).	  Moreover,	  plasma	  miRNAs	  are	  now	   considered	   as	   communicators,	   rather	   than	  merely	   passive	  markers,	   of	   cellular	  processes	   and	   thus	   may	   have	   regulatory	   roles	   in	   normal	   physiology	   and	   disease	  
	  
Figure	   1.3	   Process	   of	  miRNA	   biogenesis	  within	   the	   cell,	   adapted	   from	   (288).	  miRNA	   biogenesis	  begins	  within	   the	  nucleus	  of	   the	   cell.	   Processing	   of	   the	  pri-­‐miRNA	   and	   pre-­‐miRNA	   strands	   in	   the	  nucleus	  is	  followed	  by	  exportation	  of	   the	  pre-­‐miRNA	  strand	  into	  the	  cytoplasm	  via	  Exportin.	  Once	  within	  the	  cytoplasm,	  the	  mature	  miRNA	  strand	  is	  synthesised.	  Upon	  binding	  of	  the	  mature	  miRNA	  strand	   to	   a	  mRNA	   strand,	   the	  mRNA	   is	   degraded	   or	   its	   translation	   halted.	   This	   action	   results	   in	  reduced	  protein	  expression	  of	  the	  gene	  encoded	  by	  the	  mRNA	  strand.	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mechanisms	  (32).	  The	  utility	  of	  plasma	  miRNAs	  as	  biomarkers	  of	  disease	  is	  enhanced	  by	  their	  stability	  in	  the	  circulation	  and	  ease	  of	  sampling	  and	  analytical	  processing.	  	  Considering	   the	   multi-­‐tissue	   integrated	   nature	   of	   metabolic	   disease	   pathology,	   the	  notion	  of	  a	  blood-­‐based	  effector	  regulating	  this	  co-­‐ordinated	  response	  is	  an	  intriguing	  one.	   Much	   like	   studies	   into	   tissue	   miRNA	   regulation,	   studies	   investigating	   plasma	  miRNAs	  have	  revealed	  altered	  levels	  in	  disease	  states	  (e.g.	  (33,164,166)).	  To	  date,	  no	  studies	   have	   directly	   compared	   tissue	   miRNA	   levels	   to	   plasma	   miRNA	   levels.	  However,	  whether	  plasma	  miRNAs	  can	  be	  used	  as	  meaningful	  biomarkers	  of	  disease	  may	  be	  largely	  influenced	  by	  their	  association	  with	  tissue	  miRNA	  patterns	  of	  change	  /	  perturbations.	  Thus,	  comparisons	  of	  different	  tissue	  types	  are	  warranted.	  	  	  Given	  the	  mechanistic	  action	  of	  epigenetic	  signatures	  on	  gene	  expression,	  the	  study	  of	  epigenetics	  has	  application	  across	  all	  biological	  disciplines	  and	  is	  now	  being	  studied	  within	   various	   contexts	   as	   a	   means	   to	   better	   understand	   whole-­‐body	   metabolic	  regulation.	  One	  emerging	  area	  of	   research	  within	  epigenetics	   is	   that	  concerning	   the	  interaction	  between	  nutrition	  and	  the	  epigenome	  (173).	  This	   interaction	  appears	  to	  be	  reciprocal	  in	  nature.	  Nutrition	  can	  alter	  the	  epigenome,	  either	  transiently	  or	  over	  the	   lifespan,	   but	   in	   turn,	   the	   epigenome	   regulates	   gene	   expression	   of	   proteins	  involved	  in	  nutrient	  metabolism	  (173,174).	  Dietary	  fats	  have	  been	  implicated	  within	  the	  study	  of	  nutrigenomics	  (173),	  although	  existing	  scientific	  evidence	  is	  limited.	  	  	  Fats,	   and	   particularly	   lipoproteins	   including	   LDL	   and	   HDL,	   have	   been	   widely	  attributed	   to	   the	   transport	   of	   extracellular	   miRNAs	   (169,170,175).	   Moreover,	  nutrigenomics	   has	   advanced	   to	   consideration	   for	   how	   diet-­‐derived	   exogenous	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miRNAs,	   termed	   xenomiRs,	   can	   contribute	   to	   the	   plasma	   miRNA	   pool	   and	   alter	  circulating	   miRNA	   homeostasis	   (175,176).	   An	   increase	   in	   dietary	   lipid	   intake	   may	  enhance	   the	   number	   of	   vehicles	   for	   miRNA	   transport,	   leading	   to	   altered	   miRNA	  kinetics	  entering	  and	   leaving	  the	  cell.	  Moreover,	  miRNAs	  present	  within	  animal	  and	  plant	  matter	  can	  enter	  the	  bloodstream	  following	  digestion,	  and	  assimilate	  with	  the	  existing	   circulating	   miRNA	   pool	   (175).	   Both	   of	   these	   processes	   will	   alter	   plasma	  miRNA	  levels	  and	  are	  important	  considerations	  for	  biomarker	  studies.	  The	  notion	  of	  dietary	  transfer	  of	  genetic	  material	  has	  the	  potential	  to	  completely	  alter	  the	  way	  we	  view	  the	  field	  at	  present;	  however,	  replication	  studies	  (177,178)	  have	  thus	  far	  failed	  to	  support	  the	  initial	  theories	  (175)	  and	  findings	  (176).	  	  Whereas	   the	   concept	   of	   dietary	   miRNA	   transfer	   is	   still	   in	   its	   infancy	   and	   requires	  further	   research	   attention,	   the	   association	   between	   miRNA	   dysregulation	   and	  metabolic	   disease	   is	   well	   established.	   In	   cultured	   cell	   lines	   and	   rodent	   models	   of	  obesity	   and	   T2D,	   miRNAs	   are	   differentially	   expressed	   compared	   to	   controls	  (reviewed	  in	  (179–181)).	  Data	  from	  human	  models	  of	  obesity	  and	  T2D	  are	  consistent	  with	   this	   observation.	   The	   first	   large-­‐scale	   gene-­‐chip	   study	   comparing	   miRNA	  expression	   in	  human	  skeletal	  muscle	  of	  T2D	  and	  controls	  demonstrated	  differential	  expression	  of	  a	  third	  of	  the	  detected	  miRNAs	  (n	  =	  62)	  between	  groups	  (182).	  These	  miRNA	  data	  were	  associated	  with	  a	  targeted	  regulation	  of	  genes	  involved	  in	  relevant	  signalling	   pathways	   (182).	   Two	   more	   recent	   reports	   detailing	   circulating	   miRNA	  levels	   in	   T2D	   compared	   to	   controls	   also	   demonstrate	   altered	   regulation	   with	  metabolic	  disease.	  Ortega	  and	  colleagues	  (164)	  profiled	  a	  panel	  of	  plasma	  miRNAs	  in	  males	   with	   T2D	   or	   normal-­‐glucose	   tolerance	   in	   the	   basal	   and	   insulin-­‐stimulated	  states	  and	  reported	  significant	  differences	  in	  miRNA	  levels	  between	  groups	  that	  were	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modulated	  by	   insulin	  stimulation	  and	  some	  of	  which	  independently	  explained	  up	  to	  50	  %	  of	  the	  variance	  in	  fasting	  plasma	  glucose	  concentrations.	  Analogous	  findings	  are	  described	  by	  Wang	  et	  al.	  (183)	  with	  different	  basal	  circulating	   levels	  of	  miR-­‐24	  and	  miR-­‐29b	   measured	   between	   males	   with	   T2D	   and	   controls.	   Despite	   these	   clear	  indications	  that	  miRNAs	  are	  associated	  with	  obesity	  and	  T2D	  in	  humans,	  the	  miRNA	  response	  to	  a	  short-­‐term	  period	  of	  HFEE	  in	  humans	  is	  unknown.	  	  	  There	   are	   some	   preliminary	   indications	   that	   n-­‐3	   PUFAs,	   like	   obesity	   /	   T2D,	   may	  impact	  miRNA	  profiles.	  The	  n-­‐3	  PUFA,	  DHA,	  has	  been	  shown	  to	  alter	  the	  expression	  of	  miR-­‐192	  and	  miR-­‐30c	  in	  enterocytes	  (184),	  and	  the	  expression	  of	  miR-­‐33a	  and	  miR-­‐122	   in	   dyslipidemic	   obese	   rodents	   (185).	   Moreover,	   n-­‐3	   PUFAs	   appear	   to	   target	   a	  number	   of	   miRNAs;	   altering	   their	   regulation	   of	   cancerous	   colon	   (165)	   and	   breast	  (186)	  tumours.	  Inflammation-­‐related	  dysregulation	  of	  miRNAs	  (187,188)	  also	  may	  be	  an	  area	  in	  which	  n-­‐3	  PUFAs	  have	  mechanistic	  function,	  particularly	  within	  the	  context	  of	   obesity-­‐related,	   low-­‐grade	   inflammation.	   Taken	   together,	   these	   data	   suggest	  potential	  for	  n-­‐3	  PUFA	  dietary	  consumption	  and	  short-­‐term	  responses	  to	  HFEE	  to	  be	  regulated,	  in	  part,	  by	  altered	  miRNA	  profiles.	  	  
1.6.	  Limitations	  of	  existing	  research	  	  It	   is	   clear	   that	   insulin	   action	   is	   impaired	   in	   states	   of	   chronic	   lipid	   oversupply	   and	  insulin	  resistance.	  However,	  the	  conclusions	  drawn	  from	  existing	  research	  outlined	  in	  this	   chapter	   are	   equivocal	   regarding	   the	   impact	   of	   short-­‐term	   HFEE	   on	   insulin	  sensitivity.	   Moreover,	   the	   clinical	   relevance	   of	   n-­‐3	   PUFA	   ingestion	   for	   the	   human	  insulin-­‐resistant	   state	   requires	   clarity.	   Therefore,	   to	   address	   these	   uncertainties,	  investigations	   into	   the	   impact	   of	   diet-­‐induced	   maladaptation	   and	   potential	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amelioration	   by	   dietary	   n-­‐3	   PUFAs	   are	  warranted.	   Specifically,	   investigation	   of	   the	  impact	  of	   increasing	  dietary	  intake	  of	  FO	  within	  the	  context	  of	  elevated	  lipid	  supply	  on	  markers	  of	   insulin	   sensitivity	   is	  of	   interest,	   and	  has	  application	   in	  an	  age	  where	  energy	   and	   lipid	   excess	   is	   increasingly	   common.	   Modest	   modifications	   to	   current	  dietary	   patterns	   have	   the	   potential	   to	   improve	   metabolic	   health	   and	   slow	   the	  alarming	  rate	  of	  T2D	  development.	  	  	  A	   switch	   in	   research	   focus	   to	   that	   of	   individual	   variation	   and	   tailored	   nutrition,	   in	  combination	  with	   a	  more	   common	  blanket	   approach,	  may	  better	   facilitate	   effective	  dietary	   intake	  modifications	  within	   the	  mass	  population.	   Investigation	  of	  epigenetic	  signatures	   of	   metabolic	   disease	   has	   the	   potential	   to	   highlight	   key	   biomarkers	   of	  metabolic	  disease	  risk	  that	  may	  be	  used	  to	  predict	  an	  individual’s	  risk	  of	  developing	  T2D.	   This	   information	   can	   be	   used	   to	   implement	   strategies	   with	   a	   view	   to	  counteracting	  such	  maladaptation	  and	  protecting	   ‘at	  risk’	   individuals.	   It	   is	  currently	  unknown	   whether	   changes	   in	   miRNA	   levels	   of	   skeletal	   muscle	   and	   plasma	   are	  observed	  following	  a	  period	  of	  HFEE	  in	  humans.	  	  
	  
1.6.1	  Aims	  and	  objectives	  Overall,	  the	  aim	  of	  this	  thesis	  is	  to	  address	  current	  knowledge	  gaps	  in	  the	  literature	  regarding	  the	  metabolic,	  molecular	  and	  epigenetic	  responses	  to	  short-­‐term	  HFEE,	  as	  a	  proxy	  for	  the	  early	  maladaptation	  leading	  to	  T2D.	  Specifically,	  we	  aim	  to	  investigate	  the	  impact	  of	  short-­‐term	  lipid	  and	  energy	  excess	  on	  whole-­‐body	  glucose	  metabolism,	  skeletal	   muscle	   lipid	   metabolism	   and	   epigenetic	   regulation	   within	   skeletal	   muscle	  and	  plasma.	  Moreover,	  the	  influence	  of	  n-­‐3	  PUFA	  ingestion	  on	  these	  parameters	  will	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be	   investigated.	   These	   aims	   will	   be	   achieved	   by	   the	   successful	   completion	   of	   the	  following	  objectives:	  	   i) To	  determine	  the	  whole-­‐body	  responses	  to	  a	  well-­‐controlled	  short-­‐term	  (6	  d)	  period	  of	  HFEE,	  with	  and	  without	  FO,	  in	  humans.	  ii) To	   determine	   the	   subcellular	  molecular	  mechanisms	   of	   short-­‐term	   (6	   d)	  diet-­‐induced	  maladaptation	  in	  humans,	  and	  their	  mediation	  by	  FO.	  iii) To	  determine	  the	  epigenetic	  responses	  to	  short-­‐term	  (6	  d)	  HFEE,	  with	  and	  without	  FO,	  in	  humans.	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2.0.	  Abstract	  We	  aimed	  to	  investigate	  the	  whole-­‐body	  responses	  to	  consumption	  of	  a	  6	  d	  high-­‐fat,	  hyperenergetic	   diet	   using	   dual-­‐glucose	   stable	   isotopic	   tracer	  methodology.	   Twenty	  young,	  healthy	  males	  were	  matched	  to	  1	  of	  2	  groups;	  high-­‐fat	  control	  (HF-­‐C)	  or	  high-­‐fat	   fish	   oil	   (HF-­‐FO;	   n	  =	  10	  per	   group).	  All	   participants	   consumed	  a	  high-­‐fat,	   energy	  excess	  diet	  for	  6	  d	  (HFEE;	  150	  %	  of	  total	  energy,	  60%	  FAT,	  25%	  CHO,	  15%	  PRO)	  with	  10	  %	  of	  fats	  consumed	  as	  fish	  oil	  (FO)	  in	  HF-­‐FO.	  Participants	  attended	  the	  laboratory	  following	  an	  overnight	  fast,	  immediately	  before	  and	  after	  6	  d	  HFEE,	  for	  two	  identical	  infusion	   trials.	   During	   the	   infusion	   trials,	   a	   primed	   continuous	   [6,6-­‐2H2]	   glucose	  infusion	  and	  an	  oral	  glucose	  tolerance	  test	  (OGTT;	  73	  g	  glucose	  +	  2	  g	  [U-­‐13C]	  glucose)	  were	  used	   to	   assess	  plasma	  glucose	  kinetics.	  Blood	   samples	  were	  drawn	  at	  10	  min	  intervals	  during	   the	  OGTT.	   Insulin	   sensitivity,	  measured	  using	   a	  number	  of	   indices,	  was	  unaltered	  by	  HFEE	  in	  either	  group	  (HF-­‐C:	  -­‐2	  ±	  13	  %;	  HF-­‐FO:	  8	  ±	  8	  %	  (Matsuda))	  despite	   fat	   mass	   gains	   in	   both	   groups	   (3	   ±	   1	   %	   (pooled	   groups)).	   A	   significant	  increase	  in	  circulating	  n-­‐3	  PUFAs	  was	  observed	  post-­‐HFEE	  in	  HF-­‐FO	  only	  (107	  ±	  10	  %;	  p	  <	  0.01).	  However,	  HFEE	  did	  not	  significantly	  alter	  plasma	  glucose	  kinetics	  (Ra:	  209.3	  ±	  16.6	  to	  204.4	  ±	  17.4;	  Rd:	  264.2	  ±	  20.2	  to	  273.3	  ±	  20.2	  mg·min-­‐1·kg-­‐1:120	  min	  (pooled	  groups))	  or	  insulin	  concentrations	  (42930	  ±	  4130	  to	  43931	  ±	  3907	  pmol·L-­‐1	  (pooled	   groups))	   over	   the	   OGTT,	   irrespective	   of	   group.	   Short-­‐term	   HFEE	   does	   not	  clearly	   alter	   insulin	   sensitivity	   group	   means	   in	   a	   cohort	   of	   young,	   healthy	   males.	  However,	   a	   large	  degree	  of	   individual	   variation	  was	  evident	   in	   all	   of	   our	  measures.	  Evaluation	   with	   inferential	   statistics	   indicated	   a	   possible	   (62	   %)	   chance	   of	   FO	  consumption	   during	   short-­‐term	   HFEE	   being	   beneficial	   for	   insulin	   sensitivity	  (Matsuda)	  change.	  We	  suggest	  that	  careful	  attention	  should	  be	  afforded	  to	  individual	  characteristics	  in	  future	  investigations	  of	  short-­‐term	  HFEE.	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2.1.	  Introduction	  Dietary	  energy	  and	  fat	  overconsumption	  leading	  to	  body	  mass	  gain	  is	  associated	  with	  the	   development	   of	   obesity	   and	   insulin	   resistance	   (189,190).	   High-­‐fat,	   high-­‐energy	  diets	   have	   become	   increasingly	   common,	   particularly	   in	   Western,	   well-­‐developed	  countries,	  and	  are	  thought	  to	  be	  a	  leading	  contributor	  to	  T2D	  (191).	  Investigation	  of	  the	   early,	   adaptive	   responses	   to	   fat	   and	  energy	   excess	   is	   important	   to	   improve	  our	  understanding	   of	   the	   ensuing	   maladaptations	   that	   will	   lead	   to	   obesity,	   insulin	  resistance	  and	  T2D.	  Enhanced	  comprehension	  of	  T2D	  progression	  also	  will	  allow	  for	  more	   targeted	   lifestyle	   interventions	  designed	   to	   tackle	   these	  early	  maladaptations,	  with	  the	  aim	  of	  preventing,	  or	  slowing,	  insulin	  resistance	  development.	  	  	  Excess	   energy,	   high-­‐fat	   diets	   of	   varying	   duration	   have	   been	   used	   previously	   as	   a	  model	   to	   investigate	  the	  mechanisms	   leading	  to	  diet-­‐induced	   insulin	  resistance	  (e.g.	  (19,98,99,103)).	  Insulin	  sensitivity	  has	  been	  shown	  to	  decrease	  following	  short-­‐term	  episodes	   of	   high-­‐fat	   overfeeding	   (98,103,109).	   However,	   discrepant	   findings	   exist	  with	  some	  studies	  showing	  no	  influence	  of	  overfeeding	  periods	  on	  insulin	  sensitivity	  (19,98,99).	   Thus,	   the	   impact	   of	   short-­‐term	   overfeeding	   on	   whole-­‐body	   insulin	  sensitivity	  remains	  unclear.	  	  The	  use	  of	  different	  experimental	  protocols	  and	  the	  saturated	  /	  unsaturated	  nature	  of	  consumed	  fat	  may	  explain	  discrepant	  findings	  between	  studies.	  Previous	  overfeeding	  protocols	  have	  varied	   in	   the	  degree	  of	  nutrient	  excess,	  macronutrient	  contributions	  and	   duration	   of	   dietary	   intervention.	   Most	   studies	   have	   implemented	   an	   energy	  excess	   of	   40-­‐50	   %	   (19,98,99,108,109).	   However,	   the	   contribution	   from	   each	  macronutrient	   varied	   considerably,	   with	   percentage	   energy	   from	   fat	   (30-­‐65	   %),	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carbohydrate	  (23-­‐50	  %)	  and	  protein	  (7.5-­‐15	  %)	  different	  between	  these	  studies.	  The	  type	  of	   fat	  consumed	  was	  mainly	  saturated	  (SFA)	  (103)	  or	  equal	  proportions	  of	   the	  three	  main	   classes	  of	   fat	   (SFA,	  monounsaturated	   (MUFA),	   polyunsaturated	   (PUFA))	  (19,99).	   Consumption	   of	   additional	   energy	   as	   PUFA	   compared	   to	   equivalent	  consumption	   of	   SFA	   led	   to	   reduced	   gains	   in	   fat	   mass	   (192).	   These	   data	   suggest	   a	  potential	  beneficial	  effect	  of	  replacing	  additional	  SFA	  intake	  with	  PUFA	  intake	  on	  fat	  mass	  gains.	  However,	  the	  independent	  influence	  of	  reducing	  SFA	  vs.	  increasing	  PUFA	  on	   fat	   mass	   gains	   cannot	   be	   teased	   from	   these	   findings.	   Nonetheless,	   whether	   the	  type	  of	   fat	   consumed	  within	  overfeeding	  models	  has	   an	   impact	   on	   fat	   /	   body	  mass	  gains	  and	  associated	  changes	  in	  insulin	  sensitivity	  warrants	  consideration.	  	  	  Altering	  the	  type	  of	  dietary	  fat	  consumed,	  e.g.,	  replacement	  of	  SFA	  with	  PUFA,	  may	  be	  an	  efficacious	  lifestyle	  strategy	  with	  potential	  to	  prevent	  or	  slow	  the	  decline	  in	  insulin	  sensitivity	  that	  is	  associated	  with	  chronic	  dietary	  energy	  excess.	  SFA	  often	  contribute	  most	   significantly	   to	   total	   fats	   when	   high-­‐fat,	   high-­‐energy	   diets	   are	   consumed	  habitually,	   and	   typically,	   high	   SFA	   consumption	   is	   related	   to	   the	   development	   of	  obesity	   and	   T2D	   (191).	   However,	   this	   notion	   is	   under	   increasing	   scrutiny.	  Consumption	  of	  n-­‐3	  PUFAs,	  commonly	  found	  in	  the	  oil	  of	  cold-­‐water,	  pelagic	  fish	  (FO),	  has	   been	   suggested	   to	  have	   clinical	   relevance	   in	   the	   reduction	  of	   insulin	   resistance	  (193).	  Although,	  it	  must	  be	  acknowledged	  that	  findings	  from	  human	  studies	  also	  are	  equivocal	   in	   this	   regard	   (e.g.	   (194)).	   N-­‐3	   PUFAs	   are	   thought	   to	   improve	   insulin	  sensitivity	  through	  a	  number	  of	  mechanisms,	  including,	  increased	  fat	  oxidation	  (195),	  anti-­‐inflammatory	   properties	   (196),	   and	   altered	  membrane	   composition	   leading	   to	  improved	   signal	   transduction	   (144).	   Therefore,	   increasing	   dietary	   intake	   of	   n-­‐3	  PUFAs	  may	  be	  a	  viable	  strategy	  for	  ameliorating	  insulin	  resistance.	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  Our	   aims	   for	   this	   study	  were	   twofold.	   First,	   we	   aimed	   to	   investigate	   the	   impact	   of	  increasing	  energy	  intake	  by	  an	  additional	  50	  %,	  with	  60	  %	  of	  energy	  from	  fat	  for	  6	  d,	  on	  whole-­‐body	   insulin	  sensitivity,	  and	  associated	  metabolic	  mechanisms,	   in	  a	  group	  of	   healthy	   young	   male	   volunteers.	   Second,	   we	   aimed	   to	   investigate	   the	   impact	   of	  replacing	  10	  %	  of	  dietary	  fats	  with	  dietary	  FO	  during	  high-­‐fat,	  energy	  excess	  (HFEE)	  on	   whole-­‐body	   insulin	   sensitivity	   and	   associated	   metabolic	   mechanisms.	   The	  duration	   (6	   d)	   and	   degree	   (150	  %)	   of	   overfeeding	   and	   percentage	   contribution	   to	  total	  energy	  of	  fat	  (60	  %)	  and	  FO	  (6	  %)	  were	  selected	  following	  critical	  review	  of	  the	  literature	   (presented	   in	   Table	   1.1).	   Our	   aims	   were	   to	   try	   and	   induce	   insulin	  resistance	   with	   HFEE	   and	   to	   provide	   sufficient	   FO	   to	   have	   functional,	   measurable,	  mechanistic	   effects,	   e.g.,	   incorporation	   into	   the	   plasma	   membrane.	   Thus,	   we	  hypothesised	  that	  6	  d	  HFEE	  would	  reduce	  whole-­‐body	  insulin	  sensitivity	  and	  that	  this	  effect	  would	  be	  ameliorated	  with	   the	  substitution	  of	  10	  %	  of	   total	   fats	  with	  dietary	  FO.	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2.2.	  Methods	  
2.2.1.	  Participants	  and	  ethical	  approval	  Twenty	  healthy	  males	  who	  did	  not	  meet	   current	  UK	  government	   recommendations	  for	  physical	   activity	  were	   recruited	   from	   the	  University	  of	   Stirling	  and	  surrounding	  area	   to	   participate	   in	   this	   investigation	   (Table	   2.1).	   Following	   health	   screening,	  participants	  were	   excluded	   if	   they	   consumed	   a	   diet	   high	   in	   FO	   sources	   or	   took	   FO	  supplements,	  had	  a	   fasting	  blood	  glucose	  of	  >	  6.1	  mmol·L-­‐1,	  or	  met	  or	  exceeded	  the	  recommended	  physical	  activity	  guidelines	  for	  health	  (30	  min·d-­‐1,	  5	  x·wk-­‐1).	  	  Ethical	  approval	  was	  obtained	  from	  the	  NHS	  East	  of	  Scotland	  Research	  Ethics	  Service	  (REC	  2)	  and	  the	  study	  was	  conducted	  in	  accordance	  with	  the	  Declaration	  of	  Helsinki	  (197).	   Having	   had	   the	   study	   purpose	   and	   procedures	   explained	   in	   lay	   terms,	   all	  participants	  provided	  written,	  informed	  consent.	  	  	  
	  
	  
2.2.2.	  Study	  design	  Using	  a	  parallel	  study	  design,	  participants	  were	  matched	  to	  either	  a	  high-­‐fat	  control	  (HF-­‐C;	  n	  =	  10)	  or	  a	  high-­‐fat	  fish	  oil	  (HF-­‐FO;	  n	  =	  10)	  group	  based	  on	  age,	  body	  mass,	  
Table	  2.1	  Participant	  characteristics.	  	  
Parameter	   HF-­‐C	   HF-­‐FO	  
Age	  (y)	   21.8	  ±	  3.4	   22.9	  ±	  3.7	  
Body	  mass	  (kg)	   72.4	  ±	  7.7	   70.1	  ±	  7.9	  
BMI	  (kg·m-­‐2)	   21.8	  ±	  2.0	   21.3	  ±	  2.0	  
Physical	  activity	  (x·wk-­‐1)	   1.1	  ±	  0.4	   1.2	  ±	  0.4	  
Body	  fat	  (%)	   20.1	  ±	  1.5	   21.3	  ±	  2.1	  
Data	   are	   presented	   by	   group	   (HF-­‐C	   and	   HF-­‐FO;	   n=10	   per	   group).	   Values	   are	   means	   ±	   SD,	   no	   significant	  differences	  between	  groups	  (t-­‐test).	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habitual	  physical	  activity	  and	  habitual	  energy	   intake.	  Prior	  to	  baseline	  testing,	  a	  3	  d	  baseline	   diet,	   designed	   to	   reflect	   individual	   habitual	   energy	   and	   proportional	  macronutrient	   intake,	   was	   consumed	   by	   all	   participants.	   For	   baseline	   testing	  (infusion	   trial	   1,	   pre-­‐HFEE),	   participants	   arrived	   at	   the	   laboratory	   following	   an	  overnight	   fast.	   A	   dual	   energy	   x-­‐ray	   absorptiometry	   (DXA)	   scan	   was	   conducted	  followed	  by	  collection	  of	  a	  basal	  blood	  sample	  and	  skeletal	  muscle	  biopsy.	  Thereafter,	  participants	   completed	   an	   oral	   glucose	   tolerance	   test	   (OGTT)	   using	   dual-­‐glucose	  stable	   isotopic	   tracer	   methodology	   with	   regular	   blood	   sampling	   to	   assess	   plasma	  glucose	   kinetics	   and	   insulin	   sensitivity.	   Following	   the	  OGTT,	   a	   final	   skeletal	  muscle	  biopsy	  was	  obtained.	  	  	  Following	   baseline	   testing,	   participants	   consumed	   an	   experimental	   diet	   for	   6	   d,	  designed	  to	  represent	  an	  extreme	  Western	  diet.	  The	  diet	  comprised	  150	  %	  of	  habitual	  energy	  intake	  with	  60	  %	  of	  energy	  from	  fat,	  25	  %	  from	  carbohydrate	  and	  15%	  from	  protein.	  The	  only	  exception	  was	  that	  for	  HF-­‐FO,	  10%	  of	  fats	  were	  provided	  as	  dietary	  FO.	  A	  second	  testing	  day	  (infusion	  trial	  2,	  post-­‐HFEE)	  was	  conducted	  on	  the	  morning	  following	  day	  6	  of	  HFEE.	  All	  procedures	  were	  identical	  to	  those	  conducted	  pre-­‐HFEE.	  
Figure	  2.1A	  provides	  a	  schematic	  of	  the	  study	  design.	  
	  
2.2.3.	  Preliminary	  testing	  
Blood	  sampling	  A	  single,	  basal	  blood	  sample	  was	  collected	  in	  an	  EDTA	  vacutainer	  (Becton,	  Dickinson	  &	   Company,	   NJ,	   USA)	   from	   each	   participant	   prior	   to	   testing	   to	   ensure	   that	   fasting	  blood	  glucose	  concentrations	  were	  within	  the	  normal,	  healthy	  range	  (<	  6.1	  mmol·L-­‐1).	  Blood	   samples	   were	   centrifuged	   at	   3500	   rpm	   for	   15	   min	   at	   4	   °C	   to	   separate	   the	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plasma	   fraction.	   An	   automated	   Aries	   ILab	   benchtop	   analyser	   (Instrumentation	  Laboratories,	  MA,	  US)	  was	  used	  to	  assess	  plasma	  glucose	  concentration	  on	  the	  same	  day.	  	  
	  
Body	  mass	  During	   preliminary	   testing	   and	   at	   the	   start	   of	   each	   of	   the	   two	   infusion	   trials,	   nude	  body	   mass	   was	   recorded	   to	   the	   nearest	   0.1	   kg	   using	   a	   digital	   scale.	   Body	   mass	  recorded	   at	   the	   start	   of	   each	   infusion	   trial	   was	   used	   to	   accurately	   calculate	   the	  infusion	  pump	  rate	  to	  achieve	  the	  desired	  infusion	  rate,	  and	  to	  assess	  changes	  in	  total	  body	  mass	  resulting	  from	  6	  d	  HFEE.	  	  	  	  
2.2.4.	  Diet	  and	  physical	  activity	  control	  
Dietary	  control	  Dietary	  intake	  was	  controlled	  for	  a	  consecutive	  9	  d	  testing	  period.	  Participants	  were	  required	   to	   complete	   a	   3	   d	   weighed	   food	   and	   physical	   activity	   diary,	   that	   was	  representative	   of	   their	   weekly	   habits,	   to	   include	   2	   weekdays	   and	   1	   weekend	   day.	  Food	   diaries	   were	   analysed	   using	   dietary	   analysis	   software	   (Microdiet,	   Downlee	  Systems	  Ltd,	  UK)	  for	  average	  daily	  energy	  intake	  and	  macronutrient	  contributions.	  All	  participants	   completed	   a	   food	   preference	   questionnaire	   to	   ensure	   no	   foods	   were	  provided	   that	   were	   not	   tolerated	   by	   participants	   and	   to	   match	   dietary	   habits	   as	  closely	  as	  possible	  to	  aid	  compliance.	  	  	  Habitual	  average	  daily	  energy	  intake	  data	  were	  used	  to	  devise	  both	  the	  baseline	  and	  experimental	  diets.	  All	  baseline	  diets	  matched	   the	   total	  average	  daily	  energy	   intake	  and	  macronutrient	  composition	  of	   individuals’	  habitual	  diets	  as	  recorded	   in	   the	  3	  d	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food	   diaries.	   A	   standard	   template	   was	   used	   as	   a	   basis	   for	   devising	   baseline	   diets.	  However,	  given	  the	  individual	  variation	  in	  foods	  consumed	  between	  participants,	  an	  attempt	  was	  made	  to	  provide	  some	  of	  the	  foods	  indicated	  by	  each	  participant	  in	  their	  3	  d	  food	  diaries.	  Providing	  similar	  foods	  served	  to	  aid	  participant	  compliance	  and	  also	  to	  try	  and	  maintain	  habitual	  eating	  as	  much	  as	  possible.	  The	  food	  given	  on	  baseline	  feeding	  day	  1	  was	  repeated	  for	  baseline	  feeding	  day	  3,	  with	  a	  different	  range	  of	  foods	  provided	  on	  baseline	  feeding	  day	  2.	  Following	  consumption	  of	  the	  baseline	  diets,	  each	  participant	  consumed	  a	  6	  d	  experimental	  diet	  that	  comprised	  150	  %	  of	  their	  habitual	  energy	  intake,	  with	  60	  %	  of	  energy	  from	  fat,	  25	  %	  from	  carbohydrate	  and	  15	  %	  from	  protein.	   HF-­‐FO	   had	   10	   %	   of	   total	   fats	   in	   the	   diet	   (6	   %	   total	   energy)	   replaced	   by	  dietary	  FO	  whereas	  HF-­‐C	  received	  the	  60	  %	  fat	  from	  a	  mixture	  of	  fat	  sources	  that	  did	  not	   include	   FO	   or	   foods	   highly	   enriched	  with	   n-­‐3	   PUFAs.	   Experimental	   diets	   were	  devised	  from	  an	  initial	   template	  that	  was	  altered	  depending	  on	  the	  required	  energy	  intake.	  The	  diets	  provided	  on	  experimental	  day	  1-­‐3	  were	  repeated	  for	  experimental	  day	  4-­‐6.	  Dietary	  FO	  was	  provided	  by	  means	  of	  oily	  fish	  consumption	  from	  a	  fish	  meal	  
e.g.,	   salmon	   /	   mackerel	   fillets,	   fish	   (salmon)	   oil	   (Smartfish	   Nutrition,	   Norway;	  
Appendix	  2.1)	  added	  to	  yoghurt	  based	  smoothies	  and	  omega-­‐3	  enriched	  (salmon	  oil)	  juices	  (Smartfish	  Nutrition,	  Norway;	  Appendix	   2.2).	  Placebo	  drinks	  without	  any	  oil	  were	  given	  to	  individuals	  in	  HF-­‐C	  (Smartfish	  Nutrition,	  Norway).	  	  All	   food	  (both	  baseline	  and	  experimental	  diets)	  was	  provided	   in	  daily	   food	  bags	   for	  participants	   to	   consume	   away	   from	   the	   laboratory.	   Participants	  were	   instructed	   to	  eat	  all	  of	   the	   food	  and	  drink	  provided	  and	  not	   to	  consume	  anything	  other	   than	  that	  provided	   during	   the	   experiment.	   In	   the	   event	   that	   participants	   were	   unable	   to	  consume	   everything	   provided	   in	   their	   food	   bag,	   they	   were	   asked	   to	   return	   the	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remainder	  of	  the	  items	  so	  that	  energy	  intake	  could	  be	  recalculated	  accordingly.	  None	  of	   the	   participants	   complained	   of	   any	   intolerances	   or	   difficulties	   in	   consuming	   the	  diets.	  	  
Physical	  activity	  control	  During	  health	  screening,	  participants	  were	  asked	  to	  record	  the	  total	  average	  number	  of	  hours	  spent	  engaged	  in	  physical	  activity	  per	  week,	  as	  well	  as	  the	  specific	  activities	  that	  they	  engaged	  in	  on	  more	  than	  two	  occasions	  per	  week.	  Physical	  activity	  also	  was	  recorded	   over	   the	   same	   3	   d	   period	   as	   the	  weighed	   food	   record.	   Participants	  were	  encouraged	  to	  maintain	  their	  habitual	  activities	  of	  daily	  living	  but	  to	  refrain	  from	  any	  additional	  physical	  activity	  for	  the	  48	  h	  preceding	  both	  infusion	  trials	  (pre-­‐	  and	  post-­‐HFEE).	  	  
2.2.5.	  Testing	  days	  (infusion	  trials)	  The	  two	  infusion	  trials,	  conducted	  on	  the	  morning	  following	  consumption	  of	  the	  food	  provided	   for	  day	  3	  of	   the	  baseline	  diet	   (day	  4;	   infusion	   trial	  1	   (pre-­‐HFEE))	  and	   the	  morning	   following	  consumption	  of	   the	   food	  provided	   for	  day	  6	  of	   the	  experimental	  diet	   (day	   10;	   infusion	   trial	   2	   (post-­‐HFEE)),	   were	   identical	   in	   all	   respects.	   For	   a	  schematic	   of	   the	   infusion	   trials	   see	   Figure	   2.1B.	   All	   trials	   were	   conducted	   in	   the	  laboratories	   of	   the	   Health	   and	   Exercise	   Sciences	   Research	   Group,	   University	   of	  Stirling.	  	  Participants	   arrived	   at	   the	   laboratory	   between	   0600	   and	   0800	   following	   ~10	   h	  overnight	  fast.	  Dietary	  compliance	  was	  confirmed	  verbally	  prior	  to	  beginning	  the	  trial	  and	   nude	   body	  mass	   was	   recorded.	   Next,	   body	   composition	   was	   analysed	   by	   DXA	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(LUNAR	  iDXA;	  GE	  Healthcare	  Systems,	  UK).	  For	  each	  participant,	  the	  same	  researcher	  conducted	  both	  DXA	  scans	  (pre-­‐	  and	  post-­‐HFEE)	  and	  a	  standardised	  protocol	  of	  body	  positioning	  (198)	  was	  implemented	  for	  use	  between	  researchers.	  	  	  All	   subsequent	   procedures	  were	   conducted	  with	   participants	   lying	   on	   a	   bed	   in	   the	  supine	  position.	  First,	  a	  catheter	  was	  inserted	  into	  a	  forearm	  vein	  for	  collection	  of	  a	  basal	   venous	   blood	   sample	   followed	   by	   a	   primed	   (13.5	   µmol·kg-­‐1)	   continuous	   3	   h	  infusion	   (0.350	   µmol·kg-­‐1·min-­‐1)	   of	   [6,6-­‐2H2]	   glucose	   (Cambridge	   Isotope	  Laboratories,	   MA,	   USA)	   using	   an	   Alaris	   PK	   infusion	   pump	   (CareFusion,	   CA,	   USA).	  During	  the	  first	  hour	  of	  infusion,	  another	  catheter	  was	  inserted	  into	  the	  contralateral	  arm	   for	   repeated	  venous	  blood	   sampling.	  A	  venous	  blood	   sample	  was	   taken	  at	   –30	  min	   (30	   min	   into	   infusion	   /	   30	   min	   pre-­‐glucose	   drink;	   all	   timings	   were	   based	   on	  consumption	  of	  the	  glucose	  drink)	  and	  a	  resting	  skeletal	  muscle	  biopsy	  was	  obtained.	  For	   the	   biopsy,	   a	   5	   mm	   Bergström	   needle	   was	   inserted	   through	   a	   pre-­‐prepared	  anaesthetised	  (2	  %	  Lidocaine)	  incision	  in	  the	  skin	  and	  fascia,	  into	  the	  muscle	  belly	  of	  the	   vastus	   lateralis	   and	   a	   sample	   removed	   under	   manual	   suction.	   Muscle	   biopsy	  samples	   were	   immediately	   rinsed	   using	   ice-­‐cold	   saline	   (0.9	   %),	   any	   visible	   fat	   or	  connective	   tissue	   removed	   and	   blotted	   before	   weighing	   and	   freezing	   in	   liquid	  nitrogen	   prior	   to	   storage	   at	   -­‐80	   °C	   pending	   analysis.	   One	   hour	   into	   the	   infusion	   (0	  min),	  participants	  consumed	  a	  sugar	  drink	  (75	  g	  glucose	  given	  in	  a	  dextrose	  solution	  (73	   g	   glucose	   (80.3	   g	   dextrose	   when	   corrected	   for	   crystallisation	   (Myprotein,	  Cheshire,	  UK)	  +	  2	  g	  [U-­‐13C]	  glucose	  in	  300	  mL	  water)))	  to	  start	  the	  OGTT.	  Fluid	  intake	  was	  restricted	  throughout	  the	  trial	  to	  only	  the	  OGTT	  drink.	  Throughout	  the	  2	  h	  that	  followed	  glucose	  ingestion,	  blood	  samples	  were	  drawn	  every	  10	  min,	  and	  at	  120	  min	  (3	  h	  post	  infusion)	  a	  final	  skeletal	  muscle	  biopsy	  was	  obtained.	  Both	  biopsies	  (0	  and	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120	  min)	  were	  removed	  from	  the	  same	  leg.	  For	  infusion	  trial	  2	  (post-­‐HFEE),	  biopsies	  were	  obtained	   from	  the	  contralateral	   limb.	  The	  order	  of	   the	   first	   leg	   to	  be	  biopsied	  was	   counterbalanced	   between	   groups	   to	   eliminate	   any	   potential	   for	   order	   effects.	  Upon	  completion	  of	   the	   first	   infusion	  trial,	  participants	  were	   fed	  the	  breakfast	   from	  the	   first	   food	  bag	  of	   their	  experimental	  HFEE	  diet	   (Day	  4)	  and	  allowed	   to	   leave	   the	  laboratory	  with	  the	  rest	  of	  their	  food	  for	  that	  day	  and	  the	  following	  day.	  	  	  
	  
	  
2.2.6.	  Blood	  sampling	  and	  plasma	  analysis	  	  Blood	   samples	  were	   collected	   in	   EDTA	   vacutainers	   (Becton,	  Dickinson	  &	  Company,	  NJ,	   USA)	   and	   centrifuged	   at	   3500	   rpm	   for	   15	  min	   at	   4	   °C.	   Post-­‐centrifugation,	   the	  supernatant	   plasma	   fraction	  was	   removed	   and	   aliquotted	   into	   Eppendorf	   tubes	   for	  storage	  at	  -­‐80	  °C	  pending	  analysis.	  An	  ILab	  Aries	  benchtop	  analyser	  with	  associated	  
	  
Figure	   2.1	   Study	   design	   (A)	   and	   infusion	   trial	   (B)	   schematic.	   Both	   groups	   (HF-­‐C	   and	   HF-­‐FO)	  completed	  all	  aspects	  depicted,	  with	  the	  only	  difference	  between	  groups	  being	  the	  composition	  of	  fat	  provided	  in	  the	  experimental	  diet.	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reagents	   (Instrumentation	   Laboratories,	   MA,	   USA)	   was	   used	   to	   measure	   plasma	  glucose	   concentrations	   at	   10	   min	   intervals	   throughout	   the	   OGTT	   (0	   –	   120	   min).	  Insulin	  concentrations	  were	  measured	  at	  the	  same	  time-­‐points	  by	  ELISA	  according	  to	  the	   manufacturer’s	   instructions	   (Demeditic	   (DE2935),	   Germany).	   Plasma	  enrichments	   of	   [6,6-­‐2H2]	   glucose	   from	   the	   infusion	   and	   [U-­‐13C]	   glucose	   from	   the	  glucose	   drink	   were	   measured	   by	   GCMS	   following	   preparation	   of	   pentacetate	  derivatives	   using	   2:1	   acetic	   anhydride:pyridine	   (v/v).	   Plasma	   glucose	   enrichments	  were	   quantified	   using	   GCMS	   with	   chemical	   ionisation.	   Ions	   were	   selectively	  monitored	  at	  mass	  to	  charge	  ratios	  of	  331.1	  (M+0),	  332.1	  (M+1),	  333.1	  (M+2),	  334.1	  (M+3)	  and	  337.1	   (M+6)	  based	  on	   the	  masses	  of	   the	   labelled	   isotopes,	  and	  potential	  for	   carbon	   recycling.	   Plasma	   glucose	   enrichments	   for	   each	   ion	   were	   expressed	  relative	  to	  enrichments	  at	  331.1	  (M+0).	  A	  skew	  correction	  factor	  was	  applied	  to	  the	  U-­‐13C	  enrichments	  (337.1;	  M+6)	  to	  account	  for	  differences	  in	  the	  relative	  distribution	  of	   the	  mass	  spectra	  between	  the	  tracer	  (U-­‐13C)	  and	  tracee	  (unlabelled	  glucose).	  The	  GC	  System	  (7890A;	  Agilent	  Technologies,	  CA,	  USA)	  was	   interfaced	  with	  a	  5975C	  MS	  inert	   XL	   EI/CI	   MSD	   with	   triple-­‐axis	   detector.	   Methane	   gas	   was	   used	   for	   positive	  ionisation,	   with	   helium	   as	   the	   carrier	   gas.	   Chemstation	   software	   (Agilent	  Technologies,	  CA,	  USA)	  was	  used	  for	  data	  analysis.	  
	  
2.2.7.	  Blood	  fatty	  acid	  composition	  analysis	  Fatty	   acid	  methyl	   esters	   (FAME)	  were	   extracted	   from	  whole	   blood	   lipids	   using	   the	  Rapid	   Omega	   Test	   (199).	   Briefly,	   blood	  was	   spotted	   onto	  Whatman	   903	   cards	   and	  allowed	  to	  dry	  for	  2	  h.	  Automated	  processing	  isolated	  fatty	  acid	  methyl	  esters	  (FAME)	  from	  the	  dried	  blood	  spot	  before	  FAME	  were	  passed	  through	  a	  silica	  clean-­‐up	  column,	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eluted	   and	   re-­‐suspended	   in	   isohexane	   prior	   to	   gas-­‐liquid	   chromatography	   (GLC)	  analysis.	  	  
	  FAME	  were	  separated	  by	  GLC	  using	  a	  ThermoFisher	  Trace	  GC	  2000	  (ThermoFisher,	  Hemel	  Hempstead,	  UK)	  equipped	  with	  a	  fused	  silica	  capillary	  column	  (ZBWax,	  60m	  x	  0.32	  x	  0.25	  mm	  i.d.;	  Phenomenex,	  Macclesfield,	  UK).	  Hydrogen	  was	  used	  as	  carrier	  gas	  with	   on-­‐column	   injection.	   Individual	  methyl	   esters	  were	   identified	   from	  previously	  published	   data	   (200)	   and	   the	   Chromcard	   for	   Windows	   (version	   2.00)	   computer	  software	   (Thermoquest	   Italia	   S.p.A.,	   Milan,	   Italy)	   was	   used	   for	   data	   collection	   and	  processing.	  	  	  
2.2.8.	  Calculations	  
Insulin	  sensitivity	  	  Insulin	   sensitivity	   (or	   resistance)	   was	   estimated	   using	   plasma	   glucose	   and	   insulin	  concentrations	  in	  the	  basal	  state	  and	  /	  or	  during	  the	  OGTT	  within	  the	  calculations	  of	  a	  number	  of	  metrics	  outlined	  below.	  FPG	  =	  fasting	  plasma	  glucose,	  FPI	  =	  fasting	  plasma	  insulin.	  
	  
Matsuda	  insulin	  sensitivity	  index	  (ISI;	  (201))	  10000	  /	  SQRT	  ((FPG	  (mg·dL-­‐1)	  *FPI	  (µU·mL-­‐1))	  *	   (Mean	  OGTT	  Insulin	  *	  Mean	  OGTT	  Glucose	  (mg·dL-­‐1)))	  
	   	  
HOMA-­‐IR	  (202)	  (FPG	  (mmol·L-­‐1)	  *	  FPI	  (µU·mL-­‐1))	  /	  22.5	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HOMA-­‐β	  (202)	  (20	  *	  FPI	  (µU·mL-­‐1))	  /	  (FPG	  (mmol·L-­‐1)	  -­‐	  3.5)	  	  
Hepatic	  insulin	  resistance	  index	  (203)	  FPG	  (mmol·L-­‐1)	  *	  FPI	  (µU·mL-­‐1)	  	  
Hepatic	  insulin	  sensitivity	  index	  (204)	  1	  /	  (FPG	  (mmol·L-­‐1)	  *	  FPI	  (µU·mL-­‐1))	  
	  
Plasma	  glucose	  kinetics	  	  Total	  rates	  of	  glucose	  appearance	  (Ra)	  and	  disappearance	  (Rd)	  were	  calculated	  from	  plasma	   enrichments	   of	   [6,6-­‐2H2]	   using	   the	   modified	   single	   pool	   non-­‐steady	   state	  equations	  of	   Steele	  et	  al.	   (205).	  Exogenous	   (from	   the	  OGTT	  drink)	   and	  endogenous	  (inferred	   hepatic	   glucose	   output)	   Ra	  were	   calculated	   using	   the	   dual-­‐glucose	   tracer	  enrichments	   (i.e.	   the	   plasma	   kinetics	   of	   the	   infused	   [6,6-­‐2H2]	   and	   the	   U-­‐13C	   tracer	  added	   to	   the	   OGTT	   drink	   (with	   known	   U-­‐13C	   glucose	   enrichments	   of	   the	   ingested	  OGTT	   glucose	   drink)).	   A	   pool	   volume	   (pV)	   of	   40	   mL·kg-­‐1	   was	   used	   in	   the	   Steele	  equation	  (205)	  as	   this	  pV	  most	  reflects	   the	  plasma	  pool	   in	   the	  period	  during	  which	  steady	   state	   is	   altered,	   and	   minimises	   large	   fluctuations	   in	   calculated	   tracer	  enrichments	  during	  non-­‐steady	  state	  conditions	  (206).	  	  For	   the	   following	   equations:	   F	   =	   infusion	   rate	   (0.350	   µmol·kg-­‐1·min-­‐1),	   pV	   =	   pool	  fraction	  of	  the	  total	  extracellular	  glucose	  pool	  (40	  mL·kg-­‐1),	  C	  =	  glucose	  concentration,	  E	  =	  glucose	  enrichment,	  t	  =	  time.	  E2	  and	  E1	  correspond	  to	  the	  enrichments	  at	  time-­‐points	  t2	  and	  t1,	  respectively.	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Total	  Ra	  (mg·min-­‐1·kg-­‐1)	  (F	  -­‐	  ((pV	  *	  (C2	  +	  C1)	  /	  2)	  *	  ((E2-­‐E1)	  /	  (t2-­‐t1))))	  /	  ((E2+E1)	  /	  2)	  	  
Exogenous	  Ra	  (mg·min-­‐1·kg-­‐1)	  %	  contribution	  of	  [6,6-­‐2H2]	  glucose	  to	  total	  glucose	  concentration	  *	  Total	  Ra	  
	  
Endogenous	  Ra	  (mg·min-­‐1·kg-­‐1)	  Total	  Ra	  –	  exogenous	  Ra	  
	  
Total	  Rd	  (mg·min-­‐1·kg-­‐1)	  Total	  Ra	  –	  pV	  *	  ((C2-­‐C1)	  /	  (t2-­‐t1))	  
	  
2.2.9.	  Statistical	  analysis	  Power	  calculations	  for	  the	  study	  design	  were	  conducted	  using	  G*Power	  3	  (207)	  based	  on	  means	   and	   standard	  deviations	  of	   basal	  plasma	  glucose	   changes	   (4.59	  ±	  0.46	   to	  5.15	  ±	  0.40	  mmol·L-­‐1)	  reported	  by	  Brøns	  et	  al.	  (19).	  An	  n	  of	  8	  per	  group	  offered	  80	  %	  power	  (α	  =	  0.05)	  to	  detect	  changes	  in	  basal	  plasma	  glucose	  by	  ANOVA.	  	  	  All	  data	  were	   tested	   for	  normality	  using	   the	  Ryan	   Joiner	   test	  with	  Minitab	  software	  (version	  16;	  Minitab,	  State	  College,	  PA).	  In	  the	  case	  of	  non-­‐normally	  distributed	  data,	  Box-­‐Cox	  transformations	  were	  applied	  before	  testing	  for	  normality	  a	  second	  time.	  In	  the	   instance	   that	   data	   remained	   non-­‐normally	   distributed	   following	   Box-­‐Cox	  transformation,	  outliers	  were	  removed	  using	  the	  median	  absolute	  deviation	  method	  (208),	   and	   normality	   confirmed.	   Thus,	   all	   statistical	   analyses	   were	   performed	   on	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normally	  distributed	  data.	  A	  two-­‐way	  repeated	  measures	  ANOVA	  (IBM	  SPSS	  Statistics	  19,	   NY,	   USA)	   was	   used	   to	   assess	   differences	   between	   groups	   (HF-­‐C	   vs.	   HF-­‐FO;	  between-­‐subject	  factor),	  over	  time	  (pre-­‐	  and	  post-­‐HFEE;	  within-­‐subject	  factor).	  In	  the	  case	   of	   a	   significant	   interaction	   effect	   by	   two-­‐way	   ANOVA,	   paired	   t-­‐tests	   were	  conducted	   to	   assess	  differences	  over	   time	  within	   each	  group	  alone.	  Area	  under	   the	  plasma	   glucose	   and	   insulin	   curves	   (AUC)	   during	   the	   OGTT	   were	   calculated	   using	  GraphPad	   Prism	   version	   4	   (GraphPad	   Software	   Inc.,	   CA,	   USA)	   with	   baseline	   set	   at	  individual	   basal	   values	   (0	   min).	   Evaluation	   of	   inferential	   statistics	   was	   performed	  using	  the	  resource	  of	  Hopkins	  (209).	  Statistical	  significance	  was	  assumed	  at	  the	  level	  of	  p	  <	  0.05.	  Values	  are	  presented	  as	  mean	  ±	  standard	  error	  of	  the	  mean	  (SEM)	  unless	  stated	  otherwise.	  	  	  	  
2.3.	  Results	  
2.3.1.	  Dietary	  analysis	  Dietary	  intake	  data	  are	  presented	  in	  Table	  2.2.	  Baseline	  diets	  were	  not	  significantly	  different	   between	   groups.	   N-­‐3	   PUFA	   and	   sugar	   intake	   were	   significantly	   different	  between	  groups	  during	  HFEE.	  
	  




2.3.2.	  Body	  composition	  Changes	  in	  body	  composition	  following	  HFEE	  by	  DXA	  are	  presented	  in	  Table	  2.3.	  All	  measures	  presented	  were	  significantly	  increased	  post-­‐HFEE	  irrespective	  of	  group.	  	  
	  	  
Table	  2.2	  Macronutrient	  composition	  of	  3	  d	  baseline	  diets	  and	  6	  d	  experimental	  diets.	  	  
	   Baseline	  diets	   Experimental	  diets	  
	   HF-­‐C	   HF-­‐FO	   HF-­‐C	   HF-­‐FO	  
Energy	  (kcal)	   2614	  ±	  180	   2443	  ±	  132	   3919	  ±	  237	   3658	  ±	  203	  	  
Fat	  (g)	   104	  ±	  9	   87	  ±	  5	   261	  ±	  18	   245	  ±	  14	  
Carbohydrate	  (g)	   323	  ±	  22	   325	  ±	  33	   263	  ±	  18	   244	  ±	  13	  
Protein	  (g)	   116	  ±	  13	   108	  ±	  7	   146	  ±	  10	   137	  ±	  8	  
SFA	  (g)	   42	  ±	  3	   33	  ±	  3	   106	  ±	  7	   100	  ±	  5	  
MUFA	  (g)	   31	  ±	  4	   24	  ±	  2	   74	  ±	  4	   69	  ±	  4	  
PUFA	  (g)	   10	  ±	  2	   11	  ±	  2	   31	  ±	  2	   38	  ±	  3	  
n-­‐3	  PUFA	  (g)	   	   	   2	  ±	  0	  	   25	  ±	  2	  *	  
Sugars	  (g)	   119	  ±	  12	   133	  ±	  19	   121	  ±	  7	   77	  ±	  2	  *	  
Data	  displayed	  by	  group	  (HF-­‐C	  and	  HF-­‐FO;	  n	  =	  10	  per	  group).	  Values	  are	  means	  ±	  SEM	  (values	  displayed	  as	  0	  were	  <	  0.01),	  *	  significantly	  different	  from	  HF-­‐C	  for	  equivalent	  condition,	  p	  <	  0.05	  (ANOVA).	  	  	  
Table	  2.3	  Body	  composition	  measurement	  by	  DXA.	  
	   HF-­‐C	   HF-­‐FO	  
	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
Total	  body	  mass	  (kg)	   71.74	  ±	  3.60	  	   72.25	  ±	  3.65	   69.65	  ±	  2.32	   70.67	  ±	  2.29	  
Total	  fat	  mass	  (kg)	   13.87	  ±	  1.11	   14.16	  ±	  1.09	   14.40	  ±	  1.65	   14.85	  ±	  1.61	  
Limb	  fat	  mass	  (kg)	   6.94	  ±	  0.49	   7.01	  ±	  0.49	   7.40	  ±	  0.76	   7.66	  ±	  0.77	  
Trunk	  fat	  mass	  (kg)	   6.07	  ±	  0.72	   6.27	  ±	  0.70	   6.12	  ±	  0.90	   6.29	  ±	  0.85	  
Android	  fat	  (%)	   16.89	  ±	  2.38	   17.88	  ±	  2.29	   17.63	  ±	  2.83	   18.22	  ±	  2.72	  
Total	  lean	  mass	  (kg)	   55.30	  ±	  3.03	   55.55	  ±	  3.07	   52.89	  ±	  1.98	   53.44	  ±	  1.85	  
Data	  presented	  pre-­‐	  and	  post-­‐HFEE,	  for	  both	  groups	  (HF-­‐C	  and	  HF-­‐FO;	  n=10	  per	  group).	  Values	  are	  means	  ±	  SEM.	  All	  measures	  were	  significantly	  altered	  by	  HFEE,	  irrespective	  of	  group	  (p	  <	  0.05	  by	  ANOVA).	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2.3.3.	  Plasma	  glucose	  Plasma	   glucose	   curves	   for	   HF-­‐C	   and	   HF-­‐FO	   are	   presented	   in	   Figure	   2.2A	   and	   B,	  respectively.	  Basal	  plasma	  glucose	  concentrations	  confirm	  participants	  were	   insulin	  sensitive	   at	   the	   start	   of	   the	   study	   with	   no	   significant	   differences	   between	   groups.	  Following	  6	  d	  HFEE,	  basal	  plasma	  glucose	  levels	  were	  comparable	  to	  pre-­‐HFEE,	  with	  no	  differences	  between	  groups.	  Neither	  peak	  plasma	  glucose	  concentrations	  nor	  the	  corresponding	   time-­‐point	  were	  significantly	  altered	   following	  6	  d	  HFEE	  or	  between	  groups.	  	  The	  plasma	  glucose	  AUC	  over	  the	  course	  of	  the	  OGTT	  (120	  min)	  was	  unaltered	  by	  6	  d	  HFEE	  with	  no	  significant	  difference	  between	  groups	  (Figure	  2.2C).	  The	  AUCs	  for	  0-­‐30	  and	   0-­‐60	  min	   also	  were	   unaltered	   by	   HFEE	   and	   not	   statistically	   different	   between	  groups	  (data	  not	  shown).	  However,	  the	  mean	  change	  in	  AUCs	  across	  all	  time-­‐brackets	  (i.e.	  0-­‐30,	  0-­‐60,	  0-­‐120)	  ranged	  from	  11-­‐52	  %	  for	  HF-­‐C,	  but	  between	  -­‐6	  and	  -­‐12	  %	  for	  HF-­‐FO.	  	  




2.3.4.	  Plasma	  insulin	  Plasma	   insulin	   curves	   for	   HF-­‐C	   and	   HF-­‐FO	   are	   presented	   in	   Figure	   2.3A	   and	   B,	  respectively.	   Basal	   plasma	   insulin	   concentrations	  were	  within	   the	   insulin	   sensitive	  range	   for	   both	   groups,	   pre-­‐	   and	   post-­‐HFEE,	  with	   no	   differences	   over	   the	   course	   of	  HFEE.	  Peak	  plasma	   insulin	  concentrations	  and	   their	  corresponding	   time-­‐point	  were	  unaltered	  by	  HFEE	  and	  did	  not	  significantly	  differ	  between	  groups.	  	  The	   plasma	   insulin	   AUC	   over	   the	   120	  min	   duration	   of	   the	   OGTT	  was	   unaltered	   by	  HFEE	  with	  no	  significant	  difference	  between	  groups	  (Figure	  2.3C).	  The	  AUC	  for	  the	  first	  30	  and	  60	  min	  of	   the	  OGTT	  were	  unaltered	  by	  HFEE	   in	  either	  group	  (data	  not	  
	  
Figure	   2.2	   Plasma	   glucose	   concentrations	   for	   HF-­‐C	   (A)	   and	   HF-­‐FO	   (B)	   with	   incremental	   area	  under	   the	   curve	   (C)	   during	   the	   OGTT	   (0-­‐120	   min),	   pre-­‐	   and	   post-­‐HFEE.	   Data	   are	   expressed	   as	  means	  ±	  SEM,	  n=10	  in	  each	  group.	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shown)	  but	  the	  mean	  change	  ranged	  from	  17-­‐28	  %	  for	  HF-­‐C	  and	  from	  3-­‐8	  %	  for	  HF-­‐FO.	  	  	  	  
	  
	  
2.3.5.	  Plasma	  glucose	  enrichments	  The	  AUCs	  over	  the	  entire	  OGTT	  for	  total	  rate	  of	  appearance	  (Ra)	  of	  infused	  [6,6-­‐2H2]	  glucose	  and	  ingested	  [U-­‐13C]	  glucose,	  exogenous	  (ingested	  glucose)	  and	  endogenous	  Ra	   (glucose	   production)	   alone,	   and	   total	   rate	   of	   glucose	   disappearance	   (Rd)	   are	  presented	  in	  Table	  2.4.	  Peak	  plasma	  glucose	  Ra	  (total,	  exogenous	  and	  endogenous)	  and	   Rd	   with	   their	   respective	   time-­‐points	   are	   presented	   in	   Tables	   2.5	   and	   2.6,	  respectively.	  	  
	  
Figure	  2.3	  Plasma	  insulin	  concentrations	  for	  HF-­‐C	  (A)	  and	  HF-­‐FO	  (B)	  with	  incremental	  area	  under	  the	   curve	   (C)	   during	   the	   OGTT	   (0-­‐120	  min),	   pre-­‐	   and	   post-­‐HFEE.	   Data	   are	   expressed	   as	  means	   ±	  SEM,	  n=10	  in	  each	  group.	  	  	  






Table	  2.4	  Plasma	  stable	  isotope	  glucose	  AUCs.	  
	   HF-­‐C	   HF-­‐FO	  
	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
Total	  Ra	   209.9	  ±	  21.5	   195.6	  ±	  20.0	   208.7	  ±	  25.3	   213.3	  ±	  28.2	  
Exogenous	  Ra	   318.2	  ±	  21.1	   310.4	  ±	  14.7	   349.9	  ±	  22.6	   352.0	  ±	  27.9	  
Endogenous	  Ra	   113.0	  ±	  8.2	   118.4	  ±	  10.8	   143.1	  ±	  12.6	   139.0	  ±	  6.7	  
Total	  Rd	   255.1	  ±	  28.1	   278.2	  ±	  24.6	   273.3	  ±	  28.7	   283.2	  ±	  32.1	  
Data	  are	  presented	  in	  mg·min-­‐1·kg-­‐1:	  120	  min,	  measured	  pre-­‐	  and	  post-­‐HFEE,	  for	  HF-­‐C	  and	  HF-­‐FO.	  Values	  are	  means	  ±	  SEM,	  n	  =	  10	  per	  group.	  No	  statistically	  significant	  differences	  were	  observed	  by	  ANOVA.	  	  
Table	  2.5	  Peak	  plasma	  stable	  isotope	  glucose	  appearance	  /	  disappearance.	  
	   HF-­‐C	   HF-­‐FO	  
	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
Total	  Ra	   6.47	  ±	  0.33	   6.51	  ±	  0.26	   7.11	  ±	  0.38	   6.98	  ±	  0.43	  
Exogenous	  Ra	   4.56	  ±	  0.30	   4.82	  ±	  0.28	   5.17	  ±	  0.36	   5.35	  ±	  0.36	  
Endogenous	  Ra	   3.55	  ±	  0.13	   3.47	  ±	  0.11	   3.77	  ±	  0.15	   3.67	  ±	  0.09	  
Total	  Rd	   6.69	  ±	  0.38	   6.63	  ±	  0.28	   7.34	  ±	  0.48	   7.18	  ±	  0.50	  
Data	  are	  presented	  in	  mg·min-­‐1·kg-­‐1,	  measured	  pre-­‐	  and	  post-­‐HFEE,	  for	  HF-­‐C	  and	  HF-­‐FO.	  Values	  are	  means	  ±	  SEM,	  n	  =	  10	  per	  group.	  No	  statistically	  significant	  differences	  were	  observed	  by	  ANOVA.	  	  
Table	   2.6	   Time	   points	   corresponding	   to	   peak	   plasma	   glucose	   appearance	   /	  disappearance	  (displayed	  in	  Table	  2.5).	  
	   HF-­‐C	   HF-­‐FO	  
	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
Total	  Ra	   83	  ±	  9	   95	  ±	  11	   84	  ±	  9	   100	  ±	  6	  
Exogenous	  Ra	   105	  ±	  7	   116	  ±	  4	  *	   95	  ±	  8	   115	  ±	  4	  *	  
Endogenous	  Ra	   15	  ±	  2	   13	  ±	  2	   13	  ±	  2	   11	  ±	  1	  
Total	  Rd	   77	  ±	  6	   87	  ±	  8	   85	  ±	  8	   97	  ±	  6	  
Data	  are	  presented	  in	  min,	  measured	  pre-­‐	  and	  post-­‐HFEE,	  for	  HF-­‐C	  and	  HF-­‐FO.	  Values	  are	  means	  ±	  SEM,	  n	  =	  10	  per	  group.	  *	  significantly	  different	  from	  pre-­‐HFEE:	  main	  effect	  of	  time	  (p	  <	  0.05)	  by	  ANOVA.	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2.3.6.	  Insulin	  sensitivity	  Insulin	  sensitivity,	  assessed	  using	  a	  number	  of	   indices,	  was	  not	  significantly	  altered	  by	  HFEE	  and	  did	  not	  statistically	  differ	  between	  groups	  (Table	  2.7).	  Plots	  in	  Figure	  
2.4	   demonstrate	   the	   individual	   variation	   present	   in	   two	   representative	   indices,	  Matsuda	  ISI	  and	  HOMA-­‐IR.	  Evaluation	  of	  Matsuda	  insulin	  sensitivity	  with	  inferential	  statistics	  indicated	  a	  possible	  (62	  %)	  chance	  of	  a	  beneficial	  effect	  of	  FO	  consumption	  during	   HFEE	   (0.32	   ±	   0.68	   (90	   %	   CL)).	   Similar	   evaluation	   of	   HOMA-­‐IR	   insulin	  resistance	   with	   inferential	   statistics	   also	   indicated	   a	   possible	   (71	   %)	   chance	   of	   a	  beneficial	  effect	  of	  consuming	  FO	  during	  HFEE	  (-­‐0.46	  ±	  0.84	  (90	  %	  CL)).	  However,	  the	  mechanistic	   inference	   of	   HFEE	   for	   both	   insulin	   sensitivity	   indices	  was	   classified	   as	  unclear,	  with	  more	  data	  required.	  	  	  
	  	  
Table	   2.7	   Insulin	   sensitivity	   indices	   assessed	   using	   plasma	   glucose	   and	   insulin	   values	  during	  the	  OGTT.	  	  
	   HF-­‐C	   HF-­‐FO	  
	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
Matsuda-­‐ISI	   3.96	  ±	  0.62	   3.59	  ±	  0.50	   3.81	  ±	  0.39	   3.94	  ±	  0.36	  
HOMA-­‐IR	   2.80	  ±	  0.39	   3.20	  ±	  0.69	   2.45	  ±	  0.24	   2.35	  ±	  0.21	  
HOMA-­‐β	   177.94	  ±	  24.05	   218.22	  ±	  32.35	   162.16	  ±	  12.76	   163.65	  ±	  10.27	  
Hepatic-­‐IR	  index	   63.07	  ±	  8.74	   71.89	  ±	  15.58	   55.02	  ±	  5.38	   52.88	  ±	  4.82	  
Hepatic-­‐IS	  index	   0.02	  ±	  0.00	   0.02	  ±	  0.00	   0.02	  ±	  0.00	   0.02	  ±	  0.00	  Data	  are	  displayed	  pre-­‐	  and	  post-­‐HFEE,	  for	  both	  groups	  (HF-­‐C	  and	  HF-­‐FO;	  n=10	  per	  group).	  Values	  are	  means	  
±	   SEM	   (values	   displayed	   as	   0.00	   were	   <	   0.001).	  No	   statistically	   significant	   differences	   were	   observed	   by	  ANOVA.	  	  




2.3.7.	  Blood	  lipids	  A	   full	   blood	   FA	   profile	   is	   presented	   in	   Appendix	   2.3.	   Total	   n-­‐3	   PUFAs	   (when	  expressed	   as	   a	   percentage	   of	   total	   FAs)	   were	   significantly	   increased	   in	   HF-­‐FO	  
	  
	  
Figure	   2.4	   Individual	  Matsuda	  (A)	  and	  HOMA-­‐IR	   (B)	  responses	  to	  HFEE.	  The	  bars	  covered	  by	  a	  red	  shaded	  box	  indicate	  negative	  insulin	  sensitivity	  responses	  to	  HFEE,	  whereas	  the	  bars	  within	  a	  green	  shaded	  box	  represent	  positive	  a	  positive	  change	   in	   insulin	  sensitivity	   following	  HFEE.	  Data	  are	  expressed	  as	  individual	  values,	  n=10	  in	  each	  group.	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following	  HFEE,	  with	  no	  change	  in	  HF-­‐C	  (Figure	  2.5).	  Increased	  levels	  of	  EPA	  (0.57	  ±	  0.04	  to	  3.95	  ±	  0.38)	  and	  DHA	  (2.51	  ±	  0.14	  to	  4.21	  ±	  0.18)	  contributed	  most	  notably	  to	  the	   increases	   observed	   in	   total	   n-­‐3	   PUFAs	   in	   HF-­‐FO.	   	   The	   AA:EPA	   ratio	   was	  significantly	   decreased	   in	   HF-­‐FO	   over	   time	   (20.14	   ±	   1.57	   to	   3.01	   ±	   0.34)	   with	   no	  change	  in	  HF-­‐C.	  	  
	  
	  
Figure	  2.5	  n-­‐3	  PUFA	  composition	  of	  whole	  blood	  (n	  =	  10	  per	  group)	  pre-­‐	  and	  post-­‐HFEE	  for	  both	  HF-­‐C	  and	  HF-­‐FO,	  as	  measured	  by	  GLC.	  Data	  are	  expressed	  as	  means	  ±	  SEM,	  *	  significantly	  different	  from	  pre-­‐HFEE	  for	  its	  respective	  group,	  p	  <	  0.01	  (t-­‐test).	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2.4.	  Discussion	  We	  aimed	  to	  investigate	  various	  whole-­‐body	  glucose	  metabolism	  responses	  to	  a	  6	  d	  period	   of	   HFEE,	   and	   to	   determine	  whether	   replacing	   10	  %	   of	   dietary	   fats	  with	   FO	  could	  protect	  against	  any	  diet-­‐induced	  insulin	  resistance.	  Contrary	  to	  our	  hypothesis,	  we	   report	   that	   6	   d	   HFEE	   did	   not	   significantly	   alter	   whole-­‐body	   insulin	   sensitivity	  group	  means	  in	  our	  participant	  cohort	  of	  young,	  healthy,	  inactive	  males	  -­‐	  irrespective	  of	  FO	  consumption.	  	  	  In	   our	   hands,	   6	   d	   HFEE	   does	   not	   clearly	   alter	   insulin	   sensitivity	   group	   means	  irrespective	  of	  FO	  consumption.	  Whereas	  it	  is	  clear	  that	  long-­‐term	  HFEE	  does	  lead	  to	  declining	   insulin	   sensitivity	   (105,112),	   studies	   designed	   to	   investigate	   short-­‐term	  responses	   to	  HFEE	   report	   equivocal	   findings.	  Thus,	   our	   finding	   that	  6	  d	  HFEE	  does	  not	  lead	  to	  overall	  group	  perturbations	  in	  whole-­‐body	  insulin	  sensitivity	  is	  consistent	  with	   some	   reports	   (e.g.	   (19,98,99)),	   but	   is	   in	   contrast	   to	   other	   investigations	   (e.g.	  (103,109,112)).	  Understanding	  the	  conflicting	  results	  of	  these	  studies,	  including	  ours,	  is	   hampered	   by	   the	   use	   of	   different	   study	   populations	   and	   different	   experimental	  protocols.	  The	  primary	  differences	  in	  experimental	  protocol	  between	  studies	  include	  the	  methodology	  used	  to	  assess	  insulin	  action	  /	  sensitivity,	  and	  the	  dietary	  challenge	  including	   macronutrient	   composition	   and	   the	   extent	   /	   duration	   of	   energy	   excess.	  Future	  attempts	   to	  develop	  a	   reproducible	  model	  of	  diet-­‐induced	   insulin	   resistance	  will	  need	  to	  standardise	  some	  of	  these	  factors.	  However,	  arguably	  more	  significant	  to	  our	  understanding	  of	  human	  physiological	  responses	  to	  short-­‐term	  HFEE	  is	  the	  large	  degree	   of	   variation	   endemic	   in	   the	   majority	   of	   these	   studies	   including	   ours.	   Such	  individual	   variation	   in	   the	   response	   to	   a	   given	   stimulus	   highlights	   the	   influence	   of	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one’s	  metabolic	  phenotype,	  encompassing	  pre-­‐disposition	  and	  post-­‐transcriptional	  /	  translational	  regulation,	  for	  metabolic	  control	  and	  adaptation.	  	  Outcome	   measures	   of	   glucose	   metabolism	   and	   insulin	   sensitivity	   have	   differed	  between	   previous	   studies.	   We	   employed	   stable	   isotope	   metabolic	   tracers	   to	  investigate	  plasma	  glucose	  kinetics	   following	  consumption	  of	  an	  oral	  glucose	  bolus.	  Despite	  no	  significant	  changes	   in	  the	  rates	  of	  glucose	  appearance	  (both	  endogenous	  and	   exogenous)	   and	   disappearance,	   the	   time	   corresponding	   to	   peak	   exogenous	  glucose	  appearance	  was	  significantly	  delayed	  following	  HFEE.	  Potential	  explanations	  for	   this	   finding	   relate	   to	   alterations	   in	   digestion	   and	   absorption	   processes	   of	   the	  ingested	   glucose	   bolus.	   Levels	   of	   gut	   incretin	   proteins	   including	   gastric	   inhibitory	  peptide	  (GIP)	  have	  previously	  been	  shown	  to	  increase	  following	  HFEE	  (19)	  and	  may	  be	  a	  potential	  mechanism	  regulating	  our	  finding	  of	  delayed	  peak	  exogenous	  glucose	  appearance.	  
 There	  are	  a	  number	  of	  factors	  that	  influence	  the	  insulin	  sensitivity	  response	  to	  short-­‐term	  periods	  of	  HFEE.	  Sex-­‐specific	  differences	  influence	  substrate	  metabolism	  (210)	  and	  thus	  may	   influence	  the	   insulin	  sensitivity	  response	  to	  HFEE.	  When	  we	  consider	  that	   the	   insulin	   sensitivity	   response	   of	   our	   all-­‐male	   cohort	   and	   other	   comparable	  single-­‐sex	   male	   cohorts	   (19,99)	   did	   not	   significantly	   change	   following	   short-­‐term	  HFEE,	  it	  is	  possible	  that	  female	  sex	  is	  a	  risk	  factor	  for	  maladaptive	  responses	  to	  short-­‐term	  HFEE.	  This	  proposal	  is	  supported	  by	  experimental	  data	  from	  mixed-­‐sex	  cohorts	  where	   detrimental	   effects	   of	   overfeeding	   are	   evident	   in	   females	   but	   not	   males	  (98)(112).	   It	   is	   important	   to	   acknowledge	   that	   the	   influence	   of	   sex	   on	   the	   insulin	  sensitivity	   response	   to	   overfeeding	   may	   be	   confounded	   by	   fat	   mass.	   The	   insulin	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sensitivity	  response	  to	  short-­‐term	  overfeeding	  has	  been	  shown	  to	  differ	  between	  lean	  and	  reduced-­‐obese	  females	  (98).	  When	  we	  consider	  that	  females	  typically	  possess	  a	  greater	  proportion	  of	   their	  body	  mass	  as	   fat	  compared	  to	  males	  (210)	   it	   is	  possible	  that	   fat	  mass	  may	  be	  confounding	  our	   interpretation	  of	  sex-­‐mediated	  differences	   in	  the	  insulin	  sensitivity	  response	  to	  overfeeding.	  Therefore,	  the	  independent	  effects	  of	  fat	   mass,	   between	   and	   within	   sexes,	   on	   insulin	   sensitivity	   change	   should	   be	  investigated	  in	  future	  studies.	  	  	  Habitual	  participant	  activity	  levels	  are	  variable	  between	  studies	  and	  may	  have	  a	  role	  in	  the	  insulin	  sensitivity	  response	  to	  HFEE.	  An	  exclusion	  criterion	  was	  applied	  in	  the	  current	   study	   based	   on	   activity	   levels	   that	   met	   current	   UK	   government	  recommendations	  (no	  participant	  in	  our	  study	  exercised	  more	  than	  2	  x·wk-­‐1),	  and	  in	  the	  study	  of	  Brøns	  et	  al.	   (19)	  based	  on	  >	  10	  h·wk-­‐1.	  Both	  of	   these	  exclusion	  criteria	  permitted	   a	   degree	   of	   physical	   activity,	   and	   habitual	   activity	   levels	   reflected	   in	  cultural	  norms	  (i.e.	  Danish	  volunteers	  likely	  will	  have	  higher	  habitual	  levels	  of	  activity	  than	   UK	   counterparts)	   also	   may	   alter	   this	   characterisation	   of	   physical	   activity.	  However,	   although	   Brøns	   et	   al.	   (19)	   likely	   studied	   a	   more	   active	   cohort	   than	   was	  studied	   in	   the	   present	   investigation,	   participants	   in	   both	   studies	   would	   not	   be	  considered	  regular	  exercisers.	  Whereas	  Brøns	  et	  al.	  (19)	  reported	  a	  change	  in	  hepatic	  insulin	  sensitivity,	  but	  not	  peripheral	  insulin	  sensitivity,	  following	  HFEE,	  we	  report	  no	  change	   in	   either	   parameter	   (inferred	   from	   HOMA-­‐IR	   and	   Matsuda	   indices).	   Other	  studies	  that	  used	  active	  participant	  cohorts	  have	  demonstrated	  declining	  whole-­‐body	  insulin	   sensitivity	   following	   short-­‐term	   HFEE	   (107,109,115).	   Thus,	   the	   insulin	  sensitivity	  response	  to	  HFEE	  may	  be	  mediated	  by	  participant	  physical	  activity	  status,	  with	   greater	   perturbations	   towards	   the	   insulin-­‐resistant	   state	   observed	   in	   more	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physically	  active	  populations.	  However,	  significant	  declines	  in	  insulin	  sensitivity	  also	  have	   been	   reported	   following	   HFEE	   in	   sedentary	   individuals	   (108,112).	   Thus,	   the	  influence	  of	  physical	  activity	  on	  the	  HFEE-­‐mediated	  insulin	  sensitivity	  response	  is	  not	  completely	  clear.	  	  	  The	  influence	  of	  habitual	  physical	  activity	  levels	  on	  the	  insulin	  sensitivity	  response	  to	  HFEE	   may	   relate	   to,	   and	   /	   or	   be	   explained	   by,	   metabolic	   flexibility.	   Metabolic	  flexibility	   is	   the	   ability	   to	   adjust	   fuel	   oxidation	   to	   fuel	   availability	   (211).	   Factors	  indicative	  of	  exercise	  adaptation	  including	  skeletal	  muscle	  fibre	  type	  composition	  and	  mitochondrial	  oxidative	  capacity	  can	  impact	  metabolic	  flexibility	  (211).	  Although	  the	  mechanisms	  are	  not	  currently	  known,	  metabolic	  flexibility	  and	  insulin	  sensitivity	  do	  appear	   to	   be	   linked	   (211,212).	   With	   short-­‐term,	   HFEE	   models,	   metabolic	  perturbations	  (e.g.	  altered	  glucose	  handling)	  are	  observed	  at	  3	  d	  (103,112)	  arguably	  due	  to	   the	  metabolic	  stress	  placed	  upon	  the	  body.	  Yet,	  most	  studies,	   including	  ours,	  fail	   to	   show	   clear	   decrements	   in	   insulin	   sensitivity	   ~	   5-­‐7	   d	   (19,99),	   although	   this	  finding	   is	   equivocal	   (109,115).	   The	  metabolic	   health	   /	   flexibility	   of	   the	   individuals	  may	   enable	   the	   body	   to	   respond	   to	   the	   initial	   metabolic	   stress	   and	   adjust	   fuel	  oxidation	   accordingly	   over	   the	   subsequent	   days	   to	   adapt	   to	   the	   demands.	   Indeed,	  following	  a	  7	  d	  high-­‐fat	  diet,	  fat	  oxidation	  was	  increased	  to	  match	  fat	  intake	  by	  day	  7,	  but	   fat	   oxidation	   was	   not	   increased	   to	   match	   the	   demands	   at	   day	   2	   (213).	   This	  timescale	  of	  metabolic	  events	  also	   is	  supported	  by	  previous	  research	  examining	  the	  24	  h	  respiratory	  quotient	  over	  the	  course	  of	  a	  7	  d	  high-­‐fat	  (isocaloric)	  diet.	  These	  data	  show	  that	  it	  is	  not	  until	  day	  5	  that	  RQ	  is	  reduced	  from	  ~0.88/0.89	  (Day	  1)	  to	  ~0.80	  and	  plateaus	  thereafter	  (211).	  Moreover,	  day	  5	  is	  the	  time-­‐point	  at	  which	  the	  greatest	  gap	  in	  RQ	  between	  metabolically	  flexible	  vs.	  metabolically	  inflexible	  individuals	  exists	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(211).	  Unfortunately,	   in	   the	   present	   investigation,	  we	   did	   not	  measure	  RQ	  or	   basal	  metabolic	   rate	   and	   thus	   cannot	   infer	   changes	   in	   metabolic	   fuel	   oxidation	   over	   the	  course	  of	   the	   feeding	   intervention.	  However,	  based	  on	  our	  participants’	  body	  mass,	  insulin	   sensitivity	   and	   age,	   we	   would	   expect	   our	   participants	   to	   be	   largely	  metabolically	  flexible,	  and	  thus	  anticipate	  a	  shift	  towards	  fat	  oxidation	  during	  the	  6	  d	  feeding	   period.	   By	   increasing	   fat	   oxidation,	   fat	   accumulation,	   and	   its	   associated	  impact	  on	  insulin	  sensitivity,	  will	  be	  reduced.	  Therefore,	  metabolic	  flexibility	  and	  the	  duration	   of	   energy	   excess	   are	   likely	   important	   factors	   in	   determining	   the	   insulin	  sensitivity	  response	  to	  HFEE.	  	  	  The	   time	  course	  of	  maladaptation	   from	  the	  earliest	   signs	  of	  defective	   insulin	  action	  through	   to	   the	   diagnosis	   of	   insulin	   resistance	   and	   manifest	   T2D	   remains	   to	   be	  established.	  However,	  even	  with	  consideration	  for	  the	  timescale	  of	  insulin	  sensitivity	  change	  and	  the	  metabolic	  health	  of	  participants,	  alterations	  in	  markers	  of	  whole-­‐body	  insulin	  resistance	  may	  be	  observed	  that	  precede	  measurable	  changes	  in	  whole-­‐body	  insulin	   sensitivity.	   In	   the	  present	   study,	   significant	   increases	   in	   fat	  mass	  within	   the	  trunk,	   and	   specifically	   android,	   regions	   were	   observed.	   Increases	   in	   fat	   mass	   have	  been	   widely	   associated	   with	   T2D	   development	   (13)	   yet	   we	   failed	   to	   show	   any	  decrements	  in	  insulin	  sensitivity	  at	  the	  same	  time	  point.	  Following	  a	  2	  wk	  period	  of	  overeating,	   fat	   mass	   was	   significantly	   increased	   concomitant	   with	   reduced	   insulin	  sensitivity	  (105).	  Therefore,	   fat	  mass	  gains	  may	  precede	  the	  development	  of	   insulin	  sensitivity.	  Brøns	  et	  al.,	   (19)	  also	  did	  not	  observe	  any	  change	   in	  whole-­‐body	   insulin	  sensitivity	   following	   a	   feeding	   intervention	   largely	   analogous	   to	   the	   one	   in	   the	  present	  investigation.	  However,	  they	  did	  report	  a	  significant	  increase	  in	  basal	  hepatic	  glucose	   production	   using	   isotope	   tracer	   methodology	   (19).	   In	   the	   present	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investigation,	   the	   insulin	   sensitivity	   of	   the	   hepatocyte,	   inferred	   from	   the	   rate	   of	  endogenous	   glucose	   production,	   was	   not	   significantly	   altered	   despite	   using	   similar	  stable	  isotope	  methodology.	  However,	  a	  15	  %	  mean	  increase	  in	  HOMA-­‐IR,	  indicative	  of	   hepatic	   insulin	   resistance,	   was	   measured	   in	   the	   HF-­‐C	   group	   and	   for	   some	  individuals	   (5/10	   had	   an	   increase	   of	   >20%)	  may	   suggest	   early	  maladaptation	   of	   a	  similar	   nature	   to	   those	   documented	   in	   the	   study	   by	   Brøns	   and	   co-­‐workers	   (19).	  Moreover,	   as	   with	   HOMA-­‐IR,	   although	   a	   large	   inherent	   variability	   existed	   in	   the	  response,	  a	  mean	  17	  %	  increase	  in	  fasting	  plasma	  insulin	  levels	  in	  the	  HF-­‐C	  group	  was	  observed.	   Evaluation	   of	   individual	   values	   demonstrated	   a	   basal	   plasma	   insulin	  increase	  of	  more	  than	  20	  %	  in	  5	  out	  of	  10	  participants.	  These	  increases	  in	  the	  fasting	  plasma	   insulin	   response	   may	   explain,	   in	   part,	   the	   maintained	   insulin-­‐mediated	  suppression	   of	   hepatic	   glucose	   output	   following	   HFEE.	   Development	   of	   insulin	  resistance	   is	   thought	   to	   be	   preceded	   by	   an	   increase	   in	   basal	   plasma	   insulin	   levels,	  which	  are	  increased	  in	  order	  to	  maintain	  euglycaemia	  (8).	  It	  is	  therefore	  possible	  that	  some	   of	   our	   participants,	   particularly	   those	   in	   HF-­‐C,	   were	   showing	   early	   signs	   of	  maladaptation	  despite	  the	  absence	  of	  clear	  group	  changes	  in	  insulin	  sensitivity.	  	  	  A	   novel	   feature	   of	   our	   investigation	   was	   the	   inclusion	   of	   a	   second	   experimental	  participant	  group	  (HF-­‐FO).	  HF-­‐FO	  consumed	  a	  diet	   identical	   in	  the	  degree	  of	  energy	  excess	  and	  macronutrient	  contributions	   to	  HF-­‐C,	  but	  with	   the	  provision	  of	  FO	  at	  an	  amount	   equivalent	   to	   10	  %	  of	   the	   total	   consumed	  dietary	   lipids.	   This	   FO	  dose	  was	  chosen	  to	  elicit	  functional	  changes	  in	  fatty	  acid	  composition	  of	  the	  plasma	  membrane.	  Previous	   studies	  have	  provided	  n-­‐3	  PUFAs	  at	  a	  proportion	  as	  high	  as	  15	  %	  of	   total	  FAs	  (147).	  The	  purpose	  of	   the	  HF-­‐FO	  group	  was	   to	  ascertain	  whether	   the	  nature	  of	  consumed	  fat	  altered	  the	  metabolic	  and	  molecular	  responses	  to	  HFEE.	  During	  a	  7	  wk	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intervention,	   elevated	   fat	   intake	   in	   the	   form	   of	   PUFA	   (albeit	   n-­‐6)	   resulted	   in	   less	  visceral	   fat	   accumulation	   (a	   marker	   of	   hepatic	   insulin	   resistance)	   than	   equivalent	  intakes	   of	   SFA	   (192).	   Thus,	   markers	   of	   insulin	   sensitivity	   and	   metabolic	  maladaptation	   may	   be	   differentially	   altered	   by	   the	   type	   of	   consumed	   dietary	   fat.	  Evaluation	  of	  inferential	  statistics	  and	  the	  mean	  whole-­‐body	  responses	  to	  HFEE	  of	  a	  number	  of	   indices	  suggest	  some	  possible	  benefits	  of	  FO	  consumption	  in	  the	  present	  investigation.	  Circulating	  levels	  of	  n-­‐3	  PUFAs,	  and	  in	  particular	  the	  most	  metabolically	  active	   species,	   EPA	   and	   DHA,	   were	   significantly	   increased	   following	   HFEE	   in	   the	  group	  consuming	  FO	  (HF-­‐FO).	  These	  data	  indicate	  adequate	  FO	  dosing	  for	  detecting	  changes	   in	   whole	   blood	   lipids,	   and	   suggest	   dietary	   compliance	   to	   the	   feeding	  intervention	   with	   expected	   differences	   between	   groups.	   However,	   changes	   in	   the	  composition	  of	  plasma	  membranes	  require	   investigation	  before	   functional	  effects	  of	  FO	  intake	  can	  be	  assumed.	  Nonetheless,	  evaluation	  of	  Matsuda	  and	  HOMA-­‐IR	  insulin	  sensitivity	   indices	   with	   inferential	   statistics	   indicated	   a	   possible	   (62	   %)	   /	   (71	   %)	  chance,	   respectively,	   of	   a	   beneficial	   effect	   of	   FO	   consumption	   during	   HFEE.	  Considering	  these	   inferences	  and	  the	   large	  degree	  of	  variation	  observed	  in	  our	  data	  we	   wish	   to	   highlight	   individual	   variation	   and	   suggest	   that	   investigation	   of	  mechanisms	  relating	  to	  gene	  expression	  /	  activation	  may	  facilitate	  our	  understanding	  of	  the	  underlying	  individual	  regulation	  of	  glucose	  metabolism.	  	  In	   summary,	   6	   d	   HFEE	   leads	   to	   significant	   gains	   in	   total	   body	  mass	   and	   fat	   mass,	  largely	  consistent	  with	  the	  degree	  of	  energy	  oversupply.	  Moreover,	  FO	  consumption	  at	  a	  dose	  of	  10	  %	  of	  total	  fats	  within	  our	  model	  of	  energy	  excess	  results	  in	  elevated	  n-­‐3	   PUFA	   content	   of	   whole	   blood,	   suggesting	   adequate	   dosing	   and	   timing	   for	   lipid	  turnover.	   However,	   these	   findings	   were	   not	   translated	   into	   overall	   group	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perturbations	  in	  whole-­‐body	  insulin	  sensitivity	  in	  response	  to	  an	  oral	  glucose	  load	  in	  our	  healthy	  male	  volunteers.	  Thus,	  whereas	  some	  individuals	  did	  respond	  robustly	  to	  the	   dietary	   intervention,	   in	   our	   hands,	   6	   d	  HFEE	  with	   50	  %	   energy	   excess	   is	   not	   a	  complete	   model	   for	   investigating	   diet-­‐induced	   whole-­‐body	   insulin	   resistance	   in	  healthy,	  young,	  inactive	  males.	  	  	  Researchers	   wishing	   to	   design	   a	   reproducible	   model	   of	   diet-­‐induced	   insulin	  resistance	   in	   future	   should	   consider	   a	   time	   course	   investigation	   with	   multiple	  repeated	   measurements	   before,	   and	   extending	   past,	   6	   d	   of	   HFEE	   and	   /	   or	   study	  different	  populations.	  Particular	  attention	  should	  be	  afforded	  to	  participant	  sex	  and	  metabolic	   flexibility,	   including	  habitual	  activity	   levels,	  of	   the	  cohort.	  To	  enhance	  the	  chances	   of	   inducing	   insulin	   resistance	   during	   short-­‐term	  HFEE,	   separate	   groups	   of	  metabolically	  inflexible	  males	  and	  females,	  notably	  sedentary	  and	  overweight,	  should	  be	  used.	  However,	  there	  also	  is	  an	  argument	  for	  studying	  a	  highly	  active	  cohort	  and	  restricting	   physical	   activity	   during	   HFEE	   so	   that	   the	   change	   in	   metabolic	   stress	   is	  maximised.	   Nevertheless,	   it	  must	   be	   emphasised	   that	  mechanistic	   perturbations	   at	  the	  muscle	  level	  were	  not	  investigated	  in	  the	  current	  investigation	  and	  may	  precede	  measurable	   changes	   in	   insulin	   sensitivity.	   In	   this	   case,	   6	   d	   HFEE	   may	   be	   a	   useful	  model	   for	   investigating	   the	   underlying	   skeletal	   muscle-­‐mediated	   mechanisms	   that	  lead	  to	  the	  development	  of	  whole-­‐body	  insulin	  resistance	  in	  the	  long-­‐term.	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CHAPTER	  3	  Skeletal	  muscle	  ceramide	  content	  is	  increased	  in	  young,	  healthy	  males	  following	  6	  days	  high-­‐fat	  energy	  excess	  in	  the	  absence	  of	  changes	  in	  mitochondrial	  enzyme	  activity.	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3.0.	  Abstract	  We	  aimed	  to	  investigate	  the	  lipid-­‐mediated,	  skeletal	  muscle	  (mal)adaptations	  to	  a	  6	  d	  period	  of	  lipid	  and	  energy	  excess	  (HFEE).	  Twenty,	  young,	  healthy	  males	  were	  overfed	  (150	  %	  habitual	  energy	  intake;	  60	  %	  fat,	  25	  %	  carbohydrate,	  15	  %	  protein)	  for	  6	  d.	  Two	  identical	  trials	  were	  conducted	  immediately	  prior	  to,	  and	  following,	  HFEE.	  Basal	  blood	   samples	   collected	   during	   each	   trial	   were	   used	   to	   assess	   plasma	   lipids,	  adiponectin	  and	  TNF-­‐α.	  Basal	   skeletal	  muscle	  biopsies	   from	  each	   trial	  were	  used	   to	  assess	   phospholipid	   profiles,	   ceramide	   levels,	   and	   the	   activity	   of	   AMPK	   α2	   and	  mitochondrial	   enzymes	   (citrate	   synthase	   and	   β-­‐HAD).	   Skeletal	  muscle	   PKB	   activity	  was	  measured	  in	  both	  the	  basal	  and	  insulin-­‐stimulated	  (2	  h)	  state.	  Plasma	  levels	  of	  TG	  and	  FA	  were	  significantly	  reduced	  following	  HFEE,	   irrespective	  of	  group	  (-­‐27	  ±	  5	  %	  (TG),	  -­‐27	  ±	  9	  %	  (FA)),	  whereas	  HDL	  was	  significantly	  increased	  in	  HF-­‐FO	  only	  (19	  ±	  5	  %).	   Total	   skeletal	   muscle	   ceramide	   levels	   were	   increased	   following	   HFEE	   (HF-­‐C:	  10.18	  ±	  2.29	  to	  14.49	  ±	  2.88;	  HF-­‐FO:	  6.87	  ±	  0.79	  to	  9.70	  ±	  1.75	  nmol·mg-­‐1,	  p	  =	  0.04)	  without	   change	   in	   activities	   of	   citrate	   synthase	   or	   β-­‐HAD.	   AMPK	   α2	   activity	   was	  differentially	   regulated	   between	   groups;	   HF-­‐FO	   had	   increased	   AMPK	   α2	   activity	  following	   HFEE	   (4.08	   ±	   0.57	   to	   5.26	   ±	   0.73	   µM·mg-­‐1),	   whereas	   HF-­‐C	   had	   reduced	  AMPK	  α2	  activity	  following	  HFEE	  (4.55	  ±	  0.72	  to	  3.78	  ±	  0.87	  µM·mg-­‐1,	  interaction:	  p	  =	  0.03).	   The	   insulin-­‐stimulated	   rise	   in	   PKB	  was	   greater	   pre-­‐HFEE	   compared	   to	   post-­‐HFEE	   for	  HF-­‐C	   (106	  ±	  38	  vs.	   95	  ±	  48	  %)	  with	  no	  change	   in	  HF-­‐FO.	  HFEE	   for	  6	  d	   is	  characterised	   by	   lipid-­‐mediated	   perturbations	   at	   the	   skeletal	  muscle	   level,	   some	   of	  which	  are	  modified	  by	  FO	  consumption,	  and	  which	  collectively	  may	  help	  inform	  the	  metabolic	  basis	  for	  insulin	  resistance	  development.	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3.1.	  Introduction	  
Chapter	   2	   provided	   an	   overview	   of	   the	  whole-­‐body	   responses	   to	   6	   d	  HFEE	   in	   the	  context	   of	   glucose	   metabolism	   and	   insulin	   action.	   The	   principle	   finding	   was	   that	  insulin	   sensitivity	   group	  means	   were	   not	   significantly	   altered	   following	   6	   d	   HFEE.	  However,	   a	   large	   degree	   of	   variability	   around	   the	   mean	   change	   was	   observed	   for	  insulin	  sensitivity	  and	  other	  measures.	  Thus,	  the	  impact	  of	  different	  dietary	  practises	  on	   metabolic	   responses	   may	   be	   greater	   for	   some	   individuals	   compared	   to	   others.	  Moreover,	  the	  underlying	  regulation	  of	  insulin	  sensitivity	  may	  be	  maladaptive	  at	  the	  skeletal	  muscle	   level	  before	  whole-­‐body	  diet-­‐induced	  insulin	  resistance	  occurs.	  This	  subcellular	   regulation	   within	   skeletal	   muscle	   may	   relate	   to	   perceived	   individual	  differences	  and	  /	  or	  be	  explained,	  in	  part,	  by	  the	  role	  of	  fats	  and	  their	  intermediates,	  present	  in	  the	  circulation	  and	  intramuscularly.	  	  	  Insulin	   sensitivity	   is	   characterised	   by	   insulin	   action	   on	   skeletal	   muscle,	   liver	   and	  adipose	   tissue.	   Impairments	   in	  whole-­‐body	   insulin	   sensitivity	   are	   therefore	   largely	  reflective	   of	   defects	   in	   one	   or	  more	   of	   these	   tissues	   (42,214).	   Insulin	   sensitivity	   is	  regulated	  by	  many	  factors.	  Ectopic	  fat	  deposition,	  i.e.,	  the	  storage	  of	  fat	  in	  non-­‐adipose	  tissue	   (usually	   due	   to	   FA	   spillover	   from	  adipose	   tissue)	   is	   one	   adaptation	   resulting	  from	  fat	  oversupply	  that	  negatively	  impacts	  insulin	  signalling	  /	  sensitivity	  (215).	  An	  inability	   to	   upregulate	   fat	   oxidation	   in	   the	   presence	   of	   fat	   oversupply	   can	   lead	   to	  elevated	  tissue	  levels	  of	  TGs	  and	  other	  lipid	  moieties	  including	  DAGs,	  LcFA-­‐CoAs	  and	  ceramides	  (78).	  Accumulation	  of	  these	  lipid	  moieties,	  particularly	  in	  insulin	  sensitive	  tissues	  such	  as	  skeletal	  muscle	  and	  liver,	  can	  negatively	   impact	   insulin	  signalling	  by	  inhibiting	   the	   phosphorylation	   of	   insulin	   signalling	   intermediates	   (78).	   Therefore,	  increases	   in	   TGs,	   DAGs,	   LcFA-­‐CoAs	   and	   ceramides	   all	   have	   been	   touted	   as	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characteristic	  of	   the	  metabolic	   syndrome	   (77).	   Investigation	  of	   the	   impact	  of	   short-­‐term	   periods	   of	   HFEE	   on	   intramuscular	   fat	   accumulation,	   in	   the	   absence	   of	  measurable	  changes	  in	  whole-­‐body	  insulin	  sensitivity,	  may	  aid	  our	  understanding	  of	  insulin	  resistance	  development.	  	  	  	  	  	  Skeletal	  muscle	  ceramide	  content	  is	  altered	  with	  insulin	  resistance	  and	  affects	  insulin	  signalling.	   Ceramide	   synthesis	   is	   driven	   by	   palmitate	   availability,	   ER	   stress	   and	  inflammation,	   often	   indicated	   by	   elevated	   TNF-­‐α	   levels	   (84).	   In	   contrast,	   the	   lipid	  mediator	   adiponectin	   stimulates	   ceramide	   degradation	   (84).	   Increased	   synthesis	   of	  ceramides	   within	   in	   vitro	   cultured	   myotubes	   has	   been	   attributed	   to	   increased	  palmitate	   availability	   and	   associates	   with	   impaired	   PKB	   phosphorylation	   and	  subsequent	  glucose	  transport	  in	  a	  dose-­‐dependent	  manner	  (87).	  Ceramides	  also	  have	  been	   implicated	   in	   human	   T2D	   pathology	   (77,90,91)	  with	   increased	   intramuscular	  levels	   in	   obese,	   insulin-­‐resistant	   individuals	   compared	   to	   lean	   counterparts	   (72).	  These	  findings	  occurred	  in	  combination	  with	  reduced	  insulin	  signalling	  via	  decreased	  phosphorylation	  of	  PKBSer473	  and	  PKBThr308	  in	  the	  obese,	  insulin-­‐resistant	  cohort	  (72).	  Thus,	   skeletal	   muscle	   ceramide	   levels,	   PKB	   phosphorylation	   and	   insulin	   action	   all	  appear	  to	  be	  reciprocally	  regulated	  within	  the	  context	  of	  manifest	  insulin	  resistance.	  However,	  whether	   skeletal	  muscle	   ceramide	   levels	   are	  altered	  prior	   to	   the	  onset	  of	  insulin	  resistance	  following	  short-­‐term,	  HFEE	  in	  humans	  is	  currently	  unknown.	  	  	  The	  normal	  counter-­‐response	  to	  increased	  fat	  supply	  and	  accumulation	  is	  to	  increase	  fat	   oxidation.	   Given	   that	   fat	   oxidation	   occurs	   within	   the	   mitochondrial	   matrix,	   FA	  transport	  into,	  and	  /	  or	  the	  activity	  of	  enzymes	  within,	  the	  mitochondrial	  matrix,	  are	  both	  factors	  that	  will	  regulate	  the	  rate	  of	  fat	  oxidation.	  Moreover,	  the	  density	  and	  size	  
Chapter	  3:	  Lipid	  metabolism	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  74	  
	  	  
of	  mitochondria	  will	  impact	  fat	  oxidation.	  Fat	  oxidation	  is	  reduced	  in	  T2D	  compared	  to	   healthy	   counterparts	   (216,217)	   despite	   comparable	   intrinsic	   mitochondrial	  oxidative	   capacities	   (216).	   However,	   fat	   oxidation	   is	   limited	   by	   a	   decrease	   in	   the	  density	   of	   mitochondria	   within	   insulin-­‐resistant	   skeletal	   muscle	   tissue	   (216).	  Reduced	  mitochondrial	   content,	   by	   default,	  will	   reduce	   total	  mitochondrial	   enzyme	  activity	  and	  impact	  subsequent	  fat	  oxidation.	  	  Mitochondrial	   fat	   oxidation	   is	   largely	   regulated	   by	   AMP-­‐activated	   protein	   kinase	  (AMPK);	   a	   metabolic	   regulator	   of	   energy	   balance	   (218).	   AMPK	   regulates	   energy	  balance	   by	   increasing	   flux	   through	   ATP-­‐producing	   pathways	   and	   reducing	   flux	  through	   ATP-­‐consuming	   pathways	   (218).	   Pharmacological	   activation	   of	   AMPK	   has	  been	   shown	   to	   increase	   FA	   oxidation	   (219,220)	  whereas	   reduced	   AMPK	   activity	   is	  associated	   with	   decreased	   FA	   oxidation	   within	   skeletal	   muscle	   (220,221).	   Thus,	  investigations	  of	  AMPK	  activity	  and	  mitochondrial	  enzyme	  activity	  following	  a	  period	  of	  short-­‐term,	  HFEE	  may	  aid	  our	  understanding	  of	   the	  regulation	  of	   fat	  oxidation	   in	  these	  contexts.	  	  
Rates	   of	   fat	   oxidation	   and	   fat	   accumulation	   may	   be	   affected	   by	   the	   nature	   of	  consumed	   fat.	   Research	   has	   highlighted	   a	   TG-­‐lowering	   effect	   of	   n-­‐3	   PUFA	   intake	  (142,143),	  and	  a	  positive	  association	  between	  the	  n-­‐3	  PUFA	  composition	  of	  skeletal	  muscle	   membranes	   and	   insulin	   sensitivity	   (21).	   Moreover,	   ceramide	   synthesis	   is	  regulated	   by	   SFA	   availability	   (84)	   in	   a	   dose-­‐dependent	   manner	   (87).	   Therefore,	  reductions	   in	  SFA	   intake	  and	  /	  or	   increased	  n-­‐3	  PUFA	  consumption	  may	  reduce	  TG	  concentrations	   and	   ceramide	   synthesis,	   and	   improve	   insulin	   sensitivity.	   Thus,	   the	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influence	   of	   n-­‐3	   PUFA	   intake	   on	   lipid-­‐mediated	   responses	   to	   HFEE	   at	   the	   skeletal	  muscle	  level	  warrants	  attention.	  
	  
Our	   aims	  were	   two-­‐fold.	   First,	  we	   aimed	   to	   investigate	   the	   impact	   of	   6	   d	  HFEE	   on	  circulating	   lipid	   /	   lipid	   mediator	   levels,	   skeletal	   muscle	   ceramide	   levels,	   and	   the	  relationship	   between	   any	   changes	   in	   ceramide	   levels	   and	   PKB,	   AMPK	   or	  mitochondrial	   enzyme	   activity.	   Second,	   we	   aimed	   to	   investigate	   the	   influence	   of	  replacing	  10	  %	  of	  dietary	  fats	  with	  fish	  oil	  (FO)	  on	  these	  (mal)adaptive	  responses.	  We	  hypothesised	   that,	   1)	   6	   d	   HFEE	  would	   result	   in	   elevated	   skeletal	  muscle	   ceramide	  levels,	  2)	  changes	  in	  ceramide	  levels	  would	  associate	  with	  changes	  in	  PKB,	  AMPK	  and	  mitochondrial	  enzyme	  activity,	  and	  3)	  dietary	  FO	  consumption	  would	  ameliorate	  the	  increase	  in	  ceramide	  levels	  and	  associated	  mechanisms.	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3.2.	  Methods	  
3.2.1.	  Ethical	  approval	  Ethical	  approval	  was	  obtained	  from	  the	  NHS	  East	  of	  Scotland	  Research	  Ethics	  Service	  (REC	  2)	  and	  the	  study	  was	  conducted	  in	  accordance	  with	  the	  Declaration	  of	  Helsinki	  (197).	   Having	   had	   the	   study	   purpose	   and	   procedures	   explained	   in	   lay	   terms,	   all	  participants	  provided	  written	  informed	  consent.	  	  	  	  
3.2.2.	  Participants	  and	  study	  design	  Participants	   and	   study	   design	   have	   been	   described	   in	   detail	   in	  Chapter	   2.	   Briefly,	  twenty,	  healthy	  males	  were	  recruited	  from	  the	  University	  of	  Stirling	  and	  surrounding	  area	  to	  participate	  in	  the	  investigation.	  Participants	  were	  excluded	  if	  they	  consumed	  a	  diet	  high	  in	  fish	  oil	  sources	  or	  took	  fish	  oil	  supplements,	  had	  a	  fasting	  blood	  glucose	  of	  >	  6.1	  mmol·L-­‐1,	  or	  met	   the	  recommended	  physical	  activity	  guidelines	   for	  health	   (30	  min·d-­‐1,	  5	  x·wk-­‐1).	  	  In	  a	  randomised,	  parallel	  study	  design,	  participants	  were	  matched	  to	  either	  a	  high-­‐fat	  control	  (HF-­‐C;	  n	  =	  10)	  or	  a	  high-­‐fat,	  fish	  oil	  (HF-­‐FO;	  n	  =	  10)	  group	  based	  on	  age,	  body	  mass,	  physical	  activity	  and	  habitual	  energy	  intake.	  Two	  identical	  testing	  days	  (Figure	  
2.1B	   (Chapter	   2))	   included	   basal	   blood	   sampling	   and	   collection	   of	   two	   skeletal	  muscle	  biopsies	  per	  trial.	  One	  skeletal	  muscle	  biopsy	  was	  obtained	  in	  the	  basal	  state	  and	  the	  other	  in	  the	  insulin-­‐stimulated	  state,	  2	  h	  after	  glucose	  feeding.	  A	  3	  d	  baseline	  diet	  was	  designed	  to	  reflect	  individual	  habitual	  energy	  and	  macronutrient	  intake,	  and	  was	   consumed	   by	   all	   participants	   prior	   to	   baseline	   testing	   (infusion	   trial	   1;	   pre-­‐HFEE).	   Between	   infusion	   trials	   1	   and	   2	   (i.e.,	   pre-­‐	   and	   post-­‐HFEE),	   all	   participants	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consumed	  a	  high	  fat,	  high	  energy	  diet	  (150	  %	  of	  habitual	  energy	  intake	  with	  60	  %	  of	  energy	   from	   fat,	   25	  %	   from	   carbohydrate	   and	  15%	   from	  protein)	   for	   6	   d,	  with	   the	  only	  exception	  that	  HF-­‐FO	  had	  10	  %	  of	  dietary	  fats	  replaced	  by	  fish	  oil.	  	  	  	  
3.2.3.	  Blood	  and	  skeletal	  muscle	  processing	  	  Blood	   and	   skeletal	   muscle	   processing	   have	   been	   described	   in	   detail	   in	  Chapter	   2.	  Briefly,	   blood	   samples	   (n	   =	   15)	   were	   collected	   in	   EDTA	   vacutainers	   (Becton,	  Dickinson	  &	  Company,	  NJ,	  USA)	  and	  spun	  at	  3500	  rpm	  for	  15	  min	  at	  4	  °C.	  Post-­‐spin,	  the	   supernatant	  plasma	   fraction	  was	   removed	  and	   aliquotted	   into	  Eppendorf	   tubes	  for	  storage	  at	  -­‐80	  °C	  pending	  analysis.	  	  For	   the	   biopsy,	   a	   5	   mm	   Bergström	   needle	   was	   inserted	   through	   a	   pre-­‐prepared	  anaesthetised	  (2	  %	  Lidocaine)	  incision	  in	  the	  skin	  and	  fascia,	  into	  the	  muscle	  belly	  of	  the	   vastus	   lateralis	   and	   a	   sample	   removed	   under	   manual	   suction.	   Muscle	   biopsy	  samples	   were	   immediately	   rinsed	   using	   ice-­‐cold	   saline	   (0.9	   %),	   any	   visible	   fat	   or	  connective	  tissue	  removed.	  Next,	  samples	  were	  blotted	  and	  weighed	  before	  freezing	  in	  liquid	  nitrogen	  prior	  to	  storage	  at	  -­‐80	  °C	  pending	  analysis.	  Both	  biopsies	  (basal	  (0	  min)	   and	   insulin-­‐stimulated	   (120	   min))	   were	   removed	   from	   the	   same	   leg.	   For	  infusion	  trial	  2	  (post-­‐HFEE),	  biopsies	  were	  obtained	  from	  the	  contralateral	  limb.	  The	  order	  of	  the	  first	  leg	  to	  be	  biopsied	  was	  counterbalanced	  between	  groups	  to	  eliminate	  any	  potential	  for	  order	  effects.	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3.2.4.	  Plasma	  analyses	  Plasma	   triglyceride	   (TG),	   fatty	   acid	   (FA),	   total	   cholesterol,	   low	   density	   lipoprotein-­‐associated	   cholesterol	   (LDL)	   levels	   and	   high	   density	   lipoprotein-­‐associated	  cholesterol	   (HDL)	  were	   assessed	   from	   blood	   samples	   taken	   in	   the	   basal	   state	   (-­‐60	  min)	   pre-­‐	   and	   post-­‐HFEE	   using	   an	   ILab	   Aries	   benchtop	   analyser	   and	   associated	  reagents	   (Instrumentation	   Laboratories,	   MA,	   US).	   Plasma	   levels	   of	   TNF-­‐α	   and	  adiponectin	  were	  measured	  in	  the	  same	  samples	  using	  commercially	  available	  ELISA	  kits	   (RayBiotech,	   Inc.,	   GA)	   according	   to	   the	   manufacturer’s	   instructions.	   Gen5	  software	  (BioTek,	  Winooski,	  VT,	  USA)	  was	  used	  for	  ELISA	  data	  collection.	  
	  
	  
3.2.5.	  Skeletal	  muscle	  ceramide	  analyses	  Total	   lipids	   were	   extracted	   from	   skeletal	   muscle	   homogenates	   according	   to	   the	  method	  proposed	  by	  Folch	  et	  al.	  (222)	  with	  non-­‐lipid	  impurities	  removed	  by	  washing	  with	  0.88%	  (w/v)	  KCl.	  A	  250	  µL	  aliquot	  of	  muscle	  homogenate	  was	  extracted	  with	  6	  mL	   chloroform	   /	  methanol	   (2:1	   (v:v))	   containing	   8	   nmol	   of	   17:0	   ceramide	   (Avanti	  Polar	  Lipids	  Inc.,	  Alabaster,	  AL,	  USA)	  as	  an	  internal	  standard.	  Ceramides	  were	  isolated	  using	  solid-­‐phase	  extraction	  chromatography	  (100	  mg,	  3	  mL	  silica	  columns,	  Biotage,	  Uppsala,	   Sweden).	   The	   glycosphingolipid	   (ceramide)	   fraction	   was	   eluted	   in	   5	   mL	  acetone:methanol	  (9:1)	  and	  collected	  in	  glass	  tubes	  prior	  to	  storage	  at	  -­‐80	  °C	  pending	  analysis.	  The	  ceramide	  eluate	  was	  removed	  from	  storage	  at	  -­‐80	  °C,	  dried	  down	  under	  O2	   free	   N2	   and	   re-­‐suspended	   in	   250	   µL	   methanol	   containing	   5	   mM	   ammonium	  formate,	  and	   transferred	   into	  autosampler	  vials	   for	  analysis.	  Ceramide	  analysis	  was	  performed	   by	   liquid	   chromatography-­‐dual	   mass	   spectrometry	   (LC-­‐MS/MS)	   on	   a	  triple	   quadrupole	   tandem	   mass	   spectrometer	   (TSQ	   Quantum	   Ultra,	   Thermofisher,	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Hemel	  Hempstead,	  UK)	  in	  multiple	  reaction	  monitoring	  (MRM)	  mode	  with	  a	  Kinetex	  C8	  LC	  column	  (100	  x	  2.1mm	  x	  2.6µm,	  Phenomenex,	  Macclesfield,	  UK).	  Quantification	  was	  achieved	  by	  relating	  the	  peak	  areas	  of	  the	  muscle	  ceramides	  to	  the	  peak	  area	  of	  the	  17:0	  internal	  standard.	  	  
	  
	  
3.2.6	  Skeletal	  muscle	  mitochondrial	  enzyme	  assays	  Skeletal	   muscle	   samples	   (5-­‐12	   mg)	   were	   homogenised	   in	   100	   µl	   of	   homogenising	  solution	  (1.36	  g	  of	  0.1	  M	  KH2PO4	  +	  50	  mg	  of	  BSA	  in	  80	  mL	  ddH2O;	  pH	  adjustment	  to	  7.3	  with	  KOH	  before	  adding	  additional	  ddH2O	  to	  achieve	  a	   final	  volume	  of	  100	  mL)	  per	  1	  mg	  wet	  weight	  muscle	  using	  an	  automated	  homogeniser	  with	  1.4	  mm	  (green)	  ceramide	  beads	  (MagNaLyser,	  Roche,	  Germany).	  Samples	  were	  homogenised	  twice	  at	  7000	  rpm	  for	  10	  s,	  separated	  by	  1	  min	  on	  ice.	  Following	  homogenisation,	  all	  samples	  were	  centrifuged	  at	  14800	  rpm	  at	  4	  °C	   for	  20	  s	   to	  reduce	   foam.	  Homogenates	  were	  snap-­‐frozen	  in	  liquid	  nitrogen	  before	  performing	  two	  freeze	  /	  thaw	  cycles.	  Following	  the	   final	   thaw,	   homogenates	   (300	   µL)	   were	   transferred	   into	   individual	   glass	   vials	  (cuvettes)	  for	  analysis	  and	  positioned	  in	  the	  sample	  rotor	  according	  to	  the	  work	  list	  schedule	  on	  an	  ILab	  Aries	  benchtop	  analyser	  (Instrumentation	  Laboratories,	  MA,	  US).	  25	  µL	  of	  muscle	  homogenate	  was	  used	  for	  each	  reaction.	  The	  work	  list	  schedule	  and	  homogenate	  sample	  were	  the	  same	  for	  both	  the	  citrate	  synthase	  and	  β-­‐HAD	  reactions.	  
	  
Citrate	  synthase	  225	  µL	  of	  reagent	  1	  (TRIS	  buffer	  (pH	  8.3;	  7.5	  mL),	  DTNB	  (1.25	  mL),	  acetyl-­‐CoA	  (2	  mL)	  and	  Triton	  X-­‐100	  (10%;	  500	  µL))	  and	  the	  muscle	  homogenate	  (10	  µL)	  were	  combined	  initially,	   before	   next	   adding	   15	   µL	   of	   10	  mM	   oxaloacetate	   (reagent	   2)	   to	   start	   the	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reaction.	  Readings	  were	  taken	  at	  450	  nm	  at	  selected	  intervals	  (0,	  39,	  52,	  65,	  78,	  91,	  104,	  130,	  156,	  182	  195,	  234,	  260	  s)	  over	  a	  5	  min	  period.	  	  
	  
Beta(3)-­‐Hydroxyacyl-­‐CoA	  Dehydrogenase	  (β-­‐HAD)	  215	  µL	  of	  reagent	  1	  (TRIS-­‐HCl	  buffer	  (pH	  7.0;	  2.5	  mL),	  EDTA	  (0.5	  mL),	  NADH	  (2.5	  mL)	  and	  ddH2O	  (19.5	  mL))	  and	  5	  µL	   	  of	  reagent	  2	  (Triton	  x-­‐100	  (10%))	  were	  combined	  with	   the	  muscle	   homogenate	   (25	   µL)	   for	   an	   initial	   5	  min	   incubation	   period	   before	  taking	  a	  slope	  measurement	  at	  340	  nm	  for	  2	  min	  to	  record	  steady	  state.	  Next,	  5	  µL	  of	  5	  mM	  acetoacetyl-­‐CoA	  (reagent	  3)	  was	  added	  to	  start	  the	  reaction	  and	  the	  decrease	  in	  NADH	  was	  measured.	  Readings	  were	  taken	  at	  450	  nm	  at	  selected	  intervals	  (0,	  39,	  52,	  65,	  78,	  91,	  104,	  130	  s)	  over	  a	  2.5	  min	  period.	  
	  
Calculations	  
Citrate	  synthase	  and	  β-­‐HAD	  activity	  (µmol·g-­‐1·min-­‐1):	  ((Absorbance·min-­‐1	   (sample)	  –	  absorbance·min-­‐1	   (blank)	  *	   total	  volume)	  /	  (external	  coefficient	  *	  sample	  volume))	  *	  dilution	  factor	  Where:	  Absorbance·min-­‐1	  (blank)	  =	  0.0010	  Total	  volume	  =	  250	  µl	  	  Dilution	  factor	  =	  101	  Citrate	  synthase	  external	  coefficient	  (412	  nm)	  =	  13.6	  µmol·cm-­‐2	  Citrate	  synthase	  sample	  volume	  (muscle	  homogenate)	  =	  10	  µL	  	  β-­‐HAD	  external	  coefficient	  (412	  nm)	  =	  6.22	  µmol·cm-­‐3	  β	  -­‐HAD	  synthase	  sample	  volume	  (muscle	  homogenate)	  =	  25	  µL	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3.2.7.	  Skeletal	  muscle	  [γ-­‐32P]	  ATP	  kinase	  activity	  assays	  
PKB	  Skeletal	  muscle	  samples	  (30-­‐60	  mg)	  were	  homogenised	  in	  10	  times	  (v/w)	  PKB	  lysis	  buffer	   using	   a	   Dounce	   homogeniser.	   The	   PKB	   lysis	   buffer	   included	   40	   µL	   SBT1	  (1:1000),	   40	   µL	   β-­‐mercaptoethanol,	   40	   µL	   PMSF	   (1:1000),	   40	   µL	   benzamidine	  (1:1000)	  and	  200	  µL	  NaOV	  (1:200).	  Homogenised	  lysates	  were	  stored	  on	  dry	  ice	  prior	  to	  being	  thawed	  and	  centrifuged	  at	  14800	  rpm	  for	  30	  min	  at	  4	  °C	  to	  pellet	  debris.	  The	  supernatant	  fraction	  was	  removed	  and	  diluted	  1	  in	  5	  with	  ddH2O.	  	  
Next,	   a	   protein	   content	   assay	  was	   performed	   to	   establish	   the	   amount	   of	   protein	   in	  each	  sample.	  A	  standard	  curve	  was	  made	  using	  BSA	  and	  ddH2O	  with	  protein	  contents	  ranging	   from	  0	   to	   10	   µg.	   Samples	   (1	   µL	   +	   5	   µL	   ddH2O)	   and	   standards	   (5	   µL)	  were	  loaded	   in	   to	   their	   respective	  well	   followed	  by	  25	  µL	  protein	  assay	  reagent	  A	   (1:50)	  and	  200	  µL	  protein	  assay	  reagent	  B	  (Bio-­‐Rad	  Laboratories	  Ltd.,	  Hertfordshire,	  UK	  (for	  both	   reagents)).	   Plates	   were	   incubated	   for	   10	   min	   at	   room	   temperature	   before	  reading	   at	   750	   nm	  using	   a	  microtiter	   plate	   reader	   and	  Gen5	   software	   (BioTek,	   VT,	  USA).	  Sample	  protein	  contents	  were	  calculated	  from	  the	  standard	  curve,	  and	  adjusted	  with	  ddH2O	  so	  that	  all	  samples	  had	  identical	  protein	  contents	  per	  µL	  of	  sample.	  
	  Samples	  of	  known,	  and	  equal,	  protein	  content	  were	  immunoprecipitated	  at	  4	  °C	  for	  2	  h	  in	  PKB	  lysis	  buffer	  (50	  mM	  TrisHCl	  (pH	  7.5),	  0.1	  mM	  EGTA,	  1	  mM	  EDTA,	  1	  %	  (v/v)	  Triton	  X-­‐100,	  50	  mM	  NaF,	  5	  mM	  NaPPi,	  0.27	  M	  sucrose,	  0.1	  %	  β-­‐	  mercaptoethanol,	  1	  mM	   Na3(OV)4)	   with	   protease	   inhibitors	   (PMSF,	   DTT,	   SBT1,	   Benzamidine,	   NaOV).	  Immune	   complexes	   were	   formed	   and	   precipitated	   in	   the	   presence	   of	   protein	   G	  sepharose	  (70	  %,	  2.5	  µL	  per	  immunoprecipitation).	  Immune	  complexes	  were	  washed	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twice	  with	  an	  assay	  specific	  high	  salt	  wash	  (PKB	  lysis	  buffer	  +	  0.5	  M	  NaCl)	  with	  a	  spin	  at	  2000	  rpm	  for	  1	  min	  at	  4	  °C	  and	  aspiration	  of	  the	  supernatant	  in	  between	  steps.	  A	  third	  wash	  was	  performed	  using	  TRIS	  assay	  buffer	  (50	  mM	  TrisHCl	  (pH	  7.4),	  0.03	  %	  Brij35,	  0.1	  %	  β-­‐	  mercaptoethanol).	  Immune-­‐bead	  complexes	  were	  re-­‐suspended	  in	  10	  µL	  TRIS	  assay	  buffer,	  before	  being	  made	  up	  to	  a	  final	  reaction	  volume	  of	  50	  µL	  with	  a	  hot	   assay	  mix	   that	  was	   added	   to	   each	   sample	   at	   20	   s	   intervals.	   The	   hot	   assay	  mix	  comprised	  ATP-­‐MgCl2	  (100	  µM	  ATP	  +	  10	  mM	  MgCl2),	  γ-­‐32P	  ATP	  (panPKB;	  0.50	  x	  106	  cpm·nmoL-­‐1	   specific	   activity)	   and	   ‘crosstide’	   (GRPRTSSFAEG	   at	   30	   µM),	   a	   synthetic	  peptide	   substrate	   for	  PKB.	  After	  20	  min	  on	  a	   shaker	   (150	   rpm;	   Stuart	   SSM1,	  Bibby	  Scientific,	  Staffordshire,	  UK)	  assays	  were	  stopped	  at	  the	  same	  20	  s	   intervals	  as	  they	  were	   started	  by	   spotting	  on	   squares	  of	  P81	   chromatography	  paper	   (GE	  Healthcare,	  Buckinghamshire,	  UK)	  and	  immersing	  in	  75	  mM	  phosphoric	  acid.	  The	  assay-­‐spotted	  paper	  squares	  were	  washed	  a	  further	  3	  times	  in	  75	  mM	  phosphoric	  acid	  for	  5	  min	  at	  a	  time	   before	   a	   final	   5	  min	  wash	   in	   acetone.	   Next,	   all	   paper	   squares	  were	   dried	   and	  individually	   immersed	   in	   Gold	   Star	   LT	   Quanta	   scintillation	   fluid	   (Meridian	  Biotechnologies	  Ltd.,	  Chesterfield,	  UK).	  Radioactivity	  of	  the	  samples	  was	  quantified	  by	  scintillation	   counting	   (United	   Technologies	   Packard	   2200CA	   TriCarb	   liquid	  scintillation	   analyser)	   in	   nmoL·mg-­‐1·min-­‐1.	   For	   data	   analysis,	   all	   values	   were	  background	  subtracted	  using	  ‘blank’	  samples	  which	  were	  immunoprecipitated	  in	  the	  absence	  of	  any	  peptide	  substrate	  (crosstide).	  
	  
AMPK	  α2	  Samples	  with	  known	  protein	  contents	  (as	  described	  for	  PKB)	  were	  used	  for	  AMPK	  α2	  assays.	   The	   assay	   procedure	   was	   the	   same	   for	   AMPK	   α2	   as	   the	   assay	   procedure	  outlined	  for	  PKB,	  with	  the	  exception	  that	  samples	  were	   immunoprecipitated	  at	  4	  °C	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overnight,	   the	   final	   wash	   step	   was	   performed	   using	   HEPES	   assay	   buffer	   (50	   mM	  HEPES	   (pH	   7.4),	   1	  mM	  DTT,	   0.02	  %	   Brj35)	   and	   immune-­‐bead	   complexes	  were	   re-­‐suspended	  in	  20	  µL	  of	  HEPES	  assay	  buffer	  prior	  to	  the	  addition	  of	  hot	  assay	  mix.	  The	  hot	   assay	   mix	   comprised	   ATP-­‐MgCl2	   (200	   µM	   ATP	   +	   50	   mM	   MgCl2),	   γ-­‐32P	   ATP	  (panAMPK;	   0.25	   x	   106	   cpm·nmoL-­‐1	   specific	   activity)	   and	   the	   synthetic	   peptide	  substrate,	   ‘AMARA’	   (AMARRAASAAALARRR	  at	  200	  µM).	  The	  homogenisation	  buffer	  comprised	  50	  mM	  TrisHCl	  (pH	  7.25),	  150	  mM	  NaCl,	  50	  mM	  NaF,	  5	  mM	  NaPPi,	  1	  mM	  EDTA,	  1	  mM	  DTT,	  0.1	  mM	  benzamidine,	  0.1	  mM	  PMSF,	  5	  µg·mL-­‐1	  soya	  bean	  trypsin	  inhibitor,	  and	  1	  %	  (v/v)	  Triton	  X-­‐100.	  	  	  
3.2.8.	  Skeletal	  muscle	  phospholipid	  analysis	  Total	   lipids	   were	   extracted	   from	   skeletal	   muscle	   homogenates	   according	   to	   the	  method	  proposed	  by	  Folch	  et	  al.	  (222)	  with	  non-­‐lipid	  impurities	  removed	  by	  washing	  with	   0.88	   %	   (w/v)	   KCl.	   Phospholipids	   were	   isolated	   using	   solid-­‐phase	   extraction	  chromatography	   (silica	   columns)	   and	   eluted	   in	   5	   mL	   100	   %	   methanol	   prior	   to	  processing	   for	   GCMS	   analysis	   as	   described	   previously	   (128).	   Specifically,	  phospholipid	  fractions	  were	  removed	  from	  -­‐80	  °C	  and	  allowed	  to	  equilibrate	  to	  room	  temperature.	   Eluates	   were	   dried	   down	   under	   N2	   prior	   to	   re-­‐suspension	   in	   1	   mL	  chloroform:methanol	   (2:1)	   and	   transfer	   into	   pre-­‐weighed	   1.7	   mL	   glass	   bottles.	  Solutes	   were	   dried	   again	   under	   N2	   and	   further	   by	   leaving	   in	   a	   vacuum	   desiccator	  overnight.	  The	  following	  morning	  the	  lipid	  containing	  glass	  bottles	  were	  weighed	  and	  a	  record	  of	  the	  weight	  made.	  Chloroform:methanol	  (2:1)	  +	  BHT	  (0.5	  mL)	  was	  added	  to	  each	  bottle	  before	  flushing	  with	  N2	  and	  capping	  for	  overnight	  storage	  at	  -­‐80	  °C.	  The	  following	  morning,	  the	  lipid	  solute	  was	  transferred	  to	  a	  15	  mL	  Quickfit	  test	  tube	  and	  17:0	  standard	  was	  added	  at	  10	  %	  of	  the	  lipid	  mass.	  The	  organic	  solvent	  was	  removed	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under	  N2	  followed	  by	  addition	  of	  the	  methylating	  reagent	  (1	  %	  (v/v)	  sulphuric	  acid	  in	  methanol)	   and	   a	   5	   s	   vortex.	   Tubes	   were	   flushed	   with	   N2	   and	   a	   stopper	   added	   in	  combination	   with	   a	   piece	   of	   tissue	   to	   prevent	   any	  movement	   of	   the	   stopper	   upon	  heating.	  Heating	  involved	  an	  overnight	  incubation	  (minimum	  16	  h)	  of	  the	  tubes	  in	  a	  hot	   block	   set	   to	   50	   °C.	   The	   following	   morning	   the	   tubes	   were	   cooled	   to	   room	  temperature,	   the	   tissue	   removed	   and	   2	   mL	   of	   2	   %	   KHCO3	   followed	   by	   5	   mL	  isohexane:diethyl	   ether	   (1:1,	   v/v)	   +	  0.01	  %	   (w/v)	  BHT	  were	   added.	   Contents	  were	  mixed	  by	  gently	  inverting	  the	  tubes,	  removing	  the	  stopper	  briefly	  to	  release	  gas	  and	  then	   re-­‐applying	   the	   stopper	   and	   shaking	   vigorously.	   Next,	   tubes	  were	   centrifuged	  (with	   the	   stoppers	   removed)	   at	   1500	   rpm	   for	   2	  min.	   The	   upper	   organic	   layer	  was	  transferred	  to	  a	  clean	  15	  mL	  Quickfit	  test	  tube.	  A	  further	  5	  mL	  isohexane:diethyl	  ether	  (1:1,	  v/v)	  (no	  BHT)	  was	  added	  to	  the	  original	  tube	  and	  mixed	  and	  centrifuged	  in	  the	  same	  manner	  as	  previously	  described	  before	  again	  transferring	  the	  upper	  layer	  to	  the	  new	   15	   mL	   Quickfit	   test	   tube.	   The	   new	   solvent	   was	   evaporated	   under	   N2,	   re-­‐suspended	   in	   1	  mL	   isohexane	   and	   vortexed	   for	   5	   s,	   before	   transferring	   in	   to	   2	  mL	  autosampler	  vials,	  flushing	  with	  N2	  and	  storing	  at	  -­‐20	  °C	  prior	  to	  GLC	  analysis.	  FAME	  were	  separated	  and	  analysed	  in	  the	  same	  manner	  as	  described	  in	  ‘Blood	  lipid	  analysis’	  (Chapter	  2).	  
	  
3.2.9.	  Statistical	  analyses	  All	  data	  were	   tested	   for	  normality	  using	   the	  Ryan	   Joiner	   test	  with	  Minitab	  software	  (version	  16;	  Minitab,	  State	  College,	  PA).	  In	  the	  case	  of	  non-­‐normally	  distributed	  data,	  Box-­‐Cox	  transformations	  were	  applied	  before	  testing	  for	  normality	  a	  second	  time.	  In	  the	   instance	   that	   data	   remained	   non-­‐normally	   distributed	   following	   Box-­‐Cox	  transformation,	  outliers	  were	  removed	  using	  the	  median	  absolute	  deviation	  method	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(208),	   and	   normality	   confirmed.	   Thus,	   all	   statistical	   analyses	   were	   performed	   on	  normally	  distributed	  data.	  A	  two-­‐way	  repeated	  measures	  ANOVA	  (IBM	  SPSS	  Statistics	  19,	   NY,	   USA)	   was	   used	   to	   assess	   differences	   between	   groups	   (HF-­‐C	   vs.	   HF-­‐FO;	  between-­‐subject	  factor),	  over	  time	  (pre-­‐	  and	  post-­‐HFEE;	  within-­‐subject	  factor).	  In	  the	  case	   of	   a	   significant	   interaction	   effect	   by	   two-­‐way	   ANOVA,	   paired	   t-­‐tests	   were	  conducted	   to	   assess	   differences	   over	   time	   within	   each	   group	   alone.	   Statistical	  significance	  was	   assumed	   at	   the	   level	   of	   p	   <	   0.05.	   Values	   are	   presented	   as	  mean	   ±	  standard	  error	  of	  the	  mean	  (SEM)	  unless	  stated	  otherwise.	  	  	  
	  	  
Chapter	  3:	  Lipid	  metabolism	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  86	  
	  	  
3.3.	  Results	  
3.3.1.	  Plasma	  lipids	  Plasma	   lipid	   and	   adipokine	   levels	   are	   presented	   in	  Table	   3.1.	   Levels	   of	   plasma	  TG	  and	  FA	  were	  significantly	  decreased	  following	  HFEE	  in	  both	  groups.	  HDL-­‐associated	  cholesterol	   was	   significantly	   increased	   following	   HFEE,	   with	   a	   significant	   group	  interaction	  effect	   (p	  =	  0.02).	  Follow-­‐up	  paired	   t-­‐tests	  revealed	  a	  significant	  effect	  of	  HFEE	   in	   HF-­‐FO	   only	   (p	   <	   0.01).	   Total	   cholesterol,	   LDL-­‐associated	   cholesterol,	  adiponectin	  (p	  =	  0.09,	  main	  effect	  of	  time)	  and	  TNF-­‐α	  were	  not	  significantly	  different	  over	  time	  or	  between	  groups.	  	  	  
	  
	  
3.3.2.	  Skeletal	  muscle	  ceramides	  Total	  basal	  skeletal	  muscle	  ceramide	  levels	  were	  increased	  by	  69	  %	  (±	  32)	  following	  HFEE,	   irrespective	   of	   group	   (Figure	   3.1A).	   Statistical	   analysis	   of	   individual	   species	  
Table	  3.1	  Fasting	  plasma	  lipid	  levels.	  	  
	   HF-­‐C	   HF-­‐FO	  
	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
TG	   0.80	  ±	  0.09	   0.62	  ±	  0.06*	   0.76	  ±	  0.06	   0.48	  ±	  0.03*	  
FA	   0.66	  ±	  0.06	   0.48	  ±	  0.06*	   0.66	  ±	  0.06	   0.39	  ±	  0.06*	  
Total	  cholesterol	   4.05	  ±	  0.26	   3.86	  ±	  0.22	   3.81	  ±	  0.26	   3.98	  ±	  0.26	  
LDL	   2.92	  ±	  0.24	   2.73	  ±	  0.20	   2.69	  ±	  0.24	   2.67	  ±	  0.26	  
HDL	   1.30	  ±	  0.05	   1.36	  ±	  0.07*†	   1.32	  ±	  0.05	   1.56	  ±	  0.05*†#	  
Adiponectin	   383.1	  ±	  27.8	   387.9	  ±	  32.4	   426.3	  ±	  23.8	   458.4	  ±	  21.1	  
TNF-­‐α	   3.13	  ±	  0.37	   3.48	  ±	  0.56	   3.08	  ±	  0.38	   3.17	  ±	  0.49	  
Data	  presented	  are	  pre-­‐	  and	  post-­‐HFEE,	  for	  both	  groups	  (HF-­‐C	  and	  HF-­‐FO;	  n=10	  per	  group).	  Values	  are	  means	  ±	  SEM.	  *	  significantly	  different	  from	  pre-­‐HFEE	  (main	  effect	  of	  time),	  †	  interaction	  effect	  (both	  by	  ANOVA),	  #	  significantly	  different	   from	  pre-­‐HFEE	   for	   the	  respective	  group	  (t-­‐test),	  all	  p	  <	  0.05.	  TG,	  FA,	  total	  cholesterol,	  LDL	  and	  HDL	  are	  all	  expressed	  in	  mmol·L-­‐1,	  adiponectin	  in	  pg·µL-­‐1	  and	  TNF-­‐α	  in	  pg·mL-­‐1.	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Figure	  3.1	  Total	  skeletal	  muscle	  ceramide	  levels	  (A)	  were	  increased	  following	  HFEE	  irrespective	  of	  group.	  All	  measured	  individual	  ceramide	  species	  contributed	  to	  the	  change	  in	  total	  ceramide	  species	  but	  only	  certain	  species	  were	   significantly	  altered	   individually	  over	  the	  course	  of	  HFEE	  (B).	   In	  (B),	  data	  from	  both	  groups	  (HF-­‐C	  and	  HF-­‐FO)	  have	  been	  pooled	  together	   for	  data	  presentation.	  All	  bars	  are	  means	  ±	  SEM,	  *	  significantly	  different	  from	  pre-­‐HFEE,	  p	  <	  0.05	  by	  ANOVA.	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3.3.3.	  PKB	  activity	  PKB	   activity	  was	   significantly	   greater	   in	   the	   insulin-­‐stimulated	   state	   (2	   h)	   than	   the	  basal	  state	  (0	  h),	  irrespective	  of	  group	  or	  infusion	  trial	  (i.e.	  pre-­‐	  or	  post-­‐HFEE;	  Figure	  
3.2).	  Moreover,	  a	  significant	   interaction	  effect	  was	  present	  between	  group	  (HF-­‐C	  vs.	  HF-­‐FO)	   and	   infusion	   trial	   (pre-­‐HFEE	   vs.	   post-­‐HFEE),	   suggesting	   a	   differential	   PKB	  response	  to	  the	  feeding	  intervention	  between	  groups	  (Figure	  3.2).	  Group	  differences	  tended	  to	  exist	  regardless	  of	  HFEE	  or	  OGTT	  time-­‐point	  (p	  =	  0.053).	  	  	  




Figure	  3.2	  PKB	  activity	  in	  the	  basal	  (0	  h)	  and	  insulin	  stimulated	  states	  (2	  h)	  pre-­‐	  and	  post-­‐HFEE	  for	  both	  HF-­‐C	  and	  HF-­‐FO	  (A).	   Insulin-­‐stimulated	   change	   in	  PKB	  activity	  (B)	   for	  HF-­‐C	  and	  HF-­‐FO,	  pre-­‐	  and	  post-­‐HFEE.	  Data	  are	  expressed	  as	  means	  ±	  SEM,	  n=9	  per	  group.	  Group*HFEE	  interaction;	  p	  =	  0.033	   (*),	  PKB	  activity	  at	  2	  h	  was	   significantly	  different	   from	  0	  h,	   irrespective	  of	   group	   (p	  <	  0.01	  (*)).	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3.3.4.	  AMPK	  α2	  Basal	  (0	  min)	  skeletal	  muscle	  AMPK	  α2	  activity	  was	  significantly	  decreased	  following	  HFEE	   in	   HF-­‐C	   but	   increased	   in	   HF-­‐FO	   (Figure	   3.4;	   interaction	   effect:	   p	   =	   0.03).	  Follow-­‐up	  paired	  t-­‐tests	  revealed	  a	  significant	  effect	  of	  HFEE	  in	  HF-­‐FO	  only	  (p	  =	  0.04	  and	  0.28	  for	  HF-­‐FO	  and	  HF-­‐C,	  respectively).	  	  
	  	  
3.3.5.	  Mitochondrial	  enzyme	  activities	  Citrate	  synthase	  and	  β-­‐HAD	  activity	  in	  the	  basal	  state	  (0	  min)	  was	  unaltered	  by	  HFEE	  in	  either	  group	  (Table	  3.2).	  
	  
	  
Figure	   3.3	  Basal	   skeletal	  muscle	  AMPK	  α2	  activity	  pre-­‐	  and	  post-­‐HFEE	  for	  both	  HF-­‐C	  and	  HF-­‐FO.	  Values	  are	  means	  ±	  SEM,	  n=9	  per	  group.	  #	  significantly	  different	   from	  pre-­‐HFEE	  for	  the	   respective	  group,	  p	  <	  0.05	  by	  t-­‐test.	  	  





3.3.6.	  Fatty	  acid	  profiling	  A	  full	  skeletal	  muscle	  phospholipid	  profile	   is	  presented	  in	  Appendix	  3.1.	  Total	  SFA,	  total	   MUFA	   and	   total	   n-­‐6	   PUFAs	   were	   unaltered	   by	   HFEE	   and	   not	   significantly	  different	  between	  groups.	  A	   trend	  existed	   for	   an	   increase	   in	   total	  n-­‐3	  PUFAs	   in	   the	  phospholipid	  membrane	  of	  HF-­‐FO	  following	  HFEE	  by	  t-­‐test	  (p	  =	  0.06)	  with	  no	  change	  in	   HF-­‐C	   (p	   =	   0.74).	   Specifically,	   of	   the	   n-­‐3	   PUFAs	   increased	   in	   HF-­‐FO,	   EPA	   was	  significantly	  increased	  (p	  =	  0.01),	  however	  there	  was	  no	  change	  in	  DHA	  (p	  =	  0.26)	  by	  t-­‐test.	   Similar	   to	   blood	   lipids	   (see	   section	   2.3.7,	  Chapter	   2),	   the	   AA:EPA	   ratio	  was	  significantly	   decreased	   in	  HF-­‐FO	   (p	   =	   0.04)	   over	   time	  with	   no	   change	   in	  HF-­‐C	   (p	   =	  0.76).	  
Table	  3.2	  Mitochondrial	  enzyme	  activities.	  
	   HF-­‐C	   HF-­‐FO	  
	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
Citrate	  synthase	   29.65	  ±	  3.14	  	   27.51	  ±	  3.09	   30.69	  ±	  1.90	   27.78	  ±	  2.96	  
β-­‐HAD	   13.57	  ±	  1.31	   14.44	  ±	  0.94	   14.67	  ±	  0.62	   14.07	  ±	  0.92	  Data	  are	  presented	  pre-­‐	  and	  post-­‐HFEE,	  for	  both	  groups	  (HF-­‐C	  and	  HF-­‐FO;	  n=9	  per	  group).	  Values	  are	  means	  ±	  SEM	  (µmol·g-­‐1·min-­‐1).	  No	  significant	  differences	  between	  groups	  or	  over	  time	  (p	  >	  0.05	  by	  ANOVA).	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3.4.	  Discussion	  Consistent	   with	   our	   hypothesis,	   we	   report	   a	   significant	   increase	   in	   basal	   levels	   of	  total,	   and	   certain	   individual,	   skeletal	  muscle	   ceramide	   species	   following	   6	   d	   HFEE.	  However,	  contrary	  to	  our	  hypothesis,	  this	  change	  occurred	  irrespective	  of	  dietary	  FO	  consumption.	   Moreover,	   the	   observed	   increase	   in	   ceramide	   levels	   occurred	   in	   the	  absence	  of	  any	  changes	  in	  basal	  mitochondrial	  enzyme	  (citrate	  synthase	  and	  β-­‐HAD)	  activity.	  However,	  circulating	  TG	  and	  FA	  levels	  were	  reduced	  following	  HFEE.	  These	  observations	  may	  suggest	  an	   increase	   in	   fat	  uptake	  by	  skeletal	  muscle,	  without	  any	  change	   in	   skeletal	   muscle	   fat	   oxidation.	   AMPK	   α2	   activity,	   a	   key	   regulator	   of	   fat	  oxidation,	   was	   increased	   post-­‐HFEE	  when	   FO	  was	   consumed	   but	   decreased	   in	   the	  absence	   of	   FO	   consumption.	   Some	  FO	   consumption-­‐mediated	  differences	   also	  were	  observed	  with	  PKB	  activity.	   Insulin-­‐stimulated	  PKB	  activity	  was	  maintained	   at	  pre-­‐HFEE	  levels	  following	  HFEE	  when	  FO	  was	  consumed	  yet	  reduced	  following	  HFEE	  in	  the	   absence	   of	   FO	   consumption.	   Together,	   these	   findings	   demonstrate	   early	  (mal)adaptive	  responses	  to	  HFEE	  at	  the	  lipid	  level	  that	  occur	  in	  the	  period	  preceding	  clear	   development	   of	   whole-­‐body	   insulin	   resistance,	   and	   some	   of	   which	   are	  differentially	  mediated	  by	  FO	  intake.	  	  	  Increased	   skeletal	   muscle	   ceramide	   levels	   have	   been	   consistently	   associated	   with	  obesity	   and	   the	  metabolic	   syndrome	   (77,90,91).	   Yet,	   to	   the	   best	   of	   our	   knowledge,	  this	   is	   the	   first	   investigation	   to	  detail	   changes	   in	   skeletal	  muscle	   ceramide	   levels	   in	  response	  to	  short-­‐term,	  HFEE	  in	  the	  absence	  of	  insulin	  resistance.	  Following	  a	  longer	  (28	   d)	   high-­‐fat	   overfeeding	   intervention,	   Heilbronn	   and	   colleagues	   (108)	   reported	  significant	   increases	   in	  circulating	   total	   ceramide	   levels	   in	  sedentary,	  but	  otherwise	  healthy	   individuals;	   concomitant	   with	   impaired	   insulin	   sensitivity.	   Moreover,	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significant	   increases	   in	   certain	   individual	   ceramide	   species	   were	   observed	   (C22:0,	  C24:0),	   but	   these	   were	   not	   the	   same	   species	   as	   those	   that	   were	   increased	   in	   the	  present	  investigation	  (C18:1,	  C22:1,	  C23:0,	  C24:1).	  The	  reason	  why	  levels	  of	  different	  species	   were	   altered	   between	   studies	   (particularly	   saturated	   vs.	   unsaturated	   fat	  differences)	  is	  unknown,	  but	  may	  reflect	  study	  design	  variances	  including	  the	  tissue	  sampled,	   type	   of	   dietary	   fat	   consumed,	   duration	   of	   overfeeding	   and	   /	   or	   insulin	  sensitivity	  of	  the	  participants.	  Based	  on	  current	  data	  from	  our	  study	  and	  others,	  we	  propose	   that	   changes	   in	   ceramide	   levels	   may	   precede	   the	   development	   of	   insulin	  resistance,	   with	   elevated	   levels	   maintained	   throughout	   insulin	   resistance	  development	  (108)	  and	  metabolic	  disease	  pathology	  (72).	  	  	  Ceramides	   impair	   insulin	  sensitivity	  via	   their	   inhibitory	  effects	  on	  PKB.	  Specifically,	  ceramides	  activate	  PP2A	  and	  PKC	  isoforms,	  both	  of	  which	  dephosphorylate	  PKB	  (84).	  Inhibition	   of,	   or	   at	   least	   decreased,	   PKB	   activity	   will	   reduce	   downstream	   glucose	  uptake	   and	   hence	   PKB	   is	   an	   important	   control	   point	   for	   glucose	   homeostasis	   and	  insulin	  sensitivity.	  Although	  we	   failed	  to	  detect	  any	  overall	  mean	  changes	   in	   insulin	  sensitivity	   following	   HFEE,	   ceramide	   action	   may	   be	   otherwise	   examined	   by	  investigating	   changes	   in	   PKB	   activity.	   Elevated	   PKB	   activity	   was	   measured	   in	   the	  insulin-­‐stimulated	   state	   compared	   to	   the	   basal	   state	   in	   all	   participants	   before	   and	  after	  HFEE.	  Whereas	  an	   insulin-­‐stimulated	  rise	   in	  PKB	   is	  expected	  due	   to	   increased	  insulin	   signalling	   flux,	   the	   temporal	   response	   to	   oral	   glucose	   ingestion	   and	   its	  relationship	  with	  insulin	  sensitivity	  is	  currently	  unknown.	  A	  greater	  insulin-­‐mediated	  PKB	  response	  at	  2	  h	  post-­‐glucose	  ingestion	  is	  commonly	  considered	  as	  indicative	  of	  insulin	  sensitivity,	  whereby	  greater	  signalling	   flux	  results	   in	  elevated	  PKB	  activation	  (e.g.	   (223)).	   However,	   one	   also	   could	   argue	   that	   greater	   PKB	   activation	   2	   h	   post	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glucose	   consumption	   is	   a	   sign	  of	   insulin	   resistance.	   The	   sensitivity	   of	   the	  metabolic	  system	   may	   be	   impaired	   if	   signalling	   proteins,	   including	   PKB,	   remain	   active	   after	  blood	   glucose	   levels	   have	   returned	   to	   baseline	   levels	   as	   evidenced	   in	   the	   present	  investigation.	   Future	   investigations	   of	   the	   temporal	   relationship	   between	   PKB	   and	  insulin	  signalling	  are	  required	  to	  better	  address	  these	  complexities.	  	  	  PKB	   activity	   and	   insulin	   signalling	   may	   be	   modified	   by	   dietary	   fat	   consumption.	  Whereas	   the	   HFEE-­‐mediated	   rise	   in	   ceramide	   levels	   occurred	   irrespective	   of	   FO	  consumption,	  the	  increase	  in	  insulin-­‐stimulated	  PKB	  activity	  was	  maintained	  with	  FO	  consumption,	   but	   reduced	   in	   the	   absence	   of	   FO	   consumption,	   during	   HFEE.	   The	  reasons	   for	   these	   discrepancies	   are	   not	   immediately	   clear.	   However,	   observed	  changes	  in	  the	  phospholipid	  membrane,	  including	  a	  significant	  incorporation	  of	  EPA,	  and	  a	  tendency	  for	  total	  n-­‐3	  PUFA	  incorporation	  with	  FO	  consumption	  may	  relate	  to	  PKB	   and	   insulin	   signalling.	   Increased	   n-­‐3	   PUFA	   composition	   of	   the	   phospholipid	  membrane	  has	  been	   shown	   to	  positively	   associate	  with	   insulin	   sensitivity	   (21)	   and	  improve	   signalling	   kinetics	   (134,135).	   Thus,	   taken	   together,	   these	  data	   support	   the	  notion	   that	  changes	   in	  subcellular	  skeletal	  muscle-­‐specific	  mechanisms	  occur	   in	   the	  early	  phases	  of	  HFEE,	  are	  perhaps	  differentially	  mediated	  by	  FO	  ingestion,	  and	  likely	  precede	  whole-­‐body	  changes	  in	  insulin	  sensitivity.	  	  	  The	  balance	  between	  ceramide	  synthesis	  and	  degradation	  within	  skeletal	  muscle	  will	  determine	  the	  amount	  of	  ceramide	  within	  skeletal	  muscle,	  and	  regulate	  any	  changes	  following	  a	  given	  stimulus	  (84).	  Fat	  delivery	  to	  tissue,	  fat	  transport	  across	  the	  plasma	  membrane	   and	   stimuli	   including	   SFA	   availability	   and	   activity	   of	   serine	  palmitoyltransferase	  (SPT)	  and	  associated	  enzymes,	  drive	  ceramide	  synthesis	  (84).	  In	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contrast,	   the	   transport	   of	   lipids	   across	   the	   mitochondrial	   membrane,	   rate	   of	   fat	  oxidation,	  adiponectin	  concentrations	  and	  ceramidase	  activity	  are	  key	  determinants	  of	   ceramide	   degradation	   (224).	   Thus,	   investigation	   of	   the	   factors	   involved	   in	   these	  processes	  will	  facilitate	  understanding	  of	  the	  regulation	  of	  ceramide	  levels	  in	  tissue.	  	  FA	   availability	   in	  muscle	   is	   determined,	   in	   part,	   by	   the	   delivery	   and	   uptake	   of	   fats	  from	   the	   plasma	   pool	   into	  muscle.	   Decreased	   circulating	   levels	   of	   TGs	   and	   FAs,	   as	  measured	   in	   the	   present	   investigation,	   may	   reflect	   a	   lipid	   shift	   from	   plasma	   into	  tissue.	  This	   lipid	  shift	  will	   result	   in	   increased	  adipose	   tissue	  mass	  and	  an	   increased	  lipid	   environment	  within	   tissue	   such	   as	   skeletal	  muscle,	   particularly	  when	   adipose	  tissue	  expansion	  becomes	  saturated	  (215).	  Adipose	  tissue	  spillover	  of	  FA,	  resulting	  in	  ectopic	  fat	  deposition,	   is	  thought	  to	  result	   in	  accumulation	  of	  toxic	   lipid	  metabolites	  including	  ceramides,	  and	  drive	   insulin	  resistance	  (215).	  Given	  our	   lack	  of	  change	   in	  insulin	  sensitivity,	  it	  is	  possible	  that	  ceramide	  accumulation	  has	  to	  be	  of	  great	  enough	  magnitude	   before	   the	   insulin	   resistant	   response	   is	   observed.	   A	   time	   course	   of	  ceramide	   accumulation	   mapped	   to	   insulin	   sensitivity	   change	   is	   required	   in	   future	  investigations	  to	  better	  understand	  development	  of	  these	  maladaptations.	  	  Alternative	  explanations	  for	  the	  observed	  increase	  in	  ceramide	  levels	  may	  include	  a	  different	   stimulus	   for	   ceramide	   synthesis,	   for	   example,	   inflammation	   and	   other	  hormonal	   changes.	   Obesity	   and	   T2D	   are	   widely	   associated	   with	   low-­‐grade	  inflammation	   (137)	   and	   it	   is	   this	   pro-­‐inflammatory	   environment	   that,	   when	  uncontrolled,	   is	   considered	   highly	   detrimental	   for	   cellular	   function	   (225).	   TNF-­‐α	   is	  one	   candidate	   inflammatory	   biomarker	   that	   has	   been	   shown	   to	   activate	  sphingomyelinase	   (SMase)	   and	   drive	   ceramide	   synthesis	   in	   a	   cell-­‐free	   system	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(85,226).	  Levels	  of	  circulating	  TNF-­‐α,	  were	  not	  altered	  by	  HFEE	  at	  6	  d	  in	  the	  present	  study	   despite	   increases	   in	   skeletal	   muscle	   ceramide	   levels.	   However,	   it	   must	   be	  acknowledged	  that	  TNF-­‐α	  was	  not	  measured	  in	  tissue	  and	  measurement	  of	  a	  solitary	  blood-­‐based	  inflammatory	  marker	  is	  not	  as	  convincing	  as	  measurement	  of	  a	  panel	  of	  inflammatory	   proteins	   in	   tissue.	   Although	   the	   purported	   anti-­‐inflammatory	   effects	  associated	  with	  FO	  consumption	  (137)	  were	  not	  apparent	  from	  the	  TNF-­‐	  α	  measures	  in	   the	   current	   study,	   it	   is	   difficult	   to	   completely	   disregard	   these	   anti-­‐inflammatory	  properties	   in	   the	   absence	   of	   altered	   inflammation	   in	   HF-­‐C.	   Instead,	   the	   temporal	  resolution	  of	  an	  inflammatory	  response	  may	  offer	  clearer	  insight	  into	  such	  regulation.	  	  The	   ‘normal’	   counter-­‐response	   to	   compensate	   for	   increased	   fat	   availability,	   storage	  and	   synthesis	   would	   be	   a	   shift	   towards	   oxidative	   fat	   metabolism.	   Changes	   in	  mitochondrial	   enzyme	   activities	   and	   /	   or	   the	   regulation	   of	   mitochondrial	   lipid	  oxidation	  may	  reflect	  lipid	  changes	  within	  skeletal	  muscle.	  AMPK	  α2	  activity	  is	  widely	  considered	  to	  be	  important	  for	  fat	  oxidation	  (218,219,224).	  Activation	  of	  AMPK	  leads	  to	  increased	  CPT-­‐1	  activity	  via	  ACC-­‐mediated	  malonyl-­‐CoA	  suppression	  (224).	  Based	  on	   this	   mechanism,	   an	   increase	   in	   AMPK	   α2	   activity,	   as	   seen	   with	   HFEE	   and	   FO	  consumption,	   will	   enhance	   fat	   oxidation,	   whereas	   a	   decrease	   in	   AMPK	   α2	   activity	  (HF-­‐C)	  will	  inhibit	  fat	  oxidation	  at	  the	  level	  of	  fat	  transport	  across	  the	  mitochondrial	  membrane.	   Following	   high-­‐fat	   feeding	   in	   mice	   (227)	   and	   rats	   (228,229),	   AMPK	  activity	  was	  decreased,	  concomitant	  with	  impaired	  glucose	  tolerance,	  possibly	  due	  to	  reduced	  lipid	  oxidation.	  However,	  when	  we	  relate	  these	  observations	  to	  our	  increases	  in	   ceramide	   levels,	   which	   occurred	   irrespective	   of	   dietary	   FO	   consumption,	   the	  divergent	   group-­‐responses	   of	   AMPK	   α2	   activity	   are	   less	   clear.	   The	  mechanisms	   by	  which	  AMPK	   regulates	   energy	  balance	   are	  diverse	   in	  nature	   (217,230)	   and	  may	  be	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related	   to	  adaptations	  distinct	   from	  CPT-­‐1	  and	   fat	  oxidation.	  Basal	  activity	   levels	  of	  two	   mitochondrial	   enzymes,	   citrate	   synthase	   and	   β-­‐HAD,	   were	   not	   significantly	  altered	   following	   HFEE	   in	   the	   current	   study.	   These	   findings	   are	   consistent	   with	   a	  previous	  report	  by	  Samocha-­‐Bonet	  and	  colleagues	  (112)	  who	  observed	  no	  changes	  in	  citrate	   synthase	  or	  β-­‐HAD	  activity	   levels	   following	  3	  d	  or	  28	  d	  overfeeding.	  Finally,	  adiponectin,	   an	   adipose	   tissue	   derived	   cytokine,	   has	   been	   shown	   to	   increase	  ceramidase	  activity	  resulting	  in	  ceramide	  degradation	  to	  sphingosine	  (85).	  However,	  in	   the	  current	   investigation,	  no	  changes	   in	  plasma	  adiponectin	  concentrations	  were	  observed	  following	  HFEE,	  suggesting	  a	  lack	  of	  stimulus	  for	  ceramidase	  activity.	  Thus,	  taken	   together,	   these	   data	   suggest	   that	   fat	   oxidation	   and	   ceramide	   degradation	  remained	   relatively	   stable	   during	   the	   overfeeding	   period,	   and,	   instead,	   alternative	  mechanisms	  of	  ceramide	  regulation	  need	  to	  be	  explored	  in	  future	  investigations.	  	  Finally,	   our	   initial	   hypotheses	   centring	   on	   possible	   associations	   between	   ceramide	  levels	   and	   PKB,	   AMPK	   α2	   or	   mitochondrial	   enzyme	   activities	   were	   largely	  unsubstantiated.	   However,	   basal	   PKB	   activity	   pre-­‐HFEE	   did	   significantly	   predict	  around	  ~19	  %	  of	  the	  variance	  in	  the	  mean	  change	  in	  total	  ceramides	  over	  the	  course	  of	  HFEE.	  Whereas	  we	  cannot	  establish	  a	  cause	  and	  effect	  relationship	  from	  these	  data,	  it	  is	  interesting	  that	  higher	  basal	  PKB	  activity	  was	  associated	  with	  a	  greater	  increase	  in	  ceramide	  accumulation	  following	  HFEE.	  This	  finding	  perhaps	  infers	  that	  increased	  basal	   PKB	   activity	   is	   indicative	   of	   insulin	   resistance	   rather	   than	   insulin	   sensitivity	  although	   further	  work	   is	   necessary	   before	   this	   suggestion	   can	   be	   given	   credibility.	  Possible	  explanations	  for	  the	  lack	  of	  association	  between	  other	  seemingly	  associated	  parameters	  may	  relate	  to	  the	  temporal	  development	  of	  maladaptation	  in	  each	  of	  the	  measures	  and	  /	  or	  potential	  unaccounted	  covariate	  factors,	  e.g.,	  enzyme	  activity	  and	  /	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or	   total	   content	   /	   activation	   of	   substrate	   proteins.	   Unquestionably,	   further	  work	   is	  required	   to	   better	   characterise	   these	   subcellular	   adaptations,	   and	   their	   associated	  mechanisms,	   if	   we	   are	   to	   better	   understand	   the	   pathology	   underlying	   short-­‐term	  HFEE.	  	  	  In	  conclusion,	  we	  present	  data	  to	  suggest	  that	  some	  lipid-­‐mediated	  subcellular	  events	  result	   from	   HFEE	   that	   precede	   the	   clear	   development	   of	   whole-­‐body	   insulin	  resistance.	   Circulating	   TG	   and	   FA	   concentrations	   were	   decreased,	   skeletal	   muscle	  ceramide	   levels	   increased,	   and	   basal	   mitochondrial	   enzyme	   activities	   were	  unchanged	   by	   HFEE,	   irrespective	   of	   FO	   consumption.	   However,	   FO	   consumption	  during	  HFEE	  differentially	  altered	  basal	  AMPK	  α2	  activity	  and	  insulin-­‐stimulated	  PKB	  activity	   compared	   to	   HFEE	   without	   FO	   intake.	   One	   potential	   explanation	   for	   the	  group-­‐divergence	   in	   these	   findings	   is	   changes	   in	   the	   phospholipid	   membrane	  following	  FO	  ingestion.	  Alterations	  in	  the	  docking	  efficiency	  of	  transporter	  proteins	  in	  the	   plasma	   membrane,	   altered	   nutrient	   kinetics	   and	   signalling	   from	   membrane	  composition	   changes	   all	  may	   contribute	   to	   these	   groups	  discrepancies.	   Considering	  all	   findings	  were	   in	   the	   context	   of	   statistically	   unaltered	   insulin	   sensitivity,	   further	  work	   is	   required	   to	   elucidate	   the	   mechanisms	   of	   lipid	   regulation	   in	   the	   high-­‐fat	  overfed	   state,	   as	  well	   as	   a	   time	   course	   of	   change	   in	   ceramide	   levels	  with	   declining	  whole-­‐body	  insulin	  sensitivity.	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CHAPTER	  4	  Distinct	  subsets	  of	  skeletal	  muscle	  and	  plasma	  miRNAs	  are	  altered	  following	  short-­‐term	  high-­‐fat	  energy	  excess	  and	  /	  or	  following	  oral	  glucose	  consumption	  in	  healthy	  males.	  	  	  
Wardle	  SL,	  Macnaughton	  LS,	  McGlory	  C,	  Witard	  OCW,	  Galloway	  SR,	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  KD,	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4.0.	  Abstract	  MiRNAs	   regulate	   gene	   expression	   within	   the	   cell.	   However,	   miRNAs	   also	   exist	   at	  stable	   levels	  within	   plasma.	   Changes	   in	   tissue	   and	   plasma	  miRNA	   levels	   have	   been	  associated	  with	  metabolic	  disease	  development.	  However,	   the	   impact	  of	   short-­‐term	  high-­‐fat	  energy	  excess	  (HFEE)	  and	  /	  or	  glucose	  consumption	  on	  plasma	  and	  skeletal	  muscle	   miRNA	   levels	   in	   humans	   is	   currently	   unknown.	   We	   investigated	   changes	  (basal	  and	  following	  oral	  glucose	  consumption)	  in	  miRNA	  levels	  following	  6	  d	  HFEE	  (150	  %	  habitual	  energy	  intake;	  60	  %	  of	  energy	  from	  fat)	  in	  non-­‐active	  healthy	  males	  (n=20).	   Ten	   of	   twenty	   participants	   consumed	   10	  %	   of	   total	   fats	   from	   fish	   oil	   (FO)	  sources.	  Levels	  of	  a	  number	  of	  miRNAs	  were	  significantly	  altered	  by	  HFEE	  in	  skeletal	  muscle	  (miR-­‐106b-­‐5p,	  miR-­‐214-­‐3p,	  miR-­‐215)	  but	  not	  plasma.	  Certain	  miRNAs	  were	  responsive	  to	  the	  OGTT	  including	  miR-­‐145-­‐5p	  (plasma),	  and	  miR-­‐193a-­‐5p,	  miR-­‐206	  (skeletal	  muscle).	   No	  miRNAs	   in	   either	   tissue	   type	  were	   regulated	   by	   group	   alone;	  however,	  several	  group	  interactions	  existed	  with	  HFEE	  and	  /	  or	  the	  OGTT	  (miR-­‐7-­‐5p,	  miR-­‐27a-­‐3p	  (plasma),	  miR-­‐18a-­‐5p,	  miR-­‐145-­‐5p,	  miR-­‐214-­‐3p	  (skeletal	  muscle)).	  Basal	  levels	   of	   miR-­‐145-­‐5p	   (plasma)	   and	   miR-­‐204-­‐5p	   (skeletal	   muscle)	   significantly	  predicted	   16-­‐23	   %	   of	   the	   change	   in	   HFEE-­‐mediated	   insulin	   sensitivity.	   Certain	  miRNAs	  may	  be	  useful	  markers,	  and	  predictors,	  of	  the	  high-­‐fat	  overfed	  state	  (with	  or	  without	   FO),	   the	   response	   to	   oral	   glucose	   consumption	   and	   /	   or	   the	   combined	  influence	  of	   these.	  However,	  clear	  associations	  between	  plasma	  and	  skeletal	  muscle	  levels	   of	   these	   miRNAs	   are	   lacking,	   suggesting	   that	   investigation	   of	   these	   plasma	  miRNAs	   within	   the	   context	   of	   HFEE	   may	   not	   inform	   functional	   outcomes	   within	  skeletal	  muscle,	  but	  may	  better	  relate	  to	  other	  tissue	  types.	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4.1.	  Introduction	  Various	   metabolic	   and	   molecular	   responses	   to	   6	   d	   HFEE	   have	   been	   presented	   in	  
Chapters	   2	   and	   3.	   These	   (mal)adaptive	   responses	   to	  nutrition	  and	  energy	  balance	  are	   driven	   by	   the	   regulation	   of	   gene	   expression.	   Whereas	   such	   (mal)adaptive	  responses	   are	   reasonably	  well	   characterised	   at	   the	   genome	   level,	   regulation	  by	   the	  epigenome	   is	   less	   well	   understood.	   Epigenetic	   control	   mechanisms,	   including	  miRNAs,	   and	   their	   regulation	   of	   gene	   expression	   have	   stimulated	   research	   interest	  since	  the	  discovery	  of	  miRNAs	  two	  decades	  ago	  (159).	  	  	  	  The	   importance	   of	   miRNA	   regulation	   within	   tissue	   and	   the	   circulation	   has	   been	  investigated	   previously.	   MiRNAs	   exist	   in	   both	   tissue	   and	   the	   circulation,	   although	  their	  mechanism	  of	  action	   is	  confined	  to	   tissue.	  Given	  that	  skeletal	  muscle	  accounts	  for	   ~75	   %	   of	   non-­‐oxidative	   glucose	   disposal	   in	   the	   postprandial	   state	   (9,45),	  measurements	   of	   gene	   expression	   and	   post-­‐translational	   modification	   in	   skeletal	  muscle	   are	   often	  made	   in	   studies	   investigating	   insulin	   sensitivity	   /	   resistance	   (e.g.	  (72)).	  However,	  post-­‐transcriptional	  regulation,	  and	  in	  particular	  miRNA	  regulation,	  of	  gene	  expression	  has	  been	  less	  well	  studied	  within	  the	  context	  of	  insulin	  sensitivity.	  Only	   in	   the	  past	   5	   years,	   or	   so,	   has	   the	   role	   of	  miRNAs	  within	  T2D	  pathology	  been	  highlighted	  (231–236).	  Some	  researchers	  now	  have	  even	  suggested	  that	  T2D	  may	  be	  considered	   a	   miRNA-­‐related	   disease	   (179).	   Thus,	   the	   impact	   of	   skeletal	   muscle	  miRNA	  regulation	  in	  insulin	  resistance	  pathology	  is	  apparent.	  	  Investigation	   of	   skeletal	   muscle	   miRNA	   regulation	   provides	   insight	   into	   the	  underlying	   mechanism	   of	   insulin	   resistance.	   MiRNA	   profiling	   of	   skeletal	   muscle	   in	  T2D	  was	  initially	  confined	  to	  cell	  culture	  and	  rodent	  models	  of	  metabolic	  disease	  (e.g.	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(237–240)).	   However,	   in	   recent	   years,	   reports	   from	   human	   studies	   have	   been	  published	   (e.g.	   (241,242)).	   These	   human	   studies	   largely	   provide	   descriptive	   /	  associative	   data,	   rather	   than	   data	   from	   interventions.	   However,	   these	   studies	   do	  present	   associations	   with	   insulin	   signalling	   genes	   (242)	   and	   glucose	   /	   insulin	  concentrations	   (241).	   These	   associations	   suggest	   potential	   for	   skeletal	   muscle	  miRNAs	  to	  be	  involved	  in	  the	  regulation	  of	  insulin	  signalling	  and	  glucose	  homeostasis.	  	  	  Adipose	   tissue,	   liver	  and	  pancreatic	  β	  cells,	   like	  skeletal	  muscle,	  are	   involved	   in	   the	  regulation	   of	   energy	   excess	   and	   T2D	   pathology	   (38).	   Considering	   (mal)adaptive	  responses	   to	   energy	   excess	   span	   several	   tissue	   types,	   plasma	   miRNAs	   may	   be	  involved	   in	   this	  whole-­‐body	   response	   -­‐	   essentially	   communicating	  between	   insulin-­‐responsive	   tissues	   (164).	   MiRNAs	   have	   been	   implicated	   in	   cell-­‐cell	   communication	  (32)	   and	   are	   actively	   secreted	   into	   the	   circulation,	   rather	   than	   released	   in	   a	   non-­‐specific	  manner,	   from	   tissue	   (171,172).	   For	   these	   reasons,	   plasma	  miRNAs	  may	   be	  useful	  biomarkers	  of	  a	  variety	  of	  adaptations.	  	  	  Since	   the	  discovery	  of	  plasma	  miRNAs	   in	  2008	  (166,167),	  studies	  have	   investigated	  plasma	  miRNA	  levels	  in	  a	  variety	  of	  disease	  states,	  including	  T2D	  (33,164).	  However,	  much	   like	   the	  skeletal	  muscle	  miRNA	  studies,	   these	  data	  have	  been	   largely	  static	   in	  nature	  (i.e.,	  assessment	  of	  baseline	  levels).	  Nonetheless,	  these	  reports	  do	  lend	  support	  to	  the	  notion	  of	  altered	  miRNA	  regulation	  in	  diseased	  states.	  For	  example,	  analysis	  of	  data	   from	   a	   large	   (n	   =	   822),	   prospective,	   population-­‐based	   study	   (243),	   revealed	  lower	  plasma	  levels	  of	  miR-­‐126	  in	  individuals	  with	  T2D,	  but	  also	  in	  individuals	  with	  subsequent	  T2D	  (determined	  from	  10	  y	   follow-­‐up	  samples).	   Indeed,	  miR-­‐126	  was	  a	  significant	   predictor	   of	   the	  T2D	   state	   (243).	  Moreover,	   a	   significant	   increase	   in	   the	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levels	   of	   a	   battery	   of	   miRNAs	   involved	   in	   insulin	   biosynthesis	   and	   secretion	   was	  noted	   in	   T2D	   patients	   compared	   to	   controls	   (244).	   Although,	   in	   contrast	   to	   the	  findings	  with	  miR-­‐126	   (243),	   there	  was	   no	   significant	   difference	   between	   levels	   of	  these	  miRNAs	  in	  individuals	  with	  pre-­‐diabetes	  vs.	  controls	  (244).	  These	  data	  suggest	  that	  different	  miRNAs	  may	  be	  involved	  in	  the	  regulation	  of	  gene	  expression	  along	  the	  continuum	  between	  initial	  development	  of	  insulin	  resistance	  and	  manifest	  T2D.	  	  The	  involvement	  of	  plasma	  miRNAs	  in	  the	  regulation	  of	  skeletal	  muscle	  adaptation	  is	  now	  being	  considered	  (245).	  However,	  to	  the	  best	  of	  our	  knowledge,	  the	  association	  between	   miRNA	   levels	   in	   skeletal	   muscle	   and	   plasma	   has	   not	   been	   previously	  investigated.	  The	  usefulness	  and	  validity	  of	  miRNA	  biomarkers	  for	  understanding	  the	  underlying	   mechanisms	   of	   miRNA	   regulation	   and	   insulin	   resistance	   would	   be	  enhanced	   if	   they	   were	   highly	   related	   to	   functional	   tissue	   changes.	   Therefore,	  measurement	   of	   plasma	  miRNA	   levels	   in	   combination	   with	   tissue	   miRNA	   levels	   is	  warranted	   to	   facilitate	  mechanistic	   understanding	   of	  miRNA,	   and	   subsequent	   gene,	  regulation.	  	  	  Our	  aims	  were	  three-­‐fold.	  First,	  we	  aimed	  to	  investigate	  miRNA	  levels	  of	  both	  plasma	  and	   skeletal	  muscle	   samples	   in	   our	   healthy	  male	   volunteers	   subject	   to	   short-­‐term,	  HFEE,	  with	  and	  without	  FO	  consumption.	  In	  addition	  to	  investigating	  the	  influence	  of	  HFEE	  on	  basal	  miRNA	  levels,	  we	  aimed	  to	  characterise	  the	  miRNA	  response	  to	  an	  oral	  glucose	   load,	   and	   to	   investigate	   whether	   fluctuations	   in	   miRNA	   levels	   during	   the	  course	  of	  an	  OGTT	  were	  altered	  by	  diet.	  Finally,	  we	  aimed	  to	  investigate	  the	  degree	  of	  association	   between	   plasma	   and	   skeletal	  muscle	  miRNA	   levels,	   and	   between	   these	  miRNA	  levels	  and	  various	  measures	  presented	  in	  Chapters	  2	  and	  3.	  We	  hypothesised	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that	  plasma	  and	  skeletal	  muscle	  miRNA	  levels	  would	  be	  altered	  by	  HFEE	  (both	  basal	  and	   the	   OGTT	   response)	   and	   that	   some	   associations	   would	   exist	   between	   miRNA	  levels	  in	  different	  sample	  types	  and	  other	  metabolic	  /	  molecular	  measures.	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4.2.	  Methods	  
4.2.1.	  Plasma	  miRNA	  analysis	  
RNA	  extraction	  Total	   RNA	   was	   extracted	   from	   plasma	   samples	   using	   commercially	   available	   RNA	  isolation	   kits	   (Exiqon,	   Vedbaek,	   Denmark)	   according	   to	   the	   manufacturer’s	  instructions.	   The	   starting	   plasma	   volume	  was	   200	   µL	   and	   the	   recovered	   RNA	  was	  eluted	   in	  50	  µL	  of	  RNase	   free	  water.	   Complementary	  DNA	   (cDNA)	  was	   synthesised	  using	   the	  Qiagen	  miScript	  RT	   II	  kit	   (Qiagen	  Ltd.,	  West	  Sussex,	  UK)	  according	   to	   the	  manufacturer’s	   instructions	   in	   a	   final	   volume	  of	  20	  µL.	  A	  quality	   control	   (QC)	  plate	  array	   (Qiagen	   Ltd.,	   West	   Sussex,	   UK)	   was	   performed	   to	   confirm	   cDNA	   synthesis	  efficiency	  (data	  not	  shown)	  prior	  to	  further	  analysis.	  	  	  
Plasma	  plate	  arrays	  Plasma	  plate	  arrays	  (Qiagen	  Ltd.,	  West	  Sussex,	  UK)	  were	  prepared	  using	  SYBR	  Green	  mastermix	   (Qiagen	   Ltd.,	  West	   Sussex,	   UK)	   in	   a	   final	   reaction	   volume	   of	   15	   µL.	   The	  final	   reaction	   volume	   comprised	   7.5	   µL	   SYBR	  Green,	   1.5	   µL	   10x	  miScript	   universal	  primer,	  5.45	  µL	  RNase	  free	  water	  and	  0.55	  µL	  cDNA.	  In	  total,	  12	  plasma	  array	  plates	  were	  prepared	  using	  pooled	  samples	   from	  each	  experimental	   condition	   (HF-­‐C;	  pre-­‐	  and	   post-­‐HFEE,	   and	   HF-­‐FO;	   pre-­‐	   and	   post-­‐HFEE).	   Three	   plates	   for	   each	   condition	  were	  used	  to	  calculate	  cycle	  threshold	  (Ct)	  values	  in	  triplicate.	  Real-­‐time	  quantitative	  polymerase	  chain	  reactions	  (qRT-­‐PCR)	  were	  performed	  on	  the	  Roche	  LightCycler480	  (Roche,	  Basal,	  Switzerland).	  Reactions	  involved	  an	  initial	  10	  min	  incubation	  at	  95	  °C	  followed	  by	  45	  amplification	  cycles	  of	  95	  °C	  for	  10	  s	  and	  60	  °C	  for	  1	  min	  with	  a	  ramp	  rate	   of	   1.6	   °C·s-­‐1	   and	   an	   optical	   read	   at	   the	   end	   of	   each	   cycle.	   Reactions	   were	  completed	   with	   a	   melting	   curve	   for	   quality	   control	   to	   ensure	   that	   only	   a	   single	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amplicon	  was	  present	  in	  each	  reaction.	  Baseline	  subtracted	  Ct	  values	  were	  imported	  into	  SABiosciences	  software	  (246)	  to	  analyse	  the	  amplification	  data.	  	  	  The	   plate	   array	   data	   (Appendices	   4.1	   and	   4.2)	   were	   used	   to	   inform	   subsequent	  plasma	   qPCR	   analysis	   of	   candidate	   miRNA	   assays.	   In	   addition	   to	   using	   the	  recommended	  SNORD	  genes	  as	  internal	  controls,	  two	  other	  methods	  of	  selecting	  the	  best	  reference	  genes	  were	  used.	  First,	  Normfinder	  software	  (247)	  was	  used	  to	  detect	  the	  most	  stable	  gene,	  or	  set	  of	  genes,	  within	  the	  samples,	  and	  second,	  the	  average	  Ct	  value	  for	  each	  plate	  was	  used	  as	  a	  reference.	  Using	  all	  of	  these	  methods,	  the	  SNORDS,	  miR-­‐25-­‐3p	   and	   miR-­‐27a-­‐3p	   were	   all	   deemed	   suitable	   reference	   genes,	   and	   were	  individually	  used	  within	  2-­‐ΔΔCt	   calculations	   (248),	   along	  with	  HF-­‐C,	  pre-­‐HFEE	  as	   the	  control	   group.	   Establishing	   the	   appropriate	   reference	   gene	   is	   crucial	   to	   account	   for	  variation	   in	   reaction	   components	   and	   ensure	   that	   any	   measured	   changes	   are	  indicative	  of	  the	  intervention	  rather	  than	  changes	  in	  experimental	  factors	  (249).	  The	  miRNAs	   that	  were	   significantly	   different	   in	   the	   post-­‐HFEE	   pools	   and	   /	   or	   between	  groups	  were	  taken	  forward	  into	  analysis	  with	  individual	  primer	  assays	  in	  individual	  samples.	   These	   selected	  miRNAs	   included;	  miR-­‐7-­‐5p,	  miR-­‐15-­‐5p,	  miR-­‐18a-­‐5p,	  miR-­‐22-­‐3p,	  miR-­‐25-­‐3p	  (reference	  gene	  for	  plasma	  assays),	  miR-­‐27a-­‐3p	  (reference	  gene	  for	  skeletal	   muscle	   assays),	   miR-­‐30d-­‐5p,	   miR-­‐93-­‐5p,	   miR-­‐100-­‐5p,	   miR-­‐106b-­‐5p,	   miR-­‐126-­‐3p,	  miR-­‐145-­‐5p,	  miR-­‐193a-­‐5p,	  miR-­‐196a-­‐5p,	  miR-­‐204-­‐5p,	  miR-­‐214-­‐3p,	  miR-­‐215	  and	  miR-­‐885a-­‐5p.	  Additionally,	  the	  myomiRs,	  miR-­‐1	  and	  miR-­‐206,	  were	  measured	  in	  skeletal	  muscle	  samples	  only.	  
	  
Individual	  primer	  assays	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The	  same	  RNA	  eluates	  used	  for	  the	  plasma	  plate	  arrays	  were	  used	  for	  all	  subsequent	  plasma	   miRNA	   experiments.	   However,	   for	   the	   individual	   assays,	   cDNA	   was	  synthesised	  using	  2	  µL	  5x	  reaction	  buffer,	  5	  µL	  nuclease	  free	  water,	  1	  µL	  enzyme	  mix	  and	  2	  µL	  template	  RNA	  (Exiqon,	  Vedbaek,	  Denmark).	  cDNA	  synthesis	  reactions	  were	  incubated	  at	  42	  °C	  for	  60	  min,	  heated	  to	  95	  °C	  for	  5	  min	  and	  then	  cooled	  to	  4	  °C	  prior	  to	   storage	   at	   -­‐20	   °C	   pending	   further	   analysis.	   Samples	   were	   diluted	   1	   in	   40	   with	  RNase	  free	  water	  and	  transferred	  to	  deep-­‐well	  plates	  for	  long	  term	  storage	  at	  -­‐20	  °C.	  	  
	  
Commercially	   available	   qRT-­‐PCR	   primer	   assays	   (Exiqon,	   Vedbaek,	   Denmark)	   were	  used	  for	  miRNA	  analysis,	  with	  selection	  of	  target	  miRNAs	  determined	  from	  the	  plate	  array	  analysis	  (see,	  Plasma	  plate	  arrays).	  SYBR	  Green	  reactions	  (10	  µL)	  comprised	  5	  µL	  PCR	  mastermix,	  1	  µL	  PCR	  primer	  mix	  and	  4	  µL	  cDNA	  dilution	  (Exiqon,	  Vedbaek,	  Denmark).	  MiRNA	   levels	  were	  measured	   in	   triplicate.	   Starting	  with	  an	   initial	  1	   in	  2	  dilution,	  a	  standard	  curve	  (1	  in	  4	  dilution	  series,	  using	  a	  pooled	  sample	  consisting	  of	  cDNA	  from	  all	  participants	  in	  both	  groups)	  was	  included	  on	  each	  plate	  to	  ensure	  all	  assays	  were	   in	   the	   linear	   range.	   qRT-­‐PCR	  were	   performed	   in	   the	   same	  manner	   as	  described	   for	  Plasma	   plate	   arrays,	   and	   similarly	  with	   a	  melting	   curve	   for	   quality	  control	   to	   ensure	   that	   only	   a	   single	   amplicon	   was	   present	   in	   each	   reaction.	   All	   Ct	  values	  were	  within	  the	  linear	  range	  of	  the	  standard	  curve.	  Ct	  outliers	  were	  removed	  using	   the	   median	   absolute	   deviation	   method	   (also	   known	   as	   the	   modified	   Z-­‐score	  (208))	  with	   the	  maximum	  acceptable	   threshold	   set	   at	   3.5.	   Control	   samples	   (pooled	  cDNA	  from	  each	  participant)	  were	  included	  on	  each	  plate	  to	  allow	  standardisation	  of	  the	  Ct	  values	  for	  experiments	  that	  spanned	  several	  plates.	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Reference	  gene	  selection	  
Normfinder	   software	   (247)	   was	   used	   to	   determine	   which	   single	   gene	   or	   group	   of	  genes	  was	  at	  the	  most	  stable	  level	  within	  the	  samples.	  For	  plasma	  samples,	  miR-­‐25-­‐3p	  alone	  was	  found	  to	  be	  most	  stable	  over	  time	  and	  across	  both	  groups;	  for	  skeletal	  muscle	  samples	  the	  most	  stable	  gene	  was	  miR-­‐27a-­‐3p.	  This	  consistency	  in	  reference	  gene	  stability	  across	  both	  methods	  of	  miRNA	  analysis	  (i.e.	  plate	  arrays	  and	  individual	  primer	  assays)	  gives	  us	  confidence	   in	  our	  selection	  of	  reference	  genes.	  These	  genes	  were	  therefore	  used	  to	  determine	  the	  relative	  expression	  of	  the	  target	  genes	  within	  each	  sample	  type	  (i.e.	  plasma	  /	  muscle),	  calculated	  using	  the	  2-­‐ΔΔCt	  method	  described	  previously	  with	  HF-­‐C,	  pre-­‐HFEE	  as	  the	  control	  group.	  	  
	  
4.2.2.	  Skeletal	  muscle	  miRNA	  analysis	  Skeletal	  muscle	  samples	  (~20	  mg)	  were	  homogenised,	  and	  RNA	  extracted,	  using	  the	  Qiagen	   AllPrep	   DNA/RNA/miRNA	   universal	   kit	   (Qiagen,	   Ltd.,	   West	   Sussex,	   UK)	  according	  to	  the	  manufacturers’	  instructions.	  Prior	  to	  performing	  cDNA	  synthesis,	  all	  RNA	  samples	  were	  adjusted	  to	  a	  concentration	  of	  5ng·µL-­‐1	  with	  nuclease	  free	  water.	  cDNA	   synthesis	   reactions	   were	   performed	   using	   the	   same	   reagents	   and	   reagent	  volumes	   as	   those	   outlined	   for	   plasma	   samples	   (see,	   Individual	   primer	   assays).	  cDNA	  samples	  were	  diluted	  1	  in	  80	  using	  nuclease	  free	  water	  and	  then	  followed	  the	  same	  processing	  and	  qRT-­‐PCR	  procedure	  as	  plasma	  samples	  (see,	  Individual	  primer	  
assays).	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4.2.3.	  miRNA	  target	  prediction	  analysis:	  miRSystem	  Given	   no	   miRNA-­‐mRNA	   analyses	   were	   performed	   in	   the	   current	   investigation	   we	  used	   the	   web-­‐based	   tool,	   miRSystem	   to	   predict	   gene	   targets	   of	   our	   differentially	  regulated	  miRNAs.	  All	  differentially	   regulated	  miRNAs	  were	  entered	   into	   the	  model	  simultaneously	   (per	   tissue	   type	   and	   per	   regulatory	   subset	   (i.e.	   HFEE	   /	   OGTT)).	  Separate	  models	  were	  used	   for	  each	  subset	  of	   regulation	  and	  each	   tissue	   type.	  This	  analysis	  was	  conducted	  to	  ascertain	  whether	  common	  mRNA	  targets	  were	  shared	  to	  a	  significant	  extent	  by	  these	  miRNAs.	  	  	  
4.2.4.	  Statistical	  analysis	  
Power	  calculations	  for	  the	  study	  design	  have	  been	  discussed	  in	  Chapter	  2.	  Separate	  power	   calculations	   were	   not	   performed	   for	   the	   miRNA	   analysis	   as	   no	   prior	   data	  existed	  relating	  to	  changes	  in	  miRNA	  levels	  following	  short-­‐term	  HFEE.	  	  
	  Normality	   of	   logged	  miRNA	   data	  was	   assessed	   using	   the	   Ryan	   Joiner	   test	   (Minitab	  version	  16;	  Minitab,	  State	  College,	  PA).	  In	  the	  case	  of	  non-­‐normal	  distributions,	  Box-­‐Cox	   transformations	   were	   performed	   on	   miRNA	   fold-­‐change	   data,	   and	   the	   data	  transformed	  accordingly,	  before	  re-­‐testing	  for	  normality.	  All	  samples	  were	  normally	  distributed	   before	   conducting	   statistical	   analyses.	   Between-­‐group	   differences	   in	  miRNA	  levels	  pre-­‐	  and	  post-­‐HFEE	  and	  at	  various	  time-­‐points	  during	  the	  OGTT	  were	  determined	   by	  ANOVA	   (2	   x	   3	   x	   2	  mixed	   design	   (plasma)	   /	   2	   x	   2	   x	   2	  mixed	   design	  (muscle);	  IBM	  SPSS	  Statistics	  19,	  Chicago,	  IL,	  USA).	  Post-­‐hoc	  tests	  were	  not	  conducted	  due	  to	  only	  having	  2	  groups	  in	  the	  model	  (HF-­‐C	  vs.	  HF-­‐FO).	  Regression	  analyses	  were	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conducted	  between	  plasma	  and	   skeletal	  muscle	  miRNA	   levels,	   and	  between	  miRNA	  levels	   from	   both	   tissue	   types	   and	   Matsuda	   insulin	   sensitivity	   data	   presented	   in	  
Chapter	  2	  using	  Minitab	  software	  (version	  16;	  Minitab,	  State	  College,	  PA).	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4.3.	  Results	  
4.3.1.	  Plasma	  miRNAs	  (individual	  assays)	  Eighteen	   skeletal	  muscle	  miRNAs	  were	  measured	   in	   both	   HF-­‐C	   and	   HF-­‐FO	   groups,	  pre-­‐	  and	  post-­‐HFEE,	  at	  0	  and	  2	  h	  OGTT	  time-­‐points,	  as	  well	  as	  the	  time-­‐point	  during	  the	  OGTT	  that	  corresponded	  to	  peak	  plasma	  insulin	  levels.	  However,	  only	  13	  of	  these	  measured	  miRNAs	  were	  consistently	  detected	  in	  plasma,	  thus	  the	  other	  5	  (miR-­‐193a-­‐5p,	   miR-­‐196a-­‐5p,	   miR-­‐204-­‐5p,	   miR-­‐214-­‐3p,	   miR-­‐885-­‐5p)	   were	   removed	   from	  subsequent	  analyses.	  Table	  4.1	  shows	  mean	  relative	  levels	  for	  each	  of	  the	  detectable	  test	  miRNAs	  (n=12)	  standardised	  to	  the	  reference	  gene	  (miR-­‐25-­‐3p)	  and	  to	  baseline	  levels	  in	  the	  HF-­‐C	  group.	  	  
	  
HFEE-­‐responsive	  miRNAs	  There	   were	   no	   statistically	   significant	   changes	   in	   plasma	   levels	   of	   any	   miRNAs	   in	  response	  to	  the	  6	  d	  period	  of	  HFEE.	  There	  was	  no	  interactive	  effect	  of	  group	  on	  the	  plasma	  miRNA	  response	  to	  HFEE.	  	  	  
OGTT-­‐responsive	  miRNAs	  Transient	   changes	   in	   miR-­‐145-­‐5p	   were	   observed	   over	   the	   course	   of	   the	   OGTT,	  irrespective	  of	   group	   (p	  =	  0.02;	  Figure	   4.1C).	   Specifically,	   peak	  miRNA	   levels	  were	  observed	   at	   the	   time-­‐point	   corresponding	   to	   peak	   insulin	   levels,	  with	   fairly	   similar	  lower	  levels	  at	  0	  and	  2	  h.	  	  
	  
Interactive	  HFEE	  and	  OGTT-­‐responsive	  miRNAs	  Two	  miRNAs	  (miR-­‐7-­‐5p	  and	  miR-­‐27a-­‐3p)	  were	  significantly	  altered	  (p	  <	  0.05;	  Figure	  
4.1A-­‐B)	  over	  the	  course	  of	  the	  OGTT	  in	  a	  different	  manner	  following	  HFEE	  compared	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to	   pre-­‐HFEE.	   Post-­‐HFEE,	   levels	   of	   both	  miRNAs	  were	   highest	   at	   0	   h.	   For	  miR-­‐7-­‐5p,	  levels	  at	  the	  time-­‐point	  corresponding	  to	  peak	  plasma	  insulin	  were	  the	  lowest	  of	  the	  three	  measures,	  whereas	  for	  miR-­‐27a-­‐3p,	  the	  lowest	  levels	  were	  observed	  at	  2	  h.	  Pre-­‐HFEE,	  both	  miRNAs	  responded	  differently	  to	  the	  OGTT.	  Levels	  of	  miR-­‐7-­‐5p	  increased	  throughout	   the	  OGTT	   so	   that	   the	   lowest	   levels	  were	   observed	   at	   0	   h,	   intermediate	  levels	  at	  the	  time-­‐point	  corresponding	  to	  peak	  plasma	  insulin,	  and	  the	  highest	  levels	  at	   2	   h.	   For	   miR-­‐27a-­‐3p,	   the	   lowest	   levels	   were	   observed	   at	   the	   time-­‐point	  corresponding	   to	   peak	   plasma	   insulin	   levels,	   with	   the	   highest	   levels	   at	   2	   h,	   and	  intermediate	  levels	  at	  0	  h.	  	  	  
Group-­‐responsive	  miRNAs	  No	  miRNAs	  were	  significantly	  altered	  by	  group	  in	  the	  absence	  of	  any	  interaction	  with	  the	  within-­‐subject	  factors	  (i.e.	  HFEE	  and	  /	  or	  OGTT).	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4.3.2.	  Skeletal	  muscle	  miRNAs	  (individual	  assays)	  From	   the	   initial	   plate	   array	   analysis,	   twenty	   of	   these	   miRNAs	   were	   measured	   in	  skeletal	  muscle	  samples	  from	  both	  HF-­‐C	  and	  HF-­‐FO	  groups,	  pre-­‐	  and	  post-­‐HFEE,	  at	  0	  and	  2	  h	  OGTT	  time-­‐points.	  Table	  4.2	  shows	  mean	  relative	  levels	  for	  each	  of	  the	  test	  miRNAs	  (n	  =	  19)	  standardised	  to	  the	  reference	  gene	  (miR-­‐27a-­‐3p)	  and	  to	  baseline	  (0	  h)	  levels	  in	  the	  HF-­‐C	  group.	  	  	  
HFEE-­‐responsive	  miRNAs	  Three	  of	   the	  measured	   skeletal	  muscle	  miRNAs	  were	   significantly	   altered	  by	  HFEE,	  irrespective	   of	   group.	   These	  miRNAs	   included	  miR-­‐106b-­‐5p	   and	  miR-­‐215,	   levels	   of	  which	  were	  higher	  post-­‐HFEE,	  and	  miR-­‐214-­‐3p	  which	  was	   reduced	   following	  HFEE	  (p	   <	   0.05;	   Figure	   4.2A-­‐C).	   One	   miRNA	   (miR-­‐145-­‐5p)	   was	   significantly	   altered	  following	   6	   d	   HFEE,	   but	   differently	   between	   the	   groups	   (p	   <	   0.05	   (interaction);	  
Figure	   4.2D).	  miR-­‐145-­‐5p	   levels	   in	  HF-­‐C	  were	   increased	  with	  HFEE,	   yet	  decreased	  following	  HFEE	  in	  HF-­‐FO.	  	  
OGTT-­‐responsive	  miRNAs	  Levels	  of	  two	  of	  the	  measured	  skeletal	  muscle	  miRNAs	  (miR-­‐193a-­‐5p	  and	  miR-­‐206)	  were	   significantly	  higher	  at	  2	  h	  of	   the	  OGTT	  compared	   to	  pre-­‐OGTT	   (0	  h;	  p	  <	  0.05;	  
Figure	  4.3A-­‐B).	  	  	  
Interactive	  HFEE	  and	  OGTT-­‐responsive	  miRNAs	  Skeletal	  muscle	  levels	  of	  miR-­‐214-­‐3p	  were	  significantly	  altered	  over	  the	  course	  of	  the	  OGTT	  in	  a	  different	  manner	  following	  HFEE	  compared	  to	  pre-­‐HFEE	  (p	  =	  0.02;	  Figure	  
4.3C).	   The	  magnitude	   of	   the	   increase	   at	   2	   h	   pre-­‐HFEE	  was	  much	   greater	   than	   the	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negligible	  increases	  at	  2	  h	  post-­‐HFEE.	  Adding	  group	  into	  this	  interaction	  to	  create	  a	  3-­‐way	   interaction	   (group	  x	  OGTT	  x	  HFEE)	   resulted	   in	  one	  miRNA,	  miR-­‐18a-­‐5p,	   being	  significantly	  altered	  ((p	  <	  0.01);	  Figure	  4.3D).	  Levels	  of	  miR-­‐18a-­‐5p	  were	  increased	  at	   2	   h	   pre-­‐HFEE,	   yet	   reduced	   at	   2	   h	   post-­‐HFEE	   in	   HF-­‐FO,	   whereas	   the	   opposite	  pattern	  was	  true	  for	  HF-­‐C.	  	  




Figure	   4.2	   Skeletal	  muscle	   levels	   (collapsed	  OGTT	   time-­‐points)	   of	  miR-­‐106b-­‐5p	   (A),	  miR-­‐215	  (B),	   miR-­‐214-­‐3p	   (C)	   and	   miR-­‐145-­‐5p	   (D).	   Plots	   A,	   B	   and	   C	   show	   HFEE-­‐responsive	   miRNAs,	  whereas	   miR-­‐145-­‐5p	   in	   plot	   D	   is	   HFEE	   x	   Group-­‐responsive;	   *	   p	   <	   0.05	   by	   ANOVA.	   Values	   are	  means	  ±	  95	  %	  CIs	  (backtransformed	  data),	  n	  =	  9	  per	  group.	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HF-­‐C	   	   	   	   	   	   HF-­‐FO	  	  
	  
	  
Figure	   4.3	   Skeletal	  muscle	   levels	   of	  miR-­‐193a-­‐5p	   (A),	  miR-­‐206	   (B),	  miR-­‐214-­‐3p	   (C)	   and	  miR-­‐18a-­‐5p	  (D).	  Plots	  on	  the	  left-­‐hand	  side	  are	  from	  HF-­‐C,	  whereas	  all	  plots	  on	  the	  right-­‐hand	  side	  are	  from	  HF-­‐FO	   (n	   =	   9	   per	   group).	  Plots	   A	   and	  B	  present	  OGTT-­‐responsive	  miRNAs,	  whereas	  miR-­‐214-­‐3p	  in	  plot	  C	  is	  HFEE	  x	  OGTT-­‐responsive	  and	  miR-­‐18a-­‐5p	  in	  plot	  D	   is	  HFEE	  x	  OGTT	  x	  Group-­‐responsive;	  *	  p	  <	  0.05	  by	  ANOVA.	  Values	  are	  means	  ±	  95	  %	  CIs	  (backtransformed	  data).	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4.3.3.	  Correlations	  
Skeletal	  muscle	  vs.	  plasma	  miRNAs	  Skeletal	  muscle	  levels	  of	  miR-­‐7-­‐5p,	  miR-­‐93-­‐5p	  and	  miR-­‐100-­‐5p	  explained	  between	  11	  and	   16	   %	   of	   the	   variance	   around	   the	   mean	   plasma	   levels	   of	   the	   corresponding	  miRNA.	   However,	   these	   associations	   were	   not	   statistically	   significant.	   With	   the	  exception	  of	  miR-­‐30d-­‐5p,	  which	  explained	  5	  %	  of	  the	  variance,	  skeletal	  muscle	  levels	  of	  all	  other	  miRNAs	  explained	  less	  than	  1	  %	  of	  the	  variance	  in	  plasma	  miRNA	  levels	  (p	  >	  0.39;	  Appendix	  4.3).	  	  
	  
Plasma	  miRNAs	  vs.	  Matsuda	  ISI	  Basal	   plasma	   miR-­‐145-­‐5p	   levels	   pre-­‐HFEE	   significantly	   predicted	   16	   %	   of	   the	  variance	  in	  mean	  changes	  in	  insulin	  sensitivity	  (Matsuda)	  over	  the	  course	  of	  HFEE	  (p	  =	   0.04).	   Plasma	   levels	   of	   miR-­‐27a-­‐3p,	   miR-­‐30d-­‐5p,	   miR-­‐106b-­‐5p	   and	   miR-­‐126-­‐3p	  predicted	  between	  11	  and	  12	  %	  of	  the	  variance	  in	  mean	  changes	  in	  insulin	  sensitivity,	  but	   not	   to	   a	   statistically	   significant	   extent.	   All	   other	   plasma	  miRNAs	   predicted	   less	  than	   8	   %,	   and	   most	   less	   than	   2	   %,	   of	   the	   variance	   in	   mean	   changes	   in	   insulin	  sensitivity	  (p	  >	  0.12;	  Appendix	  4.3).	  	  
Skeletal	  muscle	  miRNAs	  vs.	  Matsuda	  ISI	  Skeletal	  muscle	  basal	  levels	  of	  miR-­‐204-­‐5p,	  pre-­‐HFEE	  significantly	  predicted	  23	  %	  of	  the	  variance	  in	  mean	  changes	  in	  insulin	  sensitivity	  (Matsuda)	  over	  the	  course	  of	  HFEE	  (p	   =	   0.03).	   Skeletal	   muscle	   levels	   of	   miR-­‐22-­‐3p,	   miR-­‐193a-­‐5p	   and	   miR-­‐214-­‐3p	  predicted	  between	  11	  and	  16	  %	  of	  the	  variance	  in	  mean	  changes	  in	  insulin	  sensitivity	  but	   these	   associations	   were	   not	   statistically	   significant.	   All	   other	   skeletal	   muscle	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miRNAs	  predicted	   less	   than	  10	  %,	  and	  most	   less	   than	  3	  %,	  of	   the	  variance	   in	  mean	  changes	  in	  insulin	  sensitivity	  (p	  >	  0.11;	  Appendix	  4.3).	  	  
miRNA	  target	  prediction	  analysis:	  miRSystem	  Predictions	   using	   miRSystem	   indicated	   that	   plasma	   OGTT-­‐responsive	   (miR-­‐7-­‐5p,	  miR-­‐27a-­‐3p,	   miR-­‐145-­‐5p)	   and	   skeletal	   muscle	   HFEE-­‐	   (miR-­‐106b-­‐5p,	   miR-­‐214-­‐3p,	  miR-­‐215)	  and	  OGTT-­‐responsive	  (miR-­‐193a-­‐5p,	  miR-­‐206,	  miR-­‐214-­‐3p)	  miRNAs	  target	  mRNAs	   involved	   in	   a	   total	   of	   765,	   779	   and	   762	   pathways	   across	   all	   integrated	  databases	   respectively	   (data	   not	   shown).	   The	   top	   10	   pathways	   targeted	   by	   these	  responsive	  miRNA	  clusters	  are	  shown	  in	  Tables	  4.3	  -­‐	  4.5.	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Table	  4.3	  miRSystem	  pathway	  analysis	  of	  relative	  plasma	  OGTT-­‐responsive	  miRNA	  levels	  (presented	  in	  Figure	  1).	  	  
Database	   Pathway	  
Total	  union	  targets	  (of	  total	  
genes)	  in	  the	  pathway	  
Score	  
Kegg	   Axon	  guidance	   43	  (129)	   7.911	  Reactome	   Axon	  guidance	   69	  (266)	   7.351	  Reactome	   Developmental	  biology	   101	  (494)	   7.157	  Kegg	   MAPK	  signalling	  pathway	   65	  (272)	   5.771	  Kegg	   Focal	  adhesion	   50	  (199)	   5.749	  Kegg	   ErbB	  signalling	  pathway	   28	  (87)	   5.329	  
Kegg	   Regulation	  of	  actin	  cytoskeleton	   50	  (213)	   5.148	  Reactome	   L1CAM	  interactions	   30	  (94)	   4.847	  
Kegg	   Neurotrophin	  signalling	  pathway	   35	  (127)	   4.678	  Kegg	   Pathways	  in	  cancer	   61	  (325)	   4.676	  Union	  targets	  refer	  to	  genes	  targeted	  by	  all	  3	  responsive	  miRNAs.	  Score	  is	  deduced	  from	  the	  sum	  of	  the	  weight	  of	  its	  miRNA	  multiplied	  by	  its	  enrichment,	  minus	  the	  log	  (p	  value)	  from	  the	  predicted	  gene	  targets.	  The	  weight	  for	  one	  miRNA	  is	  calculated	  by	  dividing	  its	  absolute	  expression	  value	  by	  the	  absolute	  sum	  of	  the	  expression	  values	  for	  all	  input	  miRNAs	  (250).	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Table	   4.4	   miRSystem	   pathway	   analysis	   of	   relative	   skeletal	   muscle	   HFEE-­‐responsive	  miRNA	  levels	  (presented	  in	  Figure	  2A-­‐C).	  	  
Database	   Pathway	  
Total	  union	  targets	  (of	  total	  
genes)	  in	  the	  pathway	  
Score	  
Reactome	   Axon	  guidance	   95	  (266)	   5.304	  Reactome	   Signalling	  by	  NGF	   130	  (494)	   4.564	  Kegg	   Pathways	  in	  cancer	   51	  (129)	   4.192	  Reactome	   Haemostasis	   122	  (467)	   4.088	  Reactome	   Developmental	  biology	   93	  (325)	   3.901	  Kegg	   Axon	  guidance	   72	  (201)	   3.762	  
Reactome	   Cyclin-­‐D-­‐associated	  events	  in	  G1	   68	  (221)	   3.734	  Reactome	   G1	  phase	   41	  (94)	   3.591	  Reactome	   Rho-­‐GTPase	  cycle	   78	  (272)	   3.318	  Reactome	   Signalling	  by	  Rho-­‐GTPases	   47	  (136)	   3.204	  Union	   targets	   refer	   to	   genes	   targeted	   by	   all	   3	   responsive	   miRNAs	   (excluding	   miR-­‐145-­‐5p	   which	   was	  HFEE*Group	   responsive).	   Score	   is	   deduced	   from	   the	   sum	   of	   the	   weight	   of	   its	   miRNA	   multiplied	   by	   its	  enrichment,	  minus	  the	  log	  (p	  value)	  from	  the	  predicted	  gene	  targets.	  The	  weight	  for	  one	  miRNA	  is	  calculated	  by	  dividing	  its	  absolute	  expression	  value	  by	  the	  absolute	  sum	  of	  the	  expression	  values	  for	  all	   input	  miRNAs	  (250).	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Table	   4.5	   miRSystem	   pathway	   analysis	   of	   relative	   skeletal	   muscle	   OGTT-­‐responsive	  miRNA	  levels	  (presented	  in	  Figure	  3A-­‐C).	  	  
Database	   Pathway	  
Total	  union	  targets	  (of	  total	  
genes)	  in	  the	  pathway	  
Score	  
Reactome	   Axon	  guidance	   50	  (266)	   4.930	  Reactome	   Hemostasis	   68	  (467)	   4.273	  Reactome	   Signalling	  by	  NGF	   42	  (221)	   3.795	  Reactome	   Developmental	  biology	   65	  (494)	   3.510	  
Reactome	   Platelet	  activation	  signalling	  and	  aggregation	   35	  (205)	   3.232	  Reactome	   NGF	  signalling	  via	  TrkA	  from	  the	  plasma	  membrane	   29	  (136)	   3.090	  Kegg	   Axon	  guidance	   25	  (129)	   3.061	  Kegg	   Pathways	  in	  cancer	   46	  (325)	   3.059	  
Kegg	   Bacterial	  invasion	  of	  epithelial	  cells	   19	  (70)	   2.844	  Reactome	   Neuronal	  system	   39	  (289)	   2.805	  Union	   targets	   refer	   to	   genes	   targeted	   by	   all	   3	   responsive	   miRNAs	   (excluding	   miR-­‐18a-­‐5p	   which	   was	  HFEE*OGTT*Group	  responsive).	  Score	  is	  deduced	  from	  the	  sum	  of	  the	  weight	  of	  its	  miRNA	  multiplied	  by	  its	  enrichment,	  minus	  the	  log	  (p	  value)	  from	  the	  predicted	  gene	  targets.	  The	  weight	  for	  one	  miRNA	  is	  calculated	  by	  dividing	  its	  absolute	  expression	  value	  by	  the	  absolute	  sum	  of	  the	  expression	  values	  for	  all	   input	  miRNAs	  (250).	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4.4.	  Discussion	  We	  report	  significant	  differences	  in	  both	  plasma	  and	  skeletal	  muscle	  miRNA	  levels	  in	  response	   to	  oral	  glucose	  consumption	  and	  /	  or	   following	  HFEE,	  with	  some	  of	   these	  perturbations	   being	   modified	   by	   FO	   consumption.	   Basal,	   pre-­‐HFEE	   plasma	   miRNA	  levels	   predicted	   up	   to	   15	  %	   of	   the	   variance	   in	  mean	   basal	   skeletal	  muscle	  miRNA	  levels.	   However,	   miRNA	   levels	   in	   these	   two	   tissue	   types	   were	   not	   significantly	  associated.	  Instead,	  basal,	  pre-­‐HFEE	  levels	  of	  miR-­‐145-­‐5p	  and	  miR-­‐204-­‐5p	  in	  plasma	  and	   skeletal	   muscle,	   respectively,	   were	   significantly	   associated	   with	   the	   HFEE-­‐mediated	   change	   in	   insulin	   sensitivity	   (Matsuda).	   These	   data	   suggest	   that	   levels	   of	  certain	  miRNAs	   in	   plasma	   and	   skeletal	   muscle	   transiently	   respond	   to	   oral	   glucose	  consumption,	   are	   HFEE-­‐responsive	   and	   may	   be	   useful	   predictors	   of	   the	   insulin	  sensitivity	  change	  following	  short-­‐term	  HFEE.	  	  Levels	  of	  certain	  miRNA	  species	  have	  been	  investigated,	  within	  the	  context	  of	  insulin	  resistance	  /	  T2D,	  in	  both	  plasma	  and	  skeletal	  muscle	  tissue	  previously	  (33,164,182).	  Moreover,	   previous	   research	   has	   detailed	   changes	   in	   miRNA	   levels	   between	  individuals	  with	  pre-­‐diabetes	  and	  manifest	  T2D	   (243).	  However,	   to	  our	  knowledge,	  miRNA	  levels	  have	  not	  been	  investigated	  in	  response	  to	  short-­‐term	  HFEE	  in	  humans.	  We	  demonstrate	  clear	  subsets	  of	  miRNA	  regulation	  with	  miRNAs	  responding	  most	  to	  HFEE,	  oral	  glucose	  consumption	  or	  a	  combination	  of	   the	   two,	  with	  FO	  consumption	  mediating	   these	   responses	   in	   some	   instances.	   Only	   miRNAs	   sampled	   in	   skeletal	  muscle,	  rather	  than	  plasma,	  were	  shown	  to	  be	  HFEE-­‐responsive	  in	  the	  current	  study.	  These	   HFEE-­‐responsive	   miRNAs	   included	   miR-­‐106b-­‐5p,	   miR-­‐145-­‐5p,	   miR-­‐214-­‐3p	  and	   miR-­‐215.	   Thus,	   these	   miRNAs	   may	   regulate	   specific	   aspects	   of	   the	   metabolic	  response	  to	  HFEE	  in	  skeletal	  muscle.	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  The	   control	   of	   glucose	   production	   is	   a	   critical	   component	   of	   glucose	   homeostasis.	  Failure	  to	  reduce	  glucose	  production	  during	  postprandial	  periods	  is	  associated	  with	  poor	   glucose	   control	   and	   impaired	   insulin	   sensitivity	   (50).	   The	   regulation	   of	  gluconeogenesis	  in	  primary	  hepatocytes	  has	  been	  attributed	  to	  miR-­‐214	  (251).	  MiR-­‐214	   overexpression	   was	   associated	   with	   suppressed	   gluconeogenesis	   whereas	  elevated	  glucose	  production	  was	  evidenced	  following	  miR-­‐214	  silencing	  (251).	  Levels	  of	   skeletal	   muscle	   miR-­‐214-­‐3p	   were	   reduced	   following	   HFEE,	   irrespective	   of	   FO	  consumption,	   in	   the	   current	   investigation.	   Based	   on	   the	  mechanism	  described,	   this	  reduction	   in	   miR-­‐214-­‐3p	   would	   be	   associated	   with	   an	   upregulation	   of	  gluconeogenesis.	  Levels	  of	  miR-­‐214-­‐3p	  also	  were	  altered	  by	  HFEE	  over	  the	  course	  of	  the	  OGTT.	  Specifically,	  miR-­‐214-­‐3p	  levels	  were	  altered	  in	  a	  different	  manner	  2	  h	  post-­‐glucose	   consumption	   following	   HFEE.	   Post-­‐HFEE	   miR-­‐214-­‐3p	   levels	   were	   largely	  comparable	  at	  both	  OGTT	  time-­‐points	  (0	  and	  2	  h)	  whereas	  miR-­‐214-­‐3p	   levels	  were	  increased	  at	  2	  h	  pre-­‐HFEE.	  This	  blunted	  rise	   in	  miR-­‐214-­‐3p	   levels	  at	  2	  h	  post-­‐HFEE	  may	   reflect	   a	  more	   insulin-­‐resistant	   state	   if	   the	   relationship	  detailed	  between	  miR-­‐214	  and	  gluconeogenesis	  in	  primary	  hepatocytes	  also	  exists	  in	  humans	  and	  miRNAs	  are	   involved	   in	  tissue	  cross-­‐talk.	  According	  to	  this	  mechanism,	  reduced	  miR-­‐214-­‐3p	  levels	  would	  correspond	  with	  an	   increase	   in	  endogenous	  glucose	  production	   (251).	  However,	   increasing	   endogenous	   glucose	   production	   in	   the	   presence	   of	   exogenous	  glucose	  availability	  would	  suggest	  a	  reduced	  sensitivity	  of	   insulin	  action.	  Given	   that	  increased	  basal	  endogenous	  glucose	  production	  is	  associated	  with	  insulin	  resistance,	  our	   findings	   of	   suppressed	  miR-­‐214-­‐3p	   levels	   may	   suggest	   early	   maladaptation	   to	  HFEE	  at	  the	  level	  of	  epigenetic	  regulation.	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Insulin	   resistance	   in	   other	   experimental	   models	   also	   has	   been	   associated	   with	  changes	   in	   miRNA	   levels.	   Some	   consistent	   changes	   are	   evident	   between	   HFEE-­‐responsive	  miRNAs	   in	   the	  present	  study	  and	  miRNA	  changes	   in	  other	  experimental	  models.	  Adipose	  tissue	  expression	  of	  miR-­‐106b	  was	  positively	  associated	  with	  insulin	  resistance	   in	   women	   with	   polycystic	   ovary	   syndrome	   or	   non-­‐polycystic	   ovary	  syndrome	   insulin	   resistance	   (252).	   Although	   our	   miRNA	   measures	   were	   sampled	  within	  skeletal	  muscle,	  if	  the	  same	  mechanism	  were	  to	  apply	  as	  in	  adipose	  tissue,	  the	  post-­‐HFEE	   increase	   in	   miR-­‐106b-­‐5p	   may,	   like	   miR-­‐214-­‐3p,	   reflect	   early	  maladaptation	   to	   HFEE.	   	   This	   contention	   is	   further	   supported	   by	   work	   in	   C2C12	  myocytes	  (238,253)	  in	  which	  miR-­‐106b	  overexpression	  resulted	  in	  insulin	  resistance	  and	  mitochondrial	  dysfunction	   (238)	  whereas	  miR-­‐106b	  silencing	   improved	   insulin	  sensitivity	   (253).	   Finally,	   miR-­‐106b	   also	   has	   been	   negatively	   related	   to	   brown	  adipocyte	   differentiation	   (254).	   Given	   the	   role	   of	   brown	   adipose	   tissue	   in	  thermoregulation	  and	  energy	  balance	  (255),	   the	  association	  between	  miR-­‐106b	  and	  brown	   adipocyte	   differentiation	  may	   be	   further	   indication	   of	   early	   HFEE-­‐mediated	  maladaptation	   that	   precedes	   clear	   development	   of	   insulin	   resistance.	   Thus,	   taken	  together	  evidence	  is	  beginning	  to	  emerge	  linking	  epigenetic	  regulation	  to	  short-­‐term	  HFEE,	  pre-­‐insulin	  resistance	  and	  manifest	  insulin	  resistance.	  	  	  Changes	   in	   the	   insulin-­‐stimulated	   response	   to	  oral	   glucose	   consumption	   can	   reflect	  metabolic	   control.	   Transient	   changes	   in	   miRNA	   levels	   over	   the	   2	   h	   following	  consumption	  of	  an	  oral	  glucose	  bolus	  were	  observed	  in	  the	  present	  investigation	  and	  may	  offer	  insight	  into	  metabolic	  perturbations	  over	  the	  same	  time-­‐frame.	  In	  contrast	  to	   HFEE-­‐responsive	   miRNAs,	   OGTT-­‐responsive	   miRNAs	   were	   observed	   in	   both	  plasma	  and	  skeletal	  muscle.	  However,	  there	  was	  no	  crossover	  between	  tissue	  types.	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In	  plasma,	   levels	  of	  miR-­‐145-­‐5p	   largely	  reflected	   the	   temporal	  plasma	   insulin	  curve	  with	   peak	  miRNA	   levels	   (of	   the	   3	  measured	   time-­‐points)	   corresponding	  with	   peak	  plasma	  insulin	  levels,	  and	  2	  h	  levels	  back	  to	  0	  h	  baseline	  levels.	  Although	  no	  data	  exist	  relating	   miR-­‐145-­‐5p	   levels	   to	   glucose	   provision,	   increased	   levels	   of	   miR-­‐145	   have	  been	  observed	   in	  mouse	  models	   of	   obesity,	   and	  mice	  deficient	   in	   the	  miR-­‐143/145	  cluster	  were	  protected	  from	  obesity-­‐related	  insulin	  resistance	  (256).	  However,	  in	  the	  present	   study,	  we	  observed	  strong	  negative	   relationships	   (r	  =	   -­‐0.70)	  between	  basal	  plasma	  miR-­‐145	  levels	  and	  the	  degree	  of	  fat	  mass	  gain	  in	  HF-­‐C.	  These	  discrepancies	  between	  studies	  may	  indicate	  different	  mechanisms	  between	  obesity	  and	  short-­‐term	  high-­‐fat	   feeding	   and	   /	   or	   reflect	   the	   differences	   in	   models,	   i.e.,	   mouse	   vs.	   human	  samples.	   Further	   research	   from	   the	  mouse	  model	   demonstrated	   that	   in	   an	   insulin-­‐stimulated	   state,	   overexpression	   of	   miR-­‐145	   did	   not	   alter	   blood	   glucose	  concentrations	  or	  hepatic	  insulin	  sensitivity	  (256).	  Thus,	  although	  some	  preliminary	  links	   to	   insulin	   action	   have	   been	   established	   in	   mouse	   models,	   the	   mechanisms	  regulating	  our	  observed	  changes	  in	  miR-­‐145-­‐5p	  levels	  over	  the	  course	  of	  an	  OGTT	  are	  elusive	  and	  further	  research	  is	  warranted	  in	  this	  regard.	  	  Plasma	  miRNA	  levels	  may	  reflect	  regulation	  in	  various	  tissue	  types,	  particularly	  with	  regards	   to	   rates	   of	   endocytosis	   into,	   and	   exocytosis	   from,	   tissue.	   Temporal	   plasma	  patterns	  of	  miR-­‐7-­‐5p	  and	  miR-­‐27a-­‐3p	  during	  the	  course	  of	   the	  OGTT	  did	  not	   follow	  plasma	   insulin	   profiles	   in	   the	   same	  manner	   as	   miR-­‐145-­‐5p	   and	   were	   modified	   by	  HFEE.	  Paralogues	  of	  miR-­‐7	  have	  been	  shown	  to	  regulate	  pancreatic	  β-­‐cell	  function	  /	  differentiation	   in	   cell	   culture	   and	   rodent	   models	   (257–259).	   Moreover,	   in	   mouse	  myoblasts,	   IRS1	   expression,	   insulin-­‐stimulated	   PKB	   phosphorylation,	   and	   glucose	  uptake	  were	  reduced	  with	  miR-­‐7a	  overexpression	   (258).	  Overexpression	  of	  miR-­‐27	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paralogues	   in	  goat	  mammary	  gland	  epithelial	   cells	   (260)	  and	  rat	  hepatocytes	   (261)	  resulted	   in	   greater	   accumulation	   of	   fat	   droplets,	   TG,	   FA	   (particularly	   SFA)	   content,	  and	   hepatic	   fibrosis,	   respectively.	   Therefore,	   although	   studied	   in	   different	   models,	  some	   indications	   exist	   that	   these	   miRNAs	   may	   be	   involved	   in	   HFEE-­‐relevant	  mechanisms	  including	  the	  response	  to	  oral	  glucose	  consumption.	  	  	  The	   regulation	   of	   skeletal	  muscle	  miRNAs	   and	   plasma	  miRNAs	   are	   not	   completely	  synergistic	  in	  certain	  models.	  To	  our	  knowledge,	  no	  previous	  studies	  exist	  comparing	  skeletal	   muscle	   miRNA	   regulation	   to	   plasma	   miRNA	   regulation	   in	   the	   same	  participants.	  In	  the	  current	  investigation,	  we	  had	  an	  additional	  plasma	  sampling	  time-­‐point	  that	  corresponded	  to	  peak	  plasma	  insulin	  levels	  that	  we	  did	  not	  have	  in	  skeletal	  muscle.	   However,	   we	   sampled	   both	   tissue	   types	   before	   (0	   h)	   and	   after	   (2	   h)	  consumption	  of	  the	  oral	  glucose	  bolus.	  Therefore,	  we	  were	  able	  to	  directly	  compare	  changes	   in	   the	  same	  miRNAs,	   in	   the	  same	  participants,	   in	  each	   tissue	   type,	  at	   these	  two	   time-­‐points.	   Changes	   in	   miRNA	   levels	   were	   observed	   in	   both	   tissue	   types.	  However,	   different	   miRNAs	   were	   altered	   in	   plasma	   compared	   to	   skeletal	   muscle.	  Skeletal	  muscle	   levels	  of	  miR-­‐193a-­‐5p	  and	  miR-­‐206	  were	  both	  elevated	  at	  2	  h	  post-­‐glucose	   consumption	   compared	   to	   0	   h.	   A	   previous	   study	   sampling	   peritoneal	  mesenchymal	   cells	   cultured	   in	   a	   high	   glucose	  medium,	   demonstrated	   that	  miR-­‐193	  was	   significantly	   increased	   and	   positively	   correlated	   with	   the	   duration	   of	   glucose	  exposure	  (262).	  Moreover,	  although	  not	  in	  the	  context	  of	  glucose	  consumption,	  miR-­‐193	  sampled	  from	  human	  subcutaneous	  adipose	  tissue	  has	  been	  shown	  to	  negatively	  relate	   to	   BMI	   following	   appropriate	   age	   and	   sex	   corrections	   (263).	   Thus,	   in	  combination	   with	   our	   data,	   miR-­‐193	  may	   be	   responsive	   to	   glucose	   concentrations	  and	   /	   or	   aspects	   of	   HFEE.	   The	   skeletal	   muscle-­‐specific	   miRNA,	   miR-­‐206,	   has	   been	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mostly	   studied	   within	   the	   context	   of	   anabolic	   stimuli	   rather	   than	   glucose	   uptake.	  However,	   in	   a	   previous	   study,	   investigation	   of	   skeletal	   muscle	   miR-­‐206	   levels	   in	  humans	   following	  oral	   essential	   amino	  acid	   ingestion,	   a	   known	  stimulus	   for	   insulin	  secretion,	   were	   not	   altered	   over	   time	   (264).	   These	   discrepancies	   between	   studies	  may	   be	   explained	   by	   the	   prior	   resistance	   exercise	   performed	   in	   the	   study	   by	  Drummond	   and	   colleagues	   (264),	   compared	   to	   basal	  measurements	   in	   the	   present	  investigation	   and	   /	   or	   the	   stimulus	   of	   glucose	   vs.	  amino	   acids.	   Further	   research	   is	  undoubtedly	   required	   to	   better	   characterise	   the	  miR-­‐206	   response	   to	   oral	   glucose	  consumption	  and	  insulin	  action.	  	  Changes	  in	  plasma	  miRNA	  levels	  are	  likely	  governed	  by	  rates	  of	  cell	  endocytosis	  and	  exocytosis.	   In	   the	   present	   investigation	   we	   performed	   regression	   analyses	   to	  investigate	   the	   association	   between	   miRNA	   levels	   in	   plasma	   and	   skeletal	   muscle.	  Although	   there	  was	   a	   tendency	   for	  plasma	   levels	  of	  miR-­‐7-­‐5p,	  miR-­‐93-­‐5p	  and	  miR-­‐100-­‐5p	   to	   associate	   with	   corresponding	   skeletal	   muscle	   levels,	   none	   of	   the	  associations	  were	  statistically	  significant.	  The	  lack	  of	  association	  between	  plasma	  and	  skeletal	  muscle	  miRNA	   levels	  may	   reflect	  disparate	   time-­‐courses	  of	   action	  and	  /	  or	  contribution	   to	   /	   from	   the	   pool	   from	   other	   tissues.	   Thus,	   whereas	   levels	   of	   our	  measured	  plasma	  miRNAs	  may	  not	  reflect	   functional	  change	  within	  skeletal	  muscle,	  they	  may	  instead	  reflect	  functional	  change	  within	  other	  tissue	  types.	  Investigation	  of	  plasma	   miRNA	   levels	   in	   combination	   with	   sampling	   in	   other	   tissues	   is	   therefore	  warranted	  to	  better	  characterise	  plasma	  miRNA	  biomarker	  applicability.	  	  	  The	   utility	   of	   miRNAs	   as	   biomarkers	   of	   given	   states	   is	   dependent	   also	   on	   their	  association	  with	  phenotypic	  measures,	  such	  as	  those	  presented	  in	  Chapters	  2	  and	  3	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of	   the	   current	   thesis.	  We	   chose	   to	   assess	   the	   association	   between	  miRNA	   levels	   in	  both	   tissue	   types	   and	   whole-­‐body	   insulin	   sensitivity	   (Matsuda).	   Considering	   this	  association	  is	  useful	  based	  on	  our	  lack	  of	  statistically	  significant	  mean	  group	  change	  in	  insulin	  sensitivity.	  If	  a	  given	  miRNA	  is	  to	  be	  a	  useful	  biomarker	  of	  insulin	  resistance	  /	  HFEE	  maladaptation	   then	  we	  would	  expect	  a	   correlation	   to	  exist	  between	  miRNA	  levels	  and	   insulin	  sensitivity	  change.	  Basal	   levels	  of	  miR-­‐145-­‐5p	  and	  miR-­‐204-­‐5p	   in	  plasma	   and	   skeletal	   muscle,	   respectively,	   significantly	   associated	   with	   the	   mean	  whole-­‐body	   insulin	   sensitivity	   response	   to	  6	  d	  HFEE.	  Changes	   in	  miR-­‐145-­‐5p	   levels	  have	  been	  associated	  with	  consumption	  of	  HF	  diets	  in	  fish	  (265)	  and	  rats	  (266)	  and	  thus	  may	   offer	   some	   preliminary	   insight	   into	   the	   relationship	   between	   basal	   miR-­‐145-­‐5p	   levels	   and	   insulin	   sensitivity	   change.	   Levels	   of	   miR-­‐204-­‐5p	   sampled	   in	  adipose	   tissue	   of	  mice	  were	   reduced	   following	   consumption	   of	   a	  HF	  diet	   (267)	   yet	  higher	   levels	   were	   observed	   in	   adipose	   tissue	   of	   a	   species	   of	   pig	   with	   large	  proportional	  fat	  mass	  compared	  to	  highly	  lean	  pigs	  (268).	  Despite	  these	  contrasting	  findings,	  the	  association	  between	  both	  miR-­‐145-­‐5p	  and	  miR-­‐204-­‐5p	  and	  HF	  diets	   in	  various	  models	   seems	   to	   fit	   with	   our	   data	   based	   on	   our	   insulin	   sensitivity	   change	  being	  mediated	  by	  HFEE.	   It	  would	  seem	   logical	   that	   these	  miRNAs	  would	   therefore	  associate	   with	   changes	   in	   mRNA	   of	   genes	   involved	   in	   the	   regulation	   of	   insulin	  sensitivity.	  Unquestionably,	   further	  work	   that	   induces	   insulin-­‐resistance	  via	  dietary	  means	  is	  required	  to	  replicate	  these	  findings	  before	  either	  miRNA	  can	  be	  considered	  predictive	  of	  insulin	  resistance	  development.	  	  Functional	   links	   between	   miRNAs	   and	   gene	   targets	   also	   can	   be	   established	   using	  bioinformatics	   programs	   such	   as	   miRSystem.	   However,	   when	   performing	   these	  analyses	   it	   is	   important	   to	   acknowledge	   that	   miRNAs	   target	   up	   to	   400	   genes	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(160,269).	   Therefore,	   without	   performing	   direct	   miRNA-­‐mRNA	   experiments	   we	  cannot	   be	   sure	   of	   the	   gene	   the	  miRNA	   is	   acting	   on.	   Future	  work	  will	   benefit	   from	  synergistically	   investigating	   miRNA	   and	   mRNA	   levels	   within	   tissue	   to	   better	  characterise	  miRNA	  function.	  Nonetheless,	  bioinformatics	  analysis	  at	  least	  enables	  us	  to	   predict	   mRNA	   targets	   of	   the	   altered	   miRNAs	   and	   consider	   whether	   changes	   in	  these	  genes	  are	  consistent	  with	  HFEE-­‐	  and	  /	  or	  group-­‐mediated	  phenotypic	  changes	  (for	   phenotype	   data	   see	  Chapters	   2	   and	   3).	   	   Predicted	   pathways	   targeted	   by	   our	  differentially	   regulated	   plasma	   miRNAs	   included	   axon	   guidance,	   developmental	  biology,	  MAPK	   signalling,	   regulation	   of	   the	   actin	   cytoskeleton,	   focal	   adhesion,	   ErbB	  signalling,	  L1CAM	  interactions,	  neurotrophin	  signalling	  and	  cancer.	  Some	  pathways,	  including	  axon	  guidance,	  developmental	  biology	  and	  cancer,	  were	  consistent	  between	  plasma	  and	  skeletal	  muscle	  miRNAs.	  However,	  other	  predicted	  pathways	  targeted	  by	  skeletal	  muscle	  miRNAs	  included	  haemostasis,	  signalling	  by	  NGF	  (alone	  and	  via	  TrkA	  from	  the	  plasma	  membrane),	  platelet	  activation	  signalling	  and	  aggregation,	  bacterial	  invasion	  of	  epithelial	   cells,	  neuronal	   system,	  Rho-­‐GTPase-­‐related	  processes	  and	  G1-­‐phase-­‐related	   processes.	   Some	   of	   these	   pathways,	   in	   both	   tissues,	   share	   common	  functionalities	   and	  have	  been	   linked	   to	   insulin	   signalling.	   For	   example,	  Rho-­‐GTPase	  function	   is	   associated	   with	   actin	   remodelling	   (270)	   and	   focal	   adhesion	   (271),	   and	  axon	   guidance	   is	   mediated	   NGF	   /	   Trk	   and	   neuronal	   signalling	   (272).	   Moreover,	  silencing	  of	  focal	  adhesion	  kinase	  in	  mice	  is	  associated	  with	  insulin	  resistance	  (273),	  actin	  remodelling	  alters	  MAPK	  signalling	  which	  in	  turn	  regulates	  insulin	  secretion	  in	  β-­‐cell	   lines	   (274)	   and	   platelet	   activation	   is	   associated	   with	   diabetes	   (275)	   and	  hyperglycaemia	   in	   human	   blood	   preparations	   (276).	   Thus,	   it	   is	   logical	   that	   these	  pathways	  may	  be	  involved	  in	  the	  HFEE	  and	  /	  or	  insulin-­‐mediated	  glucose	  responses.	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However,	   exact	   mechanisms	   of	   action	   cannot	   be	   determined	   from	   this	   limited	  analysis	  and	  further	  work	  is	  required	  to	  corroborate	  these	  findings	  and	  associations.	  	  	  In	  conclusion,	  levels	  of	  certain	  miRNAs	  in	  both	  skeletal	  muscle	  and	  plasma	  are	  altered	  by	   oral	   glucose	   consumption	   and	   /	   or	   HFEE.	   Moreover,	   miR-­‐145-­‐5p	   (plasma)	   and	  miR-­‐204-­‐5p	  (skeletal	  muscle)	  were	  significantly	  associated	  with	  the	  HFEE-­‐mediated	  change	  in	  whole-­‐body	  insulin	  sensitivity.	  Taken	  together,	  these	  data	  suggest	  a	  role	  for	  miRNAs	  in	  the	  regulation	  of	  insulin	  sensitivity.	  Future	  work	  is	  required	  to	  investigate	  the	   relationship	   between	   observed	   changes	   in	   plasma	   and	   skeletal	   muscle	   miRNA	  levels	   and	   target	   gene	   expression	   in	   skeletal	   muscle	   and	   other	   relevant	   insulin-­‐responsive	  tissues.	  	  	  	  	   	  




CHAPTER	  5	  General	  discussion	  and	  concluding	  remarks	  
	  
	  The	   overall	   aim	   of	   this	   thesis	   was	   to	   add	   experimental	   evidence	   to	   the	   current	  knowledge	   gaps	   regarding	   the	   metabolic,	   molecular	   and	   epigenetic	   responses	   to	  short-­‐term	  HFEE.	  Also,	  we	  aimed	  to	  consider	  the	  impact	  of	  n-­‐3	  PUFA	  ingestion	  within	  the	   same	   short-­‐term	   HFEE	   context	   on	   these	   metabolic,	   molecular	   and	   epigenetic	  responses.	   These	   two	   primary	   aims	  were	   achieved	   by	   successful	   completion	   of	   the	  following	  objectives:	  	   i) To	  determine	  the	  whole-­‐body	  responses	  to	  a	  well-­‐controlled,	  short-­‐term	  (6	  d)	  period	  of	  HFEE,	  with	  and	  without	  FO,	  in	  humans	  (Chapters	  2	  and	  3).	  ii) To	   determine	   the	   subcellular	  molecular	  mechanisms	   of	   short-­‐term	   (6	   d)	  diet-­‐induced	   maladaptation	   in	   humans,	   and	   their	   mediation	   by	   FO	  (Chapters	  2	  and	  3).	  iii) To	  determine	  the	  epigenetic	  responses	  to	  short-­‐term	  (6	  d)	  HFEE,	  with	  and	  without	  FO,	  in	  humans	  (Chapter	  4).	  	  The	   principal	   findings	   of	   this	   programme	   of	   work	   have	   been	   discussed	   in	   detail	  throughout	  the	  three	  experimental	  chapters	  and	  were	  primarily	  fivefold:	  	   i) Consumption	   of	   HFEE	   for	   6	   d	   did	   not	   significantly	   alter	   overall	   insulin	  sensitivity	  in	  young	  healthy	  male	  participants,	  irrespective	  of	  whether	  FO	  was	  consumed	  as	  10	  %	  of	  total	  fats.	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ii) Skeletal	   muscle	   levels	   of	   certain	   long	   and	   very	   long	   chain	   ceramide	   species	  were	  increased	  following	  6	  d	  HFEE,	  irrespective	  of	  whether	  FO	  was	  consumed	  at	  10	  %	  of	  total	  fats.	  iii) Skeletal	   muscle	   AMPK	   α2	   activity	   was	   increased	   following	   HFEE	   with	   FO	  consumption,	  but	  unchanged	  following	  HFEE	  without	  FO	  consumption.	  iv) Certain	  miRNA	  levels	  in	  plasma	  and	  skeletal	  muscle	  were	  clearly	  identified	  as	  HFEE-­‐responsive,	   OGTT-­‐responsive	   or	   a	   combination	   of	   the	   two,	   with	   FO	  consumption	  mediating	  the	  response	  in	  some	  instances.	  v) Plasma	   levels	   of	  miR-­‐145-­‐5p	   and	   skeletal	  muscle	   levels	   of	  miR-­‐204-­‐5p	  were	  significantly	  associated	  with	  the	  HFEE-­‐mediated	  change	  in	  insulin	  sensitivity.	  	  From	   these	   principal	   findings	   it	   is	   clear	   that	   the	   a	   priori	  hypotheses	   were	   largely	  unsupported	  by	  the	  experimental	  data	  generated,	  particularly	  with	  regard	  to	  overall	  group	  perturbations	  in	  insulin	  sensitivity.	  However,	  reflecting	  on	  the	  fact,	  that	  in	  the	  most	   part,	   our	   bodies	   are	   able	   to	   adapt	   and	   deal	   with	   a	   whole	   host	   of	   different	  metabolic	   stresses	   placed	  upon	   them,	   this	   ability	   is	   arguably	   as	   remarkable	   as	   it	   is	  essential.	   Imagining	  a	   scenario	  whereby	  excess	  or	   limited	  energy	  provision,	   altered	  exercise	  loads,	  varying	  temperature	  exposures,	  and	  so	  forth,	  are	  immediately	  of	  such	  detriment	   to	   our	   whole-­‐body	   function	   that	   we	   cease	   to	   adapt,	   appears	   logically	  flawed.	   Thus,	   in	   some	   ways	   we	   may	   expect	   our	   volunteers	   to	   have	   the	   metabolic	  flexibility	  to	  be	  able	  to	  adapt	  to	  the	  subjected	  short-­‐term	  HFEE.	  The	  highly	  regulated	  metabolic	  system	  that	  controls	  our	  whole-­‐body	  function	  has	  to	  be	  adaptive	  in	  order	  to	  allow	  retained	  function	   in	  a	  variety	  of	  states.	  Unquestionably,	   the	  range	   in	  which	  we	  are	  able	  to	  operate	  and	  function	  is	  very	  tight	  for	  many	  processes	  but	  the	  fact	  that	  a	  
range	  exists	   is	  key	  to	  this	  concept.	  The	  preceding	  hypotheses	  centred	  on	  the	  notion	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that	  short-­‐term	  HFEE	  would	  reduce	   insulin	  sensitivity.	  Yet,	  although	  chronic	  excess	  energy	  consumption	  is	  undeniably	  a	  primary	  risk	  factor	  for	  development	  of	  obesity,	  insulin	   resistance	   and	   T2D,	   the	   response	   to	   short-­‐term	   episodes	   of	   HFEE	   is	   likely	  dependent	  on	  a	  host	  of	   factors	  specific	   to	   the	   individual.	  Whereas	   it	   is	  questionable	  that	   such	   feeding	  periods	   could	  ever	  be	   considered	  beneficial	   for	   an	   individual,	   the	  metabolic	   flexibility	   of	   the	  Homo	   sapiens	   is	   likely	   an	   inherent	   and	   significant	   trait,	  integral	  for	  the	  lifespan	  and	  evolution.	  	  	  At	   a	   group	   level,	   6	   d	   HFEE	   did	   not	   result	   in	   significant	   perturbations	   in	   insulin	  sensitivity.	  Given	  the	  experimental	  design,	  it	  is	  not	  possible	  to	  offer	  any	  information	  on	   the	   time	   course	   of	   insulin	   sensitivity	   change.	   Intuitively,	   and	   based	   on	   the	  discussed	   literature	   throughout	   this	   thesis,	   decrements	   in	   insulin	   sensitivity	   may	  have	   been	   observed	   prior	   to,	   and	   /	   or	   extending	   past,	   our	   6	   d	   (post-­‐HFEE)	   testing	  time	  point.	  Despite	  no	  significant	  alterations	  in	  insulin	  sensitivity	  following	  6	  d	  HFEE,	  some	  of	  our	  measures	  were	  significantly	  altered	  at	  6	  d.	  Levels	  of	  circulating	  FFAs	  and	  TGs	  were	  significantly	  lower,	  and	  skeletal	  muscle	  ceramides	  significantly	  higher	  post-­‐HFEE.	   Blood	   and	   phospholipid	   membrane	   fatty	   acid	   composition	   was	   significantly	  altered	   in	   favour	   of	   n-­‐3	   PUFAs	   following	   FO	   intake.	   Fasting	   AMPK	   α2	   activity	   was	  significantly	  increased	  following	  6	  d	  HFEE	  with	  FO	  but	  unaltered	  in	  the	  absence	  of	  FO.	  Significant	  gains	  in	  fat	  mass,	  particularly	  in	  the	  central	  trunk	  region,	  were	  observed	  at	  6	  d.	  Finally,	  significant	  alterations	  in	  the	  levels	  of	  plasma	  and	  skeletal	  muscle	  miRNAs	  were	  observed	  after	  6	  d	  HFEE,	  and	   in	  some	   instances	  predicted	  a	  proportion	  of	   the	  HFEE-­‐mediated	  insulin	  sensitivity	  change,	  Taken	  together,	  these	  findings	  suggest	  that	  early	  maladaptive	  responses	  at	  the	  tissue	  level	  precede	  while	  body	  insulin	  sensitivity	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change.	   The	   utility	   of	   these	   measures	   as	   potential	   markers	   of	   susceptibility	   to	  developing	  diet-­‐induced	  insulin	  resistance	  should	  be	  explored	  further.	  	  Herein,	  the	  final	  discussion	  points	  have	  been	  divided	  into	  three	  aspects;	  the	  first	  will	  discuss	  the	  concept	  of	  energy	  balance	  and	  in	  particular	  the	  role	  of	  energy	  expenditure	  in	   this	   equation.	   Second,	   individual	   variation	   within	   the	   context	   of	   HFEE	   will	   be	  discussed,	  before	  finally	  concluding	  with	  discussion	  of	  the	  central	   limitations	  of	  this	  thesis	  and	  suggestions	  for	  future	  research.	  	  	  	  
5.1.	  Energy	  balance	  –	  The	  role	  of	  energy	  expenditure	  	  At	  this	  stage,	  the	  ‘gluttony	  vs.	  sloth’	  debate	  raised	  at	  the	  advent	  of	  this	  thesis	  is	  worth	  reconsideration.	   Whereas	   it	   is	   undeniable	   that	   excess	   energy	   provision	   and	  consumption	   has	   contributed	   to	   the	   remarkable	   escalation	   of	   T2D	   prevalence,	  particularly	   in	   the	   Western	   world,	   it	   remains	   naïve	   to	   afford	   no	   attention	   to	   the	  counter-­‐factor	   in	   the	   energy	   balance	   conundrum.	   Accumulating	   evidence	   suggests	  that	  habitual	  activity	  levels	  may	  be	  a	  key	  factor	  in	  the	  response	  to	  short-­‐term	  periods	  of	  HFEE.	  	  	  Expanding	  on	  discussions	  from	  Chapter	  2,	  the	  insulin	  sensitivity	  response	  to	  HFEE	  is	  affected	   by	   prior	   exercise	   and	   /	   or	   the	   habitual	   activity	   status	   of	   the	   participant	  cohort.	  Hagobian	  &	  Braun	  (107)	  investigated	  the	  impact	  of	  performing	  a	  single	  bout	  of	   moderate	   intensity	   endurance	   exercise	   (treadmill	   or	   cycle	   ergometer;	  corresponding	   to	   25	   %	   of	   participants’	   estimated	   daily	   energy	   expenditure)	   on	  insulin	   sensitivity	   during	   a	   period	   of	   energy	   excess.	   Crucially,	   energy	   intake	   was	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increased	  to	  match	  the	  energy	  expenditure	  induced	  by	  exercise,	  in	  order	  to	  maintain	  the	  same	  energy	  surplus	  (768	  ±	  203	  kcal·d-­‐1)	  participants	  were	  consuming	  for	  the	  3	  d	  prior	  to	  the	  exercising	  day.	  Thus,	  total	  energy	  consumed	  was	  greater	  on	  the	  exercised	  day;	   however,	   net	   energy	   balance	   was	   equal	   over	   the	   energy	   surplus	   vs.	   energy	  surplus	   +	   exercise	   days.	   The	   principal	   findings	   from	   this	   study	   were	   that	   insulin	  sensitivity	   was	   reduced	   by	   3	   d	   overfeeding	   and	   inactivity	   in	   otherwise	   habitually	  active	   individuals.	  However,	  performing	  a	  single	  endurance	  exercise	  bout	  combined	  with	  the	  same	  degree	  of	  energy	  surplus	  did	  not	  restore	  insulin	  sensitivity.	  	  	  Using	  a	  similar	  study	  design,	  Walhin	  and	  colleagues	  (115)	  studied	  active	  males	  over	  a	  7	   d	   period	   in	   which	   they	   were	   overfed	   by	   50	   %	  more	   energy	   than	   their	   habitual	  consumption.	  However,	  one	  group	  of	  participants	  simultaneously	  reduced	  their	  daily	  step	  count	   to	  <	  4000	  steps·d-­‐1	  while	   the	  other	  group	  performed	  moderate	   intensity	  treadmill	  running	  (45	  min)	  each	  day.	  Similar	  to	  Hagobian	  &	  Braun	  (107),	  exercising	  participants	  consumed	  additional	  energy	  to	  account	  for	  the	  energy	  expended	  during	  the	   exercise	   bout	   so	   that	   an	   energy	   surplus	   was	   maintained.	   In	   contrast	   to	   the	  findings	  of	  Hagobian	  &	  Braun	  (107),	  the	  exercising,	  unlike	  the	  non-­‐exercising,	  group	  were	   able	   to	   maintain	   their	   insulin	   sensitivity	   at	   pre-­‐intervention	   levels	   despite	  consuming	   a	   50	   %	   energy	   surplus	   (115).	   The	   results	   from	   this	   study	   could	   be	  interpreted	   as	   reflecting	   the	   beneficial	   effects	   of	   daily	   exercise	   during	   periods	   of	  energy	  excess,	  or	  the	  detrimental	  effects	  of	  reducing	  physical	  activity	  to	  below	  4000	  steps·d-­‐1	   in	  combination	  with	  energy	  excess.	  Considering	  the	  discrepancies	  between	  study	  findings,	  these	  data	  may	  better	  support	  the	  latter	  contention.	  Further	  support	  for	   this	   notion	   is	   evident	   from	  a	   study	   conducted	  by	  Krogh-­‐Madsen	   and	   colleagues	  (277).	   In	   this	   study,	   participants	   who	   habitually	   consumed	   >	   2000	   kcal·d-­‐1	   were	  
Chapter	  5:	  General	  discussion	  and	  concluding	  remarks	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  138	  
	  	  
randomly	  assigned	  to	  either	  maintain	  their	  physical	  activity	  at	  10000	  steps·d-­‐1	  or	  to	  drop	   their	   step	   count	   to	   1500	   steps·d-­‐1	   for	   a	   2	   wk	   period.	   Following	   the	   2	   wk	  intervention,	   a	   host	   of	   markers	   indicative	   of	   impaired	   insulin	   sensitivity	   including	  poor	  glycemic	  control	  and	  increased	  endogenous	  glucose	  production	  were	  evident	  in	  the	   reduced	   step	   count	   group	   compared	   to	   the	   participants	   who	   maintained	  recommended	   levels	   of	   habitual	   physical	   activity	   (277).	   Thus,	   reduced	   physical	  activity	  may	  be	  more	  detrimental	  for	  insulin	  sensitivity	  than	  the	  energy	  excess	  per	  se.	  Had	  we	   used	   accelerometers	   in	   the	   current	   study,	  we	  may	   have	   been	   able	   to	   offer	  information	   on	   the	   relationship	   between	   physical	   activity	   and	   insulin	   sensitivity	  change	   in	   our	   cohort.	   However,	   given	   our	  measure	   of	   physical	   activity	   at	   the	   pre-­‐screening	  stage	  as	  times	  per	  wk,	  we	  lacked	  the	  measurement	  resolution	  to	  be	  able	  to	  tease	   these	   data	   from	   our	   findings.	   More	   work	   is	   justified	   to	   investigate	   the	  (in)dependent	  effects	  of	  physical	  activity	  and	  energy	  intake	  on	  insulin	  sensitivity,	  and	  future	   models	   of	   diet-­‐induced	   insulin	   resistance	   should	   accurately	   measure	   both	  aspects	  of	  energy	  balance.	  	  	  
5.2.	  Individual	  variation	  The	  defining	   conceptual	   characteristic	  of	   this	  programme	  of	  work	  has	   to	  be	   that	  of	  individual	  variation.	  Admittedly,	  as	  is	  the	  case	  here,	  the	  individual	  variation	  inherent	  in	   each	   measured	   response	   is	   often	   considered	   more	   closely	   in	   instances	   of	   non-­‐significant	  group	  means.	  However,	  despite	  this	  increased	  scrutiny	  in	  such	  instances,	  it	  is	   irrefutable	   that	   variation	   is	   seen	   in	   every	   measure,	   in	   every	   scientific	   study	  conducted.	  Instead,	  significant	  mean	  differences	  often	  mask	  the	  need	  to	  consider	  such	  
Chapter	  5:	  General	  discussion	  and	  concluding	  remarks	  	   	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  139	  
	  	  
variation	  due	  to	  greater	  measurement	  consistency,	  rather	  than	  significance	  equating	  to	  no	  measured	  variation.	  	  	  The	  individual	  variation	  in	  each	  measured	  response	  is	  likely	  meaningful.	  The	  finding	  that	  some	  individuals	  were	  able	  to	  effectively	  adapt	  to	  the	   increased	  fat	  and	  energy	  load	   placed	   upon	   them,	   whereas	   others	   were	   placed	   under	   metabolic	   stress	   in	  response	   to	   the	   same	   load	   is	   an	   intriguing	   concept.	   The	   correlations	   presented	   in	  
Chapter	  4	  between	  levels	  of	  certain	  plasma	  and	  skeletal	  muscle	  miRNAs	  and	  insulin	  sensitivity	  responses	  shed	  light	  on	  the	  potential	  for	  epigenetic	  mechanisms	  to,	  in	  part,	  explain	  differential	  individual	  responses	  to	  the	  same	  stimulus.	  	  Variability	  in	  any	  given	  measured	  response	  is	  a	  result	  of	  measurement	  noise	  and	  /	  or	  individual	  differences.	  We	  aimed	  to	  reduce	  measurement	  noise	  by	  giving	  participants	  a	   3	   d	   baseline	   diet	   with	   prohibited	   alcohol	   intake	   and	   exercise	   during	   this	   period.	  Whereas	   these	   control	   measures	   will	   not	   completely	   eradicate	   the	   measurement	  variation,	   a	   tight	   pre-­‐experimental	   control	   can	   significantly	   improve	   the	   degree	   of	  measurement	  error.	  Analytical	  measurement	  errors	  also	  need	  to	  be	  considered.	  For	  example,	  Doctoral	  work	  by	  Dr	  Solomon	  (University	  of	  Birmingham)	  demonstrated	  the	  test,	   re-­‐test	   reliability	   of	   the	   Matsuda	   insulin	   sensitivity	   index,	   calculated	   from	   an	  OGTT,	  was	  around	  5	  %.	  This	  error	  of	  measurement	   is	  within	  the	  same	  range	  as	   the	  highly-­‐regarded	   ‘gold-­‐standard’	   methodology	   of	   the	   euglycemic-­‐hyperinsulinemic	  clamp	  (43).	  Using	  stable	  isotopic	  tracers	  in	  the	  present	  investigation	  provided	  added	  sensitivity	   in	   the	  measurement	   of	   glucose	  metabolism,	   particularly	  with	   regards	   to	  understanding	   endogenous	   and	   exogenous	   contributions	   to	   the	   total	   glucose	   pool.	  Given	   the	   sensitivity	   of	   the	   method,	   the	   variability	   in	   our	   measured	   responses,	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particularly	  in	  terms	  of	  glucose	  metabolism	  and	  insulin	  sensitivity	  is	  likely	  driven	  in	  the	  most	  part	  by	  individual	  variance.	  	  	  Each	   individual	   response	   to	   any	   given	   stimulus	   is	   governed	   by	   the	   combined	  influence	  of	   genetic	  predisposition,	   environmental	   influence	   and	  epigenetic	   control.	  However,	  the	  degree	  to	  which	  each	  of	  these	  factors	  explains	  the	  variance	  in	  any	  given	  response	   is	   dependent	   on	   the	   response	   itself.	  Whereas	   some	  phenotypic	   responses	  are	   largely	   heritable,	   others	   also	   have	   a	   large	   heritable	   component	   but	   are	   more	  variable,	  with	  a	  greater	  influence	  from	  environmental	  cues.	  Studies	  by	  Bouchard	  and	  colleagues	  (151,152)	  demonstrated	  a	  ~25	  %	  heritability	  component	   in	  the	   fat	  mass	  change	  response	  to	  long-­‐term	  overfeeding.	  Therefore,	  the	  majority	  of	  variance	  in	  the	  response	   to	   overfeeding	   is	   likely	   from	   environmental	   and	   other,	   for	   example,	  epigenetic,	   differences.	   Given	   the	   number	   of	   intertwined	   factors	   to	   consider	  within	  the	   study	   of	   HFEE,	   it	   is	   of	   little	   surprise	   that	   such	   a	   large	   degree	   of	   variation	   is	  observed	   in	   our	   measures.	   However,	   in	   order	   to	   truly	   understand	   maladaptive	  responses	  to	  HFEE	  and	  insulin	  resistance	  development,	  future	  studies	  of	  this	  nature	  need	  to	  consider	  the	  mechanisms	  governing	  individual	  responses	  to	  HFEE.	  	  	  The	  inherent	  relative	  risk	  of	  developing	  T2D	  in	  scenarios	  of	  HFEE	  is	  more	  difficult	  to	  determine	  when	  the	  degree	  of	  heritability	  within	  each	  measured	  response	  is	  reduced.	  Replication	  of	  miRNA	  studies	  is	  required	  if	  miRNA	  levels	  are	  to	  be	  useful	  biomarkers	  of	   insulin	   resistance	   development,	   and	   plasma	   miRNA	   profiling,	   given	   its	   ease	   of	  sampling,	   will	   hold	   the	   key	   to	   biomarker	   utility.	   Hopefully,	   future	   research	   will	  benefit	   from	  studies	  of	  this	  nature	  and	  enhance	  the	  validity	  of	  T2D	  prognosis	   in	  the	  long-­‐term.	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5.3.	  Thesis	  limitations	  and	  future	  directions	  	  The	   data	   presented	  within	   this	   thesis	   add	   important	   and	   novel	   information	   to	   the	  literature	  that	  will	  facilitate	  the	  advancement	  of	  knowledge	  within	  the	  field.	  However,	  a	  number	  of	  limitations	  exist	  that	  warrant	  consideration.	  	  	  As	   detailed	   in	   the	   first	   part	   of	   this	   discussion,	   energy	   expenditure	   is	   an	   important	  consideration	   for	  complete	  understanding	  of	  energy	  balance.	  All	  of	  our	  participants	  failed	  to	  meet	  current	  government	  recommendations	  for	  exercise,	  and	  were	  asked	  to	  maintain	   their	   low	   habitual	   activities	   of	   daily	   living	   without	   engaging	   in	   any	  additional	   exercise	   throughout	   the	   study	   period.	   However,	   we	   did	   not	   measure	  energy	  expenditure	  during	  the	  study	  and	  thus	  cannot	  be	  sure	  that	  energy	  expenditure	  was	  not	  enhanced	  during	  HFEE.	  Subconscious	  manipulation	  of	  physical	  activity	  levels	  when	   in	   energy	   excess	   (278),	   the	   thermogenic	   effect	   of	   food	   (279–281),	   and	   non-­‐shivering	   thermogenesis	   (282)	   all	   may	   have	   contributed	   to	   increasing	   the	   energy	  expenditure	  arm	  of	  the	  equation,	  thus	  reducing	  the	  significant	  intended	  skew	  towards	  a	   positive	   energy	   balance.	   Moreover,	   rather	   than	   solely	   extending	   time	   spent	  engaging	   in	   physical	   activity,	   reducing	   periods	   of	   sedentary	   time	   is	   important	   for	  maintaining	   /	   improving	   metabolic	   health	   (283,284).	   Thus,	   our	   participants,	   who	  were	  mostly	   students,	   would	   likely	   have	   shorter	   sedentary	   periods	   due	   to	  moving	  between	   classes	   than	   perhaps	   other	   populations.	   In	   future,	   continuous	   diurnal	  monitoring	  of	  energy	  expenditure	  using	  an	  activity	  monitor	  would	  be	  recommended	  to	  enable	  estimates	  of	  energy	  expenditure,	  physical	  activity	  and	  sedentary	  time	  to	  be	  made.	  Moreover,	  investigation	  of	  the	  impact	  of	  varying	  habitual	  activity	  levels	  on	  the	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metabolic,	  molecular	  and	  epigenetic	  responses	  to	  HFEE	  would	  be	  of	  interest	  to	  better	  understand	  the	  role	  of	  physical	  activity	  on	  metabolic	  flexibility.	  	  	  Second,	   all	   conclusions	   were	   made	   in	   the	   context	   of	   statistically	   unaltered	   insulin	  sensitivity.	  Insulin	  sensitivity	  was	  a	  dependent	  variable	  in	  the	  present	  study,	  and	  thus	  not	  a	  controlled	  variable.	  However,	  the	  study	  design	  and	  ensuing	  data	  are	  limited	  by	  the	  absence	  of	  clear	  changes	  in	  insulin	  sensitivity.	  The	  true	  value	  of	  FO	  consumption	  for	  metabolic	  disease	  risk	  within	  the	  context	  of	  HFEE	  cannot	  easily	  be	  discerned	  from	  these	  data.	  	  	  Unquestionably,	   when	   we	   consider	   the	   percentage	   change	   of	   certain	   markers	   of	  insulin	   sensitivity	   in	   the	   current	   body	   of	   work,	   the	   concept	   of	   physiological	   vs.	  statistical	  significance	  is	  raised,	  and	  forms	  the	  basis	  for	  an	  interesting	  discussion	  on	  statistical	   principles.	   However,	   given	   the	   ambiguity	   in	   interpreting	   the	   data,	  establishing	  a	  time-­‐course	  of	  declining	  insulin	  sensitivity	  in	  response	  to	  HFEE	  would	  undoubtedly	   facilitate	   the	   study	   of	   short-­‐term	   overfeeding.	   Whereas	   a	   consistent,	  reproducible	   time-­‐course	   may	   be	   confounded	   by	   the	   individual	   variability	   of	   any	  given	   response,	   attempts	   to	   at	   least	   establish	   key	   phases	   of	   insulin	   resistance	  development	  would	  be	   fruitful.	  Future	  study	  designs	  would	  be	  able	   to	  have	  greater	  focus	  on	  the	  specific	  question	  to	  be	  addressed	  by	  establishing	  a	  time-­‐course	  of	  events	  following	  HFEE.	  For	  example,	  if	  subcellular	  modifications,	  as	  suggested	  in	  the	  present	  thesis,	   do	   indeed	   precede	   the	   development	   of	   whole-­‐body	   insulin	   resistance,	   then	  interventions	  designed	  to	  target	  these	  mechanisms	  may	  elect	  a	  time-­‐course	  of	  study	  that	   is	  shorter	   in	  duration	  than	  would	  otherwise	  be	  chosen	  to	  study	  mechanisms	  of	  whole-­‐body	  adaptation.	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  Establishing	   a	   dose	   /	   time-­‐course	   relationship	   for	   FO	   intake,	   in	   addition	   to	   a	   time-­‐course	   of	   insulin	   sensitivity	   change	   also	   would	   aid	   future	   research	   in	   this	   field.	  Currently,	   the	   optimal	   dose	   and	   duration	   of	   FO	   supplementation	   for	   an	   optimal,	  functional	  cell	  membrane	  composition	  is	  not	  established.	  Moreover,	  the	  difference	  in	  dose	  and	  incorporation	  time	  for	  capsule	  /	  drink-­‐based	  FO	  supplementation	  vs.	  dietary	  FO	  intake	  is	  not	  known	  and	  may	  add	  validity	  to	  this	  area	  of	  study.	  Likewise,	  a	  caveat	  of	  many	  of	   the	   studies	   designed	   to	   investigate	   the	   impact	   of	   FO	   supplementation	   /	  intake	   is	   that	   often	   a	   daily	   dosing	   strategy	   is	   implemented.	   Given	   that	   current	  government	   recommendations	   are	   set	   at	   2	   portions	   of	   oily	   fish	   per	   week	   (285),	  investigations	  designed	  to	  replicate	  more	  habitual	  consumption	  patterns	  when	  using	  dietary	  intake	  strategies	  are	  warranted.	  	  	  The	   final	   methodological	   consideration	   in	   relation	   to	   insulin	   sensitivity	   measures	  relates	  to	  the	  use	  of	  continuous	  glucose	  monitoring	  to	  provide	  further	  information	  on	  the	   diurnal	   control	   of	   blood	   glucose	   levels.	   Importantly,	   during	   waking	   hours,	  individuals	  with	  T2D	  are	  often	  in	  a	  near-­‐continual	  postprandial	  state	  with	  regard	  to	  their	   circulating	   glucose	   levels	   (286).	   Thus,	   measurements	   that	   are	   confined	   to	   an	  acute,	   post-­‐glucose	   consumption	   time-­‐period	   often	   will	   not	   reflect	   the	   wider	  impairments	   regarding	   declining	   insulin	   sensitivity.	   Whereas	   it	   is	   not	   possible	   to	  comment	  on	  the	  24	  h	  blood	  glucose	  control	  of	  our	  participants	  in	  the	  current	  study,	  use	   of	   continuous	   glucose	   monitoring	   methodology	   would	   facilitate	   these	  investigations	  in	  future	  studies	  of	  this	  nature.	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Finally,	   all	   participants	   in	   the	   current	   study	   were	   non-­‐active	   young	   males.	   The	  influence	   of	   physical	   activity	   and	   sex	   on	   insulin	   sensitivity	   has	   been	   discussed	  previously.	   However,	   it	   is	   worth	   re-­‐emphasising	   that	   the	   age,	   sex	   and	   habitual	  physical	   activity	   status	   of	   the	   participant	   cohort	   limits	   our	   ability	   to	   generalise	  findings	  across	  other	  populations.	  Future	  studies	  should	  investigate	  the	  independent	  and	   inter-­‐related	   impact	   of	   age,	   sex,	   physical	   activity	   and	   race	   on	   the	   insulin	  sensitivity	   response	   to	   short-­‐term	   HFEE.	   Understanding	   the	   role	   of	   individual	  characteristics	   will	   facilitate	   development	   of	   tailored	   interventions	   to	   counter-­‐act	  insulin	  resistance	  for	  specific	  populations.	  	  	  	  
5.4.	  Final	  thoughts	  Despite	  these	  clear	  limitations	  of	  this	  programme	  of	  work,	  the	  data	  generated	  provide	  some	  novel	  and	  interesting	  insights	  to	  our	  understanding	  of	  the	  metabolic,	  molecular	  and	   epigenetic	   regulation	   of	   the	   whole-­‐body	   and	   subcellular	   responses	   of	   young	  healthy	  males	  to	  a	  short-­‐term	  period	  of	  HFEE.	  One	  of	  the	  most	  consistent	  outcomes	  of	  scientific	   studies	   is	   that	   further	   questions	   are	   raised,	   and	   the	   present	   thesis	   is	   no	  exception.	   In	   particular,	   building	   on	   the	   points	   made	   during	   evaluation	   of	   the	  limitations	   of	   this	   thesis,	   the	   following	   research	   questions	   warrant	   further	  investigation.	  	  	   i) What	  is	  the	  temporal	  insulin	  sensitivity	  response	  to	  HFEE?	  ii) What	   are	   the	   temporal,	   subcellular	   muscle	   /	   liver	   /	   adipose	   tissue-­‐specific	  responses	  to	  HFEE?	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iii) How	   does	   population	   mediate	   the	   metabolic,	   molecular	   and	   epigenetic	  responses	  to	  HFEE?	  iv) How	   does	   habitual	   activity	   status	   mediate	   the	   metabolic,	   molecular	   and	  epigenetic	  responses	  to	  HFEE?	  v) Is	  there	  a	  dose-­‐response	  relationship	  between	  fat	  /	  energy	  intake	  and	  insulin	  sensitivity?	  vi) Is	   there	   a	   dose-­‐response	   relationship	   between	   n-­‐3	   PUFA	   intake	   and	   insulin	  sensitivity	  within	  the	  context	  of	  HFEE?	  	  Considered	  together,	  these	  future	  study	  ideas	  could	  be	  organised	  in	  four	  phases.	  The	  aim	  of	  Phase	   1	  would	  be	   to	  establish	  a	   time-­‐course	  of	   insulin	   sensitivity	   change	   in	  response	   to	  HFEE.	   Initially,	   this	   aim	  would	  be	   achieved	   via	   an	  OGTT	  performed	  on	  day	  3,	  5,	  7,	  14	  and	  28	  of	  HFEE,	  with	  plasma	  glucose	  and	  insulin	  concentrations,	  taken	  during	   the	  OGTT,	   used	   to	   calculate	  whole-­‐body	   insulin	   sensitivity	   (Matsuda	   index).	  These	  selected	  days	  of	  sampling	  would	  enable	  the	  temporal	  fluctuations	  in	  metabolic	  flexibility	  to	  be	  studied,	  and	  in	  order	  to	  maintain	  the	  diet	  on	  each	  sampling	  day,	  the	  75	  g	  glucose	  bolus	  could	  be	  accounted	  for	  within	  the	  daily	  dietary	  intake	  for	  that	  day.	  The	   second	   aspect	   of	  Phase	   1	  would	   relate	   to	   the	   participant	   population.	   If,	   as	  we	  anticipate,	   the	   metabolic	   flexibility	   of	   an	   individual	   alters	   the	   insulin	   sensitivity	  response	   to	   HFEE	   then	   establishing	   a	   time-­‐course	   of	   insulin	   sensitivity	   change	   in	  different	  participant	  cohorts	   is	  required.	  Example	  cohorts	  should	  range	   from	  highly	  physically	   active	   individuals	   to	   sedentary	   individuals	  with	  T2D,	   include	  both	   sexes,	  and	  consider	  a	  range	  of	  ages	  /	  ethnic	  origins.	  Only	  when	  several	  parallel	  experiments	  in	   different	   participant	   cohorts	   have	   been	   conducted	   will	   we	   have	   the	   necessary	  information	  to	  begin	  devising	  short-­‐term	  experimental	  models	  of	  diet-­‐induced	  insulin	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resistance	  for	  specific	  populations.	  	  	  Once	   a	   time-­‐course	   of	   insulin	   sensitivity	   change	   has	   been	   established	   in	   several	  cohorts,	  more	  advanced	  /	  invasive	  techniques	  including	  dual	  isotopic	  glucose	  tracers	  and	   skeletal	   muscle	   /	   adipose	   tissue	   biopsies	   can	   be	   incorporated	   into	   the	   study	  design	  based	  on	  the	  point	  at	  which	  insulin	  sensitivity	  is	  compromised.	  Thus,	  Phase	  2	  would	   be	   designed	   to	   investigate	   the	   metabolic,	   molecular	   and	   epigenetic	  mechanisms	   of	   diet-­‐induced	   insulin	   resistance.	   Investigating	   the	   three	   primary	  insulin-­‐responsive	   tissues,	   skeletal	   muscle,	   liver	   and	   adipose	   tissue,	   using	   isotope	  tracers	  and	  biopsy	  sampling	  would	  facilitate	  holistic	  study	  in	  this	  area.	  	  	  
Phase	   3	   of	   the	   study	   programme	  would	   be	   the	   stage	   at	  which	   investigation	   of	   the	  impact	   of	   fish	   oil	   consumption	   during	   HFEE	   on	   insulin	   sensitivity	   would	   be	  incorporated.	  Rather	   than	  dietary	  manipulation	  during	   the	   study	  period,	   perhaps	   a	  better	  method	  would	  be	  to	  pre-­‐load	  participants	  by	  providing	  FO	  supplements	  for	  a	  4	  wk	  period	  preceding	  HFEE.	  Based	  on	  previous	  data	   from	  our	   laboratory	   (128),	   this	  time-­‐period	   of	   supplementation	  would	   facilitate	   remodelling	   of	   the	   skeletal	  muscle	  phospholipid	   membrane.	   Thus,	   if	   phospholipid	   membrane	   composition	   is	   an	  important	   functional	   change	   for	  preserving,	  or	   improving,	   insulin	  signalling,	  a	  4	  wk	  period	  of	  FO	  supplementation	  at	  5	  g·d-­‐1	  would	  achieve	  the	  desired	  effect	  (at	  least	  in	  healthy	   males).	   Using	   this	   methodology	   also	   would	   have	   the	   additional	   benefit	   of	  being	   able	   to	   feed	   both	   groups	   (HFEE	   with,	   and	   without,	   FO)	   exactly	   the	   same	  experimental	  diet	  (relative	  to	  habitual	  energy	   intake).	  Having	   just	  one	  experimental	  diet	   would	   relieve	   any	   inconsistencies	   between	   the	   diets	   consumed	   by	   the	   two	  groups,	  such	  as	  sugar	  intake,	  that	  were	  apparent	  in	  the	  present	  investigation.	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  Finally,	  the	  first	  three	  phases	  have	  been	  designed	  with	  the	  assumption	  that	  only	  one	  experimental	  diet	  and	  FO	  dose	  will	  be	  tested.	  Phase	  4,	  which	  could	  be	  implemented	  in	   concert	   with	   each	   of	   the	   3	   previous	   phases,	   relates	   to	   dose-­‐response	   work.	   	   As	  indicated	   previously,	   both	   HFEE	   and	   FO	   dose	   could	   be	   manipulated.	   Specifically,	  different	  dietary	  energy	  and	  fat	  compositions	  could	  be	   investigated	  to	  establish	  any	  dose-­‐relationship	  of	  energy	  and	  /	  or	  fat	  on	  the	  insulin	  sensitivity	  response,	  and	  /	  or	  different	   FO	   supplementation	   doses	   could	   be	   used	   during	   the	   pre-­‐load.	   Dose-­‐response	  work	  has	   the	  added	  advantage	   that	   the	  minimum	  change	   required	   to	   still	  achieve	  an	  almost	  maximal	  response	  can	  be	  opted	  for	  in	  future	  studies	  of	  this	  nature	  to	   minimise	   the	   severity	   of	   change	   and	   enhance	   compliance	   /	   validity.	   Taken	  together,	   the	   result	   of	   this	   four-­‐phase	   period	   of	   work	  would	   be	   greater,	   and	  more	  complete,	   understanding	   of	   the	   underlying	   metabolic,	   molecular	   and	   epigenetic	  responses	   to	   short-­‐term	   HFEE.	   Enhanced	   understanding	   of	   insulin	   resistance	  development,	  and	  the	  potential	  strategies	  that	  may	  be	  used	  to	  alter	  this	  development,	  can	  only	  be	  beneficial	  in	  the	  global	  pursuit	  of	  T2D	  prevention.	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Product Specification I 
 




Omega-360TM Pure 22; a marine omega-3 oil with excellent sensory characteristics with no odor or taste. 
Omega-360TM Pure 22 can be used as an ingredient in most food applications. It can replace all or part of 
the fat in an application containing fat, or it can be incorporated into a food product that normally does 
not contain fat. 
 
 
Country of Origin 
 
Omega-360TM Pure 22 is sourced and manufactured in Norway. Antioxidants are sourced primarily within 







Free fatty acids (FFA) % Max. 0,2 
Totox (2xPV+AV)  Max. 5 
 
EPA + DHA (area%) Sum 
EPA+DHA 
Min. 22 













Contains natural low levels of vitamin A and vitamin D3. 
• Vitamin A: Typically 19 - 40 µg/g 
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9 kg Bag-In-Box. Other packaging available on request. 
 
 
Storage and Shelf Life 
 
Omega-360TM Pure 22 is a premium quality product which is sensitive to oxidative degradation. 
Omega-360TM Pure 22 can be stored 12 months frozen (-18ºC) when originally sealed. Once package is 
opened, use immediately; product cannot be re-used once opened. 
 
The product can be stored chilled for a limited time period dependent upon the application. Please 
contact us for details.  
 
 
General Guidelines for Use 
 
Omega-360TM Pure 22 is typically added up to 5% in final food or beverage product. The dosage depends 
on specific application, typical consumer habits of servings per day and positioning of final product. 





Denomega has established and implemented a Quality System to ensure that Denomega’s products are 
safe and in compliance with national and international laws such as Food Legislation, HACCP and current 
Good Manufacturing Practices (cGMPs). Two vital elements of the quality system are (1) ensuring 












Kosher Omega-360TM Pure 22 is Kosher Certified. 
Halal Omega-360TM Pure 22 contains no ingredients of alcohol or pork origin. 
Vegetarian Omega-360TM Pure 22 is not suitable for vegetarians. 
Vegan Omega-360TM Pure 22 is not suitable for vegans. 









Omega-360TM Pure 22 is free from other animal bi-product derivatives and Foot and Mouth Disease. 
Næringsinnhold 100  ml 200  ml  
 
Energi                                                      95 kcal                 190 kcal
Proteiner                                                 2,5 g                          5 g
 Hvorav laktose                           0,006 g                  0,012 g
Karbohydrater                                        11  g                       22 g
 
Fett                                                   4,75 g                       9,5 g
Mettet                                                0,875 g                     1,75 g 
Enumettet                                              2,1 g                        4,2 g
Flerumettet                                         1,75 g                       3,5 g
Omega 3 1250 mg 2500  mg
 DHA 500 mg 1000  mg
 EPA 500 mg 1000  mg
Øvrige fettsyrer er fra fiskeoljer
Vitamin D3 5 µg                      10 µg
Gluten:                         Gluten fri               
Protein kilde:   Myseproteinisolat
Fett kilde:   Fiskeolje fra laks/ørret/torsk
Karbohydrat kilde:             Fruktose og glukose
Ingredienser: Juice fra konsentrat av eple, pære,
granateple, og aronia, fiskeolje, myseproteinisolat, 
pektin, aroma fra appelsin og klementin,
rosmarinekstrakt, naturlige tokoferoler, vitamin D3
og soya lecitin. 
   Ikke tilsatt: Sukker, søtningsmiddel, salt, kunstige 
   fargestoffer eller konserveringsmidler
Anbefalt dosering: Som forskrevet av lege eller 1-3 enheter 
per dag. Egnet for eldre, voksne og kan med varsomhet 
benyttes av barn fra 3 år.  Det anbefales 1-2 gram marine 
omega-3 fettsyrer per dag som primær- og sekundær preven-
sjon mot hjerte- og karsykdom. Det tilsvarer 1 stk NutriFriend 
2000 per dag.
For å ha triglyseridsenkende effekt anbefales 3-4 gram marine 
omega-3 fettsyrer per dag. Dette tilsvarer 2-3 enheter 
NutriFriend 2000 per dag.
Forsiktighetsregler: Må ikke konsumeres av personer med 
melkeproteinallergi eller melkeproteinintoleranse. Inneholder 
myseproteinisolat fra melk.
Anvendelsesområde: SMARTFISH NutriFriend 2000 er en 
næringsdrikk velegnet for personer som har behov for høye 
doseringer med de ferske omega-3 fettsyrene, EPA og DHA, og 
vitamin D3. NutriFriend 2000 er velegnet til personer med 
hjerte- og karsykdom. EPA og DHA har gunstig effekt på 
fettstoffene i blodet, og kan dermed virke forebyggende mot 
hjerte- og karsykdom. Blant annet har høye doser marine 
omega-3 fettsyrer vist å ha triglyseridsenkende effekt. Et økt 
inntakt av marine omega-3 fettsyrer har også vist å kunne 
beskytte mot nye tilfeller av hjerteinfarkt hos hjertesyke.
NutriFriend 2000 kan også anbefales til pasienter med inflam-
matoriske sykdommer som revmatisk sykdom og KOLS i sam-
råd med klinisk ernæringsfysiolog/lege.
NutriFriend 2000 er en tilskuddsernæringsdrikk. Den egner 
seg ikke som eneste næringskilde, men i kombinasjon med 
vanlig mat eller andre komplette næringsdrikker.
Forpakning: Kartonger av 200 ml. Selges enkeltvis eller i brett 
av 18 stk.
Bruksanvisning: Serveres avkjølt, ristes før bruk.
Oppbevaring: Oppbevares kjølig eller i romtemperatur, utenfor 
direkte sollys (1-25 °C). Åpnet kartong er holdbar inntil 1 døgn i 
kjøleskap.
Produksjon og GMO: Fiskeoljen er fra avskjær på norsk opp-
drettsfisk, fullt sporbar, sertifisert GMP* og Kosher. Smartfish 
inneholder ikke og er ikke fremstilt av GMO**.




Smartfish AS:  Smartfish leder utviklingen med marint 
omega-3. Selskapet har et omfattende program for klini-
ske studier. Http://no.smartfish.no/kliniske-studier
SMARTFISH formuleringer er patenterte. Smartfish er et
registrert varemerke tilhørende Smartfish AS.
Produsent: Smartfish AS, Gaustadalléen 21, 0349 Oslo
Tel: +47 22519880. Fax: +4722519881
SMARTFISH NUTRIFRIEND 2000
     LAVT OKSIDERT DHA & EPA
Smartfish NutriFriend 2000 er en næringsdrikk for spesielle medisinske 
formål, og er velegnet for personer som har behov for høye doseringer 
med ferske omega-3 fettsyrer EPA og DHA. NutriFriend 2000 er derfor 
velegnet til personer med hjerte- og kar sykdom.
Nutrifriend 2000 er en næringsdrikk med ca 85% juice fra bær og frukter 
og har en frisk og god smak.
Næringsverdi per 200 ml
Omega 3  2500 mg
DHA   1000 mg
EPA  1000 mg
Proteiner         5 g 
Vitamin D3       10 µg
Appendix	  2.3	  Blood	  lipid	  profiling	  by	  GLC.	  	  	   HF-­‐C	   HF-­‐FO	  	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
14:00	   0.57	  ±	  0.04	   0.66	  ±	  0.03	   0.57	  ±	  0.04	   0.67	  ±	  0.03	  
15:00	   0.20	  ±	  0.01	   0.24	  ±	  0.01	   0.18	  ±	  0.01	   0.24	  ±	  0.01	  
16:00	   20.97	  ±	  0.22	   20.69	  ±	  0.14	   20.80	  ±	  0.24	   20.44	  ±	  0.26	  
18:00	   11.42	  ±	  0.07	   11.51	  ±	  0.10	   11.44	  ±	  0.22	   12.03	  ±	  0.18	  
20:00	   0.25	  ±	  0.01	   0.26	  ±	  0.01	   0.24	  ±	  0.01	   0.25	  ±	  0.01	  
22:00	   0.76	  ±	  0.03	   0.80	  ±	  0.03	   0.72	  ±	  0.02	   0.76	  ±	  0.03	  
24:00	   1.13	  ±	  0.02	   1.24	  ±	  0.14	   1.13	  ±	  0.04	   1.12	  ±	  0.03	  Total	  SFA	   35.30	  ±	  0.29	   35.38	  ±	  0.30	   35.09	  ±	  0.42	   35.51	  ±	  0.32	  
16:1n-­‐9	   0.27	  ±	  0.01	   0.24	  ±	  0.01	   0.26	  ±	  0.02	   0.21	  ±	  0.01	  
16:1n-­‐7	   1.04	  ±	  0.08	   0.77	  ±	  0.05	   1.15	  ±	  0.11	   0.80	  ±	  0.07	  
18:1n-­‐9	   17.29	  ±	  0.43	   15.15	  ±	  0.48	   16.61	  ±	  0.46	   13.44	  ±	  0.29	  
18:1n-­‐7	   1.64	  ±	  0.04	   1.44	  ±	  0.04	   1.57	  ±	  0.08	   1.42	  ±	  0.04	  
20:1n-­‐9	   0.25	  ±	  0.01	   0.23	  ±	  0.01	   0.24	  ±	  0.01	   0.30	  ±	  0.01	  
24:1n-­‐9	   1.46	  ±	  0.05	   1.43	  ±	  0.04	   1.33	  ±	  0.05	   1.43	  ±	  0.05	  Total	  MUFA	   21.95	  ±	  0.46	   19.25	  ±	  0.55	   21.16	  ±	  0.61	   17.61	  ±	  0.37	  
18:2n-­‐6	   18.78	  ±	  0.82	   21.97	  ±	  0.59	   19.91	  ±	  0.69	   18.30	  ±	  0.32	  
18:3n-­‐6	   0.22	  ±	  0.02	   0.21	  ±	  0.02	   0.22	  ±	  0.04	   0.13	  ±	  0.01	  
20:2n-­‐6	   0.22	  ±	  0.01	   0.22	  ±	  0.01	   0.26	  ±	  0.01	   0.25	  ±	  0.01	  
20:3n-­‐6	   1.73	  ±	  0.12	   1.50	  ±	  0.08	   1.71	  ±	  0.14	   1.28	  ±	  0.09	  
20:4n-­‐6	   10.96	  ±	  0.34	   10.73	  ±	  0.33	   10.93	  ±	  0.36	   10.77	  ±	  0.29	  
22:4n-­‐6	   1.51	  ±	  0.05	   1.46	  ±	  0.04	   1.60	  ±	  0.07	   1.51	  ±	  0.08	  
22:5n-­‐6	   0.32	  ±	  0.02	   0.30	  ±	  0.01	   0.35	  ±	  0.03	   0.32	  ±	  0.02	  Total	  n-­‐6	  PUFA	   33.74	  ±	  0.55	   36.39	  ±	  0.36	   34.97	  ±	  0.58	   32.54	  ±	  0.34	  
18:3n-­‐3	   0.51	  ±	  0.03	   0.53	  ±	  0.03	   0.51	  ±	  0.04	   0.55	  ±	  0.02	  
20:4n-­‐3	   0.08	  ±	  0.01	   0.07	  ±	  0.00	   0.12	  ±	  0.02	   0.16	  ±	  0.02	  
20:5n-­‐3	   0.69	  ±	  0.06	   0.73	  ±	  0.05	   0.57	  ±	  0.04	   3.95	  ±	  0.38	  
22:5n-­‐3	   1.57	  ±	  0.06	   1.50	  ±	  0.06	   1.40	  ±	  0.06	   1.56	  ±	  0.05	  
22:6n-­‐3	   2.58	  ±	  0.18	   2.55	  ±	  0.15	   2.51	  ±	  0.14	   4.21	  ±	  0.18	  Total	  n-­‐3	  PUFA	   5.41	  ±	  0.26	   5.35	  ±	  0.23	   5.04	  ±	  0.16	   10.43	  ±	  0.51	  
16:0DMA	   1.26	  ±	  0.03	   1.30	  ±	  0.04	   1.33	  ±	  0.03	   1.42	  ±	  0.02	  
18:0DMA	   1.76	  ±	  0.04	   1.75	  ±	  0.05	   1.83	  ±	  0.06	   1.88	  ±	  0.07	  
18:1DMA	   0.58	  ±	  0.02	   0.58	  ±	  0.02	   0.57	  ±	  0.02	   0.61	  ±	  0.03	  Total	  DMA	   3.60	  ±	  0.07	   3.63	  ±	  0.10	   3.74	  ±	  0.08	   3.92	  ±	  0.08	  20:4n-­‐6/20:5n-­‐3	   16.66	  ±	  1.17	   15.23	  ±	  0.89	   20.14	  ±	  1.57	   3.01	  ±	  0.34	  %	  n-­‐3HUFA/Total	  HUFA	   24.87	  ±	  0.87	   25.35	  ±	  0.75	   23.46	  ±	  0.84	   40.96	  ±	  1.49	  
	  
All	  individual	  fatty	  acids	  are	  expressed	  as	  a	  percentage	  of	  total	  fatty	  acids.	  Values	  
are	  means	  ±	  SEM	  (n=10	  per	  group).	  
	   	  
Appendix	  3.1	  Skeletal	  muscle	  lipid	  profiling	  by	  GCMS.	  	  	   HF-­‐C	   HF-­‐FO	  	   Pre-­‐HFEE	   Post-­‐HFEE	   Pre-­‐HFEE	   Post-­‐HFEE	  
14:0	   0.78	  ±	  0.12	   0.76	  ±	  0.11	   0.82	  ±	  0.08	   1.18	  ±	  0.16	  
15:0	   0.67	  ±	  0.13	   0.67	  ±	  0.13	   0.56	  ±	  0.04	   0.79	  ±	  0.09	  
16:0	   20.41	  ±	  0.99	   20.73	  ±	  0.86	   20.91	  ±	  0.66	   21.16	  ±	  0.77	  
18:0	   13.18	  ±	  0.80	   12.74	  ±	  0.83	   13.32	  ±	  0.74	   12.96	  ±	  0.69	  
20:0	   0.14	  ±	  0.01	   0.12	  ±	  0.01	   0.16	  ±	  0.02	   0.18	  ±	  0.04	  
22:0	   0.23	  ±	  0.04	   0.20	  ±	  0.02	   0.24	  ±	  0.03	   0.25	  ±	  0.04	  
24:0	   0.20	  ±	  0.04	   0.20	  ±	  0.03	   0.22	  ±	  0.02	   0.20	  ±	  0.04	  Total	  SFA	   35.61	  ±	  0.61	   35.42	  ±	  0.31	   36.23	  ±	  0.91	   36.71	  ±	  0.89	  
16:1n-­‐9	   0.57	  ±	  0.27	   0.29	  ±	  0.04	   0.39	  ±	  0.07	   0.40	  ±	  0.07	  
16:1n-­‐7	   0.59	  ±	  0.15	   0.60	  ±	  0.12	   0.81	  ±	  0.14	   0.85	  ±	  0.25	  
18:1n-­‐9	   8.09	  ±	  0.37	   7.70	  ±	  0.36	   8.25	  ±	  0.42	   8.20	  ±	  0.50	  
18:1n-­‐7	   1.83	  ±	  0.08	   1.75	  ±	  0.05	   1.80	  ±	  0.11	   1.88	  ±	  0.12	  
20:1n-­‐11	   0.04	  ±	  0.02	   0.04	  ±	  0.02	   0.05	  ±	  0.03	   0.10	  ±	  0.04	  
20:1n-­‐9	   0.24	  ±	  0.08	   0.29	  ±	  0.10	   0.42	  ±	  0.19	   0.68	  ±	  0.20	  
22:1n-­‐11	   0.24	  ±	  0.12	   0.30	  ±	  0.15	   0.32	  ±	  0.15	   0.60	  ±	  0.26	  
22:1n-­‐9	   0.12	  ±	  0.02	   0.10	  ±	  0.03	   0.16	  ±	  0.03	   0.18	  ±	  0.04	  
24:1n-­‐9	   0.48	  ±	  0.10	   0.43	  ±	  0.05	   0.56	  ±	  0.07	   0.66	  ±	  0.15	  Total	  MUFA	   12.21	  ±	  0.63	   11.51	  ±	  0.72	   12.76	  ±	  0.99	   13.54	  ±	  1.34	  
18:2n-­‐6	   29.44	  ±	  0.82	   30.72	  ±	  1.25	   28.60	  ±	  1.04	   26.69	  ±	  1.38	  
18:3n-­‐6	   0.17	  ±	  0.03	   0.13	  ±	  0.01	   0.18	  ±	  0.02	   0.16	  ±	  0.02	  
20:2n-­‐6	   0.12	  ±	  0.01	   0.12	  ±	  0.01	   0.16	  ±	  0.03	   0.18	  ±	  0.03	  
20:3n-­‐6	   1.53	  ±	  0.10	   1.49	  ±	  0.10	   1.46	  ±	  0.09	   1.34	  ±	  0.13	  
20:4n-­‐6	   14.04	  ±	  0.83	   13.69	  ±	  0.75	   13.79	  ±	  0.63	   12.67	  ±	  0.65	  
22:4n-­‐6	   0.74	  ±	  0.06	   0.74	  ±	  0.03	   0.69	  ±	  0.06	   0.58	  ±	  0.05	  
22:5n-­‐6	   0.41	  ±	  0.03	   0.35	  ±	  0.03	   0.41	  ±	  0.05	   0.34	  ±	  0.04	  Total	  n-­‐6	  PUFA	   46.44	  ±	  1.10	   47.25	  ±	  1.29	   45.29	  ±	  1.60	   41.96	  ±	  2.02	  
18:3n-­‐3	   0.36	  ±	  0.03	   0.37	  ±	  0.02	   0.34	  ±	  0.02	   0.39	  ±	  0.04	  
18:4n-­‐3	   0.08	  ±	  0.04	   0.13	  ±	  0.07	   0.10	  ±	  0.06	   0.10	  ±	  0.10	  
20:4n-­‐3	   0.06	  ±	  0.02	   0.06	  ±	  0.02	   0.07	  ±	  0.02	   0.11	  ±	  0.03	  
20:5n-­‐3	   1.05	  ±	  0.15	   1.08	  ±	  0.17	   1.01	  ±	  0.15	   1.87	  ±	  0.32	  
22:5n-­‐3	   1.86	  ±	  0.09	   1.87	  ±	  0.09	   1.61	  ±	  0.22	   1.91	  ±	  0.10	  
22:6n-­‐3	   2.32	  ±	  0.20	   2.31	  ±	  0.25	   2.59	  ±	  0.38	   3.41	  ±	  0.59	  Total	  n-­‐3	  PUFA	   5.73	  ±	  0.47	   5.83	  ±	  0.54	   5.73	  ±	  0.51	   7.79	  ±	  1.07	  20:4n-­‐6/20:5n-­‐3	   16.22	  ±	  2.65	   15.71	  ±	  2.69	   16.83	  ±	  3.20	   8.37	  ±	  1.34	  %	  n-­‐3HUFA/Total	  HUFA	   24.05	  ±	  2.10	   24.44	  ±	  1.88	   24.29	  ±	  1.98	   32.04	  ±	  3.36	  20:5n-­‐3	  +	  22:6n-­‐3	   3.37	  ±	  0.34	   3.39	  ±	  0.41	   3.61	  ±	  0.50	   5.29	  ±	  0.88	  
All	   individual	   fatty	  acids	  are	  expressed	  as	  a	  percentage	  of	   total	   fatty	  acids.	  Values	  





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































	  Appendix	  4.3	  Plasma	  vs.	  skeletal	  muscle	  correlations.	  
	   Plasma	  vs.	  skeletal	  
muscle	  
miRNA	  levels	  
Plasma	  miRNA	  levels	  
vs.	  Matsuda	  ISI	  change	  
Skeletal	  muscle	  
miRNA	  levels	  vs.	  
Matsuda	  ISI	  change	  miR-­‐1	   -­‐	   -­‐	   <	  0.001	  (0.602)	  miR-­‐7-­‐5p	   11.00	  (0.097)	   <	  0.001	  (0.677)	   <	  0.001	  (0.851)	  miR-­‐15-­‐5p	   <	  0.001	  (0.60)	   7.90	  (0.123)	   <	  0.001	  (0.798)	  miR-­‐18a-­‐5p	   <	  0.001	  (0.394)	   <	  0.001	  (0.349)	   <	  0.001	  (0.349)	  miR-­‐22-­‐3p	   <	  0.001	  (0.653)	   <	  0.001	  (0.980)	   15.80	  (0.058)	  miR-­‐25-­‐3p	   -­‐	   -­‐	   10.20	  (0.106)	  miR-­‐27a-­‐3p	   -­‐	   11.70	  (0.077)	   -­‐	  miR-­‐30d-­‐5p	   4.80	  (0.192)	   11.30	  (0.081)	   <	  0.001	  (0.811)	  miR-­‐93-­‐5p	   14.20	  (0.069)	   1.70	  (0.263)	   <	  0.001	  (0.465)	  miR-­‐100-­‐5p	   15.40	  (0.06)	   <	  0.001	  (0.489)	   <	  0.001	  (0.408)	  miR-­‐106b-­‐5p	   <	  0.001	  (0.792)	   12.00	  (0.074)	   <	  0.001	  (0.937)	  miR-­‐126-­‐3p	   <	  0.001	  (0.570)	   11.90	  (0.075)	   <	  0.001	  (0.470)	  miR-­‐145-­‐5p	   <	  0.001	  (0.496)	   16.20	  (0.044)	   <	  0.001	  (0.506)	  miR-­‐193a-­‐5p	   -­‐	   -­‐	   16.00	  (0.056)	  miR-­‐196a-­‐5p	   -­‐	   -­‐	   <	  0.001	  (0.917)	  miR-­‐204-­‐5p	   -­‐	   -­‐	   22.80	  (0.026)	  miR-­‐206	   -­‐	   -­‐	   2.90	  (0.238)	  miR-­‐214-­‐3p	   -­‐	   -­‐	   11.30	  (0.094)	  miR-­‐215	   <	  0.001	  (0.642)	   <	  0.001	  (0.727)	   7.60	  (0.149)	  miR-­‐885-­‐5p	   -­‐	   -­‐	   2.80	  (0.240)	  
Data	  presented	  are	  R2	  adjusted	  values	  (p	  values).	  All	  miRNA	  samples	  were	  basal	  pre-­‐HFEE	  and	  
mixed	  groups.	  The	  Matsuda	  ISI	  was	  calculated	  as	  the	  percentage	  difference	  between	  pre-­‐	  and	  post-­‐
HFEE	  values.	  	  	  	  	  
















Comments on the CrossTalk
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Craig A. Goodman and Troy A. Hornberger
Department of Comparative Biosciences,
School of Veterinary Medicine, University
of Wisconsin-Madison, 2015 Linden Drive,
Madison, WI 53706, USA
It iswith great interest thatwe read the cross-
talk on the proposed roles that changes in
protein synthesis and protein degradation
play in disuse skeletal muscle atrophy
(Phillips &McGlory, 2014; Reid et al. 2014).
However, rather than adopting an ‘either/or’
position on this topic, we believe that a
more integrated standpoint is warranted.
For example, recent evidence suggests that
cells/tissues can simultaneously coordinate
changes in both protein synthesis and
protein degradation, including in skeletal
muscle (Baehr et al. 2014; Zhang et al.
2014). Moreover, recent evidence suggests
that, under certain conditions, an increase
in protein degradation could lead to
a decrease in protein synthesis. For
instance, the eukaryotic initiation factor
subunit 3f (eIF3f), which plays a crucial
role in protein synthesis, is targeted for
degradation by the E3 ligase atrogin-1,
and preventing the atrogin-1-induced poly-
ubiquitination of eIF3f provides protection
against starvation-induced muscle atrophy
(Csibi et al. 2009, 2010). Similarly,
myostatin-induced myotube atrophy is not
only associated with an increase in the
expression of components of the ubiquitin
proteasome system, but also an increase
in the degradation of various trans-
lation initiation and elongation factors,
ribosomal proteins, and a decrease in
the rate of protein synthesis (Lokireddy
et al. 2011, 2012). While these data are
derived from cell culture and animal
models, we must consider the possibility
that similarmechanismsmay also operate in
human models of disuse atrophy, whereby
an increase in proteolysis could play a
significant role in the decrease in protein
synthesis.
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The dominant cause of
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hindered by fallacy of
evidence?
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Although both viewpoints deliver articulate
arguments, to us, the notion of any
singular mechanism per se dominating
muscle atrophy responses to disuse is
both premature and most likely overly
simplistic. As is the case withmany adaptive
processes, disuse atrophy (as with hyper-
trophy!) follows a temporal pattern, i.e. with
greater changes dominating initial phases
(Wall et al. 2014), thereafter abating (Adams
et al. 2003). To suggest synthesis or break-
down is dominant disregards the dynamic
nature of protein balance and the likely
scenario of each process contributing to
different extents at different time-points. To
us, this is as much an issue as opposing
views being a cacophony ‘of mice and men’
(though the present authors agree with
Phillips & McGlory this may explain some
existing discordances). Additionally, whilst
Reid et al. (2014) justly state: ‘the dominant
mechanism of disuse atrophy is not known’,
this doesnotprecludeone transpiring–with
appropriate time course studies. Moreover,
suggestions: ‘rates of proteolysis vs. synthesis
cannot be quantifiedusing existingmethods
nor can differences in these rates be
measured directly’, are misleading. There
are ways to quantify synthesis and break-
down rates concomitantly in muscle, in
vivo, using combinations of stable isotope
tracers. For example, A–V balance: syn-
thesis/breakdown, net-balance (Greenhaff
et al. 2008); pulse-chase: fractional break-
down rates (Zhang et al. 1996); fractional
synthesis rates via amino acid tracers
or D2O (Wilkinson et al. 2014). Yes,
such techniques require mass-spectrometry
know-how, blood/muscle sampling and
temporal resolution, but surely represent
the best means to arrive at bona fide answers
to these longstanding questions.
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As is often the case in an academic debate,
here the affirmative and negative present
arguments that do not effectively counter
the alternatively presented hypothesis. This
is not a critique of either group; instead we
propose it is methodological in nature.
One aspect the authors have not consi-
dered in their arguments is the effect
of time. We have previously reported a
temporal effect in thehypertrophic response
in healthy individuals following resistance
training, with an acute degradative response
followed by increased pro-synthesis activity
(Elliott et al. 2012), and our current work is
examining this phenomenon duringmuscle
atrophy. Granted, this is a different research
model, but it is of interest to note.Wewould
suggest therefore that perhaps both hypo-
theses are correct. At this time, the temporal
nature of the disuse atrophy has yet to be
adequately considered.
This disparity between results that report
molecular changes and those that report
isotope-based results drives an artificial
controversy. Natural sciences often reach
such impasses when different approaches
conclude differing hypotheses. We propose
that a careful modelling of changes in both
isotope measures of protein balance and
molecular markers of pathway activity, as
a function of time, will produce a clearer
picture of themechanistic control of muscle
mass. Careful critique of each hypothesis
will lead to the rejection of one, or the
combination of the two, as suggested above.
At the risk of cliche´, more research is clearly
needed.
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Redox regulation of protein
turnover during
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The debate articulated by Drs Phillips and
McGlory (Phillips & McGlory, 2014a,b)
vs. Drs Reid, Judge and Bodine (Reid
et al. 2014a,b) regarding the importance
of decreased protein synthesis vs. increased
protein degradation in response to unload-
ing/disuse is a fascinating one indeed.
Skeletal muscle is a highly dynamic tissue
with robust protein turnover that not only
produces force and power for joint motion,
but also serves as a substrate source of amino
acids. Amino acid demand from skeletal
muscle is enhanced for protein needs when
nutrient sources are insufficient, common
in our hunter–gatherer ancestors, or when
injury and illness occur (Wolfe, 2006).
Further, teleological arguments suggest that
reduction in protein synthesis due to disuse
would save energy and substrate resources.
While the mechanisms that alter protein
turnover and atrophy with unloading
are not fully understood, pro-oxidant
(Dodd et al. 2010; Min et al. 2011)
and pro-inflammatory (Judge et al. 2007)
signalling appear to be important effectors
of atrophy and fibre-type switch. Disuse
increases the prevalence of oxidized proteins
(Lawler et al. 2014). Oxidized amino
acids could ‘tag’ proteins for degradation,
particularly when levels of chaperone heat
shock proteins are low (Senf et al. 2008).
Accumulation and cross-linking of partially
oxidized proteins could lead to cellular
toxicity, thus providing impetus for rapid
removal. Recently, reactive oxygen species
(ROS) have recently been linked to (a)
translocation of nNOSμ and downstream
activation of FoxO3a with unloading
(Lawler et al. 2014), and (b) suppression
of Akt phosphorylation and anabolic sign-
alling (Rahman et al. 2014). Future research
should focus on prospective mechanisms
that tie together unloading-induced res-
ponses in protein synthesis with proteolysis.
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Abbreviations: MPS, muscle protein
synthesis; MPB, muscle protein breakdown.
We appreciated the scientific debate raised
in the CrossTalk series regarding the physio-
logical mechanisms underpinning muscle
disuse atrophy (Phillips & McGlory, 2014).
As stated by Phillips & McGlory, the comb-
ined efforts ofmultiple research groups over
the past three decades have unequivocally
shown a decline in post-absorptive and
post-prandial muscle protein synthesis
(MPS) rates accompanying uncomplicated,
prolonged (2 weeks) disuse in humans
(e.g. Gibson et al. 1987; Ferrando et al.
1996; Glover et al. 2008; Wall et al. 2013b).
However, comparable data of how disuse
affects muscle protein breakdown (MPB)
in humans are simply not yet available. We
have recently shown that as little as 5 days of
disuse already leads to considerable muscle
atrophy (Wall et al. 2013a), an impact that
is unlikely attributed solely to a decline in
MPS. However, to date, no in vivo human
data of howMPBorMPSare affectedduring
this first week of disuse have been generated.
Calculating expected muscle loss based
on changes in MPS (and comparing this
with observed muscle loss) as a means to
indirectly infer changes (or lack thereof)
in MPB is a tantalizing but challenging
approach. Though relative changes in MPS
ormusclemass can be assessed accurately in
human disuse studies, the precise numerical
value of both parameters are subject to
variance depending upon methodological
choices. Indirect evidence from humans
concerning molecular pathways involved
in proteolysis suggests that MPB rises
rapidly and transiently at the onset of
disuse, which may represent a mechanism
to initiate the atrophy process (Wall et al.
2013a). Consequently, the appropriateness
of potential countermeasures for disuse
atrophy may be dependent upon the speed
at which they are implemented. In this
way, clinically and scientifically, timing may
really be of the essence!
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Skeletal muscle forms the bulk of body
weight and accounts for 50% of body
mass in young adult males. In addition
to its main functions of postural control
and the powering of movement, skeletal
muscle is important in the maintenance
of body shape, structure and composition.
It is also the main store of proteins in
the body. As a result, skeletal muscle
mass is highly regulated and is maintained
by the fine balance between anabolism
(protein synthesis) and catabolism (protein
degradation). Both processes are closely
coupled and are regulated by an intricate
intracellular signalling pathway controlled
by the protein kinase AKT (also known
as protein kinase B) (Nader, 2005). Thus,
anabolic signals such as resistive exercise,
growth factors such as insulin-like growth
factor (IGF) 1 and hormones such as
male sex steroids lead to its activation
(= phosphorylation) and in turn this leads
to increased protein synthesis. In contrast,
catabolic signals such as disuse, lack of
weight bearing and pro-inflammatory cyto-
kines, e.g. tumour necrosis factor (TNF)
α lead to its inactivation. The inactivation
of AKT is accompanied by decreased
protein synthesis and the activation of the
ubiquitin proteasome system. Activation
of this system leads to increased protein
proteolysis. Consequently, it is impossible
to separate decreased protein synthesis
from increased proteolysis. As a result, we
suggest that disuse atrophy arises from a
combination of bothmechanisms and none
is more dominant than the other.
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together like a horse and
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Both propositions fail to recognise that
while the magnitude of change in protein
synthesis after feeding and/or exercise is
large, muscle growth and hypertrophy are
slow temporal processes requiring multiple
bouts of stimuli. This is particularly
evident when compared with rapid
muscle loss following even acute disuse.
Therefore, protein degradation is perhaps
a more sensitive process despite smaller
fluctuations in magnitude compared with
adaptive physiological responses under-
pinned by protein synthesis. It is worth
reiterating that formuscle atrophy following
disuse to occur, complex macromolecular
protein structures must be dismantled and
ultimately degraded. The question therefore
seems not to be which is the dominant
mechanism, but rather, after disuse what
are the temporal regulators driving physio-
logical change; which process comes first
and informs the other; and finally, which
is a more sensitive process. Paradoxically,
it is worth noting that protein degradation
is an important adaptive process for
the post-loading response, culminating in
early remodelling and repair to enable
later hypertrophy. Therefore future research
should extend the work that has already
been undertaken regarding the cross-talk
between signalling mechanisms of synthesis
and degradation, which are inextricably
linked, for example pro-synthetic Akt
inhibition of pro-degradative FOXO and
vice versa (Sandri et al. 2004; Edstro¨m et al.
2006), or the duality of function of p38
MAPK (first described by Gillespie et al.
2009). Therefore, we suggest degradation
and synthesis orchestrate gains or losses
in tandem; as the old saying goes, ‘love
and marriage go together like a horse and
carriage/you cannot have one without the
other’.
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Muscle atrophy – a balanced
approach
Richard M. Aspden
Musculoskeletal Programme, School of
Medicine and Dentistry, University of
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Aberdeen AB25 2ZD, UK
While wary of sitting on the fence it seems
to me that the dichotomy between break-
down and synthesis as ‘causing’ muscle
atrophy is a false one. More than that,
surely this presumed conflict is sterile as it
does not lead to new insights for therapies.
Growth or atrophy arises from an altered
signal of muscle activity, which generally,
but is not necessarily, a consequence of
actual muscle activity. A more holistic
approach asks, ‘What processes are required
to maintain adequate function in response
to that signal?’ Atrophy would follow a loss
of this maintenance signal.
It is clearly the balance between synthesis
and breakdown that determinesmuscle size.
Both synthesis and breakdownmay increase
or decrease in response to stimulus or
disuse, and changes in one may regulate
changes in the other. It is the resulting
balance, however, that will determine
whether a muscle grows or atrophies. Reid
et al. indicate that measuring this balance
biochemically is not practical but clearly the
outcome – size – can be measured using
imaging. A more fundamental question
is what controls that balance, as it is
here that interventions are more likely to
be fruitful. Control requires a signal, a
monitoring process and a mechanism that
takes the monitored signal and converts it
into a response, ideally with a small amount
of feedback. Identifying and being able
to monitor/adjust this mechanism would
enable intervention at a high level. Setting
synthesis against breakdown is at the lowest
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This topical CrossTalk debate presents
two opposing viewpoints concerning the
predominant mechanism that governs
‘uncomplicated’ disuse skeletal muscle
atrophy in humans. Consistent with other
experts (Wall & van Loon, 2013), these
viewpoints agree that both a suppression
of muscle protein synthesis (MPS) and
acceleration of muscle protein break-
down (MPB) likely explain the more
rapid muscle loss during early (<5 days)
compared with late (>10 days) phases
of disuse (1.2 vs. 0.5% day−1). As
such, to fully elucidate the predominant
mechanism underpinning disuse muscle
atrophy, it is necessary to characterize trans-
ient changes in muscle protein metabolism
over a prolonged time-course of disuse.
This challenging prospect will be facilitated
by recent developments in the application
of deuterium oxide (2H2O) isotope tracer
methodology. The validation of oral 2H2O
isotope tracer protocols allows for the
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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dynamic in vivomeasurement of integrated
rates of myofibrillar MPS (MacDonald et al.
2013; Wilkinson et al. 2014) and MPB
(Holm et al. 2013) over acute (hours), inter-
mediate (days) and chronic (weeks) time
periods. Therefore, moving forward, future
time-course studies (Brocca et al. 2012)
should apply 2H2O tracer methodology to
measure temporal changes in MPS and
MPB during early (<5 days), intermediate
(5–10 days) and prolonged (>10 days)
phases ofmuscle disuse. These datawill help
establish the predominant mechanism that
drives muscle atrophy during early through
to later phases of disuse. Moreover, these
important data will help inform targeted
interventions (exercise, pharmaceutical,
nutritional) for ameliorating humanmuscle
atrophy and the associated hypodynamia
over a prolonged time-course of muscle
disuse.
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The topic of this crosstalk is important.
Too much time has been spent on trying to
simplify the driving factor of human disuse
to a dichotomy between decreased protein
synthesis or increased protein breakdown,
digging trenches between human research
and research based on animal data. Few
scientists argue about the importance of
a decrease in protein synthesis, yet it
is increasingly difficult to overlook the
emerging bulk of data demonstrating that
the regulation of human muscle disuse is
far more complex. Specifically, in human
research we have previously overlooked
the importance of investigating the very
early phase of disuse/unloading (1–5 days)
where the atrophy response is most strongly
manifested and consequently important
information has therefore been unnoticed.
However, a growing number of studies show
evidence of an early rise in atrogenes during
human disuse (deBoer et al. 2007; Tesch
et al. 2008; Abadi et al. 2009; Suetta et al.
2012) with time-course patterns similar to
what have previously been demonstrated
in the murine model (Sacheck et al.
2007).
Another important point that has been
overlooked in human research for years
is the age-specific way human disuse
atrophy seems to be regulated (Suetta
et al. 2012) and equally important also the
phase of muscle re-growth with subsequent
reloading (Suetta et al. 2013). Notably, this
influence of ageing on muscle mass homeo-
stasis is well documented in various animal
models. Importantly, however, many links
remain missing in the puzzle of human
muscle plasticity, which from our point of
view can be achieved only through a close
interaction between human and animal
research.
References
Abadi A, Glover EI, Isfort RJ, Raha S, Safdar A,
Yasuda N, Kaczor JJ, Melov S, Hubbard A, Qu
X, Phillips SM & Tarnopolsky M (2009). Limb
immobilization induces a coordinate
down-regulation of mitochondrial and other
metabolic pathways in men and women. PLoS
One 4, e6518.
deBoer MD, Selby A, Atherton P, Smith K,
Seynnes OR, Maganaris CN, Maffulli N,
Movin T, Narici MV & Rennie MJ (2007). The
temporal responses of protein synthesis, gene
expression and cell signalling in human
quadriceps muscle and patellar tendon to
disuse. J Physiol 585, 241–251.
Sacheck JM, Hyatt JP, Raffaello A, Jagoe RT, Roy
RR, Edgerton VR, Lecker SH & Goldberg AL
(2007). Rapid disuse and denervation atrophy
involve transcriptional changes similar to
those of muscle wasting during systemic
diseases. FASEB J 21, 140–155.
Suetta C, Frandsen U, Jensen L, Jensen MM,
Jespersen JG, Hvid LG, Beyer M, Petersson SJ,
Schrøder HD, Andersen JL, Heinemeier K,
Aagaard P, Schjerling P & Kjaer M (2012).
Aging affects the transcriptional regulation of
human skeletal muscle disuse atrophy. PLoS
One 12, 1–13.
Suetta C, Frandsen U, Mackey AL, Jensen L,
Hvid LG, Bayer ML, Petersson SJ, Schrøder
HD, Andersen JL, Aagaard P, Schjerling P &
Kjaer M (2013). Ageing is associated with
diminished muscle re-growth and myogenic
precursor cell expansion early after
immobility-induced atrophy in human
skeletal muscle. J Physiol 591, 3789–3804.
Tesch PA, vonWalden F, Gustafsson T, Linnehan
RM & Trappe TA (2008). Skeletal muscle
proteolysis in response to short-term








Hans Degens and Emma F. Hodson-Tole
School of Healthcare Science, Manchester
Metropolitan University, Manchester, UK
Onemay start to address whether enhanced
muscle proteolysis or protein synthesis is
the dominantmechanismof disuse-induced
muscle atrophy (Phillips & McGlory, 2014;
Reid et al. 2014)with a thought-experiment.
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The second law of thermodynamics implies
that any complex structure left on its own is
subject to decay. In buildings, for instance,
broken light bulbs need replacement, pre-
ferably at a rate that matches the rate of
breakdown. If replacement stops entirely the
building will slowly get darker. However,
one could also actively remove light bulbs
(apoptosis and theproteasome requireATP)
from an unused room to ensure availability
in other, utilised rooms. The latter seems
to occur during denervation-induced atro-
phy where the abundance of apoptotic and
proteasome components (Sacheck et al.
2007) and protein breakdown (Goldspink,
1976) are increased transiently during
the period of rapid atrophy. Much of
the denervation-induced atrophy was pre-
vented by inhibition of the proteasome
(Beehler et al. 2006). Since denervation-
induced atrophy is faster and more pro-
nounced than in many other models of
disuse atrophy, it will elicit qualitatively
similar, but quantitatively more pronoun-
ced, changes in protein synthesis and
breakdown. Rodent models are extremely
helpful in this context, as the pattern
of disuse-induced atrophy is similar to,
but because of the higher metabolic rate
much faster than, in humans. In agreement
with Reid et al. (2014) we suggest that
an increased rate of protein breakdown is
the predominant factor of disuse-induced
atrophy; however, potential effects of a
reduced rate of protein synthesis should not
be ignored.
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Caught in the crossfire?
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Wardle
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University of Stirling, Stirling, UK
Whereas we appreciate that the purpose of
the CrossTalk article series is to compare
and contrast two opposing viewpoints on a
given topic, the desire to promote one’s view
at the expense of all else can often under-
mine the value of the scientific debate. In
the current set of articles, the proposal and
opposing view correctly acknowledge the
integral contributions of both suppressed
skeletal muscle protein synthesis (MPS) and
elevated skeletal muscle protein breakdown
(MPB) to the atrophied state, yet both
articles by default offer little consideration
to the integrated action of these two
processes. The complexity of skeletalmuscle
atrophy, and indeed physiology, is such that
thedeterminationof eitherparty to establish
a dominant mechanism appears futile when
we consider all the contributing factors and
mechanisms at play. Instead, we suggest that
disuse atrophy should be studied using a
holistic approach where value is given to
MPS, MPB and their underlying regulatory
mechanisms. Although the simultaneous
measurement of MPS and MPB during
disuse atrophy in humans is not currently
possible, advances in the techniques used
to accurately measure in vivo MPB acutely
(Tuvdendorj et al. 2013) and over extended
timeperiods (Holm et al.2013)will facilitate
such holistic study when implemented in
combination with existing MPS (Burd et al.
2011; Wilkinson et al. 2014) and signalling
protein activation (McGlory et al. 2014)
measures. Validation of these techniques
for use in humans remains ongoing, yet
collective efforts towards the goal of such an
approach will greatly enhance our existing
knowledge base of disuse atrophy and
provide a raised platform for stimulating
interesting and beneficial discussions for the
scientific community.
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Either or is digital code, a
bit of both is human
metabolism
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We are perplexed by the heat of the
debate regarding the relative contributions
of muscle protein synthesis (MPS) and
breakdown (MPB) to the disuse-induced
loss of muscle mass. Phillips and McGlory
argue that disuse-inducedmuscle atrophy is
almost entirely due to a reduced rate ofMPS.
Meanwhile, Reid, Judge and Bodine argue
that MPB is the dominant mechanism and
essential for disuse atrophy. Neither have
definitive evidence to support their cases.
Phillips andMcGlory point to a lot of data
demonstrating a disuse-induced decrease
in MPS in vivo in human subjects but do
they have a case for disuse-induced changes
in MPS only? We contend that they do
not, largely because nothing exists until we
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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measure it. As such, MPB during muscle
disuse was measured in only one study
including seven young men (Symons et al.
2009) and it was found that prolonged bed
rest did not significantly alter it. Phillips and
McGlory use this as the case in point to
dismiss any contribution of MPB to disuse
atrophy – conceivably a bit premature. They
further argue that the calculated rate of
muscle loss based on averagemeasuredMPS
rates closely (but evidently not entirely)
matches themeasured average loss ofmuscle
volume or cross sectional area assessed
by using MRI or CT. Thus, setting aside
any uncertainties of such comparison for
the sake of the argument, there could be
significant contributionof acceleratedMPB.
Reid, Judge and Bodine focus their
arguments largely on changes in cellular
factors involved in regulating proteolysis
in non-human models. There is also
(although sometimes conflicting) evidence
for cellular adaptations indicative of
temporarily upregulated proteolysis in
human muscle (e.g. Jones et al. 2004;
Urso et al. 2006; Suetta et al. 2012) but
the relationship between these measures
and actual rates of MPB is still uncertain.
Furthermore, there is nothing to suggest
that MPB is essential (i.e. required) for
disuse atrophy; theoretically it is certainly
possible for it to occur simply as a
result of thewell-establisheddisuse-induced
reduction in MPS.
Since metabolic adaptations are usually
multifactorial and complex, it is conceivable
that muscle disuse affects both MPS and
MPB to varying degrees over time. To
find out to what extent alterations in each
contribute to disuse atrophy will require
a comprehensive (incl. fasted and fed
state) and longitudinal (early/short-term vs.
late/prolonged) simultaneous assessment of
both MPS and MPB rates.
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As to the big concern that the dominant
mechanism remains unknown in disuse
skeletal muscle atrophy, our answer is
that proteolysis is essential for the disuse
atrophy. Unloading mechanical stress,
such as microgravity, directly induced
skeletal muscle atrophy (Vandenburgh et al.
1999), indicating that skeletal muscle
cells can sense the unloading stress
without hormonal and neural signalling.
In the response of skeletal muscle cells
to unloading conditions, muscle protein
synthesis (MPS) is closely associated with
muscle protein breakdown (MPB) like
bone remodelling. In bone remodelling,
removing old bone (bone resorption)
by osteoclasts is the initiation at the
remodelling site and is followed by bone
formation by osteoblasts to repair damaged
bone. Given that disuse atrophy is an
adaptive consequence against unloading
stress, we reason that removing damaged
protein by MPB is the initiation.
In addition, disuse atrophy underlies
the resistance of skeletal muscle cells to
myotrophic IGF-1 signalling (Sandri et al.
2004; Stitt et al. 2004). We previously
reported that ubiquitin ligase Cbl-b is
a negative regulator for IGF-1 signalling
duringmuscle atrophy caused by unloading
(Nakao et al. 2009). The mechanism of
Cbl-b-induced muscle atrophy is unique; it
does not appear to involve the degradation
of structural components of the muscle,
rather it impairs muscle growth signals
in response to unloading conditions.
Unloading induced Cbl-b expression very
quickly (less than 3 h) in skeletal muscle
cells, and the IGF-1-mediated cell growth
via MPS of rodent or human myo-
cytes was not suppressed unless there
was Cbl-b induction. On the basis of
these findings, we propose that proteolysis,
especially ubiquitin-dependent proteolysis,
is the initiation for the disruption of the
MPS and MPB balance.
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The well-argued positions in this Cross-
Talk debate (Phillips & McGlory, 2014;
Reid et al. 2014) clearly indicate that
reduced muscle protein synthesis (MPS)
and elevated muscle proteolysis are both
contributing to muscle atrophy during
disuse. Concluding which is the dominant
mechanism based on current evidence
is difficult due to technical limitations,
particularly in the direct measurement of
muscle proteolysis, but also as a function
of the time point of sampling, e.g. acute vs.
chronic phases of disuse, and the population
examined.Defining thesemechanisms is key
to translation of research into appropriate
treatment. Consider the case of the elderly,
a population likely to encounter periods of
both acute and chronic disuse. Basal rates of
MPS in the postabsorptive state are similar
following 7 days of bed rest compared
with pre-bed rest values in an elderly
cohort, despite 4% loss of muscle mass
(Drummond et al. 2012). A key regulator of
muscle mass is the postprandial regulation
of MPS/MPB and we know that MPS is
reduced by 40% in the postprandial period
following acute bed rest, which potentially
accounts for this loss (Drummond et al.
2012). However, there are currently no
data directly measuring disuse-associated
changes in proteolysis in elderly individuals
in either the acute or chronic phase.
Thus, until the technical challenges are
addressed and current markers of muscle
proteolysis are embraced (e.g. MAFbx,
MuRF-1, FOXO3a) it is difficult to argue
a case against, in the elderly at least,
decreased protein synthesis as the dominant
mechanism in disuse atrophy.
References
Drummond MJ, Dickinson JM, Fry CS, Walker
DK, Gundermann DM, Reidy PT,
Timmerman KL, Markofski MM,
Paddon-Jones D, Rasmussen BB & Volpi E
(2012). Bed rest impairs skeletal muscle
amino acid transporter expression, mTORC1
signaling, and protein synthesis in response to
essential amino acids in older adults. Am J
Physiol Endocrinol Metab 302, E1113–E1122.
Phillips SM &McGlory C (2014). CrossTalk
proposal: The dominant mechanism causing
disuse muscle atrophy is decreased protein
synthesis. J Physiol 592, 5341–5343.
Reid MB, Judge AR & Bodine SC (2014).
CrossTalk proposal: The dominant
mechanism causing disuse muscle atrophy is




The relative role of
decreased protein synthesis
and increased proteolysis in
causing disuse muscle
atrophy varies through
models, muscles and species
and depends on the
duration of unloading
Maria Antonietta Pellegrino1,2,3 and
Roberto Bottinelli1,3,4
1Department of Molecular Medicine,
University of Pavia, 27100 Pavia, Italy
2Interuniversity Institute of Myology,
University of Pavia, Pavia, Italy
3Interdipartimental Centre for Biology and
Sport Medicine, University of Pavia, Pavia,
Italy
4Fondazione Salvatore Maugeri (IRCCS),
Scientific Institute of Pavia, Pavia, Italy
Our works on disuse atrophy in mice
slow (Cannavino et al. 2014) and fast
(Cannavino et al. 2015) muscle using hind-
limb unloading indicated that both an
increase of proteolysis and a decrease in
protein synthesis come into play early
in determining muscle atrophy and to
a different extent. In the early stages
of disuse, atrophy in fast muscle was
caused by proteolysis only, while, in slow
muscle, both activation of proteolysis
and reduction of protein synthesis played
a role. Furthermore, the latter studies
showed a good correlation between in
vitro parameters (catabolic and synthetic
markers) and the degree of muscle atrophy.
In fact, preventing catabolism activation,
mass was completely preserved in fast
muscle and only partially in slow muscle,
where synthetic parameter down-regulation
persisted.
Although caution is a must when
extrapolating data from animal studies to
humans because of differences between
muscles, species and experimental models
(Pellegrino et al. 2011), both proteolysis and
decreased protein synthesis should still be
considered likely candidates in humans too.
Indeed, an early and transient induction of
proteolytic markers similar to that observed
in mice (Cannavino et al. 2014, 2015) was
observed in humans (Abadi et al. 2009;
Gustafsson et al. 2010). Moreover, based
on our studies in mice, it appears that
no activation of MurF-1 and atrogin-1 at
later stages of disuse (Brocca et al. 2012)
does not necessarily mean proteolysis plays
a minor role. Therefore, we believe that
the contribution of proteolysis cannot be
excluded, unless the irrelevance of such
a process is experimentally proved. The
doubt couldbedissipated if, after preventing
the early induction of catabolic markers
in humans, the experimental variation of
muscle mass remained unaffected.
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measurable what is not so’
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Following years of research in muscle
proteinmetabolism, there is strong evidence
that muscle protein synthesis (MPS) is the
dominant factor in simple disuse atrophy.
Particularly, the theory that a decrease in
MPS during this process is based on several
studies involving in vitro, ex vivo as well as in
vivomeasurements ofMPS (Mallinson et al.
2013). Conversely, even though the theory
that proteolysis is the dominant mechanism
underlying disuse atrophy is supported by
reliable animal models, a lack in trans-
lational research makes it less credible.
However, either to confirm that MPS is
the dominant mechanism during disuse
atrophy in humans or to verify whether
instead proteolysis is the main determinant,
further research in the field is warranted.
Particularly there is a necessity to translate
findings to an in vivo setting, using accurate
direct dynamic labelling techniques able to
compatibly assess MPS and proteolysis in
humans. Indeed while MPS is currently
determined by reliable methods, proteolysis
falls behind. Recently deuterated water, a
validated technique used to assess MPS
(Gasier et al. 2010; Wilkinson et al. 2014),
has been proposed to also measure MPB,
thus allowing comparable measurements of
both aspects of muscle protein turnover
(Wolfe, 2011; Holm et al. 2013).
Therefore the development of new
techniques and approaches will help
researchers to link data coming from gene
expression, signalling pathway and protein
metabolism and thus better understanding
the main mechanism lying behind disuse
atrophy.
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are both critical in muscle
atrophy
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Surprisingly, Phillips & McGlory (2014)
disregard the extensive evidence that
increased protein breakdown is also
critically important in atrophy (Mitch &
Goldberg, 1996; Glass, 2010; Reid et al.
2014; Cohen et al. 2015). Pulse-chase
studies in rats first showed that atrophy
induced by denervation or glucocorticoids
involved accelerated proteolysis (Goldberg,
1969), and oncemethods were developed to
measure precisely rates of degradation and
synthesis in isolated muscles (Fulks et al.
1975; Tischler et al. 1982), we demonstrated
that degradation rises with denervation
(Furuno et al. 1990), disuse (Tischler et al.
1997), fasting (Li &Goldberg, 1976), cancer
(Baracos et al. 1995) and acidosis (Mitch
et al. 1994). At present, no method exists
to measure accurately degradation rates in
humanmuscles. Because proteolysis cannot
be measured accurately in humans, one
cannot conclude that it does not increase.
Also, it is invalid to predict changes in
muscle mass from measurements of over-
all synthesis, since individual cell proteins
turnover at widely different rates, and their
rates of transcription (Sacheck et al. 2007),
synthesis (Li&Goldberg, 1976; Furuno et al.
1990), and degradation (Li & Goldberg,
1976; Furuno et al. 1990; Cohen et al. 2009,
2012) vary as atrophy progresses.
Phillips & McGlory (2014) dismiss
‘as biased’ conclusions from isolated
rodentmuscles.However, suchpreparations
behave linearly for hours and are still the
only method to precisely measure turnover
rates. Such studies first demonstrated the
ability of insulin and amino acids to
suppress proteolysis (Fulks et al. 1975;
Tischler et al. 1982), later confirmed in
humans, and enabled the discovery of
the critical adaptations during atrophy:
activation of the ubiquitin–proteasome
pathway (Medina et al. 1995; Wing et al.
1995) through atrogene induction (Jagoe
et al. 2002; Lecker et al. 2004; Sacheck
et al. 2007). Phillips & McGlory (2014)
accept our finding (Jagoe et al. 2002;
Lecker et al. 2004; Reid et al. 2014)
that a common transcriptional programme
enhancesmuscle proteolysis in disease states
but state incorrectly that similar changes
do not occur with disuse. In fact, we
demonstrated that denervation and pure
disuse induce the same atrophy-related
changes as fasting and disease (Sacheck et al.
2007).
In human and animal cells, contractile
activity, nutrients, and insulin activate the
PI3K–AKT–mTOR pathway (Glass et al.
2010; Cohen et al. 2015), which promotes
translation and inhibits proteolysis by
suppressing autophagy (Efeyan et al. 2015)
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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and inactivating FoxO-mediated expression
of genes for ubiquitination (Sandri et al.
2004; Cohen et al. 2015) and autophagy
(Mammucari et al. 2007; Zhao et al. 2007).
Thus, overall rates of protein degradation
and synthesis change coordinately.
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MicroRNAs (miRNAs) are stable in the circulation and are likely to function in inter-organ
communication during a variety of metabolic responses that involve changes in gene ex-
pression, including exercise training. However, it is unknown whether differences in circulat-
ing-miRNA (c-miRNA) levels are characteristic of training modality.
Methods
We investigated whether levels of candidate c-miRNAs differ between elite male athletes of
two different training modalities (n = 10 per group) - endurance (END) and strength (STR) -
and between these groups and untrained controls (CON; n = 10). Fasted, non-exercised,
morning plasma samples were analysed for 14 c-miRNAs (miR-1, miR-16-2, miR-20a-1,
miR-21, miR-93, miR-103a, miR-133a, miR-146a, miR-192, miR-206, miR-221, miR-222,
miR-451, miR-499). Moreover, we investigated whether c-miRNA levels were associated
with quantitative performance-related phenotypes within and between groups.
Results
miR-222 was present at different levels in the three participant groups (p = 0.028) with the
highest levels being observed in END and the lowest in STR. A number of other c-miRNAs
were present at higher levels in END than in STR (relative to STR, ± 1 SEM; miR-222: 1.94
fold (1.73-2.18), p = 0.011; miR-21: 1.56 fold (1.39-1.74), p = 0.013; miR-146a: 1.50 fold
(1.38-1.64), p = 0.019; miR-221: 1.51 fold (1.34-1.70), p = 0.026). Regression analyses re-
vealed several associations between candidate c-miRNA levels and strength-related perfor-
mance measures before and after adjustment for muscle or fat mass, but not following
adjustment for group.
Conclusion
Certain c-miRNAs (miR-222, miR-21, miR-146a and miR-221) differ between endurance-
and resistance-trained athletes and thus have potential as useful biomarkers of exercise
PLOSONE | DOI:10.1371/journal.pone.0122107 April 16, 2015 1 / 15
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training and / or play a role in exercise mode-specific training adaptations. However, levels
of these c-miRNAs are probably unrelated to muscle bulk or fat reserves.
Introduction
The health benefits of regular exercise are well recognised [1]. However, the physiological ad-
aptations that occur in response to exercise training differ according to genetic predisposition
[2] and exercise modality [3,4]. These differential responses are driven by a variety of mecha-
nisms including changes in gene expression and protein abundance [5], yet the specific mecha-
nisms governing these molecular modifications remain poorly understood.
Recent research has centred on epigenetic control mechanisms, including microRNAs
(miRNAs), and their role in regulating gene expression. miRNAs are small, non-coding ribo-
nucleic acids (RNAs) that play a vital role in regulation of gene expression. A major part of
their role is in post-transcriptional regulation through direct binding to target messenger
RNAs (mRNAs), and it is estimated that at least 30% of the human gene complement is regu-
lated by miRNAs [6]. Each miRNA binds to multiple mRNAs, and each mRNA is regulated by
multiple miRNAs, providing a highly sensitive reciprocal level of regulation [7].
Differences in skeletal muscle phenotype have been associated with differences in miRNA
expression levels and with genetic differences in miRNA binding sites. In Texel sheep, regula-
tion of skeletal muscle hypertrophy has been associated with variation in a region of theMyos-
tatin gene containing binding sites for muscle-specific miRNAs [8]. In humans, levels of miR-
378 in skeletal muscle were significantly correlated with lean muscle mass gains following a 12
week resistance exercise training intervention [9]. In addition, levels of several other miRNAs
in skeletal muscle have been shown to change following acute endurance exercise and following
endurance exercise training interventions [10]. Thus, miRNAs are associated with skeletal
muscle adaptation to exercise training and in combination with underlying genetic differences,
may be involved in the differential phenotypic response to resistance and endurance
type exercise.
miRNAs are found not only in tissues (e.g. skeletal muscle) but also in a variety of body flu-
ids including plasma [11,12]. Outside the cell, RNases act to rapidly degrade RNA [13]; howev-
er, miRNAs are thought to be stable within the circulation primarily through incorporation
into secreted exosomes, but also through co-localisation with the RNA-induced silencing com-
plex (RISC) or via binding to high-density lipoproteins (HDL) [14]. Additionally, miRNAs ap-
pear to be actively secreted into the circulation since exosomes contain only a subset of
miRNAs, present in proportions different to those in their cell type of origin [15]. Recent stud-
ies have suggested that circulating miRNAs (c-miRNAs) are involved in cell-cell communica-
tion and thus may have regulatory roles in normal physiology and in disease mechanisms [14].
c-miRNAs are remarkably stable in the circulation, easy to sample, and can be readily extracted
and measured using standard qRT-PCR techniques [11]. For these reasons, the study of c-miR-
NAs may yield useful insight into the mechanisms of adaptation to exercise.
The mechanisms by which exercise adaptation is effected and coordinated across multiple
organ systems remain somewhat unclear. Training is known to alter the health and function of
not only the exercised skeletal muscle but also a number of other organs resulting in a whole
body adaptive response [16]. c-miRNAs may be acting as the orchestrators of this multi-site re-
sponse. Changes in c-miRNA levels have been demonstrated following a programme of endur-
ance training [17,18] and in response to an acute endurance [17–19] or resistance [20] exercise
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bout. Post-exercise changes in c-miRNA levels also have been shown to differ between concen-
tric and eccentric endurance exercise modalities [21]. Thus, the capacity for miRNAs to re-
spond to the exercised and trained state, along with differential c-miRNA responses to exercise
of differing modality, renders c-miRNAs potential biomarkers of specific exercise responses.
We aimed to examine whether there are differences in c-miRNA profiles between males in-
volved in different long-term training regimes, and to determine whether c-miRNAs are specif-
ic markers of particular training modes. Such differences may form part of the basis for
differences in physiological adaptation between individuals using different training modes.
First, we investigated whether levels of candidate c-miRNAs differed between individuals at two
ends of the training specificity spectrum, elite endurance (END) and strength (STR) athletes,
and in comparison to age-matched, untrained controls (CON). In addition, since endurance
and strength athletes differ phenotypically to such an extent, we conducted secondary analysis
comparing c-miRNA levels in the two athlete groups alone. Finally, we investigated the associa-
tion between c-miRNA levels and quantitative physiological variables indicative of strength or
endurance training. We hypothesised that levels of the selected c-miRNAs, which have previ-
ously been shown to be exercise-responsive, would differ between the two athlete populations
and also that c-miRNA levels would associate with respective quantitative variables.
Materials and Methods
Ethics statement
Independent ethical approval was obtained from the Lithuanian Bioethics Committee and all
procedures were in accordance with the Declaration of Helsinki (2008). All participants gave
full written informed consent prior to study commencement.
Participant characteristics
Participant characteristics are summarised in Table 1. Participants were selected from a larger
cohort of male athletes and controls recruited to a genetic association study (GeLA cohort)
conducted at the Lithuanian Sports University and for whom plasma samples were available.
The study sample comprised strength athletes (STR; n = 10), endurance athletes (END; n = 10)
and age-matched non-exercising controls (CON; n = 10). Athlete participants were selected
from a larger pool after phenotyping for athletic performance. The 10 strength athletes with
the best performance across several strength / power tests (isokinetic peak torque of arms and
legs, handgrip strength and counter-movement jump height) were selected. For the endurance
subgroup, the 10 age-matched athletes with the largest relative maximal oxygen uptake (tread-
mill) were selected (for values see Table 1; for methods see S1 Methods). All athletes trained for
13 h per week on average, and competed regionally, nationally or internationally. Endurance
athletes were involved in sports such as distance running and orienteering (sports that mostly
require use of the legs), whereas strength athletes were involved in sports such as weightlifting
and combat sports (which require a more equal contribution of arm and leg muscles). Concen-
tric and eccentric exercise components were likely similar between training types. Control par-
ticipants were age-matched to the athlete groups but otherwise selected randomly from the
control group in the genetic association study, and did not compete in any competitive sport,
or partake in any organised physical activity on more than two occasions per week.
Sampling
Participants visited the laboratory in a fasted state and at least 12 h post-exercise. Venous
blood samples (10 mL) were collected from all study participants in EDTA vacutainers and
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centrifuged at 3000 rpm for 15 min at room temperature for plasma separation. Plasma was
immediately aliquoted into 1.5 mL microcentrifuge tubes for storage at -80°C pending
subsequent analysis.
On the other visits to the laboratories over the period of several days to 3 weeks, a large vari-
ety of phenotype measurements were collected. These measurements included anthropometric
characteristics, tests of handgrip strength, isokinetic dynamometry, pull-ups, vertical jumps, an
agility shuttle run, a 30 m sprint, a Wingate test, and a continuous ramp-up spiroergometric
treadmill test to exhaustion. Details of the testing procedures and protocols are provided in S1
Methods. Fat mass (FM) was calculated from the sum of 4 skinfold measurements (triceps, bi-
ceps, subscapular and suprailiac) using the body fat percentage calculation of Durnin &
Womersley [22]. Muscle mass (MM) was estimated using standardised height and skinfold-
corrected girth measurements of the forearm, calf and thigh within the equation of Martin
et al. [23].
RNA extraction and complementary DNA (cDNA) synthesis
All molecular and statistical analyses were conducted at the University of Stirling. RNA was ex-
tracted from plasma samples using the miRNeasy Mini Kit (Qiagen Ltd., West Sussex, UK) ac-
cording to the manufacturer’s instructions with a starting volume of 200 μL. From the resulting
RNA eluate, cDNA was synthesised using the miScript II RT Kit (Qiagen Ltd., West Sussex,
UK) according to the manufacturer’s instructions using 12 μl template RNA. cDNA reactions
were diluted from 20 μL to 250 μL with double-distilled water and loaded into deep well plates
for storage at -20°C until further analysis.
miRNA analysis
Commercially available quantitative polymerase chain reaction (qRT-PCR) primer assays
(Qiagen Ltd., West Sussex, UK) were used for miRNA analysis (target miRNAs: miR-1, miR-
20a-1, miR-21, miR-133a, miR-146a, miR-206, miR-221, miR-222, miR-499; control miRNAs:
Table 1. Participant characteristics by group.
CON STR END
n 10 10 10
Age (years) 24.0 ± 2.8 22.2 ± 2.1 22.6 ± 3.7
Body mass (kg) 79.3 ± 15.6 84.8 ± 10.2 70.6 ± 7.2 †
Muscle mass (MM; kg) 41.8 ± 7.4 50.7 ± 6.7 * 42.8 ± 4.3 †
Fat mass (FM; kg) 24.3 ± 9.6 19.7 ± 4.2 13.9 ± 1.2 *†
BMI (kgm-2) 24.4 ± 3.1 25.6 ± 2.6 22.2 ± 2.5 †
VO2 max (mLkg-1min-1) 43.5 ± 2.4 50.4 ± 6.5 * 66.9 ± 4.7 *†
VO2 max (mLkg-0.75min-1) 129.2 ± 7.0 152.8 ± 5.8* 189.1 ± 6.3 *†
Wingate fatigue index (Ws-1) 6.5 ± 1.2 6.1 ± 0.7 4.8 ± 1.5 *†
Isokinetic knee extension peak torque (Nm; 30°s-1) 507.4 ± 122.9 605.6 ± 121.5 459.3 ± 54.2 †
Isokinetic elbow extension peak torque (Nm; 30°s-1) 115.4 ± 22.3 152.6 ± 46.5 * 94.2 ± 12.9 *†
Handgrip strength (kg) 121.4 ± 11.9 148.2 ± 14.6 * 111.7 ± 14.3 *†
Counter-movement jump height (cm) 36.1 ± 5.8 42.6 ± 6.3 * 37.7 ± 5.5
All values are mean ± SD. With the exception of age, all measures are signiﬁcantly different by ANOVA (p < 0.05).
* signiﬁcantly different from CON by t-test;
† signiﬁcantly different from STR by t-test (p < 0.05). VO2 max (mLkg-0.75min-1) has been included for comparison to other studies.
doi:10.1371/journal.pone.0122107.t001
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miR-16-2, miR-93, miR-103a, miR-192, miR-451). The candidate c-miRNAs measured in the
present study were selected due to their observed upregulation at rest in response to endurance
rowing training [17], for their status as myomiRs [24] or because we initially believed them to
be suitable for use as control genes [25]. miRNA levels were measured in triplicate, using the
synthesised cDNA, with the miScript SYBR Green PCR kit (Qiagen Ltd., West Sussex, UK).
A standard curve (1 in 10 dilution series starting with a 1 in 10 dilution, using a pooled sample
consisting of cDNA from all participants in all three groups) was included on each plate to as-
sess whether all assays were in the linear range. The final 15 μL reaction volume comprised: 2x
SYBR Green mix (7.5 μL), 10x miScript universal primer (1.5 μL), 10x miScript primer assay
(1.5 μL) and cDNA dilution (4.5 μL).
Real-time quantitative polymerase chain reactions (qRT-PCR) were run on the Quantica
real-time thermal cycler system (Techne, Bibby Scientific Ltd., Staffordshire, UK). An initial ac-
tivation step (95°C; 15 min) preceded 40 cycles of denaturation (94°C; 15 s), annealing (55°C;
30 s) and elongation / extension (70°C; 30 s). Reactions were completed with a melting curve
for quality control to ensure that only a single amplicon was present in each reaction. All cycle
threshold (Ct) values were within the linear range of the standard curve. Ct outliers were re-
moved using the median absolute deviation method (also known as the modified Z-score; [26])
with the maximum acceptable threshold set at 3.5. Control samples (pooled cDNA from each
participant) were included on each plate to allow standardisation of the Ct values for experi-
ments that spanned several plates.
Five control assays were selected (see above for miRNA controls list) based on previous re-
ports showing expression stability within plasma [25]. Normfinder software [27] was used to
determine which single gene or group of genes was at the most stable level within the samples.
miR-93 alone was found to be most stable across the three groups and was therefore used to de-
termine the relative expression of the target genes, calculated using the 2-ΔΔCt method [28].
Consistent with miR-93 being the most stable miRNA between groups, data from other reports
indicate that the other 4 miRNAs may not have been good candidates for control genes due to
their association with other stimuli including cancer [29]. Thus, these 4 miRNAs were added to
the set analysed as candidate genes.
miRNA target prediction
Pathways targeted by our candidate miRNAs were predicted using the web-based tool, miR-
System [30]. miRSystem integrates several databases (Kegg, Biocarta, Pathway Interaction Da-
tabase, Reactome and GO molecular function) to enable prediction of gene targets and
targeted pathways.
Statistical analysis
Power calculations. Power calculations for the study design were conducted using
GPower3 [31] based on means and standard deviations of relative c-miRNA levels reported
by Baggish et al. [17]. Power calculations were also performed on a number of physiological
measures from the current study to ensure sample sizes were adequate for detecting between-
group differences in these physiological variables. An n of 10 offered 80% power to detect be-
tween-group differences in mean miRNA levels of 0.60 SDs by ANOVA, α = 0.05. The smallest
significant between-group difference reported by Baggish et al. [17] was 1.33 SDs. In all analy-
ses described below, we have adopted the principle that because there is prior evidence for asso-
ciations between levels of the c-miRNAs tested and performance-related phenotypes, an α of
p = 0.05 is appropriate for each test.
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c-miRNA analysis by participant group. Statistical analysis was conducted using Minitab
software (version 16; Minitab, State College, PA). Box-Cox transformations were applied to
non-normally distributed data and normal distributions were confirmed using the Ryan-Joiner
test. All statistical tests were conducted on normally distributed data. Between-group differ-
ences in miRNA levels for STR, CON and END subgroups were determined by one-way
ANOVA. In the case of statistical significance by ANOVA, Tukey’s post-hoc tests were imple-
mented. Direct comparisons of miRNA levels between the two athlete groups only were con-
ducted by means of Student’s t-tests.
Association of c-miRNA expression with performance-related phenotypes. Regression
analyses (GLM) were conducted between c-miRNA levels and quantitative phenotypes related
to strength or endurance exercise. Following initial regression analyses between levels of each
candidate c-miRNA and each phenotypic measure, we ran models incorporating group (i.e.
STR, CON, END) and tissue mass (fat mass (FM) and muscle mass (MM)) as predictive vari-
ables. Adjusting for tissue mass is important as some c-miRNA levels are correlated with tissue
mass measures, and cellular miRNA pools in muscle and adipose tissue could be influencing
circulating levels; this potentially confounding factor therefore needs to be accounted for. Ad-
justing for group further accounts for unmeasured intrinsic differences between the different
types of athletes that could also be confounding uncorrected associations. All values are ex-
pressed as mean ± standard error of the mean (SEM) unless stated otherwise.
Results
c-miRNA analysis by group
Circulating levels of 14 miRNAs were measured in the athlete and control groups. Table 2
shows mean relative levels for each group for each of the test miRNAs, standardised to the ref-
erence gene (miR-93) and to levels in the control (CON) group. One-way ANOVA revealed a
statistically significant difference (p = 0.028; Fig 1A) in miR-222 levels between the three
Table 2. Levels of all measured c-miRNAs.
c-miRNA CON STR END ANOVA p value
Mean 95% CI SEM Mean 95% CI SEM Mean 95% CI SEM
miR-1 1 0.32–3.11 0.65–2.08 0.84 0.42–1.67 0.63–1.26 1.17 0.33–4.18 0.74–2.71 0.910
miR-16-2 1 0.51–1.96 0.75–1.49 1.3 0.55–3.07 0.92–2.20 0.76 0.30–1.93 0.53–1.36 0.675
miR-20a-1 1 0.44–2.27 0.71–1.65 1.03 0.43–2.42 0.72–1.74 0.62 0.25–1.50 0.43–1.07 0.657
miR-21 1 0.73–1.37 0.86–1.19 0.77 0.61–0.96 0.69–0.87 1.20 † 0.96–1.48 1.08–1.34 0.074
miR-103a 1 0.74–1.35 0.87–1.18 0.8 0.62–1.03 0.71–0.92 1.14 0.82–1.59 0.98–1.37 0.251
miR-133a UD - - UD - - UD - - -
miR-146a 1 0.76–1.32 0.88–1.16 0.75 0.57–0.97 0.66–0.86 1.12 † 0.95–1.32 1.03–1.22 0.069
miR-192 1 0.65–1.53 0.82–1.27 1.15 0.65–2.03 0.89–1.60 0.88 0.38–2.05 0.62–1.48 0.845
miR-206 1 0.11–9.18 0.55–5.17 1.54 0.48–4.95 1.00–3.28 0.28 0.05–1.52 0.16–0.91 0.392
miR-221 1 0.71–1.41 0.85–1.21 0.9 0.71–1.14 0.80–1.02 1.36 † 1.08–1.71 1.22–1.54 0.119
miR-222 1 0.73–1.37 0.86–1.19 0.66 0.44–1.00 0.55–0.83 1.29 † 1.03–1.62 1.16–1.46 0.028 *
miR-451 1 0.57–1.74 0.78–1.38 1.34 0.77–2.33 1.05–1.85 0.70 0.38–1.29 0.54–1.00 0.307
miR-499 1 0.47–2.13 0.73–1.58 0.53 0.25–1.11 0.39–0.83 0.47 0.13–1.68 0.30–1.09 0.485
Mean values are expressed relative to CON and all measurements have been standardised relative to levels of miR-93 as a control. UD = Undetectable.
* signiﬁcantly different between the three groups (One way ANOVA; p < 0.05);
† signiﬁcantly different from STR by t-test (p < 0.05).
doi:10.1371/journal.pone.0122107.t002
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groups, with levels nominally being higher than CON in the endurance (END) group and
lower than CON in the strength (STR) group. The post-hoc Tukey’s test revealed a significant
difference between STR and END (p = 0.011).
Plasma levels of all other c-miRNAs were not significantly different between groups by
ANOVA (p> 0.05; Table 2). However, as we expected to find differences between elite athletes
undergoing very different training regimes, we also conducted t-tests comparing the athlete
groups only. This secondary analysis revealed higher plasma levels of three other miRNAs in
END than in STR: miR-21 (p = 0.013), miR-146a (p = 0.019) and miR-221 (p = 0.026) (Fig 1B–
1D), with CON intermediate in mean level, as found for miR-222.
Association of c-miRNA expression with performance-related
phenotypes
The differences in circulating levels of a subset of the miRNAs tested could reflect a response of
various aspects of cellular physiology to different training regimes. Thus, we investigated
whether levels of the four miRNAs showing differences between the athlete groups were corre-
lated with values for performance in a range of tests that are indicative of the physiological ad-
aptation to different training regimes. We investigated these correlations with and without
adjustment for athlete group and anthropometric measures (FM and MM) in the regression
models. These corrections enabled us to account for inherent training / phenotypic differences
between the groups and to control for differences in body composition between groups. Differ-
ences in muscle bulk or fat reserves may influence levels of c-miRNAs either via rates of pro-
duction or via rates of uptake by these tissues, both of which have an important influence on
capacity for, or the adaptation to, exercise. The characteristics of participants in each group for
these measures are summarised in S1 Table and results of the regression models are summa-
rised in S2–S5 Tables.
Fig 1. Relative expression levels of miR-222 (A), -21 (B), -146a (C), and -221 (D) in STR, CON and END.
Box plots depict the range (upper and lower whiskers), median (centre line) and interquartile range (edge of
boxes). * significantly different between all groups (One way ANOVA; p < 0.05); † significantly different from
STR (t-test; p < 0.05).
doi:10.1371/journal.pone.0122107.g001
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Plasma miR-222 levels (S2 Table) were positively correlated with height, body mass, muscle
mass and fat mass after adjustment for group (p< 0.05). Also, plasma miR-222 levels were
positively correlated with a strength-related performance measure, isokinetic leg flexion peak
torque at various contraction velocities, after adjustment for group (p = 0.018 to 0.043), but not
in the basic model, nor after adjustment for MM or FM. None of the other performance mea-
sures were correlated with levels of this c-miRNA.
Plasma miR-21 levels (S3 Table) were not associated with anthropometric parameters, but
were negatively correlated with a subset of strength / power and endurance-related measures in
some models. These strength-related associations were true for handgrip strength in the unad-
justed model (p = 0.039) and for some velocities of isokinetic leg and arm extension peak tor-
que in the unadjusted and MM-adjusted models (p ranges from 0.015 to 0.044). A similar
negative correlation was seen with an anaerobic endurance parameter, the Wingate fatigue
index, in the unadjusted and MM-adjusted models (p< 0.045).
Plasma miR-146a levels (S4 Table) were positively correlated with height in the group-ad-
justed (p = 0.023), MM-adjusted (p< 0.001) and FM-adjusted (p = 0.016) models and nega-
tively correlated with BMI in the MM-adjusted (p = 0.010) and FM-adjusted (p = 0.005)
models. Levels of miR-146a were not associated with endurance- or power-related measure-
ments, but were negatively correlated with a subset of strength-related measures in some mod-
els. These strength-related associations were true for handgrip strength in the unadjusted, and
both MM- and FM-adjusted, models (p< 0.027), and for most measures of isokinetic arm flex-
ion and extension peak torque in the unadjusted, and both MM- and FM-adjusted, models (p
ranges from 0.002 to 0.045). No significant associations (other than for height) were observed
following adjustment for group.
Plasma miR-221 levels (S5 Table) were positively associated with height after MM- or
FM-adjustment (p < 0.038) and negatively correlated with BMI after adjustment for MM
(p = 0.016). Levels of this c-miRNA were not associated with endurance- or power-related
measurements, but were negatively associated with some strength-related measures. These
strength-related negative associations included handgrip strength in the unadjusted and
FM-adjusted models (p < 0.024) and particularly in the MM-adjusted model (p = 0.001).
Moreover, most measures of isokinetic arm flexion and extension peak torque in the MM-
adjusted models (p ranges from 0.008 to 0.046) also were negatively associated with plasma
miR-221 levels. Again, no significant associations were observed following adjustment
for group.
It should be noted that a number of myomiRs (miR-1, -133a, -206, -499) were assessed in
the present investigation; however, they are found at very low levels in the circulation, which
affected measurement consistency in our analysis. Such measurement inconsistencies also have
been noted in some reports [18,32] in the context of c-miRNAs and we would recommend a
pre-amplification step when investigating these miRNAs in future.
Predicted miRNA targets
Given the differences between the athlete groups in a subset of the miRNAs tested (miR-21,
miR-146a, miR-221 and miR-222) and the association between levels of these c-miRNAs and a
subset of performance parameters, we conducted an analysis to ascertain whether common
mRNA targets were shared to a significant extent by these c-miRNAs. Predictions using miR-
System indicated that these four miRNAs, when added into the model simultaneously, target
mRNAs contained in a total of 736 pathways across all integrated databases (data not shown).
The top 8 pathways targeted by all four miRNAs together (arbitrarily selected based on a
score> 3.0) are shown in Table 3.
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Discussion
We report a significant difference in circulating miR-222 levels between male endurance ath-
letes, strength athletes and age-matched untrained controls. Moreover, in endurance athletes,
plasma levels of miR-21, miR-146a and miR-221, as well as miR-222, were significantly higher
than in strength athletes. Levels of these c-miRNAs were significantly associated with perfor-
mance parameters indicative of training mode, such as isokinetic peak torque and VO2max,
particularly in tissue-corrected models. To the best of our knowledge this study is the first to
investigate levels of c-miRNAs in distinct athlete groups and in comparison to untrained con-
trols in a single study, and also is the first to offer a comprehensive range of quantitative pheno-
typic variables for comparative assessment in the same individuals.
Data from previous investigations of the candidate c-miRNAs and their direction of change
in association with exercise adaptation have been somewhat inconsistent. Moreover, the poten-
tial for differential regulation by endurance and resistance exercise has not previously been ad-
dressed in a single study. In response to both an acute, single-bout endurance exercise test and
a 12 wk period of longitudinal endurance exercise training, Baggish et al. [17] reported an in-
crease of the same four c-miRNAs found to be higher in endurance athletes here (miR-21,
-146a, -221 and -222). In another study, plasma miR-146a and -221 levels were reduced 3 days
after performing an acute bout of resistance exercise [20], consistent with our findings in
strength trained athletes, although longitudinal data to relate acute effects to sustained training
responses are lacking. These data suggest that levels of particular c-miRNAs may change in op-
posite directions following endurance vs. resistance exercise. However, other studies have re-
ported conflicting results. Some studies report no change in circulating levels of miR-21 and
-222 following acute resistance exercise [20]; others report lower circulating levels of miR-21,
and -222 in individuals with high (151.2 mLkg-0.75min-1) compared to low (104.2 mLkg-
0.75min-1) VO2max [33]; or a reduction in miR-21 in previously trained males after 12 wk of
further endurance exercise training [18]. However, our endurance athletes have an even higher
VO2max (see Table 1) and may not be directly comparable to these aforementioned studies.
These contrasting findings may suggest an increased responsiveness of these c-miRNAs to un-
controlled environmental influences and consideration should be given to subtle differences in
subgroup selection, study design and participant physiology.
Athletes training and competing in diverse exercise modes display clear phenotypic differ-
ences. Endurance athletes are typically lighter, leaner, have higher cardiorespiratory fitness,
Table 3. miRSystem pathway analysis.
Database Pathway Total union targets (of total genes in the pathway) Score
Pathway interaction database Direct p53 effectors 31 (of 137) 4.430
Pathway interaction database PDGFR-β signalling 26 (of 126) 3.862
Pathway interaction database c-myb transcription factor network 17 (of 81) 3.511
Go molecular function (Tier 2) Protein binding transcription factor activity 45 (of 369) 3.445
Kegg TGF-β signalling 17 (of 84) 3.347
Kegg Pathways in cancer 43 (of 325) 3.310
Kegg MAPK signalling 36 (of 272) 3.167
Pathway interaction database SHP2 signalling 14 (of 54) 3.143
Union targets refers to genes targeted by all 4 miRNAs; score is deduced from the sum of the weight of its miRNA multiplied by its enrichment, minus the
log (p value) from the predicted gene targets. The weight for one miRNA is calculated by dividing its absolute expression value by the absolute sum of the
expression values for all input miRNAs [30].
doi:10.1371/journal.pone.0122107.t003
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and are less strong and less powerful than their resistance-trained counterparts. These differ-
ences are underlain by genetic predisposition and training mode, and these influences combine
and interact in complicated ways, being mediated largely through epigenetic regulation. By in-
vestigating associations between levels of our differentially regulated c-miRNAs and quantita-
tive phenotypic variables we can better understand this epigenetic regulation of phenotype. A
strength of our study was that we took the important additional step of adjusting for the type
of athlete / training mode in our statistical analyses, which has been done only rarely in previ-
ous studies. We found that correcting for group had the clearest influence on associations be-
tween levels of our candidate c-miRNAs and physiological characteristics. This finding may
indicate that the unmeasured intrinsic differences (or other unmeasured environmental differ-
ences, such as subtle differences in diet) between different kinds of athlete, or athletes on differ-
ent training regimes, have a role in driving the uncorrected associations and justify the
adjustment for group. Furthermore, we also adjusted for two measures of tissue mass, which,
again, has been done only rarely in previous studies. It can be hypothesised that tissue mass
may correlate with the pool size of c-miRNAs available for endocytosis / exocytosis. However,
the fact that we observed associations in the models corrected for tissue mass suggests that be-
tween-group differences in c-miRNA levels are likely unrelated to tissue mass, and hence does
not provide support for the ‘pool’ hypothesis. At this stage it is possible only to speculate about
alternative explanations, but possible factors explaining the between-group differences include
training characteristics, innate contractile properties of the muscle, and habitual dietary differ-
ences. Further work is required to better define the relationship between changes in c-miRNA
levels and performance / health-related phenotypes.
Aerobic capacity is a hallmark of the endurance trained state. In the present study, the en-
durance-trained cohort had significantly greater relative VO2max than the strength-trained co-
hort. However, VO2max was not significantly associated with levels of any of the candidate
miRNAs, in either the uncorrected or group- / tissue mass-corrected models. We did note that
miR-21 was significantly inversely associated with Wingate fatigue index, a measure derived
from the Wingate test of anaerobic endurance capacity [34], in the uncorrected (r = -0.39) and
muscle mass-corrected (r = -0.38) models, but the other mi-RNAs showed no association with
this measure. Thus, with the potential exception of miR-21, differences in c-miRNA levels be-
tween groups are not involved in differences in aerobic or anaerobic endurance capacity be-
tween, or within, groups. This conclusion is therefore consistent with findings from Bye et al.
[33] who reported a lack of association between VO2max and miR-222 and only a weak associ-
ation (r = -0.20) between endurance capacity (VO2max) and miR-21.
Strength and power phenotypes are characteristic of resistance-trained individuals. Thus,
whether markers of strength and / or power performance (which were significantly higher in
our strength-trained cohort compared to the endurance-trained athletes) were significantly as-
sociated with c-miRNA levels in uncorrected and group- / tissue mass-corrected models was
investigated. In the uncorrected model, total handgrip strength was significantly negatively as-
sociated with circulating levels of miR-21, -146a and -221. We had expected these associations
to exist in the absence of any corrections because of the selection criteria we applied for inclu-
sion in each group. However, upon correction for group, these associations are no longer ap-
parent; suggesting that the variation in c-miRNA levels within groups does not associate with
the variation in total handgrip strength within groups. In this regard, candidate c-miRNA lev-
els do not associate with strength per se; rather c-miRNA levels must associate with other be-
tween-group differences that are explanatory for the variation. Differences in fat mass may
explain some of the variation in plasma miR-21 levels with regards to strength phenotypes, but
neither fat mass nor muscle mass explains the variation in levels of any other c-miRNA. In fact,
correction for group appears to be the only correction factor that alters the associations relative
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to the uncorrected model for all differentially regulated c-miRNAs. For miR-21, -146a and-
221, negative associations with several markers of strength, most notably isokinetic peak torque
at various contraction velocities, are apparent in the uncorrected and / or muscle mass-
corrected models. For miR-21 and -221 in particular, it is likely that individuals with lower lev-
els of these c-miRNAs are stronger per unit of muscle mass (i.e. possess greater specific force).
The only c-miRNA to differ significantly between all groups (including controls), miR-222, is
not significantly associated with any parameter in the uncorrected or tissue mass-corrected
models. With group accounted for, miR-222 significantly associates with some anthropometric
and strength measures. However, the association between miR-222 and isokinetic peak torque
at faster flexion velocities is actually positive in nature. This direction of association is in con-
trast to previously reported associations and to what we would expect from the case-control
analysis. These findings suggest that, rather than training mode, other between-group factors;
for example, dietary habits, physical size and skeletal muscle fibre type differences, may be hav-
ing a greater effect on miR-222 level. Although the lack of clear associations between miR-222
and performance phenotypes is disappointing following the results from the case-control anal-
yses, this disconnect highlights the value of including quantitative phenotype measures in
study designs. Since miRNAs have inhibitory actions on gene expression, the lower levels of
candidate c-miRNAs observed in our strength cohort would suggest removal of suppression of
gene expression. Considering the miRSystem pathway analysis demonstrated that the associat-
ed set of miRNAs target genes were involved in skeletal muscle remodelling, our conclusion
would be that remodelling processes governed by the products of these genes may be involved
in strength training-related muscle adaptation.
Although no tissue was collected for gene expression analysis of our c-miRNA targets, bio-
informatic analyses with miRSystem [30] at least allows us to predict the mRNA targets of the
candidate miRNAs investigated in our study and consider whether these are consistent with
the observed phenotypic differences between groups. Predicted pathways targeted by our dif-
ferentially regulated miRNAs included signalling pathways involved in cell growth and inflam-
mation. Specifically, platelet-derived growth factor receptor (PDGF-R), transforming growth
factor beta (TGF-β) and mitogen-activated protein kinase (MAPK) signalling pathways as well
as transcription factor networks (c-Myb transcription factor network, protein binding tran-
scription factor activity) were identified. PDGF-R signalling has been implicated in blood vessel
growth via recruitment of vascular smooth muscle cells [35] and appears to be regulated by
miR-146a in particular [36]. TGF-β also is involved in cell growth and control of inflammation
[37] while MAPK signalling occurs in several tissues and is implicated in many diverse physio-
logical processes including gene expression regulation and cell differentiation [38]. In the con-
text of exercise training, well-known adaptations include enhanced angiogenesis leading to a
greater microvascular volume [39], anti-inflammatory responses leading to a more optimal
hormonal environment [16] and enhanced skeletal muscle cell differentiation and proliferation
[40]. Thus, it is logical that these pathways may be involved in the training response although
exact mechanisms of action cannot be determined from this analysis.
Despite the limited influence of correction for muscle mass or fat mass within our models,
given that c-miRNAs must be released by a tissue and ultimately act on mRNAs within a tissue,
it is important to consider how c-miRNAs relate to tissue mass. Within an exercise context, an
obvious source of non-specific miRNA release into plasma is from muscle-damaging exercise.
Banzet et al. [21] revealed enhanced levels of muscle-specific c-miRNAs (myomiRs; miR-1,
-133a, -133b and -208) following a bout of eccentric exercise, compared to pre-exercise levels
(with no change observed following concentric endurance exercise). This led the authors to
conclude that changes in c-miRNA levels were driven by the damaging nature of eccentric ex-
ercise and muscle leakage in the post-exercise period (up to 6 h). However, markers of muscle
PlasmaMiRNA Levels and Training Mode
PLOSONE | DOI:10.1371/journal.pone.0122107 April 16, 2015 11 / 15
damage were not different between groups in that study, not all muscle miRNAs are present in
the circulation and the direction of change of c-miRNA levels is not always consistent with
non-specific release from tissue (i.e. increased levels in the circulation) [21,41]. Furthermore,
recent reports [18,19] suggest limited associations between c-miRNA levels and muscle dam-
age, or a failure to detect muscle-specific miRNAs following exhaustive exercise. Therefore, we
believe it is unlikely that muscle leakage is the primary cause of changes in c-miRNA levels, al-
though more work is required to confirm this belief, and to better understand other aspects of
c-miRNA regulation in general.
In summary, a subset of c-miRNAs (miR-21, -146a, -221 and -222) are associated with train-
ing-related performance parameters in a manner consistent with them being involved in the
whole-body adaptive response to differential forms of exercise training. Thus, these c-miRNAs
may be useful biomarkers of exercise training and / or have potential roles in exercise mode-
specific training adaptations. However, their levels in the circulation appear to be unrelated to
having more muscle bulk or larger fat reserves (with the exception of the miR-21 relationship
with differences in fat mass), and thus it is unlikely that they are limited by the amount of tissue
available for the release / uptake of c-miRNAs. Nonetheless, whether the presence of c-miRNAs
in the circulatory system is regulated primarily by tissue exocytosis or endocytosis still remains
of interest and further research is warranted to investigate the relationship between observed
differences in c-miRNA levels and target gene expression in relevant tissues within the context
of exercise training.
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Commentaries on Viewpoint: What is the relationship between acute measure
of muscle protein synthesis and changes in muscle mass?
COMMENTARY RESPONSE TO VIEWPOINT: “WHAT IS THE
RELATIONSHIP BETWEEN ACUTE MEASURES OF MUSCLE
PROTEIN SYNTHESIS AND CHANGES IN MUSCLE MASS?”
TO THE EDITOR: Mitchell et al. (3) critique putative links between
acute muscle protein synthesis (MPS) and ensuing hypertrophy
after resistance exercise (RE) training (RT). Just two papers
have addressed this longitudinally. The first reports that young
but not older individuals exhibit acute (fasted mixed muscle
MPS, 24 h post-RE) increases in MPS (2); yet hypertrophy
gains, assessed by DXA and fiber area, were equal. Similarly,
poor quantitative MPS linkages were reported 1–6 h post-RE
(myofibrillar muscle, fed state) with ensuing hypertrophy (4),
i.e., two study’s suggesting bona fide dissociation. However,
for (2), prior reports of age-related temporal differences in
acute MPS responses to RE (1) and lack of intra/inter age
group correlations (2) mitigate such resounding conclusions.
Also, in (4), RE was under fed state conditions; this is signif-
icant because consumption of protein feeds extends (not am-
plifies) elevations in MPS post-RE (5). Therefore, MPS re-
sponses 1–6 h post-RE were chiefly predominated by feeding,
i.e., the coupling of which to RE may not aptly reflect inter-
individual variation (5), e.g., due to isolated mechano-auto/
paracrine responses to RE. Yet, acute MPS can/does inform on
group interventions for RT-induced muscle hypertrophy, sig-
nifying it a practicable, informative end-point. But, could
quantitative relationships still exist and what defines “acute”
post-RE MPS? Fasted/fed? Immediately (!6 h?)/later ("24?)
What muscle fraction(s)? Is there an applicable “snapshot”?
Without defining acute this is indiscernible. The authors justi-
fiably raise potential technical, temporal, methodological con-
founder(s). Because hypertrophy is a heterogeneous and tem-
porally dynamic process we hypothesize that (coupled to not
isolating/fractionating/holistically capturing “acute” MPS) in-
terindividual trajectories and plateauing hypertrophy in the
face of fixed study end-points are the major barriers to defining
quantitative links between acute MPS and RT-induced hyper-
trophy.
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COMMENT VIEWPOINT: “WHAT IS THE RELATIONSHIP
BETWEEN ACUTE MEASURES OF MUSCLE PROTEIN
SYNTHESIS AND CHANGES IN MUSCLE MASS?”
TO THE EDITOR: Mitchell et al. (4) state that acute measure-
ments of muscle protein synthesis may not necessarily
reflect the magnitude of hypertrophy during long-term train-
ing studies, which we agree with. Two points deserve
further comment: 1) magnitude of muscle protein synthesis
does not necessarily equate with hypertrophy, but rather
remodeling, and 2) limitations of acute measurements are a
primary reason some in the field advocate for long-term
measurements of synthesis. Regarding the first point, as the
authors mention, synthesis is more commonly measured
than breakdown and is likely the driving factor behind
phenotypic change. However, it is still important to consider
that breakdown can change the outcomes. If a high rate of
synthesis is accompanied by equal or slightly lower rates of
degradation, one would have hypertrophy, whereas the other
may not. Importantly though, both are indicative of remod-
eling. This concept is clear when one studies endurance
exercise where there is a high degree of protein remodeling,
and phenotypic change, without hypertrophy (5). Regarding
our second point, we have advocated for the use of deute-
rium oxide to measure long-term changes in protein synthe-
sis (1, 3) because of the limitations of acute protein synthe-
sis measurements (4). We have even emphasized this point
in a previous “Viewpoint” (2). Although acute measure-
ments of protein synthesis have value, the overall outcome
of a long-term treatment or intervention should be assessed
by long-term measurement techniques to understand the
integrated responses over time. We hope that others, like
Mitchell et al., continue to recognize this important point.
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THE POSTEXERCISE INCREASE IN MUSCLE PROTEIN
SYNTHESIS RATE IS INDICATIVE OF SKELETAL MUSCLE
RECONDITIONING RATHER THAN MUSCLE HYPERTROPHY
PER SE
TO THE EDITOR: We regard the acute muscle protein synthetic
response to exercise as an indicator of skeletal muscle
reconditioning rather than predictive for muscle hypertro-
phy. For example, a single bout of endurance-type exercise
also acutely increases muscle protein fractional synthetic
rate (FSR) (1–3). The increase in the muscle protein syn-
thetic response to endurance type exercise is generally not
accompanied by substantial gains in muscle mass and, as
such, is far from predictive for muscle hypertrophy in
healthy, lean individuals. Instead, the postexercise increase
in muscle protein synthesis is rather representative of mus-
cle reconditioning, comprising muscle repair and remodel-
ing. Consequently, the postexercise increase in muscle pro-
tein FSR should not be regarded as a marker for exercise
training induced hypertrophy but rather as an indicator of
skeletal muscle reconditioning, which comes in many dif-
ferent forms and measures. The muscle protein synthetic
response to a single bout of resistance type exercise training
may provide some insight in the extent of muscle hypertro-
phy observed during more prolonged resistance type exer-
cise training but does not provide a quantitative estimation
of hypertrophy in the individual (4).
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COMMENT ON VIEWPOINT: WHAT IS THE RELATIONSHIP
BETWEEN ACUTE MEASURES OF MUSCLE PROTEIN
SYNTHESIS AND CHANGES IN MUSCLE MASS?
TO THE EDITOR: Mitchell and colleagues (2) present a nicely
balanced viewpoint regarding the discordance between acute
measurements of muscle protein synthesis (MPS) and long-
term muscle mass gains in response to exercise training and
nutrition. Individual genetic and other physiological character-
istics, as well as methodological limitations of the endpoint
measures, are correctly identified as contributing factors to the
hypertrophic variability inherent in these types of training
studies (1). However, the practicalities of controlling long-term
training studies themselves are not addressed.
Consideration is warranted for the difficulties in control-
ling extended-duration intervention studies to generate ap-
propriately valid and reliable results. Changes and variabil-
ity in diet, timing of exercise in relation to meal ingestion,
sleep patterns, daily stress, and compliance with the training
regimen will contribute to the considerable intrinsic vari-
ability of measured changes in muscle mass (3). Small
differences between interventions may easily be missed
when these confounding factors are coupled with the vari-
ations outlined in the Viewpoint. Acute measurements are
much easier to control and differences between interven-
tions often can be easily detected. Therefore, any disconnect
between acute metabolic studies and long-term changes in
muscle mass do not necessarily reflect the worth of the
metabolic studies.
There is no question that acute measurements of MPS alone
should not be used to predict the training response of any given
individual. However, with appropriate appreciation for their
limitations, these methods can play a valuable role in acquiring
information to help determine appropriate training and nutri-
tion interventions for various populations.
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COMMENTARY RESPONSE TO VIEWPOINT: “WHAT IS THE
RELATIONSHIP BETWEEN ACUTE MEASURES OF MUSCLE
PROTEIN SYNTHESIS AND CHANGES IN MUSCLE MASS?”
TO THE EDITOR: The authors raise several insightful points while
describing the discordance they observe between acute mea-
sures of postexercise muscle protein synthesis (MPS) and the
subsequent resistance exercise (RE) training-induced muscle
hypertrophy (1, 2). Although the authors suggest that intersub-
ject variability in the MPS response to RE is a likely major
contributory factor, the impact of recruiting individuals naive
to the mode of RE employed cannot be overstated. Moderate
(60–75% of 1-repetition maximum) noneccentric RE in unac-
customed individuals has been shown to result in myofibrillar
damage, increased inflammatory signaling (5), and induction of
the unfolded protein response (4), events that are thought to
modulate MPS drive. Moreover, we have observed that 24 h
after a single-bout of unaccustomed concentric RE, the tran-
scriptional “program” elicited in muscle appears dependent on
whether damage has purportedly occurred and varies between
individuals (3). Specifically, we observed a discord in the
transcriptional regulation of gene pathways associated with
MPS signaling, which could in part explain the variability
observed by the authors. In contrast, the transcriptional re-
sponse to a repeat session of RE performed days later was
consistent across volunteers and was not punctuated by in-
creased markers of muscle damage (3). Collectively, these
observations suggest that, when attempting to translate acute,
exercise-induced changes in MPS to longer term gains in
muscle mass, using subjects who have already undergone a
period of familiarization to laboratory RE protocols may offer
a more promising approach.
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NEED FOR MEASURES OF SATELLITE CELL ACTIVATION
ALONG WITH MUSCLE PROTEIN SYNTHESIS?
TO THE EDITOR: The Viewpoint by Mitchell and colleagues (4)
provides a timely reminder that acute responses to exercise-
nutrient interventions are not always the perfect proxy for
chronic training-induced adaptations and/or changes in func-
tional outcomes. Skeletal muscle displays remarkable plasticity
with the capacity to alter the type and amount of protein in
response to habitual level of contractile activity, the prevailing
substrate availability, and environmental conditions (3). Such
“adaptation plasticity” is common to all vertebrates but a large
variation in the degree of adaptability between humans is
evident, explaining the large inter-individual responses after
exercise-nutrient interventions (2). The author’s state that an
individual’s “inherited genetic predisposition, epigenetic influ-
ence, and transcriptional plasticity” are potential sources for
“hypertrophic variability” after resistance training (RT). Added
to that list is the possibility that satellite cell activation may
underlie part of the variability in the muscle hypertrophic
response. Previous work shows the acute satellite cell response
to a single bout of resistance exercise is associated with the
subsequent accretion of lean mass (LM) after 16 wk RT (1).
Although this suggests postexercise measures of satellite cell
activity could be a valid surrogate of an individual’s ability to
accrue LM after RT, acute measures of MPS still provide
important mechanistic insight to the “anabolic” events in re-
sponse to exercise-nutrient interventions. Ultimately it is clear
that chronic training studies with comprehensive time-course
responses of selected cellular and functional outcomes are
required to provide mechanistic insight as to why training-
nutrient interventions result in variable responses between
individuals.
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ARE NOT INTRACELLULAR HEAT AND NEURAL
ELECTRICITY STRESSES THE CAUSE OF EXERCISE-INDUCED
PROTEIN SYNTHESIS?
TO THE EDITOR: Dr. Mitchell and colleagues (5) support their
thesis for a possible lack of correlation between acute and
chronic muscle protein synthesis (MPS) partly with their Refs.
14, 15, and 16. The conclusion for such a lack is drawn in all
of these three references. However, while in Refs. 15 and 16
the quadriceps hypertrophy after 10 or 16 wk of resistance
training (RT) was between 5 and 9.5% the same in Ref. 14 after
16 wk RT was 37–40%. In our view, the difference was
because in Ref. 14 the load was progressively increased during
the RT, while in Refs. 15 and 16 it was not. Qualitatively, it is
the same difference as between MPS response after acute and
chronic RT.
Myocytes are extremely vulnerable to overheating, because
they can increase energy production more than 100-fold in less
than a second. They do not have intracellular convective heat
transfer because almost 80% of their water is entrapped in the
myofibrils. The anaerobic nature of RT increases with the
increase of loading because more energy is released during
contraction, when muscle capillaries are compressed, prevent-
ing blood flow and cooling. Elevated myocyte temperature
prevents protein synthesis, causes protein denaturation, and
stimulates heat shock protein synthesis, which during postex-
ercise repair in excess damaged protein (3, 4). This reasoning
is supported by the similar effect produced by the blood flow
restriction (2). Stimulation of protein synthesis by electric field
(1) hints that excessive muscle neural electricity, triggered by
unaccustomed loading, should have supportive MPS effect.
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TO THE EDITOR: Mitchell and colleagues have identified an impor-
tant problem: can a single measurement of protein synthesis be
extrapolated to provide changes in muscle mass(1)? Muscle mass
is often used as a surrogate for muscle protein content, but
although muscle weight reflects muscle mass, muscle weight
includes muscle proteins, adipose tissue (especially, in aged or
type II diabetes), and up to 70% water (3). For example loss of
muscle mass in exercise reflects loss of water with or without loss
of muscle protein. As suggested by Mitchell, although an increase
in protein synthesis suggests increased muscle protein mass, no
conclusion is possible without measurement of protein degrada-
tion. Infusion of L-(1–13C) leucine or L-(ring-2H5) phenylalanine
has been used to measure whole body or skeletal muscle protein
metabolism in humans (2). In animal models, rates of protein
synthesis and degradation are often assayed ex vivo by measuring
the rate of tyrosine incorporation into protein (protein synthesis)
plus the release of tyrosine from muscle proteins (protein degra-
dation) (4). This approach, however, does not allow both synthesis
and degradation information to be gathered from the same animal.
The rate of protein degradation is virtually always greater than the
rate of protein synthesis regardless of whether undergoing muscle
hypertrophy or atrophy. If the goal of measuring protein synthesis
is to provide an index of changes in muscle protein mass, we
suggest that investigators assess the distribution of the areas of
myofibers in a cross section of muscle as described for assessing
the effects of XIAP on muscle hypertrophy (5).
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SIGNIFICANCE OF LONG-TERM STUDIES IN RESISTANCE
TRAINING AND MUSCLE HYPERTROPHY
TO THE EDITOR: Muscle being a postmitotic tissue is endowed with
an efficient means of cell replacement to avoid muscle cell death
and maintain skeletal mass. This is carried out through the dy-
namic balance between muscle protein synthesis and degradation
(1). Muscle hypertrophy occurs when protein synthesis exceeds
protein breakdown. Although the Viewpoint authors (2) agree
with the importance of acute measurements in understanding
mechanisms of divergent exercises and nutritional manipulations,
they advocate the need for long-term studies to understand the
holistic adaptations due to altered phenotype.
Muscle hypertrophy is a multifactorial process involving me-
chanical tension, muscle damage, and metabolic stress. In addi-
tion, many have observed numerous other factors, such as genetic
predisposition, epigenetic influence, and transcriptional plasticity,
age, gender, habitual physical activity, and training status, to
influence the hypertrophic response to a training protocol affect-
ing both the rate and the total gain in lean muscle mass. Hormones
and cytokines, namely growth hormone, testosterone, interleu-
kin-5, interleukin-6, etc., are also shown to play complex roles in
hypertrophic process (3). Additionally, some of these hormones
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have effects on immune system, bone remodeling, and extracel-
lular fluid volume. A 20-wk-long RT revealed greater adaptability
within endocrine system only in younger men (4). A discrepancy
in immune responses to short-term and moderate exercise training
is reported recently (5). Exercise-induced free norepinephrine
concentration was reported to have effect on circulating hemato-
poietic stem and progenitor cell number and functionality (3). In
the light of such varied complexities, it is appropriate to pursue
long-term effects of exercise training on muscle hypertrophy.
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The maintenance of skeletal muscle
mass is dependent upon the temporal
and coordinated interaction between
muscle/myofibrillar protein synthesis
(MPS) and muscle protein breakdown
(MPB). Resistance exercise (RE) alone
elevates MPS and, to a lesser extent, MPB
such that net muscle protein balance (NPB)
remains negative. However, when RE is
coupled with protein ingestion there is an
accumulative effect on MPS resulting in a
positive NPB (Phillips et al. 2005). Thus,
repeated bouts of RE coupled with protein
feeding is a viable strategy to maximise
skeletal muscle hypertrophy and strength.
The impact of protein feeding on RE-
induced increases inMPShas receivedmuch
attention. One study has demonstrated
that in young healthy males ∼20 g
of high-quality protein is sufficient to
maximise RE-induced rates of MPS over
4 h post-exercise (Moore et al. 2009).
However, the interplay between the timing
and quantity of protein consumed and
subsequent anabolic responses throughout
the course of a whole day is still poorly
understood. In particular, there is a lack of
data examining how the pattern of post-RE
protein ingestion influences MPS later in
the recovery phase (i.e. 4–12 h). A recent
article published in The Journal of Physio-
logy attempts to address this knowledge gap
and in doing so provides valuable insights
into how post-RE protein feeding strategies
might be manipulated to optimise muscle
anabolism. In an elegantly designed study,
Areta et al. (2013) examined three groups
of eight healthy, trained males. Participants
performed a bout of bilateral leg extension
RE followed by the consumption of 80 g
of whey protein over 12 h of recovery
ingested as either 8 × 10 g every 1.5 h,
4 × 20 g every 3 h or 2 × 40 g every 6 h.
A stable isotope infusion was coupled with
frequent skeletal muscle biopsy sampling to
determine rates of MPS for 12 h post-RE.
The data demonstrate that although all
feeding strategies elevated MPS during the
12 h recovery period, consuming 20 g of
whey protein every 3 h was the super-
ior strategy for stimulating MPS rates.
The authors concluded that these findings
have the potential to maximise outcomes
of resistance training designed to elicit a
maximal hypertrophic response.
The data of Areta et al. show that
manipulating the pattern of protein
ingestion followingREcanhave a significant
impact on the subsequent muscle anabolic
response. The divergent feeding strategies
of Areta et al. were used to mimic possible
patterns of protein intake commonly
observed in resistance-trained athletes.
That is, 8 × 10 g every 1.5 h represents a
‘grazing’ approach, whereas 2 × 40 g every
6 h relates to the ‘three square meals per
day’ approach. Yet, both of these strategies
were inferior for stimulating MPS over
12 h of post-RE recovery compared with
4 × 20 g ingested every 3 h. However, it is
important to note that this response was
characterised when protein was ingested
alone, and as the authors acknowledge,
this finding cannot be evaluated in the
context of a mixed meal. Indeed, it is
commonplace to consume protein in the
form of a mixed-macronutrient meal.
Therefore, it is reasonable to postulate
that macronutrient co-ingestion could alter
intestinal transit, thus influencing amino
acid absorption kinetics (Deutz et al. 1995)
andperhapsMPS.Moreover, this studyused
high-quality whey protein and it remains
to be seen if a similar pattern of MPS
post-RE would be observed using the same
feeding strategieswith a slow-releaseprotein
such as casein. Such information may be
valuable to individuals who choose not
to (or are unable to) ingest high-quality
protein in supplemental form following
exercise, but instead consume whole-food
protein sources.
Areta et al. should be highly commended
for underlining the importance of not only
the quantity, but particularly the pattern
of post-RE protein ingestion to maximise
the rate of MPS over 12 h. However, as a
note of caution, their findings are limited
to a healthy young male population. In
this regard, recent evidence demonstrates
that the elderly require more protein
(40 to > 20 g) to elicit optimal increases in
RE-induced rates of MPS than the young
(Yang et al. 2012). It is therefore reasonable
to consider whether the temporal influence
of post-REprotein feedingonelderlymuscle
could be different compared to that of
young. In this regard, the next logical step
is to apply the model of Areta et al. in
elderly and other populations, in whom
maintenance of muscle mass is a critical
determinant of longevity and quality of life.
Yet, it should be acknowledged that Areta
et al. afford data pertaining to only 12 h
of recovery from RE. Hence, whether the
acute responses of MPS to RE and protein
feeding translate into a long-term functional
response remains unknown.
The findings of Areta et al. will no doubt
also grasp the attention of coaches and
athletes alike. As such, some may cite the
use of a bilateral exercise stimulus and
absence of participants with large amounts
of leanmass (>75 kg) as issues that preclude
full applicability in a ‘real-world’ setting.
To date, it is unclear whether exercising a
greater volume of muscle mass is limiting
forMPS in response to a given protein dose.
Therefore, individuals with greater muscle
mass or those engaged in whole-body RE
training sessions may require ingestion of
a greater protein dose to stimulate MPS
maximally. With regard to the notion of
applicability to the ‘real-world’ setting, it
also may be significant that the participants
entered the experimental trial in the fasted
state. As a result the authors are unable
to identify whether a pre-exercise meal
would influence the MPS response to RE
and various feeding strategies. This point
becomes more relevant when considering
the impact of insulin on MPB with
regard to the true growth response and
therefore the long-term applicability of the
findings. Future studies assessing MPS and
MPB in both the clinical and the athletic
setting following RE and feeding are now
required.
The study by Areta et al. also reveals novel
nutrient–exercise interactions in cellular
signalling. PhosphorylatedmTORSer2448 was
∼2- to ∼6-fold above resting values
throughout the 12 h recovery period
independent of protein feeding strategy.
Phosphorylation of p70S6KThr389 was also
increased above baseline, again in all feeding
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strategies. However, there was discordance
between the degree of p70S6KThr389
phosphorylation and the MPS response.
In fact, the magnitude of phosphorylated
p70S6KThr389 displayed a 2 × 40 g to
> 4 × 20 g to > 8 × 10 g pattern at 1 and
7 h post-RE. This finding is surprising
given that phosphorylated p70S6KThr389 is
a key player in protein synthesis yet it
was the 4 × 20 g strategy that induced
the most favourable influence on MPS
but median impact on phosphorylated
p70S6KThr389. However, it is important to
recognise that the timing of the biopsies
at 1 and 7 h coincided with a greater
volume of protein consumed prior to
those biopsies for the 2 × 40 g condition,
whichmay explain the discordance between
p70S6KThr389 signalling and MPS.
The common method employed to assay
protein phosphorylation, a proxy of activity,
in an exercise science setting, and in the
present investigation, is Western blotting
(WB). In contrast to the quantitative and
reproducible techniques used to measure
MPS, WB is a semi-quantitative method.
Additionally, phosphorylated p70S6KThr389
is recognised as a key controller of
ribosomal biogenesis. So although the
phosphorylation of p70S6KThr389 post-RE
does not correspond to the greatest acute
MPS response it may in fact be leading to
greater levels of ribosomal transcription.
Interestingly, phosphorylation of p70S6K
following RE often occurs in the nucleus,
where ribosomal biogenesis commences. A
caveat of the field is that no study has
employed cellular fractionation techniques
to reveal whether different RE and feed-
ings strategies alter the ratio of nuclear
to cytoplasmic phosphorylated p70S6K
in human skeletal muscle. Hence, the
lack of concordance between the MPS
and signalling response in this and
numerous other works emphasises the need
for the development of new measures
regarding readouts of ribosomal biogenesis
in addition to fully quantitative methods
to ascertain signalling activity following RE
and nutrition.
To conclude, the study by Areta et al.
contributes novel data to the body of
literature highlighting the importance
of the timing and quantity of protein
consumed post-RE for muscle anabolism.
By mimicking the habitual feeding
strategies of many athletes engaged in
resistance training, the authors move
closer to bridging the gap between science
and the applied setting. Future work
that identifies the impact of different
macronutrients consumed in combination,
i.e. fat, carbohydrate, protein and fibre,
on MPS in both elderly and young is
warranted. Furthermore, there is growing
interest in whether having greater amounts
of muscle mass, or indeed exercising
muscle mass involved in trainin impact
RE-induced rates of MPS. Thus, future
studies that examine the MPS response
in individuals with large muscle mass,
performing real-world RE, may provide
informative data for clinical and athletic
practice.
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